KR101400905B1 - Novel pyridopyrazines and their use as modulators of kinases - Google Patents

Abstract

The present invention relates to pyrido [2,3-b] pyrazine derivatives of formulas (I) and (II), and methods for their preparation and their use as medicaments for the treatment of malignant tumors and other disorders associated with pathological cell proliferation.

Pyrido [2,3-b] pyrazine, pathological cell proliferation

Description

Novel pyridopyrazines and their use as modulators of kinases

The present invention affects the function of tyrosine kinases, serine / threonine kinases and lipid kinases, particularly for the control of kinase modulators in the form of pyrido [2,3-b] pyrazine and methods for their preparation and for misdirected cellular signaling processes. The present invention relates to a cycle and to use as a medicament for the treatment of malignant or benign tumors and other disorders based on pathological cell proliferation, such as restenosis, psoriasis, atherosclerosis and cirrhosis of the liver.

Activation of protein kinases is a pivotal event in cellular signaling processes. Aberrant kinase activation is observed in various pathological conditions. Targeting inhibition of kinases is thus a fundamental therapeutic goal.

Phosphorylation of proteins is generally initiated by extracellular signals and represents a general mechanism for regulating various cellular events such as metabolic processes, cell growth, cell migration, cell differentiation, membrane delivery and apoptosis. The kinase protein family is due to protein phosphorylation. They catalyze the transfer of phosphates to specific substrate proteins. Based on substrate specificity, kinases are classified into three major classes, tyrosine kinases, serine / threonine kinases and lipid kinases. Receptor tyrosine kinases and cytoplasmic tyrosine, serine / threonine and lipid kinases are both important proteins in cellular signaling. Overexpression or degeneration of these proteins is an important part of disorders based on pathological cell proliferation. This includes metabolic disorders, disorders of connective tissue and blood vessels, and malignant and benign tumors. In tumor initialization and development, they often occur as oncogenes, i.e. as aberrant systemically active kinase proteins. The result of such excessive kinase activation is, for example, unregulated cell growth and reduced cell death. Stimulation of tumor-induced growth factors may also be a cause of kinase hyperstimulation. The development of kinase modulators is thus important, especially in all pathogenic processes affected by kinases.

The ras-Raf-Mek-Erk and PI3K-Akt signaling cascades play a pivotal role in cell growth, cell proliferation, apoptosis, adhesion, migration and glucose metabolism. Thus, a fundamental relevance in the pathogenesis of disorders such as cancer, neurodegeneration and inflammatory disorders is demonstrated in both ras-Raf-Mek-Erk and PI3K-Akt signaling pathways. Thus, the individual components of these signal cascades intervene in a variety of disease processes to constitute an important therapeutic point of occurrence. See Weinstein-Oppenheimer C.R. et al 2000, Chang F. et al 2003, Katso R. et al 2001 and Lu Y. et al 2003].

The molecular and biochemical properties of the two signal pathways can first be described separately below.

Many growth factors, cytokines and oncogenes introduce their growth-promoting signals through activation of G-protein-bound ras, which activates serine-threonine kinase Raf and mitogen-activated protein kinase kinases 1 and 2 Causing activation of (MAPKK1 / 2 or Mek1 / 2) and the activation of MAPK 1 and 2, known as phosphorylation and extracellular signal-regulated kinases (Erk1 and 2). In comparison to other shoot pathways, the ras-Raf-Mek-Erk signaling pathway is associated with a number of proto-oncogenes including ligands, tyrosine kinase receptors, G proteins, kinases and nuclear transcription factors. Tyrosine-kinases, such as EGFR (Mendelsohn J. et al., 2000), are often caused by overexpression and mutations in the course of tumor processes, often for downstream ras-Raf-Mek-Erk signaling pathways. Embed a structural activity signal. Ras mutations mutated 30% of all human tumors [Kleif S.N. et al., 1999, Marshall C., 1999], the highest incidence of 90% in pancreatic carcinoma (Friess H. et al., 1996, Sirivatanauksorn V. et al., 1998). In the case of c-Raf, unregulated expression and / or activation is described in various tumors (Hosino R. et al., 1999, McPhillips F. et al., 2001). B-Raf point mutations are detected in 66% of all human malignant melanoma, 14% of ovarian carcinoma and 12% of colon carcinoma (Davies H. et al., 2002). Thus, it is not surprising that Erk1 / 2 is involved in the basic stages of many cellular processes, such as cell growth, cell proliferation and cell differentiation. See Lewis T.S. et al., 1998, Chang F. et al., 2003].

In addition, the elements of Raf kinases also have Mek-Erk-dependent, anti-cell death, whose molecular steps have not been fully described yet. Possible interaction partners described for Mek-Erk-dependent Raf activity are Ask1, Bcl-2, Akt and Bag1. See Chen J et al., 2001, Troppmaier J. et al., 2003, Rapp U.R. et al., 2004, Gotz R. et al., 2005]. Both Mek-Erk-dependent and Mek-Erk-dependent signaling mechanisms are presumed to regulate the activation of upstream ras and Raf stimuli.

Homozymes of phosphatidylinositol 3-kinase (PI3Ks) basically act as lipid kinases, and PtdIns (3) P, PtdIns (3,4) P2, PtdIns (3,4,) in the second messenger lipid PtdIns 5) Catalyzes D3 phosphorylation to P3 phosphatidylinositol phosphate. Class I PI3Ks are constructed from the structural point of view of catalytic subunits (p110 alpha, beta, gamma, delta) and regulatory subunits (p85 alpha, beta or p101 gamma). In addition, Class II (PI3K-C2alpha, PI3K-C2beta) and Class III (Vps34p) enzymes have a family of PI3 kinases. See Wymann M.P. et al., 1998, Van Haesebroeck B. et al., 2001]. PIP elevation induced by PI3K first activates the proliferative ras-Raf-Mek-Erk signaling pathway through ras cuffing (Rodrigue-Viciana P. et al., 1994), and secondary Akt to cell membranes. And subsequently overexpress this kinase to stimulate anti-cell death signaling pathways. See Alessi DR. et al., 1996, Chang H.W. et al., 1997, Moore S.M. et al., 1998]. Thus, activation of PI3Ks performs at least two important mechanisms of tumor development, in particular activation of cell growth and cell differentiation, and inhibition of apoptosis. In addition, PI3Ks also have protein-phosphorylation properties (Dhand et al., 1994, Bondeva T. et al., 1998, Bondev A. et al., 1999, VanHaesebroeck B. et al., 1999). This may lead to, for example, serine autophosphorylation, which essentially regulates PI3Ks. It is also known that PI3Ks are kinase-dependent, regulatory effector properties in the regulation of heart contraction. See Crackower M.A. et al., 2002, Patrucco et al., 2004]. In addition, PI3Kdelta and PI3Kgamma are specifically expressed in hematopoietic cells, thus homozyme-specific PI3Kdelta in the treatment of inflammatory disorders such as rheumatoid, asthma and allergy and in the treatment of B and T cell lymphomas. And a potential point of onset for PI3Kgamma inhibitors (Okkenhaug K. et al., 2003, Ali K. et al., 2004, Sujobert P. et al., 2005). Recently identified as a proto-oncogene [Shayesteh L. et al., 1999, Ma Y.Y. et al., 2000, Samuels Y. et al., 2004, Campbell I.G. et al., 2004, Levine D.A., 2005] PI3Kalpha is an important target in the treatment of tumor disorders. The importance of the PI3K species as a target for active ingredient development thus broadens accordingly. Chang F. & Lee J.T. et al, 2003].

PI3K-related kinases (PIKKs) are equally important, including serine / threonine kinase mTOR, ATM, ATR, h-SMG-1 and DNA-PK. See Chiang G.G. et al 2004]. Its catalytic domain has high sequence homology with the catalytic domain of PI3Ks.

In addition, loss of the tumor suppressor protein PTEN [Li J. et al., 1997, Steck P.A. et al., 1997], invert the function of phosphorylation initiated by PI3K and cause overactivity of Akt and its downstream cascade components, thus highlighting the causal importance of PI3K as a target molecule for tumor treatment. do.

Various inhibitors of the individual components of the ras-Raf-Mek-Erk and PI3K-Akt signaling pathways are already published and patented.

Current developments in the field of kinase-inhibitors, particularly the ras-Raf-Mek-Erk and PI3K-Akt pathways, have been assessed in the reviews by the reviews by J.S. Sebolt-Leopold et al., 2004, and R. Wetzker et al., 2004]. This document contains an extensive list of patents describing the synthesis and use of low molecular weight ras-Raf-Mek-Erk and PI3K inhibitors.

Kinase inhibitors Bay 43-9006 (WO 99/32111, WO 03/068223) have already been tested in clinical trials for serine / threonine kinases and tyrosine kinases such as Raf, VEGFR2 / 3, Flt-3, PDGFR, c-Kit and A relatively nonspecific inhibition pattern of additional kinases. It significantly affects these inhibitors in melanoma with high B-Raf mutation rates as well as in advanced tumor disorders induced by angiogenesis (eg for renal cell carcinoma). The clinical action of Bay 43-9006 has now also been measured in patients with unresponsive solid tumors, for example in combination with docetaxel. To date, mild side effects and promising anti-tumor effects have been described. Inhibition of kinases in the PI3K-Akt signaling pathway was not described or shown in Bay 43-9006.

Mek1 / 2 inhibitor PD0325901 (WO 02/06213) is currently in Phase I clinical trial. Precursor material CI-1040 (WO 00/35435, WO 00/37141) was recognized by its high Mek specificity and target affinity. However, these compounds have been found to be metabolically labile in phase I / II studies. Clinical data for the successor substance PD0325901 is still in force. However, the interaction with Erk1 or Erk2 and the inhibition or PI regulation of PI3K-Akt signaling pathways have not been disclosed or shown for these Mek inhibitors.

The PI3K inhibitors disclosed so far are still in preclinical trials. ICOS represents PI3K inhibitor IC87114 with high PI3Kdelta isoenzyme specificity (WO 01/81346). PI103 (WO 04/017950) (Yamanouchi / Piramed) describes selectivity versus PI3Kalpha isoform. However, a high field in the study exists in the early development of PI3K inhibitors (review of R. Wetzker et al., 2004).

Inhibitors of the SAPK signaling pathway of Jnk or p38 have been described in Gum R.J., 1998, Bennett B.L. et al 2001, Davies S.P. et al 2000]. However, no action to inhibit PI3K or specific inhibition of Erk1 or Erk2 or other specific inhibition of SAPKs, Erk1, Erk2, or PI3K has been shown for these SAPK inhibitors.

6- or 7-substituted pyrido [2,3-b] pyrazine derivatives have been found to have broad concentrations in pharmaceutical chemistry as pharmacologically active compounds and as synthetic units.

For example, WO 04/104002 and WO 04/104003 describe pyrido [2,3-b] pyrazine which can be 6- or 7-substituted by urea, thiourea, amidine or guanidine groups. These compounds are characterized as inhibitors or modulators of kinases, in particular tyrosine and serine / threonine kinases, and their use as a medicament has been reported. In contrast, the use of these compounds as lipid kinases, alone or in combination with tyrosine and serine / threonine kinases, is not described.

WO 99/17759 also describes pyrido [2,3-b] pyrazine with the alkyl-, aryl- and heteroaryl-substituted carbamate in the 6-position. These compounds are intended for use to modulate the action of serine-threonine protein kinases.

WO 05/007099 (Kawakami et al.) Describes in particular urea-substituted pyrido [2,3-b] pyrazine as an inhibitor of serine / threonine kinase PKB. However, this application did not further limit the R radicals, where the range of substitution for urea should be described, but the range of substitution of urea was not explicitly indicated. For these compounds, their use in the treatment of cancer disorders has been reported. However, no specific implementation of urea-substituted pyridopyrazines having these biological properties is provided. In addition, the pyridopyrazine described herein is significantly different in structure from the pyrido [2,3-b] pyrazine of the present invention.

Further implementations of 6- and 7-urea-substituted pyrido [2,3-b] pyrazine are reported in WO 05/056547 (Bemis et al.). However, the compounds of this patent have further carbonyl, sulfoxy, sulfone or imine substitutions in the 2- or 3-position and are structurally significantly different from the pyrido [2,3-b] pyrazine of the invention described herein. It means. Pyridopyrazines reported in WO 05/056547 are described as inhibitors of protein kinases, in particular GSK-3, Syk and JAK-3. For such compounds, reported uses include the use in the treatment of proliferative disorders. The use of these compounds is described alone or as modulators of lipid kinases, in combination with serine / threonine kinases.

WO 04/005472 (White et al.) Describes 6-carbamate-substituted pyrido [2,3-b] pyrazine which inhibits the growth of bacteria, in particular as an antimicrobial substance. Antitumor action is not described.

Additionally, certain diphenylquinoxalines and -pyrido [2, with specific alkylpyrrolidine, alkylpiperidine or alkylsulfonamide radicals in the phenyl ring, which may also have a urea or carbamate substitution at the 6- or 7-position; 3-b] pyrazine has been described in WO 03/084473 (Barnett et al.), WO 03/086394 (Bilodeau et al.) And WO 03/086403 (Lindsley et al.) As inhibitors of serine / threonine kinase Akt activity. have. For these compounds, their use for treating cancer disorders has been reported. For the pyrido [2,3-b] pyrazine working compounds described herein, no limited indication of biological action is specified. It is also structurally significantly different from the pyrido [2,3-b] pyrazine of the present invention described in the present invention.

In addition, WO 03/024448 (Delorme et al.) Also contains carbamate as an additional substituent, and amide- and acrylamide-substituted pyrido can be used as a histone deacetylase inhibitor for the treatment of cell proliferative disorders. [2,3-b] pyrazine is described.

In addition, C. Temple, Jr .; J. Med. Chem. 1990, 3044-3050, an implementation is used which severs the synthesis of 6-ethylcarbamate-substituted pyrido [2,3-b] pyrazine derivatives. The antitumor action is not described and is not clear.

The synthesis of additional derivatives of 6-ethylcarbamate-substituted pyrido [2,3-b] pyrazines is described in the literature (RD Elliott, J. Org. Chem. 1968, 2393-2397) The biological action of this is not described and is unclear.

C. Templet, Jr. et al. J. Med. Chem. 1968, 1216-1218 describe the synthesis and investigation of 6-ethylcarbamate-substituted pyrido [2,3-b] pyrazines as potentially active anti-malaria components. The antitumor action is not described and is not clear.

DESCRIPTION OF THE INVENTION

The present invention thus directs the provision of novel compounds suitable as modulators of receptor tyrosine kinases, cytoplasmic tyrosine kinases, serine / threonine kinases and lipid kinases. The present invention also contemplates that not all kinases present in succession in a misregulated signaling cascade-for example Raf-Mek-Erk or PI3K-Akt-need to be present as oncogenic kinases or as structurally active enzymes. Inactive kinases are considered as therapeutic target proteins, ie, novel compounds can bind to and affect signaling by both active and inactive kinases.

The invention also relates to one individual kinase or two or more kinases, in particular Erk1 / 2 and PI3K, one signaling cascade or a different signaling cascade, as modulators of receptor tyrosine kinases, cytoplasmic tyrosine kinases, serine / threonine kinases and lipid kinases, In particular, it is directed to the provision of novel compounds having characteristics affecting ras-Raf-Mek-Erk and PI3K-Akt. Dual mechanisms, ie, simultaneous inhibition of two or more signaling cascades, compared to therapeutic onset in only one signaling pathway, increase the effect in the treatment of all onset processes affected by kinases, due to additional effects. You can.

Surprisingly, for example, a novel compound from the group of pyrido [2,3-b] pyrazine 6- or 7-substituted by urea or thiourea residues can be used to modulate a cell signaling process that is misdirected. In particular for affecting the action of receptor tyrosine kinases, cytoplasmic tyrosine kinases, serine / threonine kinases and lipid kinases, and based on, for example, malignant or benign tumor disorders of the breast, prostate, lung, skin, ovary, and cell proliferation It has been found to be suitable for the manufacture of a medicament for treating other disorders.

A first aspect of the invention describes a novel compound of the group of pyrido [2,3-b] pyrazine of formula (I).

In the formula (I)

(A) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted aryl" wherein "substituted aryl" is substituted by one or more substituents identically or differently selected from the group consisting of: :

(a) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, NHX1, N (alkyl) ₂ , NHC (O) alkyl, NHC (O) cycloalkyl, NHC ) aryl, NHC (O) heteroaryl, NHC (O) aryl, NHC (O) heteroaryl, alkyl, NHS (O ₂₎ alkyl, NHS (O ₂₎ cycloalkyl, NHS (O ₂₎ heterocyclyl, NHS (O ₂₎ aryl, NHS (O ₂₎ heteroaryl, NHS (O ₂₎ aryl, NHS (O ₂₎ heteroaryl-alkyl, S-alkyl, S aryl, S-heteroaryl, OX2, OC (O) alkyl, OC (O) cycloalkyl, OC (O) heterocyclyl, OC (O) aryl, OC (O) heteroaryl, OC (O) aryl, OC (O) heteroaryl-alkyl, OS (O ₂₎ alkyl, OS (O ₂₎ cycloalkyl, OS (O ₂₎ heterocyclyl, OS (O ₂₎ aryl, OS (O ₂₎ heteroaryl, OS (O ₂₎ aryl, OS (O ₂₎ heteroaryl, alkyl, C ( C (O) N (alkyl) ₂ , C (O) N (cycloalkyl) ₂ , C (O) N (aryl) _2, C (O) N (heteroaryl) _2, S (O) alkyl, S (O) aryl, S (O ₂₎ alkyl, S (O ₂₎ aryl, S (O ₂₎ NH-alkyl, S (O ₂₎ NH aryl, S (O ₂₎ NH-heteroaryl, S (O ₂₎ NH-arylalkyl, S (O ₂₎ O-alkyl, S (O ₂₎ O aryl, S (O ₂ ) O arylalkyl "

Wherein X 1, X 2, X 3, X 4 are each independently selected from the group consisting of: “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl Alkyl "

Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "(C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N ₃ , NH cycloalkyl, S heteroaryl, NH heteroarylalkyl, NHarylalkyl, NHheterocyclyl, NHheterocyclylalkyl, NX5X6, S cycloalkyl, S cycloalkylalkyl, S aryl, S arylalkyl, Sheteroaryl, O heterocyclyl, O heterocyclylalkyl, O cycloalkyl, O cycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, Oheteroarylalkyl, _{(X7-O) p X8 (} p = 1, 2, 3, 4, 5), OP (O) (OX9) (OX10), C (O) OX11, C (O) NH 2, C (O) NHX12 , C (O) NX13X14, S (O 2) X15, P (O) (OH) 2, P (O) (OX16) (OX17), Si (X18) (X19) (X20), OSi (X21) ( (O) N (O) N (O) N (O) N (O) OX24, O) NHX35, NX36C (O) NX37X38, OS (O 2 ) X39, NHC (O) X40 , NX41C (O) X42, C (O) X43, OC (O) X44, S (O) X45, S (O 2) NHX46, S (O 2) NX47X48, S (O ₂ ) OX49, O (X50-O) _p -H (p = 1,2,3,4,5)

Further provided that "N (alkyl) ₂ " is further substituted by one or more substituents selected from the following substituent group (b);

Here, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X29, X30, X31, X32, X33, X34, X35, X36, X37, X38, X39, X40, X41, X42, X43, X44, X45, X46, X47, X48, X49 and X50 are each independently It is selected from the group: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", where, alternatively , X13, X14 and / or X26, X27 and / or X30, X31 and / or X37, X38 and / or X47, X48 may also together form a "heterocyclyl"

Further provided that if one of the Z3 or Z4 radicals is "substituted aryl" substituted by "heterocyclylalkyl", then the remaining Z3 or Z4 radicals are in each case not "substituted or unsubstituted aryl",

Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(b) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHX 51, NX 52 X 53, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) X54, C (O) OX55, C (O) NHX56, C (O) NX57X58, OX59, O (X60-O) r H (r = 1, 2, 3, 4, 5), O (X61-O) r X62 (r = 1, 2, 3, 4, 5), OC (O) X63, OC (O) OX64, OC (O) NHX65 , OC (O) NX66X67, OP (O) (OX68) (OX69), OSi (X70) (X71) (X72), OS (O 2) X73, NHC (O) X74, NX75C (O) X76, NHC ( O) OX77, NHC (O) NHX78, NHC (O) NX79X80, NX81C (O) OX82, NX83C (O) NHX84, NX85C (O) NX86X87, NHS (O 2) X88, NX89S (O 2) X90, SX91, S (O) X92, S ( O 2) X93, S (O 2) NHX94, S (O 2) NX95X96, S (O 2) OX97, P (O) (OX98) (OX99), Si (X100) ( X101) (X102) "

Here, X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X100, X101, X102 are each independently selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, X57, X58 and / or X66, X67 and / or X79, X80 and / or X86, X87 and / or X95 and X96 taken together are also "heterocyclyl"Lt; / RTI >

Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX103, NX104X105, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X106, C (O) OX107, C (O) NHX108, C (O) NX109X110, OX111, O (X112-O) s H (s = 1, 2, 3, 4, 5), O (X113-O) s X114 (s = 1, 2, 3, 4, 5), OC (O) X115, OC (O) OX116, OC (O) NHX117 , OC (O) NX118X119, OP (O) (OX120) (OX121), OSi (X122) (X123) (X124), OS (O 2) X125, NHC (O) X126, NX127C (O) X128, NHC ( O) OX129, NHC (O) NHX130, NHC (O) NX131X132, NX133C (O) OX134, NX135C (O) NHX136, NX137C (O) NX138X139, NHS (O 2) X140, NX141S (O 2) X142, SX143, S (O) X144, S ( O 2) X145, S (O 2) NHX146, S (O 2) NX147X148, S (O 2) OX149, P (O) (OX150) (OX151), Si (X152) ( X153) (X154) "

Wherein X103, X104, X105, X106, X107, X108, X109, X110, X111, X112, X113, X114, X115, X116, X117, X118, X119, X120, X121, X122, X123, X124, X125, X127, X128, X129, X130, X131, X132, X133, X134, X135, X136, X137, X138, X139, X140, X141, X142, X143, X144, X145, X146, X147, X148, X149, X150, X152, X153, X154 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Quot; heteroarylalkyl ", wherein, alternatively, X109, X110 and / or X118, X119 and / or X131, X132 and / or X138, X139 and / or X147, X148 are also taken together to form a "Lt; / RTI >

Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHX 155, NX 156 X 157, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) X158, C (O) OX159, C (O) NHX160, C (O) NX161X162, OX163, O (X164-O) t H (t = 1, 2, 3, 4, 5), O (X165-O) t X166 (t = 1, 2, 3, 4, 5), OC (O) X167, OC (O) OX168, OC (O) NHX169 , OC (O) NX170X171, OP (O) (OX172) (OX173), OSi (X174) (X175) (X176), OS (O 2) X177, NHC (O) X178, NX179C (O) X180, NHC ( O) OX181, NHC (O) NHX182, NHC (O) NX183X184, NX185C (O) OX186, NX187C (O) NHX188, NX189C (O) NX190X191, NHS (O 2) X192, NX193S (O 2) X194, SX195, S (O) X196, S ( O 2) X197, S (O 2) NHX198, S (O 2) NX199X200, S (O 2) OX201, P (O) (OX202) (OX203), Si (X204) ( X205) (X206) "

Wherein X155, X156, X157, X158, X159, X160, X161, X162, X163, X164, X165, X166, X167, X168, X169, X170, X171, X172, X173, X174, X172, X176, X191, X192, X193, X194, X191, X196, X197, X198, X191, X200, X201, X202, X203, X203, X204, X205, X206 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Quot; heteroarylalkyl ", wherein, alternatively, X161, X162 and / or X170, X171 and / or X183, X184 and / or X190, X191 and / or X199, X200 are also taken together to form a "Lt; / RTI >

Or both of the Z3 and Z4 radicals or both of the Z3 and Z4 radicals are independently "substituted aryl ",wherein" substituted aryl "is substituted by one or more substituents which are the same or different selected from the group consisting of:

_{(c) "(C 9 -C} 30) _{alkyl, NX207X208, NH (C 9 -C} 30) alkyl, NHC (O) cycloalkyl-alkyl, NHC (O) heterocyclyl-alkyl, NHC (O) (C ₉ - C ₃₀₎ alkyl, NX209C (O) X210, NX211C (O) (C 9 -C 30) alkyl, NHC (O) OX212, NX213C (O) OX214, NHC (O) NHX215, NHC (O) NX216X217, NX218C ( O) NHX219, NX220C (O) NX221X222, NHS (O 2) cycloalkylalkyl, NHS (O _{2) heterocyclylalkyl, NX223S (O 2) X224,} O (C 9 -C 30) alkyl, S-cycloalkyl, S-heterocyclyl, S-alkyl aryl, S-alkyl-heteroaryl, S-alkyl-cycloalkyl, S-heterocyclyl-alkyl, S (C ₉ -C ₃₀₎ alkyl, OC (O) cycloalkyl-alkyl, OC (O) heterocyclyl _{alkyl, OC (O) (C 9} -C 30) alkyl, OS (O ₂₎ cycloalkylalkyl, OS (O _{2) heterocyclylalkyl, OS (O 2) (C} 9 -C 30) alkyl, OC ( C (O) heterocyclyl, C (O) arylalkyl, C (O) NHC226, OC (O) NX227X228, OP (O) (OX229) (OX230) (O) alkyl-heteroaryl, C (O) cycloalkylalkyl, C (O) alkyl, heterocyclyl, C (O) (C ₉ -C ₃₀₎ alkyl, _{C (O) O (C 9} -C 30) alkyl, C (O) NH (C 9 -C 30) alkyl, C (O) NX231X232, C (O) NHOX233, C (O) NX234-OX235, C ( S (O) heteroaryl, S (O) arylalkyl, S (O) heteroarylalkyl, S (O) heterocyclyl, S ) cycloalkyl-alkyl, S (O) heterocyclyl-alkyl, S (O) (C ₉ -C ₃₀₎ alkyl, S (O ₂₎ cycloalkyl, S (O ₂₎ heterocyclyl, S (O ₂₎ heteroaryl S (O ₂ ) heteroarylalkyl, S (O ₂ ) heteroarylalkyl, S (O ₂ ) cycloalkylalkyl, S (O ₂ ) heterocyclylalkyl, S (O ₂ ) (C ₉ -C ₃₀ ) alkyl, S (O ₂₎ NH-cycloalkyl, S (O ₂₎ NH-heterocyclyl, S (O ₂₎ NH-heteroaryl-alkyl, S (O ₂₎ NH-cycloalkyl-alkyl, S (O ₂₎ NH-heterocyclyl _{alkyl, S (O 2) NH (} C 9 -C 30) alkyl, S (O ₂₎ O-cycloalkyl, S (O ₂₎ O-heterocyclyl, S (O ₂₎ O-heteroaryl, S (O ₂₎ O-alkyl-heteroaryl, S (O ₂₎ O-cycloalkyl-alkyl, S (O _{2) O-heterocyclyl-alkyl, S (O 2) O (} C 9 -C 30) alkyl, P (O) (OH) 2, P (O) (OX241) (O X242), Si (X243) (X244) (X245), OSi (X246) (X247) (X248)

Wherein X207, X208, X209, X210, X211, X212, X213, X214, X215, X216, X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, X243, X244, X245, X246, X247, X248 are each independently selected from the group consisting of alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl " X221, X222 and / or X227, X228 and / or X231, X232 and / or X236, X237 and / or X239, X240 may also in each case form a "heterocyclyl"

However, the substituent "N _{(alkyl) 2", "C (O} ) N ( _{alkyl) 2", "C (O} ) N ( _{cycloalkyl) 2", "C (O} ) N ( aryl) _2", "C (O) N (heteroaryl) ₂ "is further substituted by one or more substituents selected from the following substituent group (i);

Further provided that if one of the Z3 or Z4 radicals is "substituted aryl" substituted by "heterocyclylalkyl", then the remaining Z3 or Z4 radicals in each case are not "unsubstituted or substituted aryl",

Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX249, NX250X251, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X252, C (O) OX253, C (O) NHX254, C (O) NX255X256, OX257, O (X258-O) u H (u = 1, 2, 3, 4, 5), O (X259-O) u X260 (u = 1, 2, 3, 4, 5), OC (O) X261, OC (O) OX262, OC (O) NHX263 , OC (O) NX264X265, OP (O) (OX266) (OX267), OSi (X268) (X269) (X270), OS (O 2) X271, NHC (O) X272, NX273C (O) X274, NHC ( O) OX275, NHC (O) NHX276, NHC (O) NX277X278, NX279C (O) OX280, NX281C (O) NHX282, NX283C (O) NX284X285, NHS (O 2) X286, NX287S (O 2) X288, SX289, S (O) X290, S ( O 2) X291, S (O 2) NHX292, S (O 2) NX293X294, S (O 2) OX295, P (O) (OX296) (OX297), Si (X298) ( X299) (X300) "

Wherein X224, X250, X251, X252, X253, X254, X255, X256, X257, X258, X259, X260, X261, X262, X263, X264, X265, X266, X267, X268, X269, X270, X271, X272, X273, X274, X275, X276, X277, X278, X279, X280, X281, X282, X283, X284, X285, X286, X287, X288, X289, X290, X291, X292, X293, X294, X295, X298, X299, X300 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, X255, X256 and / or X264, X265 and / or X277, X278 and / or X284, X285 and / or X293, Quot; reel "

Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals are each independently selected by one or more substituents identically or differently selected from the group consisting of:

(d) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHX301, NX302X303, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) X304, C (O) OX305, C (O) NHX306, C (O) NX307X308, OX309, O (X310-O) uu H (uu = 1, 2, 3, 4, 5), O (X311-O) uu X312 (uu = 1, 2, 3, 4, 5), OC (O) X313, OC (O) OX314, OC (O) NHX315 , OC (O) NX316X317, OP (O) (OX318) (OX319), OSi (X320) (X321) (X322), OS (O 2) X323, NHC (O) X324, NX325C (O) X326, NHC ( O) OX327, NHC (O) NHX328, NHC (O) NX329X330, NX331C (O) OX332, NX333C (O) NHX334, NX335C (O) NX336X337, NHS (O 2) X338, NX339S (O 2) X340, SX341, S (O) X342, S ( O 2) X343, S (O 2) NHX344, S (O 2) NX345X346, S (O 2) OX347, P (O) (OX348) (OX349), Si (X350) ( X351) (X352) "

Wherein X301, X302, X303, X304, X305, X306, X307, X308, X309, X310, X311, X312, X313, X314, X315, X316, X317, X318, X319, X320, X321, X322, X323, X324, X325, X326, X327, X328, X329, X330, X331, X333, X333, X334, X338, X336, X337, X338, X339, X340, X341, X342, X343, X344, X345, X346, X347, X348, X350, X351, X352 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, X307, X308 and / or X316, X317 and / or X329, X330 and / or X336, X337 and / or X345, X346 may also be combined in each case together to form a "heterocycle Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (d) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX353, NX354X355, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X356, C (O) OX357, C (O) NHX358, C (O) NX359X360, OX361, O (X362-O) v H (v = 1, 2, 3, 4, 5), O (X363-O) v X364 (v = 1, 2, 3, 4, 5), OC (O) X365, OC (O) OX366, OC (O) NHX367 , OC (O) NX368X369, OP (O) (OX370) (OX371), OSi (X372) (X373) (X374), OS (O 2) X375, NHC (O) X376, NX377C (O) X378, NHC ( O) OX379, NHC (O) NHX380, NHC (O) NX381X382, NX383C (O) OX384, NX385C (O) NHX386, NX387C (O) NX388X389, NHS (O 2) X390, NX391S (O 2) X392, SX393, S (O) X394, S ( O 2) X395, S (O 2) NHX396, S (O 2) NX397X398, S (O 2) OX399, P (O) (OX400) (OX401), Si (X402) ( X403) (X404) "

Wherein X353, X354, X355, X356, X357, X358, X359, X360, X361, X362, X363, X364, X365, X366, X367, X368, X369, X370, X371, X372, X373, X374, X377, X378, X379, X380, X381, X382, X383, X384, X385, X386, X387, X388, X389, X390, X391, X392, X393, X394, X395, X396, X397, X398, X399, X402, X403, X404 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, X389 and / or X388, X389 and / or X397, X398 are also taken together in each case together to form a "heterocycle" in the form of "heterocyclyl, heteroaryl, heteroarylalkyl," or, alternatively, X359, X360 and / or X368, X369 and / Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHX 405, NX 406 X 407, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) X408, C (O) OX409, C (O) NHX410, C (O) NX411X412, OX413, O (X414-O) w H (w = 1, 2, 3, 4, 5), O (X415-O) w X416 (w = 1, 2, 3, 4, 5), OC (O) X417, OC (O) OX418, OC (O) NHX419 , OC (O) NX420X421, OP (O) (OX422) (OX423), OSi (X424) (X425) (X426), OS (O 2) X427, NHC (O) X428, NX429C (O) X430, NHC ( O) OX431, NHC (O) NHX432, NHC (O) NX433X434, NX435C (O) OX436, NX437C (O) NHX438, NX439C (O) NX440X441, NHS (O 2) X442, NX443S (O 2) X444, SX445, S (O) X446, S ( O 2) X447, S (O 2) NHX448, S (O 2) NX449X450, S (O 2) OX451, P (O) (OX452) (OX453), Si (X454) ( X455) (X456) "

Here, X405, X406, X407, X408, X409, X410, X411, X412, X413, X414, X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, X421 and / or X420, X421 and / or X433, X434 and / or X440, X441 and / or X449, X450 may also be combined in each case together to form a "heterocycle Quot; reel "

And one of the Z3 and Z4 radicals is independently selected from the group consisting of or independently selected from the group consisting of Z3 and Z4 radicals independently selected from the group consisting of:

(e) hydrogen;

(f) halogen, F, Cl, Br, I;

(g) unsubstituted and substituted alkyl, or (C ₉ -C ₃₀₎ alkyl, wherein, optionally, alkyl, or (C ₉ -C ₃₀₎ alkyl radical by one or more substituents the same or different selected from the group consisting of the following: Lt; / RTI >

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHX 457, NX 458 X 459, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) X460, C (O) OX461, C (O) NHX462, C (O) NX463X464, OX465, O (X466-O) x H (x = 1, 2, 3, 4, 5), O (X467-O) x X468 (x = 1, 2, 3, 4, 5), OC (O) X469, OC (O) OX470, OC (O) NHX471 , OC (O) NX472X473, OP (O) (OX474) (OX475), OSi (X476) (X477) (X478), OS (O 2) X479, NHC (O) X480, NX481C (O) X482, NHC ( O) OX483, NHC (O) NHX484, NHC (O) NX485X486, NX487C (O) OX488, NX489C (O) NHX490, NX491C (O) NX492X493, NHS (O 2) X494, NX495S (O 2) X496, SX497, S (O) X498, S ( O 2) X499, S (O 2) NHX500, S (O 2) NX501X502, S (O 2) OX503, P (O) (OX504) (OX505), Si (X506) ( X507) (X508) "

Here, X457, X458, X459, X460, X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485, X486, X487, X488, X489, X490, X491, X492, X493, X494, X495, X496, X497, X498, X499, X500, X501, X502, X503, X506, X507, X508 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or X492, X493 and / or X501, X502 are also taken together in each case together to form a "heterocycle "," heteroaryl, heteroarylalkyl ", or, alternatively, X463, X464 and / or X472, X473 and / or X485, X486 and / Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX509, NX510X511, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X512, C (O) OX513, C (O) NHX514, C (O) NX515X516, OX517, O (X518-O) y H (y = 1, 2, 3, 4, 5), O (X519-O) y X520 (y = 1, 2, 3, 4, 5), OC (O) X521, OC (O) OX522, OC (O) NHX523 , OC (O) NX524X525, OP (O) (OX526) (OX527), OSi (X528) (X529) (X530), OS (O 2) X531, NHC (O) X532, NX533C (O) X534, NHC ( O) OX535, NHC (O) NHX536, NHC (O) NX537X538, NX539C (O) OX540, NX541C (O) NHX542, NX543C (O) NX544X545, NHS (O 2) X546, NX547S (O 2) X548, SX549, S (O) X550, S ( O 2) X551, S (O 2) NHX552, S (O 2) NX553X554, S (O 2) OX555, P (O) (OX556) (OX557), Si (X558) ( X559) (X560) "

Here, X59, X510, X511, X512, X513, X514, X515, X516, X517, X518, X519, X520, X521, X522, X523, X524, X525, X526, X527, X528, X529, X530, X533, X534, X535, X536, X537, X538, X539, X540, X541, X542, X543, X544, X545, X546, X547, X548, X549, X550, X551, X552, X553, X554, X555, X556, X557, X558, X559, X560 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, X524, X524 and / or X524, X525 and / or X537, X538 and / or X544, X545 and / or X553, X554 are also referred to as "heterocycle Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX561, NX562X563, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X564, C (O) OX565, C (O) NHX566, C (O) NX567X568, OX569, O (X570-O) z H (z = 1, 2, 3, 4, 5), O (X571-O) z X572 (z = 1, 2, 3, 4, 5), OC (O) X573, OC (O) OX574, OC (O) NHX575 , OC (O) NX576X577, OP (O) (OX578) (OX579), OSi (X580) (X581) (X582), OS (O 2) X583, NHC (O) X584, NX585C (O) X586, NHC ( O) OX587, NHC (O) NHX588, NHC (O) NX589X590, NX591C (O) OX592, NX593C (O) NHX594, NX595C (O) NX596X597, NHS (O 2) X598, NX599S (O 2) X600, SX601, S (O) X602, S ( O 2) X603, S (O 2) NHX604, S (O 2) NX605X606, S (O 2) OX607, P (O) (OX608) (OX609), Si (X610) ( X611) (X612) "

Here, X561, X562, X563, X564, X565, X566, X567, X568, X569, X570, X571, X572, X573, X574, X575, X576, X577, X578, X579, X580, X581, X582, X583, X584, X585, X586, X587, X588, X589, X590, X591, X592, X593, X594, X595, X596, X597, X598, X599, X600, X601, X602, X603, X604, X605, X606, X607, X608, X609, X610, X611, X612 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, X567, X568 and / or X576, X577 and / or X589, X590 and / or X596, X597 and / or X605, Quot; reel "

(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX613, NX614X615, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X616, C (O) OX617, C (O) NHX618, C (O) NX619X620, OX621, O (X622-O) a H (a = 1, 2, 3, 4, 5), O (X623-O) a X624 (a = 1, 2, 3, 4, 5), OC (O) X625, OC (O) OX626, OC (O) NHX627 , OC (O) NX628X629, OP (O) (OX630) (OX631), OSi (X632) (X633) (X634), OS (O 2) X635, NHC (O) X636, NX637C (O) X638, NHC ( O) OX639, NHC (O) NHX640, NHC (O) NX641X642, NX643C (O) OX644, NX645C (O) NHX646, NX647C (O) NX648X649, NHS (O 2) X650, NX651S (O 2) X652, SX653, S (O) X654, S ( O 2) X655, S (O 2) NHX656, S (O 2) NX657X658, S (O 2) OX659, P (O) (OX660) (OX661), Si (X662) ( X663) (X664) "

Wherein X613, X614, X615, X616, X617, X618, X619, X620, X621, X622, X623, X624, X625, X626, X627, X628, X629, X630, X631, X632, X633, X634, X635, X636, X637, X638, X639, X640, X641, X642, X643, X644, X645, X646, X647, X648, X649, X650, X651, X652, X653, X654, X655, X656, X657, X658, X659, X662, X663, X664 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, X649, X648, X649 and / or X657, X658 are also each individually referred to as "heterocycle, heteroaryl, heteroarylalkyl ", or, alternatively, X619, X620 and / or X628, X629 and / Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX665, NX666X667, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X668, C (O) OX669, C (O) NHX670, C (O) NX671X672, OX673, O (X674-O) b H (b = 1, 2, 3, 4, 5), O (X675- O) b X676 (b = 1, 2, 3, 4, 5), OC (O) X677, OC (O) OX678, OC (O) NHX679 , OC (O) NX680X681, OP (O) (OX682) (OX683), OSi (X684) (X685) (X686), OS (O 2) X687, NHC (O) X688, NX689C (O) X690, NHC ( O) OX691, NHC (O) NHX692, NHC (O) NX693X694, NX695C (O) OX696, NX697C (O) NHX698, NX699C (O) NX700X701, NHS (O 2) X702, NX703S (O 2) X704, SX705, S (O) X 706, S (O ₂ ) X 707, S (O ₂ ) NHX 708, S (O ₂ ) NX709X710, S (O ₂ ) OX711, P (O) (OX712) X715) (X716) "

Herein, X665, X666, X667, X668, X669, X670, X671, X672, X673, X674, X675, X676, X677, X678, X679, X680, X681, X682, X683, X684, X685, X686, X689, X690, X691, X692, X693, X694, X695, X696, X697, X698, X699, X700, X701, X702, X703, X704, X705, X706, X707, X708, X709, X710, X711, X712, X713, X714, X715, X716 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or X700, X701 and / or X709, X710 are also taken together in each case together to form "heterocyclyl, heteroarylalkyl, Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX717, NX718X719, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X720, C (O) OX721, C (O) NHX722, C (O) NX723X724, OX725, O (X726-O) c H (c = 1, 2, 3, 4, 5), O (X727-O) c X728 (c = 1, 2, 3, 4, 5), OC (O) X729, OC (O) OX730, OC (O) NHX731 , OC (O) NX732X733, OP (O) (OX734) (OX735), OSi (X736) (X737) (X738), OS (O 2) X739, NHC (O) X740, NX741C (O) X742, NHC ( O) OX743, NHC (O) NHX744, NHC (O) NX745X746, NX747C (O) OX748, NX749C (O) NHX750, NX751C (O) NX752X753, NHS (O 2) X754, NX755S (O 2) X756, SX757, S (O) X758, S ( O 2) X759, S (O 2) NHX760, S (O 2) NX761X762, S (O 2) OX763, P (O) (OX764) (OX765), Si (X766) ( X767) (X768) "

Wherein X717, X718, X719, X720, X721, X722, X723, X724, X725, X726, X727, X728, X729, X730, X731, X732, X733, X734, X735, X736, X737, X738, X739, X740, X741, X742, X743, X744, X745, X746, X747, X748, X749, X750, X751, X752, X753, X754, X755, X756, X757, X758, X759, X760, X761, X762, X763, X766, X767, X768 are each independently selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclic keulril alkyl, aryl, arylalkyl, X723, X724, and / or X732, X733 and / or X745, X746 and / or X752, X753 and / or X761, X762 are also each individually referred to as "heterocyclyl, heteroarylalkyl, Quot; reel "

(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH ₃ , NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHX 769, NX 770 X 771, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) X772, C (O) OX773, C (O) NHX774, C (O) NX775X776, OX777, O (X778-O) d H (d = 1, 2, 3, 4, 5), O (X779-O) d X780 (d = 1, 2, 3, 4, 5), OC (O) X781, OC (O) OX782, OC (O) NHX783 , OC (O) NX784X785, OP (O) (OX786) (OX787), OSi (X788) (X789) (X790), OS (O 2) X791, NHC (O) X792, NX793C (O) X794, NHC ( O) OX795, NHC (O) NHX796, NHC (O) NX797X798, NX799C (O) OX800, NX801C (O) NHX802, NX803C (O) NX804X805, NHS (O 2) X806, NX807S (O 2) X808, SX809, S (O) X810, S ( O 2) X811, S (O 2) NHX812, S (O 2) NX813X814, S (O 2) OX815, P (O) (OX816) (OX817), Si (X818) ( X819) (X820) "

Wherein X769, X770, X771, X772, X773, X774, X775, X776, X777, X778, X779, X780, X781, X782, X783, X784, X785, X786, X787, X788, X789, X790, X793, X794, X795, X796, X797, X798, X799, X800, X801, X802, X803, X804, X805, X806, X807, X808, X809, X810, X811, X812, X813, X814, X815, X818, X819, X820 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, X775, X776 and / or X784, X785 and / or X797, X798 and / or X804, X805 and / or X813, Quot; reel ";

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX821, NX822X823, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X824, C (O) OX825, C (O) NHX826, C (O) NX827X828, OX829, O (X830-O) e H (e = 1, 2, 3, 4, 5), O (X831-O) e X832 (e = 1, 2, 3, 4, 5), OC (O) X833, OC (O) OX834, OC (O) NHX835 , OC (O) NX836X837, OP (O) (OX838) (OX839), OSi (X840) (X841) (X842), OS (O 2) X843, NHC (O) X844, NX845C (O) X846, NHC ( O) OX847, NHC (O) NHX848, NHC (O) NX849X850, NX851C (O) OX852, NX853C (O) NHX854, NX855C (O) NX856X857, NHS (O 2) X858, NX859S (O 2) X860, SX861, S (O) X862, S ( O 2) X863, S (O 2) NHX864, S (O 2) NX865X866, S (O 2) OX867, P (O) (OX868) (OX869), Si (X870) ( X871) (X872) "

Here, X821, X822, X823, X824, X825, X826, X827, X828, X829, X830, X831, X832, X833, X834, X835, X836, X837, X838, X839, X840, X841, X842, X845, X846, X847, X848, X849, X850, X851, X852, X853, X854, X855, X856, X857, X858, X859, X860, X861, X862, X863, X864, X865, X866, X867, X870, X871, X872 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, X827, X828 and / or X836, X837 and / or X849, X850 and / or X856, X857 and / or X865, Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX873, NX874X875, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X876, C (O) OX877, C (O) NHX878, C (O) NX879X880, OX881, O (X882-O) f H (f = 1, 2, 3, 4, 5), O (X883-O) f X884 (f = 1, 2, 3, 4, 5), OC (O) X885, OC (O) OX886, OC (O) NHX887 , OC (O) NX888X889, OP (O) (OX890) (OX891), OSi (X892) (X893) (X894), OS (O 2) X895, NHC (O) X896, NX897C (O) X898, NHC ( O) OX899, NHC (O) NHX900, NHC (O) NX901X902, NX903C (O) OX904, NX905C (O) NHX906, NX907C (O) NX908X909, NHS (O 2) X910, NX911S (O 2) X912, SX913, S (O) X914, S ( O 2) X915, S (O 2) NHX916, S (O 2) NX917X918, S (O 2) OX919, P (O) (OX920) (OX921), Si (X922) ( X923) (X924) "

Here, X873, X874, X875, X876, X877, X878, X879, X880, X881, X882, X883, X884, X885, X886, X887, X888, X889, X890, X891, X892, X893, X894, X897, X898, X899, X900, X901, X902, X903, X904, X905, X906, X907, X908, X909, X910, X911, X912, X913, X914, X915, X916, X917, X918, X919, X920, X921, X922, X923, X924 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or X908, X909 and / or X917, X918 are also taken together in each case together to form a "heterocycle, Quot; reel "

(k) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHX 925, NX 926 X 927, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) X928, C (O) OX929, C (O) NHX930, C (O) NX931X932, OX933, O (X934-O) g H (g = 1, 2, 3, 4, 5), O (X935-O) g X936 (g = 1, 2, 3, 4, 5), OC (O) X937, OC (O) OX938, OC (O) NHX939 , OC (O) NX940X941, OP (O) (OX942) (OX943), OSi (X944) (X945) (X946), OS (O 2) X947, NHC (O) X948, NX949C (O) X950, NHC ( O) OX951, NHC (O) NHX952, NHC (O) NX953X954, NX955C (O) OX956, NX957C (O) NHX958, NX959C (O) NX960X961, NHS (O 2) X962, NX963S (O 2) X964, SX965, S (O) X966, S ( O 2) X967, S (O 2) NHX968, S (O 2) NX969X970, S (O 2) OX971, P (O) (OX972) (OX973), Si (X974) ( X975) (X976) "

Wherein X925, X926, X927, X928, X929, X930, X931, X932, X933, X934, X935, X936, X937, X938, X939, X940, X941, X942, X943, X944, X945, X946, X949, X950, X951, X952, X953, X954, X955, X956, X957, X958, X959, X960, X961, X962, X963, X964, X965, X966, X967, X968, X969, X970, X971, X974, X975, X976 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, X931, X941 and / or X940, X941 and / or X953, X954 and / or X960, X961 and / or X969, X970 are also each individually referred to as "heterocycle Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHX 977, NX 978 X 979, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 h, P (O)} (OH) 2, C (O) X980, C (O) OX981, C (O) NHX982, C (O) NX983X984, OX985, O (X986-O) h h (h = 1, 2, 3, 4, 5), O (X987- O) h X988 (h = 1, 2, 3, 4, 5), OC (O) X989, OC (O) OX990, OC (O) NHX991 , OC (O) NX992X993, OP (O) (OX994) (OX995), OSi (X996) (X997) (X998), OS (O 2) X999, NHC (O) X1000, NX1001C (O) X1002, NHC ( O) OX1003, NHC (O) NHX1004, NHC (O) NX1005X1006, NX1007C (O) OX1008, NX1009C (O) NHX1010, NX1011C (O) NX1012X1013, NHS (O 2) X1014, NX1015S (O 2) X1016, SX1017, S (O) X1018, S ( O 2) X1019, S (O 2) NHX1020, S (O 2) NX1021X1022, S (O 2) OX1023, P (O) (OX1024) (OX1025), Si (X1026) ( X1027) (X1028) "

X998, X999, X990, X998, X999, X990, X998, X999, X1001, X1002, X1003, X1004, X1005, X1006, X1007, X1008, X1009, X1010, X1011, X1012, X1013, X1014, X1015, X1016, X1017, X1018, X1019, X1020, X1021, X1022, X1023, X1026, X1027, X1028 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or X1021, X1022 and / or X1021, X1022 are also each individually "heterocycle Quot; reel "

(l) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX1029, NX1030X1031, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X1032, C (O) OX1033, C (O) NHX1034, C (O) NX1035X1036, OX1037, O (X1038-O) i H (i = 1, 2, 3, 4, 5), O (X1039-O) i X1040 (i = 1, 2, 3, 4, 5), OC (O) X1041, OC (O) OX1042, OC (O) NHX1043 , OC (O) NX1044X1045, OP (O) (OX1046) (OX1047), OSi (X1048) (X1049) (X1050), OS (O 2) X1051, NHC (O) X1052, NX1053C (O) X1054, NHC ( O) OX1055, NHC (O) NHX1056, NHC (O) NX1057X1058, NX1059C (O) OX1060, NX1061C (O) NHX1062, NX1063C (O) NX1064X1065, NHS (O 2) X1066, NX1067S (O 2) X1068, SX1069, S (O) X1070, S ( O 2) X1071, S (O 2) NHX1072, S (O 2) NX1073X1074, S (O 2) OX1075, P (O) (OX1076) (OX1077), Si (X1078) ( X1079) (X1080) "

Herein, X1029, X1030, X1031, X1032, X1033, X1034, X1035, X1036, X1037, X1038, X1039, X1040, X1041, X1042, X1043, X1044, X1045, X1046, X1047, X1048, X1049, X1050, X1051, X1052, X1053, X1054, X1055, X1056, X1057, X1058, X1059, X1060, X1061, X1062, X1063, X1064, X1065, X1066, X1067, X1068, X1069, X1070, X1071, X1072, X1073, X1074, X1075, X1078, X1079, X1080 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, X1035, X1036 and / or X1044, X1045 and / or X1057, Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX1081, NX1082X1083, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X1084, C (O) OX1085, C (O) NHX1086, C (O) NX1087X1088, OX1089, O (X1090-O) j H (j = 1, 2, 3, 4, 5), O (X1091-O) j X1092 (j = 1, 2, 3, 4, 5), OC (O) X1093, OC (O) OX1094, OC (O) NHX1095 , OC (O) NX1096X1097, OP (O) (OX1098) (OX1099), OSi (X1100) (X1101) (X1102), OS (O 2) X1103, NHC (O) X1104, NX1105C (O) X1106, NHC ( O) OX1107, NHC (O) NHX1108, NHC (O) NX1109X1110, NX1111C (O) OX1112, NX1113C (O) NHX1114, NX1115C (O) NX1116X1117, NHS (O 2) X1118, NX1119S (O 2) X1120, SX1121, S (O) X1122, S ( O 2) X1123, S (O 2) NHX1124, S (O 2) NX1125X1126, S (O 2) OX1127, P (O) (OX1128) (OX1129), Si (X1130) ( X1131) (X1132) "

Herein, X1081, X1082, X1083, X1084, X1085, X1086, X1087, X1088, X1089, X1090, X1091, X1092, X1093, X1094, X1095, X1096, X1097, X1098, X1099, X1100, X1101, X1102, X1103, X1105, X1106, X1107, X1108, X1109, X1110, X1111, X1112, X1113, X1114, X1115, X1116, X1117, X1118, X1119, X1120, X1121, X1122, X1123, X1124, X1125, X1126, X1127, X1128, X1129, X1130, X1131, X1132 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, X1087, X1088 and / or X1096, X1097 and / or X1109, X1110 and / or X1116, X1117 and / or X1125, X1126 are also taken together in each case "Quot; reel "

(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heteroaryl cycles reel, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) X1133, C (O) OX1134, C (O) NX1135X1136, S (O 2) X1137, S (O 2) OX1138 "

Here, X1133, X1134, X1135, X1136, X1137, X1138 is selected from the group consisting of the following, each independently: hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heteroaryl, Cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, X1135, X1136 may together form a" heterocyclyl "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX1139, NX1140X1141, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X1142, C (O) OX1143, C (O) NHX1144, C (O) NX1145X1146, OX1147, O (X1148-O) k H (k = 1, 2, 3, 4, 5), O (X1149-O) k X1150 (k = 1, 2, 3, 4, 5), OC (O) X1151, OC (O) OX1152, OC (O) NHX1153 , OC (O) NX1154X1155, OP (O) (OX1156) (OX1157), OSi (X1158) (X1159) (X1160), OS (O 2) X1161, NHC (O) X1162, NX1163C (O) X1164, NHC ( O) OX1165, NHC (O) NHX1166, NHC (O) NX1167X1168, NX1169C (O) OX1170, NX1171C (O) NHX1172, NX1173C (O) NX1174X1175, NHS (O 2) X1176, NX1177S (O 2) X1178, SX1179, S (O) X1180, S ( O 2) X1181, S (O 2) NHX1182, S (O 2) NX1183X1184, S (O 2) OX1185, P (O) (OX1186) (OX1187), Si (X1188) ( X1189) (X1190) "

Here, X1139, X1140, X1141, X1142, X1143, X1144, X1145, X1146, X1147, X1148, X1149, X1150, X1151, X1152, X1153, X1154, X1155, X1156, X1157, X1158, X1159, X1160, X1161, X1162, X1163, X1164, X1165, X1166, X1167, X1168, X1169, X1170, X1171, X1172, X1173, X1174, X1175, X1176, X1177, X1178, X1179, X1180, X1181, X1182, X1183, X1184, X1185, X1188, X1189, X1190 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or X1174, X1175 and / or X1183, X1184 are also taken together in each case together to form a "heterocyclyl, heteroarylalkyl, Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHX1191, NX1192X1193, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) X1194, C (O) OX1195, C (O) NHX1196, C (O) NX1197X1198, OX1199, O (X1200-O) l H (l = 1, 2, 3, 4, 5), O (X1201-O) _l X1202 , OC (O) NX1206X1207, OP (O) (OX1208) (OX1209), OSi (X1210) (X1211) (X1212), OS (O 2) X1213, NHC (O) X1214, NX1215C (O) X1216, NHC ( O) OX1217, NHC (O) NHX1218, NHC (O) NX1219X1220, NX1221C (O) OX1222, NX1223C (O) NHX1224, NX1225C (O) NX1226X1227, NHS (O 2) X1228, NX1229S (O 2) X1230, SX1231, S (O) X1232, S ( O 2) X1233, S (O 2) NHX1234, S (O 2) NX1235X1236, S (O 2) OX1237, P (O) (OX1238) (OX1239), Si (X1240) ( X1241) (X1242) "

Here, X1191, X1192, X1193, X1194, X1195, X1196, X1197, X1198, X1199, X1200, X1201, X1202, X1203, X1204, X1205, X1206, X1207, X1208, X1209, X1210, X1211, X1212, X1213, X1214, X1215, X1216, X1217, X1218, X1219, X1220, X1221, X1222, X1223, X1224, X1225, X1226, X1227, X1228, X1229, X1230, X1231, X1232, X1233, X1234, X1235, X1236, X1237, X1240, X1241, X1242 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, X1197, X1198 and / or X1206, X1207 and / or X1219, X1220 and / or X1226, X1227 and / or X1235, X1236 are also taken together in each case together to form a heterocycle Quot; reel "

or

(B) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently "substituted heteroaryl" wherein "substituted heteroaryl" is substituted by one or more substituents selected from the group consisting of:

(a) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, NHV1, N (alkyl) _2, NHC (O) alkyl, NHC (O) cycloalkyl, NHC (O) heterocyclyl, NHC (O ) aryl, NHC (O) heteroaryl, NHC (O) aryl, NHC (O) heteroaryl, alkyl, NHS (O ₂₎ alkyl, NHS (O ₂₎ cycloalkyl, NHS (O ₂₎ heterocyclyl, NHS (O ₂₎ aryl, NHS (O ₂₎ heteroaryl, NHS (O ₂₎ aryl, NHS (O ₂₎ heteroaryl-alkyl, S-alkyl, S aryl, S-heteroaryl, O-alkyl, O-cycloalkyl, O-cyclopenten (O) heterocyclyl, OC (O) heterocyclyl, OC (O) alkyl, Oaryl, Oarylalkyl, Oheteroaryl, O-heteroarylalkyl, Oheterocyclylalkyl, OC ) aryl, OC (O) heteroaryl, OC (O) aryl, OC (O) heteroaryl-alkyl, OS (O ₂₎ alkyl, OS (O ₂₎ cycloalkyl, OS (O ₂₎ heterocyclyl, OS (O ₂₎ aryl, OS (O ₂₎ heteroaryl, OS (O ₂₎ aryl, OS (O ₂₎ heteroaryl, alkyl, C (O) alkyl, C (O) aryl, C (O) heteroaryl, C (O) OV2, C (O) NHV 3, C (O) N _{(alkyl) 2, C (O) N} ( _{cycloalkyl) 2, C (O) N} ( _{aryl) 2, C (O) N} ( _{heteroaryl) 2, S (O 2)} NH alkyl, S (O2) NH aryl, S (O2) NH-heteroaryl, S (O ₂₎ NH-arylalkyl, S (O ₂₎ O-alkyl, S (O ₂₎ O aryl, S (O ₂₎ O-arylalkyl "

Wherein V 1, V 2, V 3 are each independently selected from the group consisting of: “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl”

Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "(C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N ₃ , NH cycloalkyl, S heteroaryl, S heteroaryl, S heteroaryl, NH heteroarylalkyl, NHheterocyclyl, NHheterocyclylalkyl, NV4V5, S cycloalkyl, S cycloalkylalkyl, Saryl, Sarylalkyl, Sheteroaryl, S Heteroarylalkyl, S heterocyclyl, S heterocyclylalkyl, O cycloalkyl, O cycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, O _{V6-O) p H (p} = 1, 2, 3, 4, 5), O (V7-O) p V8 (p = 1, 2, 3, 4, 5), OP (O) (OV9) ( OV10), C (O) OV11 , C (O) NH2, C (O) NHV12, C (O) NV13V14, S (O 2) V15, P (O) (OH) 2, P (O) (OV16) (O) OV28, OC (O) NV26V27, NHC (O) OV28, OC (O) NHC (O) NHV29, NHC (O) NV30V31, NV32C (O) OV33, NV34C (O) NHV35, NV36C (O) NV37V38, NV39S (O 2) V40, NHS (O 2) V41, OS (O 2) V42, NHC (O) V43, NV44C (O) V45, C (O) V46, OC (O ) V47, S (O) V48 , S (O 2) NHV49, S (O 2) NV50V51, S (O 2) OV52 "

Further provided that "N (alkyl) ₂ " is further substituted by one or more substituents selected from the following substituent group (b);

Herein, V4, V5, V6, V7, V8, V9, V10, V11, V12, V13, V14, V15, V16, V17, V18, V19, V20, V21, V22, V23, V24, V25, V28, V29, V30, V31, V32, V33, V34, V35, V36, V37, V38, V39, V40, V41, V42, V43, V44, V45, V46, V47, V48, V49, each independently are selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl Alternatively, V13, V14 and / or V26, V27 and / or V30, V31 and / or V37, V38 and / or V50 and V51 may also form a "heterocyclyl"

Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(b) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, _{, CN, CF 3, N 3} , NH 2, NHV53, NV54V55, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V56, C (O) OV57, C (O) NHV58, C (O) NV59V60, OV61, O (V62-O) r H (r = 1, 2, 3, 4, 5), O (V63-O) r V64 (r = 1, 2, 3, 4, 5), OC (O) V65, OC (O) OV66, OC (O) NHV67 , OC (O) NV68V69, OP (O) (OV70) (OV71), OSi (V72) (V73) (V74), OS (O 2) V75, NHC (O) V76, NV77C (O) V78, NHC ( O) OV79, NHC (O) NHV80, NHC (O) NV81V82, NV83C (O) OV84, NV85C (O) NHV86, NV87C (O) NV88V89, NHS (O 2) V90, NV91S (O 2) V92, SV93, S (O) V94, S ( O 2) V95, S (O 2) NHV96, S (O 2) NV97V98, S (O 2) OV99, P (O) (OV100) (OV101), Si (V102) ( V103) (V104) "

Herein, V53, V54, V55, V56, V57, V58, V59, V60, V61, V62, V63, V64, V65, V66, V67, V68, V69, V70, V71, V72, V73, V77, V78, V79, V80, V81, V82, V83, V84, V85, V86, V87, V88, V89, V90, V91, V92, V93, V94, V95, V96, V97, V102, V103, V104 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V69 and / or V68, V69 and / or V81, V82 and / or V88, V89 and / or V97 and V98 are also referred to as "heterocyclyl"Lt; / RTI >

Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV105, NV106V107, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V108, C (O) OV109, C (O) NHV110, C (O) NV111V112, OV113, O (V114-O) s H (s = 1, 2, 3, 4, 5), O (V115-O) s V116 (s = 1, 2, 3, 4, 5), OC (O) V117, OC (O) OV118, OC (O) NHV119 , OC (O) NV120V121, OP (O) (OV122) (OV123), OSi (V124) (V125) (V126), OS (O 2) V127, NHC (O) V128, NV129C (O) V130, NHC ( O) OV131, NHC (O) NHV132, NHC (O) NV133V134, NV135C (O) OV136, NV137C (O) NHV138, NV139C (O) NV140V141, NHS (O 2) V142, NV143S (O 2) V144, SV145, S (O) V146, S ( O 2) V147, S (O 2) NHV148, S (O 2) NV149V150, S (O 2) OV151, P (O) (OV152) (OV153), Si (V154) ( V155) (V156) "

Here, V105, V106, V107, V108, V109, V110, V111, V112, V113, V114, V115, V116, V117, V118, V119, V120, V121, V122, V123, V124, V125, V126, V129, V130, V131, V132, V133, V134, V135, V136, V137, V138, V139, V140, V141, V142, V143, V144, V145, V146, V147, V148, V149, V150, V151, V152, V153, V154, V155, V156 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V111, V112 and / or V120, V121 and / or V133, V134 and / or V140, V141 and / or V149, V150 are also referred to as "heterocyclyl"Lt; / RTI >

Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHV 157, NV158V159, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) V160, C (O) OV161, C (O) NHV162, C (O) NV163V164, OV165, O (V166-O) t H (t = 1, 2, 3, 4, 5), O (V167-O) t V168 (t = 1, 2, 3, 4, 5), OC (O) V169, OC (O) OV170, OC (O) NHV171 , OC (O) NV172V173, OP (O) (OV174) (OV175), OSi (V176) (V177) (V178), OS (O2) V179, NHC (O) V180, NV181C ) OV183, NHC (O) NHV184 , NHC (O) NV185V186, NV187C (O) OV188, NV189C (O) NHV190, NV191C (O) NV192V193, NHS (O 2) V194, NV195S (O 2) V196, SV197, S (O) V198, S (O 2) V199, S (O 2) NHV200, S (O 2) NV201V202, S (O 2) OV203, P (O) (OV204) (OV205), Si (V206) (V207 ) (V208) "

Here, V157, V158, V159, V160, V161, V162, V163, V164, V165, V166, V167, V168, V169, V170, V171, V172, V173, V174, V172, V176, V177, V178, V181, V182, V183, V184, V185, V186, V187, V188, V189, V190, V191, V192, V193, V194, V195, V196, V197, V198, V199, V200, V201, V202, V203, V206, V207, V208 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V163, and / or V185, V186 and / or V192, V193 and / or V201, V202 may also be taken together to form a "heterocyclyl"Lt; / RTI >

Or both Z3 and Z4 radicals, or both Z3 and Z4 radicals are independently "substituted heteroaryl ",wherein" substituted heteroaryl "is substituted by one or more substituents which may be the same or different selected from the group consisting of Being:

_{(c) "(C 9 -C} 30) _{alkyl, NV209V210, NH (C 9 -C} 30) alkyl, NHC (O) cycloalkyl-alkyl, NHC (O) heterocyclyl-alkyl, NHC (O) (C ₉ - C ₃₀₎ alkyl, NV211C (O) V212, NV213C (O) (C 9 -C 30) alkyl, NHC (O) OV214, NV215C (O) OV216, NHC (O) NHV217, NHC (O) NV218V219, NV220C ( O) NHV221, NV222C (O) NV223V224, NHS (O 2) cycloalkylalkyl, NHS (O ₂₎ heterocyclylalkyl, NV225S (O2) V226, O-heterocyclyl, O (C ₉ -C ₃₀₎ alkyl, S-cycloalkyl, S-heterocyclyl, S-alkyl aryl, S-alkyl-heteroaryl, S-alkyl-cycloalkyl, S-heterocyclyl-alkyl, S (C ₉ -C ₃₀₎ alkyl, OC (O) cycloalkyl-alkyl, OC (O ) _{heterocyclyl-alkyl, OC (O) (C 9} -C 30) alkyl, OC (O) OV227, OC (O) NHV228, OC (O) NV229V230, OP (O) (OV231) (OV232), OS ( O ₂₎ cycloalkylalkyl, OS (O2) _{heterocyclyl-alkyl, OS (O 2) (C} 9 -C 30) alkyl, C (O) cycloalkyl, C (O) heterocyclyl, C (O) aryl Alkyl, C (O) heteroarylalkyl, C (O) cycloalkylalkyl, C (O) heterocyclylalkyl, C ) (C ₉ -C ₃₀₎ alkyl, C (O) O (C 9 -C 30) alkyl, C (O) NH (C 9 -C 30) alkyl, C (O) NV233V234, C (O) NHOV235, C (O) NV236-OV237, C (O) NHNV238V239, C (O) NV240NV241V242, S (O) V243, S (O 2) V244, S (O 2) NH -cycloalkyl, S (O ₂₎ NH heterocycle S (O ₂ ) NH heteroarylalkyl, S (O ₂ ) NH cycloalkylalkyl, S (O ₂ ) NHheterocyclylalkyl, S (O ₂ ) NH (C ₉ -C ₃₀ ) O ₂₎ O-cycloalkyl, S (O ₂₎ O-heterocyclyl, S (O ₂₎ O-heteroaryl, S (O ₂₎ O-heteroaryl-alkyl, S (O ₂₎ O-cycloalkyl-alkyl, S (O ₂ ) O heterocyclylalkyl, S (O ₂ ) O (C ₉ -C ₃₀ ) alkyl, P (O) (OH) 2, P (O) OV245 (OV246), Si (V247) V249), OSi (V250) (V251) (V252) "

Here, V209, V210, V211, V212, V213, V214, V215, V216, V217, V218, V219, V220, V221, V222, V223, V224, V225, V226, V227, V228, V229, V230, V233, V234, V235, V236, V237, V238, V239, V240, V241, V242, V243, V244, V245, V246, V247, V248, V249, V250, V251, V252 are each independently selected from the group consisting of : "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl", wherein, alternatively, V218, V219 and / or V223, V224 and / or V229, V230 and / or V233, V234 and / or V238, V239 and / or V241, V242 may also form a "heterocyclyl"

However, the substituent "N _{(alkyl) 2", "C (O} ) N ( _{alkyl) 2", "C (O} ) N ( _{cycloalkyl) 2", "C (O} ) N ( aryl) _2", "C (O) N (heteroaryl) ₂ "is further substituted by one or more substituents selected from the following substituent group (i);

Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV253, NV254V255, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V256, C (O) OV257, C (O) NHV258, C (O) NV259V260, OV261, O (V262-O) u H (u = 1, 2, 3, 4, 5), O (V263-O) u V264 (u = 1, 2, 3, 4, 5), OC (O) V265, OC (O) OV266, OC (O) NHV267 , OC (O) NV268V269, OP (O) (OV270) (OV271), OSi (V272) (V273) (V274), OS (O 2) V275, NHC (O) V276, NV277C (O) V278, NHC ( (O) OV279, NHC (O) NHV280, NHC (O) NV281V282, NV283C (O) OV284, NV285C (O) NHV286, NV287C (O) NV288V289, NHS (O2) V290, NV291S _{O) V294, S (O 2} ) V295, S (O 2) NHV296, S (O 2) NV297V298, S (O 2) OV299, P (O) (OV300) (OV301), Si (V302) (V303) (V304) "

Here, V253, V254, V255, V256, V257, V258, V259, V260, V261, V262, V263, V264, V265, V266, V267, V268, V269, V270, V271, V272, V273, V277, V278, V279, V280, V281, V282, V283, V284, V285, V286, V287, V288, V289, V290, V291, V292, V293, V294, V295, V296, V297, V298, V302, V303, V304 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroarylalkyl ", wherein, alternatively, V259, V260 and / or V268, V269 and / or V281, V282 and / or V288, V289 and / or V297, V298 are also referred to as "heterocyclyl"Lt; / RTI >

Here, optionally, additionally one of the Z3, Z4 radicals or additionally both Z3, Z4 radicals may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(d) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV305, NV306V307, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V308, C (O) OV309, C (O) NHV310, C (O) NV311V312, OV313, O (V314-O) v H (v = 1, 2, 3, 4, 5), O (V315-O) v V316 (v = 1, 2, 3, 4, 5), OC (O) V317, OC (O) OV318, OC (O) NHV319 , OC (O) NV320V321, OP (O) (OV322) (OV323), OSi (V324) (V325) (V326), OS (O 2) V327, NHC (O) V328, NV329C (O) V330, NHC ( (O) NH332, NHC (O) NV333V334, NV335C (O) OV336, NV337C (O) NHV338, NV339C (O) NV340V341, NHS (O2) V342, NV343S (O2) V344, SV345, S _{O) V346, S (O 2} ) V347, S (O 2) NHV348, S (O 2) NV349V350, S (O 2) OV351, P (O) (OV352) (OV353), Si (V354) (V355) (V356) "

Here, V305, V306, V307, V308, V309, V310, V311, V312, V313, V314, V315, V316, V317, V318, V319, V320, V321, V322, V323, V324, V325, V326, V329, V330, V331, V332, V333, V334, V335, V336, V337, V338, V339, V340, V341, V342, V343, V344, V345, V346, V347, V348, V349, V350, V351, V352, V353, V354, V355, V356 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V311, V312 and / or V320, V321 and / or V333, V334 and / or V340, V341 and / or V349, V350 are also referred to as "heterocyclyl"Lt; / RTI >

Wherein, optionally, the aforementioned substituents of substituent group (d) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHV 357, NV 358V 359, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) V360, C (O) OV361, C (O) NHV362, C (O) NV363V364, OV365, O (V366-O) w H (w = 1, 2, 3, 4, 5), O (V367-O) w V368 (w = 1, 2, 3, 4, 5), OC (O) V369, OC (O) OV370, OC (O) NHV371 , OC (O) NV372V373, OP (O) (OV374) (OV375), OSi (V376) (V377) (V378), OS (O 2) V379, NHC (O) V380, NV381C (O) V382, NHC ( (O) OV383, NHC (O) NHV384, NHC (O) NV385V386, NV387C (O) OV388, NV389C (O) NHV390, NV391C (O) NV392V393, NHS (O2) V394, NV395S _{O) V398, S (O 2} ) V399, S (O 2) NHV400, S (O 2) NV401V402, S (O 2) OV403, P (O) (OV404) (OV405), Si (V406) (V407) (V408) "

Here, V357, V358, V359, V360, V361, V362, V363, V364, V365, V366, V367, V368, V369, V370, V371, V372, V373, V374, V375, V376, V377, V378, V381, V382, V383, V384, V385, V386, V387, V388, V389, V390, V391, V392, V393, V394, V395, V396, V397, V398, V399, V400, V401, V402, V403, V406, V407, V408 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V363, V373 and / or V372, V373 and / or V385, V386 and / or V392, V393 and / or V401, V402 are also referred to as "heterocyclyl"Lt; / RTI >

Here, optionally, the aforementioned substituents of substituent group (i) and / or substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHV 409, NV410V411, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) V412, C (O) OV413, C (O) NHV414, C (O) NV415V416, OV417, O (V418-O) x H (x = 1, 2, 3, 4, 5), O (V419-O) x V420 (x = 1, 2, 3, 4, 5), OC (O) V421, OC (O) OV422, OC (O) NHV423 , OC (O) NV424V425, OP (O) (OV426) (OV427), OSi (V428) (V429) (V430), OS (O 2) V431, NHC (O) V432, NV433C (O) V434, NHC ( O) OV435, NHC (O) NHV436, NHC (O) NV437V438, NV439C (O) OV440, NV441C (O) NHV442, NV443C (O) NV444V445, NHS (O 2) V446, NV447S (O2) V448, SV449, S (O) V450, S (O 2) V451, S (O 2) NHV452, S (O 2) NV453V454, S (O 2) OV455, P (O) (OV456a) (OV456b), Si (V456c) (V456d ) (V456e) "

Herein, V409, V410, V411, V412, V413, V414, V415, V416, V417, V418, V419, V420, V421, V422, V423, V424, V425, V426, V427, V428, V429, V430, V433, V434, V435, V436, V437, V438, V439, V440, V441, V442, V443, V444, V445, V446, V447, V448, V449, V450, V451, V452, V453, V454, V455, V456a, V456c, V456d, V456e is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or V444, V445 and / or V453, V454 are also taken together to form a "heterocyclyl"Lt; / RTI >

And one of the Z3, Z4 radicals is independently selected from the group consisting of, or neither of the Z3, Z4 radicals is independently selected from the group consisting of:

(e) hydrogen;

(f) halogen, F, Cl, Br, I;

(g) unsubstituted and substituted alkyl, or (C ₉ -C ₃₀₎ alkyl, wherein, optionally, alkyl, or (C ₉ -C ₃₀₎ alkyl radical by one or more substituents the same or different selected from the group consisting of the following: Lt; / RTI >

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV457, NV458V459, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V460, C (O) OV461, C (O) NHV462, C (O) NV463V464, OV465, O (V466-O) y H (y = 1, 2, 3, 4, 5), O (V467-O) y V468 (y = 1, 2, 3, 4, 5), OC (O) V469, OC (O) OV470, OC (O) NHV471 , OC (O) NV472V473, OP (O) (OV474) (OV475), OSi (V476) (V477) (V478), OS (O 2) V479, NHC (O) V480, NV481C (O) V482, NHC ( (O2) V496, SV497, S (O) OV483, NHC (O) NHV484, NHC (O) NV485V486, NV487C (O) OV488, NV489C (O) NHV490, NV491C (O) NV492V493, NHS _{O) V498, S (O 2} ) V499, S (O 2) NHV500, S (O 2) NV501V502, S (O 2) OV503, P (O) (OV504) (OV505), Si (V506) (V507) (V508) "

Here, V457, V458, V459, V460, V461, V462, V463, V464, V465, V466, V467, V468, V469, V470, V471, V472, V473, V474, V475, V476, V477, V478, V501, V502, V503, V504, V505, V508, V482, V483, V484, V485, V486, V487, V488, V489, V490, V491, V492, V493, V494, V495, V496, V497, V498, V499, V506, V507, V508 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or V492, V493 and / or V501, V502 may also be combined in each case together to form a "heterocycle Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV509, NV510V511, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V512, C (O) OV513, C (O) NHV514, C (O) NV515V516, OV517, O (V518-O) z H (z = 1, 2, 3, 4, 5), O (V519-O) z V520 (z = 1, 2, 3, 4, 5), OC (O) V521, OC (O) OV522, OC (O) NHV523 , OC (O) NV524V525, OP (O) (OV526) (OV527), OSi (V528) (V529) (V530), OS (O 2) V531, NHC (O) V532, NV533C (O) V534, NHC ( O) OV535, NHC (O) NHV536, NHC (O) NV537V538, NV539C (O) OV540, NV541C (O) NHV542, NV543C (O) NV544V545, NHS (O 2) V546, NV547S (O 2) V548, SV549, S (O) V550, S ( O 2) V551, S (O 2) NHV552, S (O 2) NV553V554, S (O 2) OV555, P (O) (OV556) (OV557), Si (V558) ( V559) (V560) "

Herein, V509, V510, V511, V512, V513, V514, V515, V516, V517, V518, V519, V520, V521, V522, V523, V524, V525, V526, V527, V528, V553, V554, V557, V554, V554, V553, V554, V553, V553, V554, V554, V553, V554, V554, V553, V554, V554, V558, V559, V560 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or V544, V545 and / or V553, V554 may also be referred to as "heteroaryl, heteroarylalkyl, Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV561, NV562V563, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V564, C (O) OV565, C (O) NHV566, C (O) NV567V568, OV569, O (V570-O) a H (a = 1, 2, 3, 4, 5), O (V571-O) a V572 (a = 1, 2, 3, 4, 5), OC (O) V573, OC (O) OV574, OC (O) NHV575 , OC (O) NV576V577, OP (O) (OV578) (OV579), OSi (V580) (V581) (V582), OS (O 2) V583, NHC (O) V584, NV585C (O) V586, NHC ( O) OV587, NHC (O) NHV588, NHC (O) NV589V590, NV591C (O) OV592, NV593C (O) NHV594, NV595C (O) NV596V597,

_{NHS (O 2) V598, NV599S} (O 2) V600, SV601, S (O) V602, S (O 2) V603, S (O 2) NHV604, S (O 2) NV605V606, S (O 2) OV607, P (O) (OV608) (OV609), Si (V610) (V611) (V612)

Herein, V561, V562, V563, V564, V565, V566, V567, V568, V569, V570, V571, V572, V573, V574, V575, V576, V577, V578, V579, V580, V581, V582, V609, V608, V609, V608, V608, V608, V608, V608, V606, V608, V608, V608, V610, V611, V612 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V567, V568 and / or V576, V577 and / or V589, V590 and / or V596, V597 and / or V605, V606 are also referred to in each case together as "heterocycle Quot; reel "

(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV613, NV614V615, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V616, C (O) OV617, C (O) NHV618, C (O) NV619V620, OV621, O (V622-O) b H (b = 1, 2, 3, 4, 5), O (V623-O) b V624 (b = 1, 2, 3, 4, 5), OC (O) V625, OC (O) OV626, OC (O) NHV627 , OC (O) NV628V629, OP (O) (OV630) (OV631), OSi (V632) (V633) (V634), OS (O 2) V635, NHC (O) V636, NV637C (O) V638, NHC ( O) OV639, NHC (O) NHV640, NHC (O) NV641V642, NV643C (O) OV644, NV645C (O) NHV646, NV647C (O) NV648V649, NHS (O 2) V650, NV651S (O 2) V652, SV653, S (O) V654, S ( O 2) V655, S (O 2) NHV656, S (O 2) NV657V658, S (O 2) OV659, P (O) (OV660) (OV661), Si (V662) ( V663) (V664) "

Herein, V613, V614, V615, V616, V617, V618, V619, V620, V621, V622, V623, V624, V625, V626, V627, V628, V629, V630, V631, V632, V633, V634, V637, V639, V640, V637, V639, V640, V641, V642, V643, V644, V645, V646, V647, V648, V649, V650, V651, V652, V653, V654, V655, V656, V657, V658, V659, V662, V663, V664 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or V648, V649 and / or V657, V658 may also be referred to in each case together as "heterocyclyl, heteroarylalkyl ", or alternatively, V619, V620 and / or V628, V629 and / or V641, V642 and / Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV665, NV666V667, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V668, C (O) OV669, C (O) NHV670, C (O) NV671V672, OV673, O (V674-O) c H (c = 1, 2, 3, 4, 5), O (V675-O) c V676 (c = 1, 2, 3, 4, 5), OC (O) V677, OC (O) OV678, OC (O) NHV679 , OC (O) NV680V681, OP (O) (OV682) (OV683), OSi (V684) (V685) (V686), OS (O 2) V687, NHC (O) V688, NV689C (O) V690, NHC ( O) OV691, NHC (O) NHV692, NHC (O) NV693V694, NV695C (O) OV696, NV697C (O) NHV698, NV699C (O) NV700V701, NHS (O 2) V702, NV703S (O2) V704, SV705, S (O) V706, S (O 2) V707, S (O 2) NHV708, S (O 2) NV709V710, S (O 2) OV711, P (O) (OV712) (OV713), Si (V714) (V715 ) (V716) "

Herein, V665, V666, V667, V668, V669, V670, V671, V672, V673, V674, V675, V676, V677, V678, V679, V680, V681, V682, V683, V684, V685, V686, V690, V690, V690, V691, V692, V693, V694, V695, V696, V697, V698, V699, V700, V701, V702, V703, V704, V705, V706, V707, V708, V709, V710, V711, V714, V715, V716 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V671, and / or V700, V701, and / or V709, V710 may also be referred to in each case together as "heterocycle, heteroaryl, heteroarylalkyl ", or alternatively, V671, V672 and / or V680, V681 and / Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV717, NV718V719, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V720, C (O) OV721, C (O) NHV722, C (O) NV723V724, OV725, O (V726-O) d H (d = 1, 2, 3, 4, 5), O (V727-O) d V728 (d = 1, 2, 3, 4, 5), OC (O) V729, OC (O) OV730, OC (O) NHV731 , OC (O) NV732V733, OP (O) (OV734) (OV735), OSi (V736) (V737) (V738), OS (O 2) V739, NHC (O) V740, NV741C (O) V742, NHC ( (O) OV743, NHC (O) NHV744, NHC (O) NV745V746, NV747C (O) OV748, NV749C (O) NHV750, NV751C (O) NV752V753, NHS (O2) V754, NV755S _{O) V758, S (O 2} ) V759, S (O 2) NHV760, S (O 2) NV761V762, S (O 2) OV763, P (O) (OV764) (OV765), Si (V766) (V767) (V768) "

Here, V717, V718, V719, V720, V721, V722, V723, V724, V725, V726, V727, V728, V729, V730, V731, V732, V733, V734, V735, V736, V737, V738, V741, V742, V743, V744, V745, V746, V747, V748, V749, V750, V751, V752, V753, V754, V755, V756, V757, V758, V759, V760, V761, V762, V763, V766, V767, V768 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V723, and / or V745, V746, and / or V752, V753, and / or V761, V762 may also be referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV769, NV770V771, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V772, C (O) OV773, C (O) NHV774, C (O) NV775V776, OV777, O (V778-O) e H (e = 1, 2, 3, 4, 5), O (V779-O) e V780 (e = 1, 2, 3, 4, 5), OC (O) V781, OC (O) OV782, OC (O) NHV783 , OC (O) NV784V785, OP (O) (OV786) (OV787), OSi (V788) (V789) (V790), OS (O 2) V791, NHC (O) V792, NV793C (O) V794, NHC ( O) OV795, NHC (O) NHV796, NHC (O) NV797V798, NV799C (O) OV800, NV801C (O) NHV802, NV803C (O) NV804V805, NHS (O 2) V806, NV807S (O 2) V808, SV809, S (O) V810, S ( O 2) V811, S (O 2) NHV812, S (O 2) NV813V814, S (O 2) OV815, P (O) (OV816) (OV817), Si (V818) ( V819) (V820) "

Here, V769, V770, V771, V772, V773, V774, V775, V776, V777, V778, V779, V780, V781, V782, V783, V784, V785, V786, V787, V788, V789, V790, V793, V794, V795, V796, V797, V798, V799, V800, V801, V802, V803, V804, V805, V806, V807, V808, V809, V810, V811, V812, V813, V814, V815, V818, V819, V820 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V775, V785 and / or V797, V798 and / or V804, V805 and / or V813, V814 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV821, NV822V823, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V824, C (O) OV825, C (O) NHV826, C (O) NV827V828, OV829, O (V830-O) f H (f = 1, 2, 3, 4, 5), O (V831- O) f V832 (f = 1, 2, 3, 4, 5), OC (O) V833, OC (O) OV834, OC (O) NHV835 , OC (O) NV836V837, OP (O) (OV838) (OV839), OSi (V840) (V841) (V842), OS (O 2) V843, NHC (O) V844, NV845C (O) V846, NHC ( O) OV847, NHC (O) NHV848, NHC (O) NV849V850, NV851C (O) OV852, NV853C (O) NHV854, NV855C (O) NV856V857, NHS (O 2) V858, NV859S (O 2) V860, SV861, S (O) V862, S ( O 2) V863, S (O 2) NHV864, S (O 2) NV865V866, S (O 2) OV867, P (O) (OV868) (OV869), Si (V870) ( V871) (V872) "

Here, V821, V822, V823, V824, V825, V826, V827, V828, V829, V830, V831, V832, V833, V834, V835, V836, V837, V838, V839, V840, V841, V842, V845, V846, V847, V848, V849, V850, V851, V852, V853, V854, V855, V856, V857, V858, V859, V860, V861, V862, V863, V864, V865, V866, V867, V870, V871, V872 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V827 and / or V849, V850 and / or V856, V857 and / or V865 and V866 are also referred to in each case together as "heterocycle, heteroaryl, heteroarylalkyl"Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV873, NV874V875, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V876, C (O) OV877, C (O) NHV878, C (O) NV879V880, OV881, O (V882-O) g H (g = 1, 2, 3, 4, 5), O (V883-O) g V884 (g = 1, 2, 3, 4, 5), OC (O) V885, OC (O) OV886, OC (O) NHV887 , OC (O) NV888V889, OP (O) (OV890) (OV891), OSi (V892) (V893) (V894), OS (O 2) V895, NHC (O) V896, NV897C (O) V898, NHC ( O) OV899, NHC (O) NHV900, NHC (O) NV901V902, NV903C (O) OV904, NV905C (O) NHV906, NV907C (O) NV908V909, NHS (O 2) V910, NV911S (O 2) V912, SV913, S (O) V914, S ( O 2) V915, S (O 2) NHV916, S (O 2) NV917V918, S (O 2) OV919, P (O) (OV920) (OV921), Si (V922) ( V923) (V924) "

Here, V873, V874, V875, V876, V877, V878, V879, V880, V881, V882, V883, V884, V885, V886, V887, V888, V889, V890, V891, V892, V893, V894, V997, V898, V899, V900, V901, V902, V903, V904, V905, V906, V907, V908, V909, V910, V911, V912, V913, V914, V915, V916, V917, V918, V919, V922, V923, V924 are each independently selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclic keulril alkyl, aryl, arylalkyl, V880 and / or V888, V889 and / or V901, V902 and / or V908, V909 and / or V917, V918 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

(k) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHV 925, NV 926 V 927, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 h, P (O)} (OH) 2, C (O) V928, C (O) OV929, C (O) NHV930, C (O) NV931V932, OV933, O (V934-O) h h (h = 1, 2, 3, 4, 5), O (V935-O) h V936 (h = 1, 2, 3, 4, 5), OC (O) V937, OC (O) OV938, OC (O) NHV939 , OC (O) NV940V941, OP (O) (OV942) (OV943), OSi (V944) (V945) (V946), OS (O 2) V947, NHC (O) V948, NV949C (O) V950, NHC ( O) OV951, NHC (O) NHV952, NHC (O) NV953V954, NV955C (O) OV956, NV957C (O) NHV958, NV959C (O) NV960V961, NHS (O 2) V962, NV963S (O 2) V964, SV965, S (O) V966, S ( O 2) V967, S (O 2) NHV968, S (O 2) NV969V970, S (O 2) OV971, P (O) (OV972) (OV973), Si (V974) ( V975) (V976) "

Here, V925, V926, V927, V928, V929, V930, V931, V932, V933, V934, V935, V936, V937, V938, V939, V940, V941, V942, V943, V944, V945, V946, V949, V950, V951, V952, V953, V954, V955, V956, V957, V958, V959, V960, V961, V962, V963, V964, V965, V966, V967, V968, V969, V970, V974, V975, V976 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V931, V941 and / or V940, V941 and / or V953, V954 and / or V960, V961 and / or V969, V970 may also in each case be referred to as "heterocycle Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV977, NV978V979, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V980, C (O) OV981, C (O) NHV982, C (O) NV983V984, OV985, O (V986-O) i H (i = 1, 2, 3, 4, 5), O (V987-O) i V988 (i = 1, 2, 3, 4, 5), OC (O) V989, OC (O) OV990, OC (O) NHV991 , OC (O) NV992V993, OP (O) (OV994) (OV995), OSi (V996) (V997) (V998), OS (O2) V999, NHC (O) V1000, NV1001C ) OV1003, NHC (O) NHV1004, NHC (O) NV1005V1006, NV1007C (O) OV1008, NV1009C (O) NHV1010, NV1011C (O) NV1012V1013, NHS (O2) V1014, NV1015S _{) V1018, S (O 2)} V1019, S (O 2) NHV1020, S (O 2) NV1021V1022, S (O 2) OV1023, P (O) (OV1024) (OV1025), Si (V1026) (V1027) ( V1028)

Here, V977, V978, V979, V980, V981, V982, V983, V984, V985, V986, V987, V988, V989, V990, V991, V992, V993, V994, V995, V996, V997, V1001, V1002, V1003, V1004, V1005, V1006, V1007, V1008, V1009, V1010, V1011, V1012, V1013, V1014, V1015, V1016, V1017, V1018, V1019, V1020, V1021, V1022, V1023, V1026, V1027, V1028 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V983, V984 and / or V992, V993 and / or V1005, V1006 and / or V1012, V1013 and / or V1021 and V1022 are also referred to in each case together as "heterocycle Quot; reel "

(l) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV1029, NV1030V1031, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V1032, C (O) OV1033, C (O) NHV1034, C (O) NV1035V1036, OV1037, O (V1038-O) j H (j = 1, 2, 3, 4, 5), O (V1039-O) j V1040 (j = 1, 2, 3, 4, 5), OC (O) V1041, OC (O) OV1042, OC (O) NHV1043 , OC (O) NV1044V1045, OP (O) (OV1046) (OV1047), OSi (V1048) (V1049) (V1050), OS (O 2) V1051, NHC (O) V1052, NV1053C (O) V1054, NHC ( O) OV1055, NHC (O) NHV1056, NHC (O) NV1057V1058, NV1059C (O) OV1060, NV1061C (O) NHV1062, NV1063C (O) NV1064V1065, NHS (O2) V1066, NV1067S _{O) V1070, S (O 2} ) V1071, S (O 2) NHV1072, S (O 2) NV1073V1074, S (O 2) OV1075, P (O) (OV1076) (OV1077), Si (V1078) (V1079) (V1080) "

Here, V1029, V1030, V1031, V1032, V1033, V1034, V1035, V1036, V1037, V1038, V1039, V1040, V1041, V1042, V1043, V1044, V1045, V1046, V1047, V1048, V1049, V1050, V1053, V1054, V1055, V1056, V1057, V1058, V1059, V1060, V1061, V1062, V1063, V1064, V1065, V1066, V1067, V1068, V1069, V1070, V1071, V1072, V1073, V1078, V1079, V1080 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V1035 and / or V1057, V1058 and / or V1064, V1065 and / or V1073 and V1074 are also referred to in each case together as "heterocycle, heteroaryl, heteroarylalkyl ", or alternatively, V1035, V1036 and / or V1044, V1045 and / Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV1081, NV1082V1083, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V1084, C (O) OV1085, C (O) NHV1086, C (O) NV1087V1088, OV1089, O (V1090-O) k H (k = 1, 2, 3, 4, 5), O (V1091-O) k V1092 (k = 1, 2, 3, 4, 5), OC (O) V1093, OC (O) OV1094, OC (O) NHV1095 , OC (O) NV1096V1097, OP (O) (OV1098) (OV1099), OSi (V1100) (V1101) (V1102), OS (O 2) V1103, NHC (O) V1104, NV1105C (O) V1106, NHC ( O) OV1107, NHC (O) NHV1108, NHC (O) NV1109V1110, NV1111C (O) OV1112, NV1113C (O) NHV1114, NV1115C (O) NV1116V1117, NHS (O2) V1118, NV1119S _{O) V1122, S (O 2} ) V1123, S (O 2) NHV1124, S (O 2) NV1125V1126, S (O 2) OV1127, P (O) (OV1128) (OV1129), Si (V1130) (V1131) (V1132) "

Here, V1081, V1082, V1083, V1084, V1085, V1086, V1087, V1088, V1089, V1090, V1091, V1092, V1093, V1094, V1095, V1096, V1097, V1098, V1099, V1100, V1101, V1102, V1105, V1106, V1107, V1108, V1109, V1110, V1111, V1112, V1113, V1114, V1115, V1116, V1117, V1118, V1119, V1120, V1121, V1122, V1123, V1124, V1125, V1126, V1127, V1130, V1131, V1132 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, V1087, V1097 and / or V1096, V1097 and / or V1109, V1110 and / or V1116, V1117 and / or V1125, V1126 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) V1133 , C (O) OV1134, C (O) NV1135V1136, S (O 2) V1137, S (O 2) OV1138 "

Here, V1133, V1134, V1135, V1136, V1137, V1138 is selected from the group consisting of the following, each independently: hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heteroaryl, Cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, V1135, V1136 may together form a" heterocyclyl "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHV1139, NV1140V1141, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) V1142, C (O) OV1143, C (O) NHV1144, C (O) NV1145V1146, OV1147, O (V1148-O) l H (l = 1, 2, 3, 4, 5), O (V1149-O) l V1150 (l = 1, 2, 3, 4, 5), OC (O) V1151, OC (O) OV1152, OC (O) NHV1153 , OC (O) NV1154V1155, OP (O) (OV1156) (OV1157), OSi (V1158) (V1159) (V1160), OS (O 2) V1161, NHC (O) V1162, NV1163C (O) V1164, NHC ( O) OV1165, NHC (O) NHV1166, NHC (O) NV1167V1168, NV1169C (O) OV1170, NV1171C (O) NHV1172, NV1173C (O) NV1174V1175, NHS (O2) V1176, NV1177S _{O) V1180, S (O 2} ) V1181, S (O 2) NHV1182, S (O 2) NV1183V1184, S (O 2) OV1185, P (O) (OV1186) (OV1187), Si (V1188) (V1189) (V1190) "

Here, V1139, V1140, V1141, V1142, V1143, V1144, V1145, V1146, V1147, V1148, V1149, V1150, V1151, V1152, V1153, V1154, V1155, V1156, V1157, V1158, V1159, V1160, V1163, V1164, V1165, V1166, V1167, V1168, V1169, V1170, V1171, V1172, V1173, V1174, V1175, V1176, V1177, V1178, V1179, V1180, V1181, V1182, V1183, V1184, V1185, V1188, V1189, V1190 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or V1174, V1175 and / or V1183, V1184 may also be combined in each case together to form a "heterocycle Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHV 1191, NV 1192V1193, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) V1194, C (O) OV1195, C (O) NHV1196, C (O) NV1197V1198, OV1199, O (V1200-O) m H (m = 1, 2, 3, 4, 5), O (V1201-O) m V1202 (m = 1, 2, 3, 4, 5), OC (O) V1203, OC (O) OV1204, OC (O) NHV1205 , OC (O) NV1206V1207, OP (O) (OV1208) (OV1209), OSi (V1210) (V1211) (V1212), OS (O 2) V1213, NHC (O) V1214, NV1215C (O) V1216, NHC ( (O) OV1217, NHC (O) NHV1218, NHC (O) NV1219V1220, NV1221C (O) OV1222, NV1223C (O) NHV1224, NV1225C (O) NV1226V1227, NHS (O2) V1228, NV1229S _{O) V1232, S (O 2} ) V1233, S (O 2) NHV1234, S (O 2) NV1235V1236, S (O 2) OV1237, P (O) (OV1238) (OV1239), Si (V1240) (V1241) (V1242) "

Here, V1191, V1192, V1193, V1194, V1195, V1196, V1197, V1198, V1199, V1200, V1201, V1202, V1203, V1204, V1205, V1206, V1207, V1208, V1209, V1210, V1211, V1212, V1215, V1216, V1217, V1218, V1219, V1220, V1221, V1222, V1223, V1224, V1225, V1226, V1227, V1228, V1229, V1230, V1231, V1232, V1233, V1234, V1240, V1241, V1242 are each independently selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkenyl the Kiel / RTI > and / or V1219, V1220 and / or V1226, V1227 and / or V1235, V1236 are also referred to in each case together as "heteroaryl, heteroarylalkyl ", or, alternatively, V1197, V1198 and / or V1206, V1207 and / Quot; cyclic "

or

(C) one of the Z3, Z4 radicals or both Z3, Z4 radicals is independently substituted by "substituted alkyl" wherein "substituted alkyl" is substituted by one or more substituents selected from the group consisting of:

(a) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHW ₁ , NW ₂ W ₃ , NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W4, C (O) OW5, C (O) NHW6, C (O) NW7W8, OW9, O (W10-O) r H (r = 1, 2, 3, 4, 5), O (W11-O) _r W12 (r = 1,2,3,4,5), OC (O) W13, OC , OC (O) NW16W17, OP (O) (OW18) (OW19), OSi (W20) (W21) (W22), OS (O 2) W23, NHC (O) W24, NW25C (O) W26, NHC ( O) OW27, NHC (O) NHW28, NHC (O) NW29W30, NW31C (O) OW32, NW33C (O) NHW34, NW35C (O) NW36W37, NHS (O 2) W38, NW39S (O 2) W40, SW41, S (O) W42, S ( O 2) W43, S (O 2) NHW44, S (O 2) NW45W46, S (O 2) OW47, P (O) (OW48) (OW49), Si (W50) ( W51) (W52) "

Wherein W1, W2, W3, W4, W5, W6, W7, W8, W9, W10, W11, W12, W13, W14, W15, W16, W17, W18, W19, W20, W21, W22, W25, W26, W27, W28, W29, W30, W31, W32, W33, W34, W35, W36, W37, W38, W39, W40, W41, W42, W43, W44, W45, W46, W47, W50, W51, W52 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or < RTI ID = 0.0 &Quot; reel "

Provided that "C (O) NHaryl", "C (O) NH heteroaryl", "C (O) NH cycloalkyl", "C (O) NH heterocyclyl" are selected from the following substitution groups (i) Further substituted by one or more substituents;

Wherein, optionally, the aforementioned substituents of substituent group (a) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHW 53, NW 54 W 55, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W56, C (O) OW57, C (O) NHW58, C (O) NW59W60, OW61, O (W62-O) s H (s = 1, 2, 3, 4, 5), O (W63-O) t W64 (t = 1, 2, 3, 4, 5), OC (O) W65, OC (O) OW66, OC (O) NHW67 , OC (O) NW68W69, OP (O) (OW70) (OW71), OSi (W72) (W73) (W74), OS (O 2) W75, NHC (O) W76, NW77C (O) W78, NHC ( O) OW79, NHC (O) NHW80, NHC (O) NW81W82, NW83C (O) OW84, NW85C (O) NHW86, NW87C (O) NW88W89, NHS (O 2) W90, NW91S (O 2) W92, SW93, S (O) W94, S ( O 2) W95, S (O 2) NHW96, S (O 2) NW97W98, S (O 2) OW99, P (O) (OW100) (OW101), Si (W102) ( W103) (W104) "

Wherein W53, W54, W55, W56, W57, W58, W59, W60, W61, W62, W63, W64, W65, W66, W67, W68, W69, W70, W71, W72, W73, W74, W77, W78, W79, W80, W81, W82, W83, W84, W85, W86, W87, W88, W89, W90, W91, W92, W93, W94, W95, W96, W97, W98, W99, W100, W101, W102, W103, W104 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or W81, W82 and / or W88, W89 and / or W97, W98 are also each individually referred to as "heterocycle Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHW 105, NW 106 W 107, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W108, C (O) OW109, C (O) NHW110, C (O) NW111W112, OW113, O (W114-O) t H (t = 1, 2, 3, 4, 5), O (W115-O) t W116 (t = 1, 2, 3, 4, 5), OC (O) W117, OC (O) OW118, OC (O) NHW119 , OC (O) NW120W121, OP (O) (OW122) (OW123), OSi (W124) (W125) (W126), OS (O 2) W127, NHC (O) W128, NW129C (O) W130, NHC ( O) OW131, NHC (O) NHW132, NHC (O) NW133W134, NW135C (O) OW136, NW137C (O) NHW138, NW139C (O) NW140W141, NHS (O 2) W142, NW143S (O 2) W144, SW145, S (O) W146, S ( O 2) W147, S (O 2) NHW148, S (O 2) NW149W150, S (O 2) OW151, P (O) (OW152) (OW153), Si (W154) ( W155) (W156) "

Here, W105, W106, W107, W108, W109, W110, W111, W112, W113, W114, W115, W116, W117, W118, W119, W120, W121, W122, W123, W124, W125, W126, W127, W128, W129, W130, W131, W132, W133, W134, W135, W136, W137, W138, W139, W140, W141, W142, W143, W144, W145, W146, W147, W148, W149, W150, W151, W152, W154, W155, W156 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W110, W112 and / or W120, W121 and / or W133, W134 and / or W140, W141 and / or W149, W150 are also referred to in each case together as "heterocycle Quot; reel "

Or Z3, Z4 that one of the radicals or Z3, Z4 two radicals, independently "(C ₉ -C ₃₀₎ alkyl"

Here, "(C ₉ -C ₃₀₎ alkyl" are independently optionally can be substituted by one or more substituents the same or different, from the group consisting of the following chosen:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW157, NW158W159, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) W160, C (O) OW161, C (O) NHW162, C (O) NW163W164, OW165, O (W166-O) u H (u = 1, 2, 3, 4, 5), O (W167-O) u W168 (u = 1, 2, 3, 4, 5), OC (O) W169, OC (O) OW170, OC (O) NHW171 , OC (O) NW172W173, OP (O) (OW174) (OW175), OSi (W176) (W177) (W178), OS (O 2) W179, NHC (O) W180, NW181C (O) W182, NHC ( O) OW183, NHC (O) NHW184, NHC (O) NW185W186, NW187C (O) OW188, NW189C (O) NHW190, NW191C (O) NW192W193, NHS (O 2) W194, NW195S (O 2) W196, SW197, S (O) W198, S ( O 2) W199, S (O 2) NHW200, S (O 2) NW201W202, S (O 2) OW203, P (O) (OW204) (OW205), Si (W206) ( W207) (W208) "

Here, W157, W158, W159, W160, W161, W162, W163, W164, W165, W166, W167, W168, W169, W170, W171, W172, W173, W174, W175, W176, W177, W178, W181, W182, W183, W184, W185, W186, W187, W188, W189, W190, W191, W192, W193, W194, W195, W196, W197, W198, W199, W200, W201, W202, W203, W206, W207, W208 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W163, W164 and / or W172, W173 and / or W185, W186 and / or W192, W193 and / or W201, W202 may also be combined in each case together to form a "heterocycle Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW209, NW210W211, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) W212, C (O) OW213, C (O) NHW214, C (O) NW215W216, OW217, O (W218-O) v H (v = 1, 2, 3, 4, 5), O (W219-O) v W220 (v = 1, 2, 3, 4, 5), OC (O) W221, OC (O) OW222, OC (O) NHW223 , OC (O) NW224W225, OP (O) (OW226) (OW227), OSi (W228) (W229) (W230), OS (O 2) W231, NHC (O) W232, NW233C (O) W234, NHC ( (O 2) W 248, NW 247 C (O) NH 242, NW 243 C (O) NW 244 W 245, NHS (O ₂ ) W 246, NW 247 S (O ₂ ) W 248, SW 249, S (O) W250, S ( O 2) W251, S (O 2) NHW252, S (O 2) NW253W254, S (O 2) OW255, P (O) (OW256) (OW257), Si (W258) ( W259) (W260) "

Herein, W209, W210, W211, W212, W213, W214, W215, W216, W217, W218, W219, W220, W221, W222, W223, W224, W225, W226, W227, W228, W229, W230, W233, W234, W235, W236, W237, W238, W239, W240, W241, W242, W243, W244, W245, W246, W247, W248, W249, W250, W251, W252, W253, W254, W255, W256, W257, W258, W259, W260 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W215, W216 and / or W224, W225 and / or W237, W238 and / or W244, W245 and / or W253, W254 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

And one of the Z3 and Z4 radicals is independently selected from the group consisting of or independently selected from the group consisting of Z3 and Z4 radicals independently selected from the group consisting of:

(b) hydrogen;

(c) halogen, F, Cl, Br, I;

(d) unsubstituted or substituted alkyl or (C ₉ -C ₃₀ ) alkyl, wherein optionally an alkyl or (C ₉ -C ₃₀ ) alkyl radical is optionally substituted by one or more substituents, which are the same or different selected from the group consisting of Lt; / RTI >

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHW 457, NW 458W 459, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W460, C (O) OW461, C (O) NHW462, C (O) NW463W464, OW465, O (W466-O) x H (x = 1, 2, 3, 4, 5), O (W467-O) x W468 (x = 1, 2, 3, 4, 5), OC (O) W469, OC (O) OW470, OC (O) NHW471 , OC (O) NW472W473, OP (O) (OW474) (OW475), OSi (W476) (W477) (W478), OS (O 2) W479, NHC (O) W480, NW481C (O) W482, NHC ( O) OW483, NHC (O) NHW484, NHC (O) NW485W486, NW487C (O) OW488, NW489C (O) NHW490, NW491C (O) NW492W493, NHS (O 2) W494, NW495S (O 2) W496, SW497, S (O) W498, S ( O 2) W499, S (O 2) NHW500, S (O 2) NW501W502, S (O 2) OW503, P (O) (OW504) (OW505), Si (W506) ( W507) (W508) "

Where W457, W458, W459, W460, W461, W462, W463, W464, W465, W466, W467, W468, W469, W470, W471, W472, W473, W474, W475, W476, W477, W478, W479, W481, W482, W483, W484, W485, W486, W487, W488, W489, W490, W491, W492, W493, W494, W491, W496, W497, W498, W499, W500, W501, W502, W503, W506, W507, W508 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Or W492 and / or W491 and / or W501, W502 are also each individually referred to as "heterocycle, heteroaryl, heteroarylalkyl ", or, alternatively, W463, W464 and / or W472, W473 and / or W485, W486 and / Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW509, NW510W511, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) W512, C (O) OW513, C (O) NHW514, C (O) NW515W516, OW517, O (W518-O) y H (y = 1, 2, 3, 4, 5), O (W519-O) y W520 (y = 1, 2, 3, 4, 5), OC (O) W521, OC (O) OW522, OC (O) NHW523 , OC (O) NW524W525, OP (O) (OW526) (OW527), OSi (W528) (W529) (W530), OS (O 2) W531, NHC (O) W532, NW533C (O) W534, NHC ( O) OW535, NHC (O) NHW536, NHC (O) NW537W538, NW539C (O) OW540, NW541C (O) NHW542, NW543C (O) NW544W545, NHS (O 2) W546, NW547S (O 2) W548, SW549, S (O) W550, S ( O 2) W551, S (O 2) NHW552, S (O 2) NW553W554, S (O 2) OW555, P (O) (OW556) (OW557), Si (W558) ( W559) (W560) "

Here, W59, W510, W511, W512, W513, W514, W515, W516, W517, W518, W519, W520, W521, W522, W523, W524, W525, W526, W527, W528, W529, W530, W533, W534, W535, W536, W537, W538, W539, W540, W541, W542, W543, W544, W545, W546, W547, W548, W549, W550, W551, W552, W553, W554, W555, W558, W559, W560 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W515, W516 and / or W524, W525 and / or W537, W538 and / or W544, W545 and / or W553 and W554 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHW 561, NW 562W 563, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W564, C (O) OW565, C (O) NHW566, C (O) NW567W568, OW569, O (W570-O) z H (z = 1, 2, 3, 4, 5), O (W571- O) z W572 (z = 1, 2, 3, 4, 5), OC (O) W573, OC (O) OW574, OC (O) NHW575 , OC (O) NW576W577, OP (O) (OW578) (OW579), OSi (W580) (W581) (W582), OS (O 2) W583, NHC (O) W584, NW585C (O) W586, NHC ( O) OW587, NHC (O) NHW588, NHC (O) NW589W590, NW591C (O) OW592, NW593C (O) NHW594, NW595C (O) NW596W597, NHS (O 2) W598, NW599S (O 2) W600, SW601, S (O) W602, S ( O 2) W603, S (O 2) NHW604, S (O 2) NW605W606, S (O 2) OW607, P (O) (OW608) (OW609), Si (W610) ( W611) (W612) "

Here, W561, W562, W563, W564, W565, W566, W567, W568, W569, W570, W571, W572, W573, W574, W575, W576, W577, W578, W579, W580, W581, W582, W585, W586, W587, W588, W589, W590, W591, W592, W593, W594, W595, W596, W597, W598, W599, W600, W601, W602, W603, W604, W605, W606, W607, W610, W611, W612 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W567, W568 and / or W576, W577 and / or W589, W590 and / or W596, W597 and / or W605, W606 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

(e) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHW 613, NW 614W615, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W616, C (O) OW617, C (O) NHW618, C (O) NW619W620, OW621, O (W622-O) a H (a = 1, 2, 3, 4, 5), O (W623-O) a W624 (a = 1, 2, 3, 4, 5), OC (O) W625, OC (O) OW626, OC (O) NHW627 , OC (O) NW628W629, OP (O) (OW630) (OW631), OSi (W632) (W633) (W634), OS (O 2) W635, NHC (O) W636, NW637C (O) W638, NHC ( O) OW639, NHC (O) NHW640, NHC (O) NW641W642, NW643C (O) OW644, NW645C (O) NHW646, NW647C (O) NW648W649, NHS (O 2) W650, NW651S (O 2) W652, SW653, S (O) W654, S ( O 2) W655, S (O 2) NHW656, S (O 2) NW657W658, S (O 2) OW659, P (O) (OW660) (OW661), Si (W662) ( W663) (W664) "

Here, W613, W614, W615, W616, W617, W618, W619, W620, W621, W622, W623, W624, W625, W626, W627, W628, W629, W630, W631, W632, W633, W634, W635, W636, W637, W638, W639, W640, W641, W642, W643, W644, W645, W646, W647, W648, W649, W650, W651, W652, W653, W654, W655, W656, W657, W658, W659, W662, W663, W664 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W641, W642 and / or W648, W649 and / or W657, W658 are also referred to in each case together as "heterocycle, heteroaryl, heteroarylalkyl ", or, alternatively, W619, W620 and / or W628, W629 and / Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW665, NW666W667, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) W668, C (O) OW669, C (O) NHW670, C (O) NW671W672, OW673, O (W674-O) b H (b = 1, 2, 3, 4, 5), O (W675-O) b W676 (b = 1, 2, 3, 4, 5), OC (O) W677, OC (O) OW678, OC (O) NHW679 , OC (O) NW680W681, OP (O) (OW682) (OW683), OSi (W684) (W685) (W686), OS (O 2) W687, NHC (O) W688, NW689C (O) W690, NHC ( O) OW691, NHC (O) NHW692, NHC (O) NW693W694, NW695C (O) OW696, NW697C (O) NHW698, NW699C (O) NW700W701, NHS (O 2) W702, NW703S (O 2) W704, SW705, S (O) W706, S ( O 2) W707, S (O 2) NHW708, S (O 2) NW709W710, S (O 2) OW711, P (O) (OW712) (OW713), Si (W714) ( W715) (W716) "

Here, W665, W666, W667, W668, W669, W670, W671, W672, W673, W674, W675, W676, W677, W678, W679, W680, W681, W682, W683, W684, W685, W686, W687, W688, W689, W690, W691, W692, W693, W694, W695, W696, W697, W698, W699, W700, W701, W702, W703, W704, W705, W706, W707, W708, W709, W710, W711, W712, W713, W714, W715, W716 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W671, W671 and / or W709, W710 are also each individually referred to as "heterocycle, heteroaryl, heteroarylalkyl ", or, alternatively, W671, W672 and / or W680, W681 and / or W693, W694 and / Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW717, NW718W719, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, c (O) W720, c (O) OW721, c (O) NHW722, c (O) NW723W724, OW725, O (W726-O) c H (c = 1, 2, 3, 4, 5), O (W727-O) c W728 (c = 1, 2, 3, 4, 5), OC (O) W729, OC (O) OW730, OC (O) NHW731 , OC (O) NW732W733, OP (O) (OW734) (OW735), OSi (W736) (W737) (W738), OS (O 2) W739, NHC (O) W740, NW741C (O) W742, NHC ( O) OW743, NHC (O) NHW744, NHC (O) NW745W746, NW747C (O) OW748, NW749C (O) NHW750, NW751C (O) NW752W753, NHS (O 2) W754, NW755S (O 2) W756, SW757, S (O) W758, S ( O 2) W759, S (O 2) NHW760, S (O 2) NW761W762, S (O 2) OW763, P (O) (OW764) (OW765), Si (W766) ( W767) (W768) "

Here, W717, W718, W719, W720, W721, W722, W723, W724, W725, W726, W727, W728, W729, W730, W731, W732, W733, W734, W735, W736, W737, W738, W739, W740, W741, W742, W743, W744, W745, W746, W747, W748, W749, W750, W751, W752, W753, W754, W755, W756, W757, W758, W759, W760, W761, W762, W763, W766, W767, W768 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W723, W724 and / or W732, W733 and / or W745, W746 and / or W752, W753 and / or W761, W762 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel ";

(f) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

F, Cl, Br, I, CN, C ₁ -C ₆ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, SO ₃ H, CF ₃ , N ₃ , NH ₂ , NHW 769, NW 770W771, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, , P (O) (OH) 2, C (O) W772, C (O) OW773, C (O) NHW774, C (O) NW775W776, OW777, O (W778-O) d H (d = 1, 2 , 3, 4, 5), O (W779-O) d W780 (d = 1, 2, 3, 4, 5), OC (O) W781, OC (O) OW782, OC (O) NHW783, OC ( O) NW784W785, OP (O) (OW786) (OW787), OSi (W788) (W789) (W790), OS (O 2) W791, NHC (O) W792, NW793C (O) W794, NHC (O) OW795 , NHC (O) NHW796, NHC (O) NW797W798, NW799C (O) OW800, NW801C (O) NHW802, NW803C (O) NW804W805, NHS (O 2) W806, NW807S (O 2) W808, SW809, S (O _{) W810, S (O 2)} W811, S (O 2) NHW812, S (O 2) NW813W814, S (O 2) OW815, P (O) (OW816) (OW817), Si (W818) (W819) ( W820) "

Wherein W769, W770, W771, W772, W773, W774, W775, W776, W777, W778, W779, W780, W781, W782, W783, W784, W785, W786, W787, W788, W789, W790, W793, W794, W795, W796, W797, W798, W799, W800, W801, W802, W803, W804, W805, W806, W807, W808, W809, W810, W811, W812, W813, W814, W815, W816, W817, W818, W819, W820 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W775, W785 and / or W797, W798 and / or W804, W805 and / or W813, W814 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHW 821, NW 822W823, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W824, C (O) OW825, C (O) NHW826, C (O) NW827W828, OW829, O (W830-O) e H (e = 1, 2, 3, 4, 5), O (W831-O) e W832 (e = 1, 2, 3, 4, 5), OC (O) W833, OC (O) OW834, OC (O) NHW835 , OC (O) NW836W837, OP (O) (OW838) (OW839), OSi (W840) (W841) (W842), OS (O 2) W843, NHC (O) W844, NW845C (O) W846, NHC ( O) OW847, NHC (O) NHW848, NHC (O) NW849W850, NW851C (O) OW852, NW853C (O) NHW854, NW855C (O) NW856W857, NHS (O 2) W858, NW859S (O 2) W860, SW861, S (O) W862, S ( O 2) W863, S (O 2) NHW864, S (O 2) NW865W866, S (O 2) OW867, P (O) (OW868) (OW869), Si (W870) ( W871) (W872) "

Here, W821, W822, W823, W824, W825, W826, W827, W828, W829, W830, W831, W832, W833, W834, W835, W836, W837, W838, W839, W840, W841, W842, W845, W846, W847, W848, W849, W850, W851, W852, W853, W854, W855, W856, W857, W858, W859, W860, W861, W862, W863, W864, W865, W866, W867, W868, W869, W870, W871, W872 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W827, W837 and / or W849, W850 and / or W856, W857 and / or W865, W866 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel ";

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW873, NW874W875, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) W876, C (O) OW877, C (O) NHW878, C (O) NW879W880, OW881, O (W882-O) f H (f = 1, 2, 3, 4, 5), O (W883-O) f W884 (f = 1, 2, 3, 4, 5), OC (O) W885, OC (O) OW886, OC (O) NHW887 , OC (O) NW888W889, OP (O) (OW890) (OW891), OSi (W892) (W893) (W894), OS (O 2) W895, NHC (O) W896, NW897C (O) W898, NHC ( O) OW899, NHC (O) NHW900, NHC (O) NW901W902, NW903C (O) OW904, NW905C (O) NHW906, NW907C (O) NW908W909, NHS (O 2) W910, NW911S (O 2) W912, SW913, S (O) W914, S ( O 2) W915, S (O 2) NHW916, S (O 2) NW917W918, S (O 2) OW919, P (O) (OW920) (OW921), Si (W922) ( W923) (W924) "

Here, W873, W874, W875, W876, W877, W878, W879, W880, W881, W882, W883, W884, W885, W886, W887, W888, W889, W890, W891, W892, W893, W894, W895, W897, W898, W899, W900, W901, W902, W903, W904, W905, W906, W907, W908, W909, W910, W911, W912, W913, W914, W915, W916, W917, W918, W919, W922, W923, W924 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or W908, W909 and / or W917, W918 are also each < RTI ID = 0.0 &Quot; reel "

(g) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", where, optionally, The above substituents of the substituent group (i) may each independently of each other be substituted by one or more substituents, which may be the same or different selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHW 925, NW 926W 927, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W928, C (O) OW929, C (O) NHW930, C (O) NW931W932, OW933, O (W934-O) g H (g = 1, 2, 3, 4, 5), O (W935-O) g W936 (g = 1, 2, 3, 4, 5), OC (O) W937, OC (O) OW938, OC (O) NHW939 , OC (O) NW940W941, OP (O) (OW942) (OW943), OSi (W944) (W945) (W946), OS (O 2) W947, NHC (O) W948, NW949C (O) W950, NHC ( O) OW951, NHC (O) NHW952, NHC (O) NW953W954, NW955C (O) OW956, NW957C (O) NHW958, NW959C (O) NW960W961, NHS (O 2) W962, NW963S (O 2) W964, SW965, S (O) W966, S ( O 2) W967, S (O 2) NHW968, S (O 2) NW969W970, S (O 2) OW971, P (O) (OW972) (OW973), Si (W974) ( W975) (W976) "

Here, W925, W926, W927, W928, W929, W930, W931, W932, W933, W934, W935, W936, W937, W938, W939, W940, W941, W942, W943, W944, W945, W946, W947, W948, W949, W950, W951, W952, W953, W954, W955, W956, W957, W958, W959, W960, W961, W962, W963, W964, W965, W966, W967, W968, W969, W970, W971, W974, W975, W976 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W931, W941 and / or W940, W941 and / or W953, W954 and / or W960, W961 and / or W969, W970 are also referred to in each case together as "heterocycle Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW977, NW978W979, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 h, P (O)} (OH) 2, C (O) W980, C (O) OW981, C (O) NHW982, C (O) NW983W984, OW985, O (W986-O) h h (h = 1, 2, 3, 4, 5), O (W987-O) h W988 (h = 1, 2, 3, 4, 5), OC (O) W989, OC (O) OW990, OC (O) NHW991 , OC (O) NW992W993, OP (O) (OW994) (OW995), OSi (W996) (W997) (W998), OS (O 2) W999, NHC (O) W1000, NW1001C (O) W1002, NHC ( O) OW1003, NHC (O) NHW1004, NHC (O) NW1005W1006, NW1007C (O) OW1008, NW1009C (O) NHW1010, NW1011C (O) NW1012W1013, NHS (O 2) W1014, NW1015S (O 2) W1016, SW1017, S (O) W1018, S ( O 2) W1019, S (O 2) NHW1020, S (O 2) NW1021W1022, S (O 2) OW1023, P (O) (OW1024) (OW1025), Si (W1026) ( W1027) (W1028) "

Wherein W977, W978, W979, W980, W981, W982, W983, W984, W985, W986, W987, W988, W989, W990, W991, W992, W993, W994, W995, W996, W997, W998, W999, W1000, W1001, W1002, W1003, W1004, W1005, W1006, W1007, W1008, W1009, W1010, W1011, W1012, W1013, W1014, W1015, W1016, W1017, W1018, W1019, W1020, W1021, W1022, W1023, W1024, W1025, W1026, W1027, W1028 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W983, W984 and / or W992, W993 and / or W1005, W1006 and / or W1012, W1013 and / or W1021, W1022 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

(h) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", where, optionally, The above substituents of the substituent group (i) may each independently of each other be substituted by one or more substituents, which may be the same or different selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW1029, NW1030W1031, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) W1032, C (O) OW1033, C (O) NHW1034, C (O) NW1035W1036, OW1037, O (W1038-O) i H (i = 1, 2, 3, 4, 5), O (W1039-O) i W1040 (i = 1, 2, 3, 4, 5), OC (O) W1041, OC (O) OW1042, OC (O) NHW1043 , OC (O) NW1044W1045, OP (O) (OW1046) (OW1047), OSi (W1048) (W1049) (W1050), OS (O 2) W1051, NHC (O) W1052, NW1053C (O) W1054, NHC ( O) OW1055, NHC (O) NHW1056, NHC (O) NW1057W1058, NW1059C (O) OW1060, NW1061C (O) NHW1062, NW1063C (O) NW1064W1065, NHS (O 2) W1066, NW1067S (O 2) W1068, SW1069, S (O) W1070, S ( O 2) W1071, S (O 2) NHW1072, S (O 2) NW1073W1074, S (O 2) OW1075, P (O) (OW1076) (OW1077), Si (W1078) ( W1079) (W1080) "

Herein, W1029, W1030, W1031, W1032, W1033, W1034, W1035, W1036, W1037, W1038, W1039, W1040, W1041, W1042, W1043, W1044, W1045, W1046, W1047, W1048, W1049, W1050, W1053, W1054, W1055, W1056, W1057, W1058, W1059, W1060, W1061, W1062, W1063, W1064, W1065, W1066, W1067, W1068, W1069, W1070, W1071, W1072, W1073, W1074, W1075, W1078, W1079, W1080 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, / RTI > and / or W1057, W1058 and / or W1064, W1065 and / or W1073, W1074 may also be referred to in each case together as "heterocyclyl, heteroarylalkyl ", or alternatively, W1035, W1036 and / or W1044, W1045 and / Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW1081, NW1082W1083, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) W1084, C (O) OW1085, C (O) NHW1086, C (O) NW1087W1088, OW1089, O (W1090-O) j H (j = 1, 2, 3, 4, 5), O (W1091-O) j W1092 (j = 1, 2, 3, 4, 5), OC (O) W1093, OC (O) OW1094, OC (O) NHW1095 , OC (O) NW1096W1097, OP (O) (OW1098) (OW1099), OSi (W1100) (W1101) (W1102), OS (O 2) W1103, NHC (O) W1104, NW1105C (O) W1106, NHC ( O) OW1107, NHC (O) NHW1108, NHC (O) NW1109W1110, NW1111C (O) OW1112, NW1113C (O) NHW1114, NW1115C (O) NW1116W1117, NHS (O 2) W1118, NW1119S (O 2) W1120, SW1121, S (O) W1122, S ( O 2) W1123, S (O 2) NHW1124, S (O 2) NW1125W1126, S (O 2) OW1127, P (O) (OW1128) (OW1129), Si (W1130) ( W1131) (W1132) "

Here, W1081, W1082, W1083, W1084, W1085, W1086, W1087, W1088, W1089, W1090, W1091, W1092, W1093, W1094, W1095, W1096, W1097, W1098, W1099, W1100, W1101, W1102, W1103, W1105, W1106, W1107, W1108, W1109, W1110, W1111, W1112, W1113, W1114, W1115, W1116, W1117, W1118, W1119, W1120, W1121, W1122, W1123, W1124, W1125, W1126, W1127, W1128, W1129, W1130, W1131, W1132 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W1087, W1097 and / or W1096, W1097 and / or W1109, W1110 and / or W1116, W1117 and / or W1125, W1126 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

(j) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) W1133 , C (O) OW1134, C (O) NW1135W1136, S (O 2) W1137, S (O 2) OW1138 "

Here, W1133, W1134, W1135, W1136, W1137, W1138 is selected from the group consisting of the following, each independently: hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heteroaryl, Cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, W1135 and W1136 may together form a "heterocyclyl &

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHW 1139, NW 1140W1141, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) W1142, C (O) OW1143, C (O) NHW1144, C (O) NW1145W1146, OW1147, O (W1148-O) k H (k = 1, 2, 3, 4, 5), O (W1149-O) _k W1150 (k = 1, 2, 3, 4, 5), OC (O) W1151, OC (O) OW1152, OC , OC (O) NW1154W1155, OP (O) (OW1156) (OW1157), OSi (W1158) (W1159) (W1160), OS (O 2) W1161, NHC (O) W1162, NW1163C (O) W1164, NHC ( O) OW1165, NHC (O) NHW1166, NHC (O) NW1167W1168, NW1169C (O) OW1170, NW1171C (O) NHW1172, NW1173C (O) NW1174W1175, NHS (O 2) W1176, NW1177S (O2) W1178, SW1179, S (O) W1180, S (O 2) W1181, S (O 2) NHW1182, S (O 2) NW1183W1184, S (O 2) OW1185, P (O) (OW1186) (OW1187), Si (W1188) (W1189 ) (W1190) "

Here, W1139, W1140, W1141, W1142, W1143, W1144, W1145, W1146, W1147, W1148, W1149, W1150, W1151, W1152, W1153, W1154, W1155, W1156, W1157, W1158, W1159, W1160, W1161, W1162, W1163, W1164, W1165, W1166, W1167, W1168, W1169, W1170, W1171, W1172, W1173, W1174, W1175, W1176, W1177, W1178, W1179, W1180, W1181, W1182, W1183, W1184, W1185, W1188, W1189, W1190, and are each independently selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkenyl the Kiel W1174, W1168 and / or W1174, W1175 and / or W1183, W1184 are also each individually referred to as "heteroaryl, heteroaryl, heteroarylalkyl ", or alternatively, W1145, W1146 and / or W1154, W1155 and / Quot; cyclic "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHW1191, NW1192W1193, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) W1194, C (O) OW1195, C (O) NHW1196, C (O) NW1197W1198, OW1199, O (W1200-O) l H (l = 1, 2, 3, 4, 5), O (W1201-O) _l W1202 (l = 1,2,3,4,5), OC (O) W1203, OC (O) OW1204, OC , OC (O) NW1206W1207, OP (O) (OW1208) (OW1209), OSi (W1210) (W1211) (W1212), OS (O 2) W1213, NHC (O) W1214, NW1215C (O) W1216, NHC ( O) OW1217, NHC (O) NHW1218, NHC (O) NW1219W1220, NW1221C (O) OW1222, NW1223C (O) NHW1224, NW1225C (O) NW1226W1227, NHS (O 2) W1228, NW1229S (O 2) W1230, SW1231, S (O) W1232, S ( O 2) W1233, S (O 2) NHW1234, S (O 2) NW1235W1236, S (O 2) OW1237, P (O) (OW1238) (OW1239), Si (W1240) ( W1241) (W1242) "

Here, W1191, W1192, W1193, W1194, W1195, W1196, W1197, W1198, W1199, W1200, W1201, W1202, W1203, W1204, W1205, W1206, W1207, W1208, W1209, W1210, W1211, W1212, W1213, W1214, W1215, W1216, W1217, W1218, W1219, W1220, W1221, W1222, W1223, W1224, W1225, W1226, W1227, W1228, W1229, W1230, W1231, W1232, W1233, W1234, W1235, W1236, W1237, W1240, W1241, W1242 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, W1197, W1198 and / or W1206, W1207 and / or W1219, W1220 and / or W1226, W1227 and / or W1235, W1236 are also referred to in each case together as "heterocycle Quot; reel "

or

(A) one of the Z3, Z4 radicals or both Z3, Z4 radicals is each independently selected from the group consisting of:

(1) "NZ10Z11, OZ12, SZ13"

Wherein one of Z10, Z11 radicals or both Z10, Z11 radicals and Z12, Z13 radicals are each independently selected from the group consisting of:

(a) "hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"

Provided that both Z10 and Z11 radicals are not simultaneously hydrogen;

Further provided that the Z12 radical is not hydrogen;

Further provided that the aforementioned substituents of substituent group (a) are further substituted by one or more substituents, each of which is independently the same or differently selected from the group consisting of:

(i) "(C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, N ₃ , NH cycloalkyl, S heteroaryl, NH heteroarylalkyl, NHheterocyclyl, NHheterocyclylalkyl, NQ1Q2, S cycloalkyl, S cycloalkylalkyl, Saryl, Sarylalkyl, Sheteroaryl, S Heteroarylalkyl, S heterocyclyl, S heterocyclylalkyl, O cycloalkyl, O cycloalkylalkyl, Oarylalkyl, Oheteroaryl, Oheteroarylalkyl, Oheterocyclyl, Oheterocyclylalkyl, O _{Q3-O) p H (p} = 1, 2, 3, 4, 5), O (Q4-O) p Q5 (p = 1, 2, 3, 4, 5), OP (O) (OQ6) ( OQ7), C (O) OQ8 , C (O) NH2, C (O) NHQ9, C (O) NQ10Q11, S (O 2) Q12, P (O) (OH) 2, P (O) (OQ13) OC (O) NHQ22, OC (O) NQ23Q24, NHC (O) OQ25, OC (O) QQ14, Si (Q15) NHC (O) NHQ26, NHC (O) NQ27Q28, NQ29C (O) OQ30, NQ31C (O) Q43, OC (O) Q44, NH (O) Q39, NHC (O) Q40, NQ41C (O) Q45, S (O 2) NHQ46, S (O 2) NQ47Q48, S (O 2) OQ49 "

"N (alkyl) ₂ " is further substituted by one or more substituents selected from the following substituent group (ii);

Here, Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q25, Q26, Q27, Q28, Q29, Q30, Q31, Q32, Q33, Q34, Q35, Q36, Q37, Q38, Q39, Q40, Q41, Q42, Q43, Q44, Q45, Q46, Q47, each independently are selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl Q23, Q24 and / or Q27, Q28 and / or Q34, Q35 and / or Q47, Q48 may also in each case form a "heterocyclyl" However,

Here, optionally, the aforementioned substituents of substituent group (a) and / or substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHQ 50, NQ 51 Q 52, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) Q53, C (O) OQ54, C (O) NHQ55, C (O) NQ56Q57, OQ58, O (Q59-O) r H (r = 1, 2, 3, 4, 5), O (Q60-O) r Q61 (r = 1, 2, 3, 4, 5), OC (O) Q62, OC (O) OQ63, OC (O) NHQ64 , OC (O) NQ65Q66, OP (O) (OQ67) (OQ68), OSi (Q69) (Q70) (Q71), OS (O 2) Q72, NHC (O) Q73, NQ74C (O) Q75, NHC ( O) OQ76, NHC (O) NHQ77, NHC (O) NQ78Q79, NQ80C (O) OQ81, NQ82C (O) NHQ83, NQ84C (O) NQ85Q86, NHS (O2) Q87, NQ88S _{O) Q91, S (O 2} ) Q92, S (O 2) NHQ93, S (O 2) NQ94Q95, S (O 2) OQ96, P (O) (OQ97) (OQ98), Si (Q99) (Q100) (Q101) "

Q61, Q52, Q53, Q54, Q55, Q56, Q57, Q58, Q59, Q60, Q61, Q62, Q63, Q64, Q65, Q66, Q67, Q68, Q69, Q70, Q74, Q75, Q76, Q77, Q78, Q79, Q80, Q81, Q82, Q83, Q84, Q85, Q86, Q87, Q88, Q89, Q90, Q91, Q92, Q93, Q94, Q95, Q96, Q99, Q100, Q101 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q56, Q57 and / or Q65, Q66 and / or Q78, Q79 and / or Q85, Q86 and / or Q94 and Q95 may also be combined in each case together to form a "heterocycle Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHQ 102, NQ 103Q104, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) Q105, C (O) OQ106, C (O) NHQ107, C (O) NQ108Q109, OQ110, O (Q111-O) s H (s = 1, 2, 3, 4, 5), O (Q112-O) s Q113 (s = 1, 2, 3, 4, 5), OC (O) Q114, OC (O) OQ115, OC (O) NHQ116 , OC (O) NQ117Q118, OP (O) (OQ119) (OQ120), OSi (Q121) (Q122) (Q123), OS (O 2) Q124, NHC (O) Q125, NQ126C (O) Q127, NHC ( (O2) Q141, SQ142, S (O) OQ128, NHC (O) NHQ129, NHC (O) NQ130Q131, NQ132C (O) OQ133, NQ134C (O) NHQ135, NQ136C (O) NQ137Q138, NHS _{O) Q143, S (O 2} ) Q144, S (O 2) NHQ145, S (O 2) NQ146Q147, S (O 2) OQ148, P (O) (OQ149) (OQ150), Si (Q151) (Q152) (Q153) "

Q114, Q115, Q116, Q117, Q118, Q119, Q120, Q121, Q122, Q123, Q124, Q125, Q123, Q123, Q123, Q123, Q123, Q123, Q104, Q105, Q106, Q107, Q108, Q109, Q110, Q111, Q126, Q127, Q128, Q129, Q130, Q131, Q132, Q133, Q134, Q135, Q136, Q137, Q138, Q139, Q140, Q141, Q142, Q143, Q144, Q145, Q146, Q147, Q148, Q149, Q151, Q152, Q153 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q108, Q109 and / or Q117, Q118 and / or Q130, Q131 and / or Q137, Q138 and / or Q146, Q147 are also each individually referred to as "heterocycle Quot; reel "

_{(b) "(C 9 -C} 30) alkyl, C (O) Q154, C (O) OQ155, C (O) NQ156Q157, S (O 2) Q158, S (O 2) OQ159"

Here, Q154, Q155, Q156, Q157, Q158, Q159 is selected from the group consisting of the following independently "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, Heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, Q156 and Q157 may together form a "heterocyclyl &

Here, optionally, the aforementioned substituents of substituent group (b) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHQ160, NQ161Q162, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) Q163, C (O) OQ164, C (O) NHQ165, C (O) NQ166Q167, OQ168, O (Q169-O) t H (t = 1, 2, 3, 4, 5), O (Q170-O) t Q171 (t = 1, 2, 3, 4, 5), OC (O) Q172, OC (O) OQ173, OC (O) NHQ174 , OC (O) NQ175Q176, OP (O) (OQ177) (OQ178), OSi (Q179) (Q180) (Q181), OS (O 2) Q182, NHC (O) Q183, NQ184C (O) Q185, NHC ( NQ192C (O) NHQ193, NQ194C (O) NQ195Q196, NHS (O2) Q197, NQ198S (O2) Q199, SQ200, S (O) OQ186, NHC (O) NHQ187, NHC (O) NQ188Q189, NQ190C _{O) Q201, S (O 2} ) Q202, S (O 2) NHQ203, S (O 2) NQ204Q205, S (O 2) OQ206, P (O) (OQ207) (OQ208), Si (Q209) (Q210) (Q211) "

Q171, Q172, Q173, Q174, Q172, Q176, Q177, Q178, Q179, Q180, Q181, Q182, Q183, Q183, Q183, Q183, Q183, Q184, Q185, Q186, Q187, Q188, Q189, Q190, Q191, Q192, Q193, Q194, Q195, Q196, Q197, Q198, Q199, Q200, Q201, Q202, Q203, Q204, Q205, Q206, Q209, Q210, Q211 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q166, Q167 and / or Q175, Q176 and / or Q188, Q189 and / or Q195, Q196 and / or Q204 and Q205 may also be taken together in each case together to form a "heterocyclyl "Can be formed,

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHQ212, NQ213Q214, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) Q215, C (O) OQ216, C (O) NHQ217, C (O) NQ218Q219, OQ220, O (Q221-O) u H (u = 1, 2, 3, 4, 5), O (Q222-O) u Q223 (u = 1, 2, 3, 4, 5), OC (O) Q224, OC (O) OQ225, OC (O) NHQ226 , OC (O) NQ227Q228, OP (O) (OQ229) (OQ230), OSi (Q231) (Q232) (Q233), OS (O 2) Q234, NHC (O) Q235, NQ236C (O) Q237, NHC ( (O2) Q251, SQ252, S (O) O2, NHC (O) NHQ239, NHC (O) NQ240Q241, NQ242C (O) OQ243, NQ244C (O) NHQ245, NQ246C (O) NQ247Q248, NHS _{O) Q253, S (O 2} ) Q254, S (O 2) NHQ255, S (O 2) NQ256Q257, S (O 2) OQ258, P (O) (OQ259) (OQ260), Si (Q261) (Q262) (Q263) "

Q212, Q213, Q214, Q215, Q216, Q217, Q218, Q219, Q220, Q221, Q222, Q223, Q224, Q225, Q226, Q227, Q228, Q229, Q230, Q231, Q232, Q233, Q234, Q235, Q236, Q237, Q238, Q239, Q240, Q241, Q242, Q243, Q244, Q245, Q246, Q247, Q248, Q249, Q250, Q251, Q252, Q253, Q254, Q255, Q256, Q257, Q258, Q261, Q262, Q263 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q218, Q219 and / or Q227, Q228 and / or Q240, Q241 and / or Q247, Q248 and / or Q256, Q257 are also each individually referred to as "heterocycle Quot; reel ";

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHQ264, NQ265Q266, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) Q267, C (O) OQ268, C (O) NHQ269, C (O) NQ270Q271, OQ272, O (Q273-O) v H (v = 1, 2, 3, 4, 5), O (Q274-O) v Q275 (v = 1, 2, 3, 4, 5), OC (O) Q276, OC (O) OQ277, OC (O) NHQ278 , OC (O) NQ279Q280, OP (O) (OQ281) (OQ282), OSi (Q283) (Q284) (Q285), OS (O 2) Q286, NHC (O) Q287, NQ288C (O) Q289, NHC ( (O2) Q301, NQ302S (O2) Q303, SQ304, S (O) OCH290, NHC (O) NHQ291, NHC (O) NQ292Q293, NQ294C (O) OQ295, NQ296C (O) NHQ297, NQ298C _{O) Q305, S (O 2} ) Q306, S (O 2) NHQ307, S (O 2) NQ308Q309, S (O 2) OQ310, P (O) (OQ311) (OQ312), Si (Q313) (Q314) (Q315) "

Here, Q264, Q265, Q266, Q267, Q268, Q269, Q270, Q271, Q272, Q273, Q274, Q275, Q276, Q277, Q278, Q279, Q280, Q281, Q282, Q283, Q284, Q285, Q286, Q287, Q288, Q289, Q290, Q291, Q292, Q293, Q294, Q295, Q296, Q297, Q298, Q299, Q300, Q301, Q302, Q303, Q304, Q305, Q306, Q307, Q308, Q309, Q310, Q311, Q313, Q314, Q315 are each independently selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, H. Tero heterocyclyl alkyl, aryl, arylalkyl Quot; heteroaryl, heteroarylalkyl ", wherein, alternatively, Q270, Q271 and / or Q279, Q280 and / or Q292, Q293 and / or Q299, Q300 and / or Q308, Quot; cyclic "

Or one of the Z < 10 > and Z < 11 > radicals is independently selected from the group consisting of or independently selected from the group consisting of:

(c) "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, C (O) Q316 , C (O) OQ317, C (O) NQ318Q319, S (O 2) Q320, S (O 2) OQ321 "

Here, Q316, Q317, Q318, Q319, Q320, Q321 is selected from the group consisting of the following independently "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, Heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, Q318, Q319 may also form a" heterocyclyl "

Wherein, optionally, the aforementioned substituents of substituent group (c) may be substituted by one or more substituents, each of which, independently of one another, is identically or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHQ322, NQ323Q324, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) Q325, C (O) OQ326, C (O) NHQ327, C (O) NQ328Q329, OQ330, O (Q331-O) w H (w = 1, 2, 3, 4, 5), O (Q332-O) w Q333 (w = 1, 2, 3, 4, 5), OC (O) Q334, OC (O) OQ335, OC (O) NHQ336 , OC (O) NQ337Q338, OP (O) (OQ339) (OQ340), OSi (Q341) (Q342) (Q343), OS (O 2) Q344, NHC (O) Q345, NQ346C (O) Q347, NHC ( O) OQ348, NHC (O) NHQ349, NHC (O) NQ350Q351, NQ352C (O) OQ353, NQ354C (O) NHQ355, NQ356C (O) NQ357Q358, NHS (O2) Q359, NQ360S _{O) Q363, S (O 2} ) Q364, S (O 2) NHQ365, S (O 2) NQ366Q367, S (O 2) OQ368, P (O) (OQ369) (OQ370), Si (Q371) (Q372) (Q373) "

Q332, Q333, Q334, Q338, Q336, Q337, Q338, Q339, Q340, Q341, Q342, Q343, Q344, Q345, Q342, Q366, Q366, Q367, Q368, Q369, Q366, Q369, Q368, Q369, Q368, Q369, Q366, Q366, Q366, Q367, Q368, Q369, Q371, Q372, Q373 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q328 and / or Q337, Q338 and / or Q350, Q351 and / or Q357, Q358 and / or Q366, Q367 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHQ374, NQ375Q376, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) Q377, C (O) OQ378, C (O) NHQ379, C (O) NQ380Q381, OQ382, O (Q383-O) x H (x = 1, 2, 3, 4, 5), O (Q384-O) x Q385 (x = 1, 2, 3, 4, 5), OC (O) Q386, OC (O) OQ387, OC (O) NHQ388 , OC (O) NQ389Q390, OP (O) (OQ391) (OQ392), OSi (Q393) (Q394) (Q395), OS (O 2) Q396, NHC (O) Q397, NQ398C (O) Q399, NHC ( O) OQ400, NHC (O) NHQ401, NHC (O) NQ402Q403, NQ404C (O) OQ405, NQ406C (O) NHQ407, NQ408C (O) NQ409Q410, NHS (O2) Q411, NQ412S _{O) Q415, S (O 2} ) Q416, S (O 2) NHQ417, S (O 2) NQ418Q419, S (O 2) OQ420, P (O) (OQ421) (OQ422), Si (Q423) (Q424) (Q425) "

Q392, Q393, Q394, Q395, Q396, Q397, Q396, Q396, Q396, Q396, Q394, Q394, Q396, Q394, Q394, Q396, Q396, Q397, Q414, Q414, Q414, Q414, Q414, Q415, Q416, Q417, Q418, Q419, Q420, Q421, Q422, Q413, Q411, Q412, Q413, Q414, Q499, Q400, Q401, Q402, Q403, Q404, Q405, Q406, Q407, Q408, Q409, Q410, Q423, Q424, Q425 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Quot; heteroarylalkyl ", wherein Q380, Q381 and / or Q389, Q390 and / or Q402, Q403 and / or Q409, Q410 and / or Q418, Q419 are also in each case "Quot; reel ";

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHQ426, NQ427Q428, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) Q429, C (O) OQ430, C (O) NHQ431, C (O) NQ432Q433, OQ434, O (Q435-O) y H (y = 1, 2, 3, 4, 5), O (Q436-O) y Q437 (y = 1, 2, 3, 4, 5), OC (O) Q438, OC (O) OQ439, OC (O) NHQ440 , OC (O) NQ441Q442, OP (O) (OQ443) (OQ444), OSi (Q445) (Q446) (Q447), OS (O 2) Q448, NHC (O) Q449, NQ450C (O) Q451, NHC ( NQ456eC (O) NQ456eC (O) NQ456fQ456g, NHS (O2) Q456h, NQ456iS (O2) Q456j, SQ456k, S (O) OQ452, NHC (O) NHQ453, NHC (O) NQ454Q455, NQ456aC (O) OQ456b, NQ456cC _{O) Q456l, S (O 2} ) Q456m, S (O 2) NHQ456n, S (O 2) NQ456- OQ456p, S (O 2) OQ456q, P (O) (OQ456r) (OQ456s), Si (Q456t) ( Q456u) (Q456v) "

Here, Q426, Q427, Q428, Q429, Q430, Q431, Q432, Q433, Q434, Q435, Q436, Q437, Q438, Q439, Q440, Q441, Q442, Q443, Q444, Q445, Q446, Q447, Q450, Q451, Q452, Q453, Q454, Q455, Q456a, Q456b, Q456c, Q456d, Q456e, Q456f, Q456g, Q456h, Q456i, Q456j, Q456k, Q456l, Q456m, Q456n, Q456-O, Q456p, Q456q, Q456r, Q456s, Q456t, Q456u, Q456v is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, Q432, Q433 and / or Q441, Q442 and / or Q454, Q455 and / or Q456f, Q456g and / or Q456-O, Q456p, and also in each case the term "alkyl, heteroaryl, heteroarylalkyl" Together can form a "heterocyclyl",

And one of the Z3 and Z4 radicals is independently selected from the group consisting of or independently selected from the group consisting of Z3 and Z4 radicals independently selected from the group consisting of:

(d) hydrogen;

(e) halogen, F, Cl, Br, I;

(f) unsubstituted or substituted alkyl or (C ₉ -C ₃₀ ) alkyl, wherein optionally an alkyl or (C ₉ -C ₃₀ ) alkyl radical is optionally substituted with one or more substituents which may be the same or different selected from the group consisting of Lt; / RTI >

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHQ457, NQ458Q459, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) Q460, C (O) OQ461, C (O) NHQ462, C (O) NQ463Q464, OQ465, O (Q466-O) z H (z = OC (O) OQ470, OC (O) NHQ471 (z = 1, 2, 3, 4, 5), O (Q467-O) _z Q468 , OC (O) NQ472Q473, OP (O) (OQ474) (OQ475), OSi (Q476) (Q477) (Q478), OS (O 2) Q479, NHC (O) Q480, NQ481C (O) Q482, NHC ( O) OQ483, NHC (O) NHQ484, NHC (O) NQ485Q486, NQ487C (O) OQ488, NQ489C (O) NHQ490, NQ491C (O) NQ492Q493, NHS (O2) Q494, NQ495S (O2) Q496, SQ497, SQ497 _{O) Q498, S (O 2} ) Q499, S (O 2) NHQ500, S (O 2) NQ501Q502, S (O 2) OQ503, P (O) (OQ504) (OQ505), Si (Q506) (Q507) (Q508) "

Where Q457, Q458, Q459, Q460, Q461, Q462, Q463, Q464, Q465, Q466, Q467, Q468, Q469, Q470, Q471, Q472, Q473, Q474, Q475, Q476, Q477, Q478, Q479, Q480, Q481, Q482, Q483, Q484, Q485, Q486, Q487, Q488, Q489, Q490, Q491, Q492, Q493, Q494, Q495, Q496, Q497, Q498, Q499, Q500, Q501, Q502, Q503, Q504, Q505, Q506, Q507, Q508 are each independently selected from the following group consisting of: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclic keulril alkyl, aryl, arylalkyl, Quot; heteroarylalkyl ", wherein, alternatively, Q463, Q464 and / or Q472, Q473 and / or Q485, Q486 and / or Q492, Q493 and / or Q501, Quot; reel "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ509, NQ510Q511, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q512, C (O) OQ513, C (O) NHQ514, C (O) NQ515Q516, OQ517, O (Q518-O) _a H (a = 1, 2, 3, 4, 5), O (Q519-O) _a Q520 (a = 1, 2, 3, 4, 5), OC (O) Q521, OC (O) OQ522, OC (O) NHQ523 , OC (O) NQ524Q525, OP (O) (OQ526) (OQ527), OSi (Q528) (Q529) (Q530), OS (O 2) Q531, NHC (O) Q532, NQ533C (O) Q534, NHC ( O) OQ535, NHC (O) NHQ536, NHC (O) NQ537Q538, NQ539C (O) OQ540, NQ541C (O) NHQ542, NQ543C (O) NQ544Q545, NHS (O2) Q546, NQ547S _{O) Q550, S (O 2} ) Q551, S (O 2) NHQ552, S (O 2) NQ553Q554, S (O 2) OQ555, P (O) (OQ556) (OQ557), Si (Q558) (Q559) (Q560) "

Q512, Q512, Q511, Q512, Q513, Q514, Q515, Q516, Q517, Q518, Q519, Q520, Q521, Q522, Q523, Q524, Q525, Q526, Q527, Q528, Q529, Q530, Q533, Q534, Q535, Q536, Q537, Q538, Q539, Q540, Q541, Q542, Q543, Q544, Q545, Q546, Q547, Q548, Q549, Q550, Q551, Q552, Q553, Q554, Q555, Q558, Q559, Q560 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q515, Q516 and / or Q524, Q525 and / or Q537, Q538 and / or Q544, Q545 and / or Q553, Q554 are also referred to in each case together as "heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHQ561, NQ562Q563, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, SO ₃ H, P (O) (OH) ₂ , C (O) Q564, C (O) OQ565, C (O) NHQ566, C (O) NQ567Q568, OQ569, O (Q570-O) _b H (b = 1, 2, 3, 4, 5), O (Q571-O) b Q572 (b = 1, 2, 3, 4, 5), OC (O) Q573, OC (O) OQ574, OC (O) NHQ575 , OC (O) NQ576Q577, OP (O) (OQ578) (OQ579), OSi (Q580) (Q581) (Q582), OS (O 2) Q583, NHC (O) Q584, NQ585C (O) Q586, NHC ( O) OQ587, NHC (O) NHQ588, NHC (O) NQ589Q590, NQ591C (O) OQ592, NQ593C (O) NHQ594, NQ595C (O) NQ596Q597, NHS (O2) Q598, NQ599S O) Q602, S (O ₂ ) Q603, S (O ₂ ) NHQ604, S (O ₂ ) NQ605Q606, S (O ₂ ) OQ607, P (O) (OQ608) (OQ609), Si (Q610) (Q611) (Q612) "

Q561, Q562, Q563, Q564, Q565, Q566, Q567, Q568, Q569, Q570, Q571, Q572, Q573, Q574, Q575, Q585, Q586, Q587, Q588, Q589, Q590, Q591, Q592, Q593, Q594, Q595, Q596, Q597, Q598, Q599, Q600, Q601, Q602, Q603, Q604, Q605, Q606, Q607, Q608, Q610, Q611, Q612 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q567, Q568 and / or Q576, Q577 and / or Q589, Q590 and / or Q596, Q597 and / or Q605, Q606 may also be referred to in each case together as "heterocyclyl, heteroarylalkyl, Quot; reel "

(g) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ613, NQ614Q615, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q616, C (O) OQ617, C (O) NHQ618, C (O) NQ619Q620, OQ621, O (Q622-O) _c H (c = 1, 2, 3, 4, 5), O (Q623-O) _c Q624 (c = 1, 2, 3, 4, 5), OC (O) Q625, OC (O) OQ626, OC (O) NHQ627 , OC (O) NQ628Q629, OP (O) (OQ630) (OQ631), OSi (Q632) (Q633) (Q634), OS (O ₂ ) Q635, NHC (O) Q636, NQ637C (O) Q638, NHC ( O) OQ639, NHC (O) NHQ640, NHC (O) NQ641Q642, NQ643C (O) OQ644, NQ645C (O) NHQ646, NQ647C (O) NQ648Q649, NHS (O2) Q650, NQ651S (O2) Q652, SQ653, S ( O) Q654, S (O ₂ ) Q655, S (O ₂ ) NHQ656, S (O ₂ ) NQ657Q658, S (O ₂ ) OQ659, P (O) (OQ660) (OQ661), Si (Q662) (Q663) (Q664) "

Where Q613, Q614, Q615, Q616, Q617, Q618, Q619, Q620, Q621, Q622, Q623, Q624, Q625, Q626, Q627, Q628, Q629, Q630, Q631, Q632, Q633, Q634, Q635, Q636, Q637, Q638, Q639, Q640, Q641, Q642, Q643, Q644, Q645, Q646, Q647, Q648, Q649, Q650, Q651, Q652, Q653, Q654, Q655, Q656, Q657, Q658, Q659, Q660, Q661, Q662, Q663, Q664 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q649, Q642 and / or Q649 and / or Q657, Q658 are also referred to in each case together as "heterocycle, heteroaryl, heteroarylalkyl ", or, alternatively, Q619, Q620 and / or Q628, Q629 and / Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ665, NQ666Q667, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q668, C (O) OQ669, C (O) NHQ670, C (O) NQ671Q672, OQ673, O (Q674-O) _d H (d = 1, 2, 3, 4, 5), O (Q675-O) _d Q676 (d = 1, 2, 3, 4, 5), OC (O) Q677, OC (O) OQ678, OC (O) NHQ679 , OC (O) NQ680Q681, OP (O) (OQ682) (OQ683), OSi (Q684) (Q685) (Q686), OS (O 2) Q687, NHC (O) Q688, NQ689C (O) Q690, NHC ( O) OQ691, NHC (O) NHQ692, NHC (O) NQ693Q694, NQ695C (O) OQ696, NQ697C (O) NHQ698, NQ699C (O) NQ700Q701, NHS (O2) Q702, NQ703S _{O) Q706, S (O 2} ) Q707, S (O 2) NHQ708, S (O 2) NQ709Q710, S (O 2) OQ711, P (O) (OQ712) (OQ713), Si (Q714) (Q715) (Q716) "

Where Q665, Q666, Q667, Q668, Q669, Q670, Q671, Q672, Q673, Q674, Q675, Q676, Q677, Q678, Q679, Q680, Q681, Q682, Q683, Q684, Q685, Q686, Q687, Q688, Q689, Q690, Q691, Q692, Q693, Q694, Q695, Q696, Q697, Q698, Q699, Q700, Q701, Q702, Q703, Q704, Q705, Q706, Q707, Q708, Q709, Q710, Q711, Q712, Q713, Q714, Q715, Q716 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Quot; heteroaryl, heteroarylalkyl ", wherein, alternatively, Q671, Q672 and / or Q680, Q681 and / or Q693, Q694 and / or Q700, Q701 and / Quot; reel "

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ717, NQ718Q719, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q720, C (O) OQ721, C (O) NHQ722, C (O) NQ723Q724, OQ725, O (Q726-O) _e H (e = 1, 2, 3, 4, 5), O (Q727-O) _e Q728 (e = 1, 2, 3, 4, 5), OC (O) Q729, OC (O) OQ730, OC (O) NHQ731 , OC (O) NQ732Q733, OP (O) (OQ734) (OQ735), OSi (Q736) (Q737) (Q738), OS (O ₂ ) Q739, NHC (O) Q740, NQ741C (O) Q742, NHC ( O) OQ743, NHC (O) NHQ744, NHC (O) NQ745Q746, NQ747C (O) OQ748, NQ749C (O) NHQ750, NQ751C (O) NQ752Q753, NHS (O2) Q754, NQ755S (O2) Q756, SQ757, S ( O) Q758, S (O ₂ ) Q759, S (O ₂ ) NHQ760, S (O ₂ ) NQ761Q762, S (O ₂ ) OQ763, P (O) (OQ764) (OQ765), Si (Q766) (Q767) (Q768) "

Where Q717, Q718, Q719, Q720, Q721, Q722, Q723, Q724, Q725, Q726, Q727, Q728, Q729, Q730, Q731, Q732, Q733, Q734, Q735, Q736, Q737, Q738, Q739, Q740, Q741, Q742, Q743, Q744, Q745, Q746, Q747, Q748, Q749, Q750, Q751, Q752, Q753, Q754, Q755, Q756, Q757, Q758, Q759, Q760, Q761, Q762, Q763, Q764, Q765, Q766, Q767, Q768 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q723, Q724 and / or Q732, Q733 and / or Q745, Q746 and / or Q752, Q753 and / or Q761, Q762 are also in each case" heterocycle. "Quot; reel "

(h) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents identically or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ769, NQ770Q771, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q772, C (O) OQ773, C (O) NHQ774, C (O) NQ775Q776, OQ777, O (Q778-O) _f H (f = 1, 2, 3, 4, 5), O (Q779-O) _f Q780 (f = 1, 2, 3, 4, 5), OC (O) Q781, OC (O) OQ782, OC (O) NHQ783 , OC (O) NQ784Q785, OP (O) (OQ786) (OQ787), OSi (Q788) (Q789) (Q790), OS (O 2) Q791, NHC (O) Q792, NQ793C (O) Q794, NHC ( (O) OQ795, NHC (O) NHQ796, NHC (O) NQ797Q798, NQ799C (O) OQ800, NQ801C (O) NHQ802, NQ803C (O) NQ804Q805, NHS (O2) Q806, NQ807S _{O) Q810, S (O 2} ) Q811, S (O 2) NHQ812, S (O 2) NQ813Q814, S (O 2) OQ815, P (O) (OQ816) (OQ817), Si (Q818) (Q819) (Q820) "

Q769, Q770, Q770, Q771, Q772, Q773, Q774, Q775, Q776, Q777, Q778, Q779, Q780, Q781, Q782, Q783, Q784, Q785, Q786, Q787, Q788, Q789, Q790, Q793, Q794, Q795, Q796, Q797, Q798, Q799, Q800, Q801, Q802, Q803, Q804, Q805, Q806, Q807, Q808, Q809, Q810, Q811, Q812, Q813, Q814, Q815, Q818, Q819, Q820 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q775, Q776 and / or Q784, Q785 and / or Q797, Q798 and / or Q804, Q805 and / or Q813 and Q814 are also referred to in each case together as "heterocyclyl, heteroarylalkyl, Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHQ 821, NQ822Q823, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) Q824, C (O) OQ825, C (O) NHQ826, C (O) NQ827Q828, OQ829, O (Q830-O) g H (g = 1, 2, 3, 4, 5), O (Q831-O) g Q832 (g = 1, 2, 3, 4, 5), OC (O) Q833, OC (O) OQ834, OC (O) NHQ835 , OC (O) NQ836Q837, OP (O) (OQ838) (OQ839), OSi (Q840) (Q841) (Q842), OS (O 2) Q843, NHC (O) Q844, NQ845C (O) Q846, NHC ( O) OQ847, NHC (O) NHQ848, NHC (O) NQ849Q850, NQ851C (O) OQ852, NQ853C (O) NHQ854, NQ855C (O) NQ856Q857, NHS (O2) Q858, NQ859S (O2) Q860, SQ861, S ( _{O) Q862, S (O 2} ) Q863, S (O 2) NHQ864, S (O 2) NQ865Q866, S (O 2) OQ867, P (O) (OQ868) (OQ869), Si (Q870) (Q871) (Q872) "

Where Q821, Q822, Q823, Q824, Q825, Q826, Q827, Q828, Q829, Q830, Q831, Q832, Q833, Q834, Q835, Q836, Q837, Q838, Q839, Q840, Q841, Q842, Q843, Q844, Q845, Q846, Q847, Q848, Q849, Q850, Q851, Q852, Q853, Q854, Q855, Q856, Q857, Q858, Q859, Q860, Q861, Q862, Q863, Q864, Q865, Q866, Q867, Q868, Q869, Q870, Q871, Q872 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q827, Q827 and / or Q836, Q837 and / or Q849, Q850 and / or Q856, Q857 and / or Q865 and Q866 are also referred to in each case together as "heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHQ873, NQ874Q875, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, SO ₃ H, P (O) (OH) ₂ , C (O) Q876, C (O) OQ877, C (O) NHQ878, C (O) NQ879Q880, OQ881, O (Q882-O) _h H (h = 1, 2, 3, 4, 5), O (Q883-O) h Q884 (h = 1, 2, 3, 4, 5), OC (O) Q885, OC (O) OQ886, OC (O) NHQ887 , OC (O) NQ888Q889, OP (O) (OQ890) (OQ891), OSi (Q892) (Q893) (Q894), OS (O 2) Q895, NHC (O) Q896, NQ897C (O) Q898, NHC ( (O2) Q912, NQ911S (O2) Q912, SQ913, S (O) OQ899, NHC (O) NHQ900, NHC (O) NQ901Q902, NQ903C (O) OQ904, NQ905C (O) NHQ906, NQ907C _{O) Q914, S (O 2} ) Q915, S (O 2) NHQ916, S (O 2) NQ917Q918, S (O 2) OQ919, P (O) (OQ920) (OQ921), Si (Q922) (Q923) (Q924) "

Q873, Q874, Q875, Q876, Q877, Q878, Q879, Q880, Q881, Q882, Q883, Q884, Q885, Q886, Q887, Q888, Q889, Q890, Q891, Q892, Q893, Q894, Q897, Q898, Q899, Q900, Q901, Q902, Q903, Q904, Q905, Q906, Q907, Q908, Q909, Q910, Q911, Q912, Q913, Q914, Q915, Q916, Q917, Q918, Q919, Q922, Q923, Q924 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Q879, Q880 and / or Q888, Q889 and / or Q901, Q902 and / or Q908, Q909 and / or Q917, Q918 are also referred to in each case together as "heterocycle Reels ",

(j) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , NH, CN, CF ₃ , N ₃ , NH ₂ , NHQ 925, NQ 926 Q 927, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) Q928, C (O) OQ929, C (O) NHQ930, C (O) NQ931Q932, OQ933, O (Q934-O) i H (i = 1, 2, 3, 4, 5), O (Q935-O) i Q936 (i = 1, 2, 3, 4, 5), OC (O) Q937, OC (O) OQ938, OC (O) NHQ939 , OC (O) NQ940Q941, OP (O) (OQ942) (OQ943), OSi (Q944) (Q945) (Q946), OS (O ₂ ) Q947, NHC (O) Q948, NQ949C (O) Q950, NHC ( O) OQ951, NHC (O) NHQ952, NHC (O) NQ953Q954, NQ955C (O) OQ956, NQ957C (O) NHQ958, NQ959C (O) NQ960Q961, NHS (O2) Q962, NQ963S (O2) Q964, SQ965, S ( O) Q966, S (O ₂ ) Q967, S (O ₂ ) NHQ968, S (O ₂ ) NQ969Q970, S (O ₂ ) OQ971, P (O) (OQ972) (OQ973), Si (Q974) (Q975) (Q976) "

Where Q925, Q926, Q927, Q928, Q929, Q930, Q931, Q932, Q933, Q934, Q935, Q936, Q937, Q938, Q939, Q940, Q941, Q942, Q943, Q944, Q945, Q946, Q947, Q948, Q949, Q950, Q951, Q952, Q953, Q954, Q955, Q956, Q957, Q958, Q959, Q960, Q961, Q962, Q963, Q964, Q965, Q966, Q967, Q968, Q969, Q970, Q971, Q972, Q973, Q974, Q975, Q976 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q931, Q932 and / or Q940, Q941 and / or Q953, Q954 and / or Q960, Q961 and / or Q969, Q970 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ977, NQ978Q979, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q980, C (O) OQ981, C (O) NHQ982, C (O) NQ983Q984, OQ985, O (Q986-O) _j H (j = 1, 2, 3, 4, 5), O (Q987-O) _j Q988 (j = 1, 2, 3, 4, 5), OC (O) Q989, OC (O) OQ990, OC (O) NHQ991 , OC (O) NQ992Q993, OP (O) (OQ994) (OQ995), OSi (Q996) (Q997) (Q998), OS (O ₂ ) Q999, NHC (O) Q1000, NQ1001C (O) Q1002, NHC ( O) OQ1003, NHC (O) NHQ1004, NHC (O) NQ1005Q1006, NQ1007C (O) OQ1008, NQ1009C (O) NHQ1010, NQ1011C (O) NQ1012Q1013, NHS (O2) Q1014, NQ1015S (O2) Q1016, SQ1016, SQ1016 O) Q1018, S (O ₂ ) Q1019, S (O ₂ ) NHQ1020, S (O ₂ ) NQ1021Q1022, S (O ₂ ) OQ1023, P (O) (OQ1024) (OQ1025), Si (Q1026) (Q1027) (Q1028) "

Where Q977, Q978, Q979, Q980, Q981, Q982, Q983, Q984, Q985, Q986, Q987, Q988, Q989, Q990, Q991, Q992, Q993, Q994, Q995, Q996, Q997, Q998, Q999, Q1000, Q1001, Q1002, Q1003, Q1004, Q1005, Q1006, Q1007, Q1008, Q1009, Q1010, Q1011, Q1012, Q1013, Q1014, Q1015, Q1016, Q1017, Q1018, Q1019, Q1020, Q1021, Q1022, Q1023, Q1024, Q1024, Q1024 Q1026, Q1027, Q1028 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q983, Q984 and / or Q992, Q993 and / or Q1005, Q1006 and / or Q1012, Q1013 and / or Q1021, Q1022 are also in each case" heterocycle Reels ",

(k) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl", where, optionally, The above substituents of the substituent group (i) may each independently of each other be substituted by one or more substituents, which may be the same or different selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ1029, NQ1030Q1031, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q1032, C (O) OQ1033, C (O) NHQ1034, C (O) NQ1035Q1036, OQ1037, O (Q1038-O) _k H (k = 1, 2, 3, 4, 5), O (Q1039-O) _k Q1040 (k = 1, 2, 3, 4, 5), OC (O) Q1041, OC (O) OQ1042, OC (O) NHQ1043 , OC (O) NQ1044Q1045, OP (O) (OQ1046) (OQ1047), OSi (Q1048) (Q1049) (Q1050), OS (O ₂ ) Q1051, NHC (O) Q1052, NQ1053C (O) Q1054, NHC ( O) OQ1055, NHC (O) NHQ1056, NHC (O) NQ1057Q1058, NQ1059C (O) OQ1060, NQ1061C (O) NHQ1062, NQ1063C (O) NQ1064Q1065, NHS (O2) Q1066, NQ1067S (O2) Q1068, SQ1069 O) Q1070, S (O ₂ ) Q1071, S (O ₂ ) NHQ1072, S (O ₂ ) NQ1073Q1074, S (O ₂ ) OQ1075, P (O) (OQ1076) (OQ1077), Si (Q1078) (Q1079) (Q1080) "

Where Q1029, Q1030, Q1031, Q1032, Q1033, Q1034, Q1035, Q1036, Q1037, Q1038, Q1039, Q1040, Q1041, Q1042, Q1043, Q1044, Q1045, Q1046, Q1047, Q1048, Q1049, Q1050, Q1051, Q1052, Q1053, Q1054, Q1055, Q1056, Q1057, Q1058, Q1059, Q1060, Q1061, Q1062, Q1063, Q1064, Q1065, Q1066, Q1067, Q1068, Q1069, Q1070, Q1071, Q1072, Q1073, Q1074, Q1075, Q1077, Q1077 Q1078, Q1079, Q1080 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1035, Q1036 and / or Q1044, Q1045 and / or Q1057, Q1058 and / or Q1064, Q1065 and / or Q1073, Q1074 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ1081, NQ1082Q1083, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q1084, C (O) OQ1085, C (O) NHQ1086, C (O) NQ1087Q1088, OQ1089, O (Q1090-O) _l H (l = 1, 2, 3, 4, 5), O (Q1091-O) _l Q1092 (l = 1, 2, 3, 4, 5), OC (O) Q1093, OC (O) OQ1094, OC (O) NHQ1095 , OC (O) NQ1096Q1097, OP (O) (OQ1098) (OQ1099), OSi (Q1100) (Q1101) (Q1102), OS (O ₂ ) Q1103, NHC (O) Q1104, NQ1105C (O) Q1106, NHC ( O) OQ1107, NHC (O) NHQ1108, NHC (O) NQ1109Q1110, NQ1111C (O) OQ1112, NQ1113C (O) NHQ1114, NQ1115C (O) NQ1116Q1117, NHS (O2) Q1118, NQ1119S (O2) Q1120, SQ112 O) Q1122, S (O ₂ ) Q1123, S (O ₂ ) NHQ1124, S (O ₂ ) NQ1125Q1126, S (O ₂ ) OQ1127, P (O) (OQ1128) (OQ1129), Si (Q1130) (Q1131) (Q1132) "

Where Q1081, Q1082, Q1083, Q1084, Q1085, Q1086, Q1087, Q1088, Q1089, Q1090, Q1091, Q1092, Q1093, Q1094, Q1095, Q1096, Q1097, Q1098, Q1099, Q1100, Q1101, Q1102, Q1103, Q1104 Q1105, Q1106, Q1107, Q1108, Q1109, Q1110, Q1111, Q1112, Q1113, Q1114, Q1115, Q1116, Q1117, Q1118, Q1119, Q1120, Q1121, Q1122, Q1123, Q1124, Q1125, Q1126, Q1127, Q1128,11 Q1130, Q1131, Q1132 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1087, Q1088 and / or Q1096, Q1097 and / or Q1109, Q1110 and / or Q1116, Q1117 and / or Q1125, Q1126 are also in each case" heterocycle. " Reels ",

(l) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) Q1133 , C (O) OQ1134, C (O) NQ1135Q1136, S (O ₂ ) Q1137, S (O ₂ ) OQ1138 "

Wherein Q1133, Q1134, Q1135, Q1136, Q1137, Q1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero Cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, Q1135, Q1136 together may also form" heterocyclyl ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ1139, NQ1140Q1141, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q1142, C (O) OQ1143, C (O) NHQ1144, C (O) NQ1145Q1146, OQ1147, O (Q1148-O) _m H (m = 1, 2, 3, 4, 5), O (Q1149-O) _m Q1150 (m = 1, 2, 3, 4, 5), OC (O) Q1151, OC (O) OQ1152, OC (O) NHQ1153 , OC (O) NQ1154Q1155, OP (O) (OQ1156) (OQ1157), OSi (Q1158) (Q1159) (Q1160), OS (O ₂ ) Q1161, NHC (O) Q1162, NQ1163C (O) Q1164, NHC ( O) OQ1165, NHC (O) NHQ1166, NHC (O) NQ1167Q1168, NQ1169C (O) OQ1170, NQ1171C (O) NHQ1172, NQ1173C (O) NQ1174Q1175, NHS (O2) Q1176, NQ1177S (O2) Q1178, SQ1178, SQ1178 O) Q1180, S (O ₂ ) Q1181, S (O ₂ ) NHQ1182, S (O ₂ ) NQ1183Q1184, S (O ₂ ) OQ1185, P (O) (OQ1186) (OQ1187), Si (Q1188) (Q1189) (Q1190) "

Where Q1139, Q1140, Q1141, Q1142, Q1143, Q1144, Q1145, Q1146, Q1147, Q1148, Q1149, Q1150, Q1151, Q1152, Q1153, Q1154, Q1155, Q1156, Q1157, Q1158, Q1159, Q1160, Q1161, Q1162, Q1162 Q1163, Q1164, Q1165, Q1166, Q1167, Q1168, Q1169, Q1170, Q1171, Q1172, Q1173, Q1174, Q1175, Q1176, Q1177, Q1178, Q1179, Q1180, Q1181, Q1182, Q1183, Q1184, Q1185, Q1186, Q1188, Q1189, Q1190 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, Q1145, Q1146 and / or Q1154, Q1155 and / or Q1167, Q1168 and / or Q1174, Q1175 and / or Q1183, Q1184 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHQ1191, NQ1192Q1193, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) Q1194, C (O) OQ1195, C (O) NHQ1196, C (O) NQ1197Q1198, OQ1199, O (Q1200-O) nH (n = 1 , 2, 3, 4, 5), O (Q1201-O) nQ1202 (n = 1, 2, 3, 4, 5), OC (O) Q1203, OC (O) OQ1204, OC (O) NHQ1205, OC (O) NQ1206Q1207, OP (O) (OQ1208) (OQ1209), OSi (Q1210) (Q1211) (Q1212), OS (O ₂ ) Q1213, NHC (O) Q1214, NQ1215C (O) Q1216, NHC (O) OQ1217, NHC (O) NHQ1218, NHC (O) NQ1219Q1220, NQ1221C (O) OQ1222, NQ1223C (O) NHQ1224, NQ1225C (O) NQ1226Q1227, NHS (O2) Q1228, NQ1229S (O2) Q1230, SQ1231, SQ1231 Q1232, S (O ₂ ) Q1233, S (O ₂ ) NHQ1234, S (O ₂ ) NQ1235Q1236, S (O ₂ ) OQ1237, P (O) (OQ1238) (OQ1239), Si (Q1240) (Q1241) (Q1242 ) "

Where Q1191, Q1192, Q1193, Q1194, Q1195, Q1196, Q1197, Q1198, Q1199, Q1200, Q1201, Q1202, Q1203, Q1204, Q1205, Q1206, Q1207, Q1208, Q1209, Q1210, Q1211, Q1212, Q1213, Q1214, Q1214 Q1215, Q1216, Q1217, Q1218, Q1219, Q1220, Q1221, Q1222, Q1223, Q1224, Q1225, Q1226, Q1227, Q1228, Q1229, Q1230, Q1231, Q1232, Q1233, Q1234, Q1235, Q1236, Q1237, Q1238, Q1239 Q1240, Q1241, Q1242 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, Q1197, Q1198 and / or Q1206, Q1207 and / or Q1219, Q1220 and / or Q1226, Q1227 and / or Q1235, Q1236 are also in each case" heterocycle. " Reels ",

And

Z1 and Z2 radicals are each independently selected from the group consisting of: "hydrogen, NZ14Z15"

Provided that when Z1 = H, Z2 = NZ14Z15, and when Z1 = NZ14Z15, Z2 = H;

Wherein Z14 and Z15 are each independently selected from the group consisting of:

(a) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (Y1) NZ16Z17 , C (= NZ18) Z19, C (Y2) NZ20Y3Z21 "

Provided that Z14 and Z15 are simultaneously hydrogen or "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl" No,

Further provided that one of the Z14, Z15 radicals is hydrogen or "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, hetero Arylalkyl ", the remaining Z14, Z15 radicals are in each case" C (Y1) NZ16Z17 "," C (= NZ18) Z19 "or" C (Y2) NZ20Y3Z21 ",

Wherein Y1, Y2, Y3 are each independently selected from the group consisting of "O, S, = NH, = NZ22",

Wherein Z16, Z17, Z18, Z19, Z20, Z21, Z22 are each independently selected from the group consisting of:

(1) hydrogen

(2) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl"

Wherein said substituents of substitution group (a) and / or substitution group (2) may be optionally substituted each independently by one or more substituents, identically or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU 1, NU2U3, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U4, C (O) OU5, C (O) NHU6, C (O) NU7U8, OU9, O (U10-O) _r H (r = 1, 2, 3, 4, 5), O (U11-O) _r U12 (r = 1, 2, 3, 4, 5), OC (O) U13, OC (O) OU14, OC (O) NHU15 , OC (O) NU16U17, OP (O) (OU18) (OU19), OSi (U20) (U21) (U22), OS (O ₂ ) U23, NHC (O) U24, NU25C (O) U26, NHC ( O) OU27, NHC (O) NHU28, NHC (O) NU29U30, NU31C (O) OU32, NU33C (O) NHU34, NU35C (O) NU36U37, NHS (O2) U38, NU39S (O2) U40, SU41, S ( O) U42, S (O ₂ ) U43, S (O ₂ ) NHU44, S (O ₂ ) NU45U46, S (O ₂ ) OU47, P (O) (OU48) (OU49), Si (U50) (U51) (U52) "

Where U1, U2, U3, U4, U5, U6, U7, U8, U9, U10, U11, U12, U13, U14, U15, U16, U17, U18, U19, U20, U21, U22, U23, U24, U25, U26, U27, U28, U29, U30, U31, U32, U33, U34, U35, U36, U37, U38, U39, U40, U41, U42, U43, U44, U45, U46, U47, U48, U49, U50, U51, U52 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U7, U8 and / or U16, U17 and / or U29, U30 and / or U36, U37 and / or U45, U46 may also in each case be" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU53, NU54U55, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U56, C (O) OU57, C (O) NHU58, C (O) NU59U60, OU61, O (U62-O) _r H (r = 1, 2, 3, 4, 5), O (U63-O) _r U64 (r = 1, 2, 3, 4, 5), OC (O) U65, OC (O) OU66, OC (O) NHU67 , OC (O) NU68U69, OP (O) (OU70) (OU71), OSi (U72) (U73) (U74), OS (O ₂ ) U75, NHC (O) U76, NU77C (O) U78, NHC ( O) OU79, NHC (O) NHU80, NHC (O) NU81U82, NU83C (O) OU84, NU85C (O) NHU86, NU87C (O) NU88U89, NHS (O2) U90, NU91S (O2) U92, SU93, S ( O) U94, S (O ₂ ) U95, S (O ₂ ) NHU96, S (O ₂ ) NU97U98, S (O ₂ ) OU99, P (O) (OU100) (OU101), Si (U102) (U103) (U104) "

Where U53, U54, U55, U56, U57, U58, U59, U60, U61, U62, U63, U64, U65, U66, U67, U68, U69, U70, U71, U72, U73, U74, U75, U76, U77, U78, U79, U80, U81, U82, U83, U84, U85, U86, U87, U88, U89, U90, U91, U92, U93, U94, U95, U96, U97, U98, U99, U100, U101, U102, U103, U104 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U59, U60 and / or U68, U69 and / or U81, U82 and / or U88, U89 and / or U97, U98 may also in each case be" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU105, NU106U107, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U108, C (O) OU109, C (O) NHU110, C (O) NU111U112, OU113, O (U114-O) _s H (s = 1, 2, 3, 4, 5), O (U115-O) _s U116 (s = 1, 2, 3, 4, 5), OC (O) U117, OC (O) OU118, OC (O) NHU119 , OC (O) NU120U121, OP (O) (OU122) (OU123), OSi (U124) (U125) (U126), OS (O ₂ ) U127, NHC (O) U128, NU129C (O) U130, NHC ( O) OU131, NHC (O) NHU132, NHC (O) NU133U134, NU135C (O) OU136, NU137C (O) NHU138, NU139C (O) NU140U141, NHS (O2) U142, NU143S (O2) U144, SU145, S ( O) U146, S (O ₂ ) U147, S (O ₂ ) NHU148, S (O ₂ ) NU149U150, S (O ₂ ) OU151, P (O) (OU152) (OU153), Si (U154) (U155) (U156) "

Where U105, U106, U107, U108, U109, U110, U111, U112, U113, U114, U115, U116, U117, U118, U119, U120, U121, U122, U123, U124, U125, U126, U127, U128, U129, U130, U131, U132, U133, U134, U135, U136, U137, U138, U139, U140, U141, U142, U143, U144, U145, U146, U147, U148, U149, U150, U151, U152, U153, U154, U155, U156 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U111, U112 and / or U120, U121 and / or U133, U134 and / or U140, U141 and / or U149, U150 are also in each case" heterocycle. " Reels ",

(3) C (O) Z23,

Wherein Z23 is independently selected from the group consisting of:

(a) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Wherein said substituents in substitution group (a) may each be optionally substituted independently by one or more substituents selected the same or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU157, NU158U159, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U160, C (O) OU161, C (O) NHU162, C (O) NU163U164, OU165, O (U166-O) _t H (t = 1, 2, 3, 4, 5), O (U167-O) _t U168 (t = 1, 2, 3, 4, 5), OC (O) U169, OC (O) OU170, OC (O) NHU171 , OC (O) NU172U173, OP (O) (OU174) (OU175), OSi (U176) (U177) (U178), OS (O ₂ ) U179, NHC (O) U180, NU181C (O) U182, NHC ( O) OU183, NHC (O) NHU184, NHC (O) NU185U186, NU187C (O) OU188, NU189C (O) NHU190, NU191C (O) NU192U193, NHS (O2) U194, NU195S (O2) U196, SU197, S ( O) U198, S (O ₂ ) U199, S (O ₂ ) NHU200, S (O ₂ ) NU201U202, S (O ₂ ) OU203, P (O) (OU204) (OU205), Si (U206) (U207) (U208) "

Where U157, U158, U159, U160, U161, U162, U163, U164, U165, U166, U167, U168, U169, U170, U171, U172, U173, U174, U175, U176, U177, U178, U179, U180, U181, U182, U183, U184, U185, U186, U187, U188, U189, U190, U191, U192, U193, U194, U195, U196, U197, U198, U199, U200, U201, U202, U203, U204, U205, U206, U207, U208 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U163, U164 and / or U172, U173 and / or U185, U186 and / or U192, U193 and / or U201, U202 are also in each case a" heterocycle Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU209, NU210U211, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U212, C (O) OU213, C (O) NHU214, C (O) NU215U216, OU217, O (U218-O) _u H (u = 1, 2, 3, 4, 5), O (U219-O) _u U220 (u = 1, 2, 3, 4, 5), OC (O) U221, OC (O) OU222, OC (O) NHU223 , OC (O) NU224U225, OP (O) (OU226) (OU227), OSi (U228) (U229) (U230), OS (O ₂ ) U231, NHC (O) U232, NU233C (O) U234, NHC ( O) OU235, NHC (O) NHU236, NHC (O) NU237U238, NU239C (O) OU240, NU241C (O) NHU242, NU243C (O) NU244U245, NHS (O2) U246, NU247S (O2) U248, SU249, S ( O) U250, S (O ₂ ) U251, S (O ₂ ) NHU252, S (O ₂ ) NU253U254, S (O ₂ ) OU255, P (O) (OU256) (OU257), Si (U258) (U259) (U260) "

Where U209, U210, U211, U212, U213, U214, U215, U216, U217, U218, U219, U220, U221, U222, U223, U224, U225, U226, U227, U228, U229, U230, U231, U232, U233, U234, U235, U236, U237, U238, U239, U240, U241, U242, U243, U244, U245, U246, U247, U248, U249, U250, U251, U252, U253, U254, U255, U256, U257, U258, U259, U260 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U215, U216 and / or U224, U225 and / or U237, U238 and / or U244, U245 and / or U253, U254 are also in each case" heterocycle Reels ",

Wherein, optionally, said substituents in substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU261, NU262U263, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U264, C (O) OU265, C (O) NHU266, C (O) NU267U268, OU269, O (U270-O) _v H (v = 1, 2, 3, 4, 5), O (U271-O) _v U272 (v = 1, 2, 3, 4, 5), OC (O) U273, OC (O) OU274, OC (O) NHU275 , OC (O) NU276U277, OP (O) (OU278) (OU279), OSi (U280) (U281) (U282), OS (O ₂ ) U283, NHC (O) U284, NU285C (O) U286, NHC ( O) OU287, NHC (O) NHU288, NHC (O) NU289U290, NU291C (O) OU292, NU293C (O) NHU294, NU295C (O) NU296U297, NHS (O2) U298, NU299S (O2) U300, SU301, S ( O) U302, S (O ₂ ) U303, S (O ₂ ) NHU304, S (O ₂ ) NU305U306, S (O ₂ ) OU307, P (O) (OU308) (OU309), Si (U310) (U311) (U312) "

Where U261, U262, U263, U264, U265, U266, U267, U268, U269, U270, U271, U272, U273, U274, U275, U276, U277, U278, U279, U280, U281, U282, U283, U284, U285, U286, U287, U288, U289, U290, U291, U292, U293, U294, U295, U296, U297, U298, U299, U300, U301, U302, U303, U304, U305, U306, U307, U308, U309, U310, U311, U312 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U267, U268 and / or U276, U277 and / or U289, U290 and / or U296, U297 and / or U305, U306 are also in each case a" heterocycle Reels ",

(4) Z16, Z17 can also independently optionally form "heterocyclyl";

(5) "C (O) C (O) U313, S (O ₂ ) NU314U315"

Wherein U313, U314 and U315 are each independently selected from the group consisting of:

(I) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF ₃ , N ₃ , NH ₂ , NHU316, NU317U318, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U319, C (O) OU320, C (O) NHU321, C (O) NU322U323, OU324, O (U325-O) _w H ( w = 1, 2, 3, 4, 5), O (U326-O) _w U327 (w = 1, 2, 3, 4, 5), OC (O) U328, OC (O) OU329, OC (O NHU330, OC (O) NU331U332, OP (O) (OU333) (OU334), OSi (U335) (U336) (U337), OS (O ₂ ) U338, NHC (O) U339, NU340C (O) U341, NHC (O) OU342, NHC (O) NHU343, NHC (O) NU344U345, NU346C (O) OU347, NU348C (O) NHU349, NU350C (O) NU351U352, NHS (O2) U353, NU354S (O2) U355, SU356, S (O) U357, S (O ₂ ) U358, S (O ₂ ) NHU359, S (O ₂ ) NU360U361, S (O ₂ ) OU362, P (O) (OU363) (OU364), Si (U365) ( U366) (U367) "

Where U316, U317, U318, U319, U320, U321, U322, U323, U324, U325, U326, U327, U328, U329, U330, U331, U332, U333, U334, U335, U336, U337, U338, U339, U340, U341, U342, U343, U344, U345, U346, U347, U348, U349, U350, U351, U352, U353, U354, U355, U356, U357, U358, U359, U360, U361, U362, U363, U364, U365, U366, U367 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U322, U323 and / or U331, U332 and / or U344, U345 and / or U351, U352 and / or U360, U361 may also in each case be" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU368, NU369U370, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U371, C (O) OU372, C (O) NHU373, C (O) NU374U375, OU376, O (U377-O) xH (x = 1 , 2, 3, 4, 5), O (U378-O) _x ) _x U379 (x = 1, 2, 3, 4, 5), OC (O) U380, OC (O) OU381, OC (O) NHU382, OC (O) NU383U384, OP (O) (OU385) (OU386), OSi (U387) (U388) (U389), OS (O ₂ ) U390, NHC (O) U391, NU392C (O) U393, NHC (O) OU394, NHC (O) NHU395, NHC (O) NU396U397, NU398C (O) OU399, NU400C (O) NHU401, NU402C (O) NU403U404, NHS (O2) U405, NU406S (O2) U407, SU408, S (O) U409, S (O ₂ ) U410, S (O ₂ ) NHU411, S (O ₂ ) NU412U413, S (O ₂ ) OU414, P (O) (OU415) (OU416), Si (U417) (U418 ) (U419) "

Where U368, U369, U370, U371, U372, U373, U374, U375, U376, U377, U378, U379, U380, U381, U382, U383, U384, U385, U386, U387, U388, U389, U390, U391, U392, U393, U394, U395, U396, U397, U398, U399, U400, U401, U402, U403, U404, U405, U406, U407, U408, U409, U410, U411, U412, U413, U414, U415, U416, U417, U418, U419 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U374, U375 and / or U383, U384 and / or U396, U397 and / or U403, U404 and / or U412, U413 are also in each case a" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU420, NU421U422, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U423, C (O) OU424, C (O) NHU425, C (O) NU426U427, OU428, O (U429-O) _y H (y = 1, 2, 3, 4, 5), O (U430-O) _y U431 (y = 1, 2, 3, 4, 5), OC (O) U432, OC (O) OU433, OC (O) NHU434 , OC (O) NU435U436, OP (O) (OU437) (OU438), OSi (U439) (U440) (U441), OS (O ₂ ) U442, NHC (O) U443, NU444C (O) U445, NHC ( O) OU446, NHC (O) NHU447, NHC (O) NU448U449, NU450C (O) OU451, NU452C (O) NHU453, NU454C (O) NU455U456, NHS (O2) U457, NU458S (O2) U459, SU460, S ( O) U461, S (O ₂ ) U462, S (O ₂ ) NHU463, S (O ₂ ) NU464U465, S (O ₂ ) OU466, P (O) (OU467) (OU468), Si (U469) (U470) (U471) "

Where U420, U421, U422, U423, U424, U425, U426, U427, U428, U429, U430, U431, U432, U433, U434, U435, U436, U437, U438, U439, U440, U441, U442, U443, U444, U445, U446, U447, U448, U449, U450, U451, U452, U453, U454, U455, U456, U457, U458, U459, U460, U461, U462, U463, U464, U465, U466, U467, U468, U469, U470, U471 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U426, U427 and / or U435, U436 and / or U448, U449 and / or U455, U456 and / or U464, U465 are also in each case together a" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHU472, NU473U474, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) U475, C (O) OU476, C (O) NHU477, C (O) NU478U479, OU480, O (U481-O) _z H (z = 1, 2, 3, 4, 5), O (U482-O) _z U483 (z = 1, 2, 3, 4, 5), OC (O) U484, OC (O) OU485, OC (O) NHU486 , OC (O) NU487U488, OP (O) (OU489) (OU490), OSi (U491) (U492) (U493), OS (O ₂ ) U494, NHC (O) U495, NU496C (O) U497, NHC ( O) OU498, NHC (O) NHU499, NHC (O) NU500U501, NU502C (O) OU503, NU504C (O) NHU505, NU506C (O) NU507U508, NHS (O2) U509, NU510S (O2) U511, SU512, S ( O) U513, S (O ₂ ) U514, S (O ₂ ) NHU515, S (O ₂ ) NU516U517, S (O ₂ ) OU518, P (O) (OU519) (OU520), Si (U521) (U522) (U523) "

Where U472, U473, U474, U475, U476, U477, U478, U479, U480, U481, U482, U483, U484, U485, U486, U487, U488, U489, U490, U491, U492, U493, U494, U495, U496, U497, U498, U499, U500, U501, U502, U503, U504, U505, U506, U507, U508, U509, U510, U511, U512, U513, U514, U515, U516, U517, U518, U519, U520, U521, U522, U523 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, U478, U479 and / or U487, U488 and / or U500, U501 and / or U507, U508 and / or U516, U517 are also in each case a" heterocycle. " Reels ",

Here, alternatively, U314, U315 may also together form “heterocyclyl”,

And

Z5 radicals are independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF ₃ , N ₃ , NH ₂ , NHA1, NA2A3, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) A4, C (O) OA5, C (O) NHA6, C (O) NA7A8, OA9, O (A10-O) _r H ( r = 1, 2, 3, 4, 5), O (A11-O) _r A12 (r = 1, 2, 3, 4, 5), OC (O) A13, OC (O) OA14, OC (O NHA15, OC (O) NA16A17, OP (O) (OA18) (OA19), OSi (A20) (A21) (A22), OS (O ₂ ) A23, NHC (O) A24, NA25C (O) A26, NHC (O) OA27, NHC (O) NHA28, NHC (O) NA29A30, NA31C (O) OA32, NA33C (O) NHA34, NA35C (O) NA36A37, NHS (O2) A38, NA39S (O2) A40, SA41, S (O) A42, S (O ₂ ) A43, S (O ₂ ) NHA44, S (O ₂ ) NA45A46, S (O ₂ ) OA47, P (O) (OA48) (OA49), Si (A50) ( A51) (A52) "

Where A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, A7, A8 and / or A16, A17 and / or A29, A30 and / or A36, A37 and / or A45, A46 may also in each case be" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHA53, NA54A55, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) A56, C (O) OA57, C (O) NHA58, C (O) NA59A60, OA61, O (A62-O) _s H (s = 1, 2, 3, 4, 5), O (A63-O) _t A64 (t = 1, 2, 3, 4, 5), OC (O) A65, OC (O) OA66, OC (O) NHA67 , OC (O) NA68A69, OP (O) (OA70) (OA71), OSi (A72) (A73) (A74), OS (O ₂ ) A75, NHC (O) A76, NA77C (O) A78, NHC ( O) OA79, NHC (O) NHA80, NHC (O) NA81A82, NA83C (O) OA84, NA85C (O) NHA86, NA87C (O) NA88A89, NHS (O ₂ ) A90, NA91S (O ₂ ) A92, SA93, S (O) A94, S (O ₂ ) A95, S (O ₂ ) NHA96, S (O ₂ ) NA97A98, S (O ₂ ) OA99, P (O) (OA100) (OA101), Si (A102) ( A103) (A104) "

Where A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, A59, A60 and / or A68, A69 and / or A81, A82 and / or A88, A89 and / or A97, A98 are also in each case" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHA105, NA106A107, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) A108, C (O) OA109, C (O) NHA110, C (O) NA111A112, OA113, O (A114-O) _t H (t = 1, 2, 3, 4, 5), O (A115-O) _t A116 (t = 1, 2, 3, 4, 5), OC (O) A117, OC (O) OA118, OC (O) NHA119 , OC (O) NA120A121, OP (O) (OA122) (OA123), OSi (A124) (A125) (A126), OS (O ₂ ) A127, NHC (O) A128, NA129C (O) A130, NHC ( O) OA131, NHC (O) NHA132, NHC (O) NA133A134, NA135C (O) OA136, NA137C (O) NHA138, NA139C (O) NA140A141, NHS (O2) A142, NA143S (O2) A144, SA145, S ( O) A146, S (O ₂ ) A147, S (O ₂ ) NHA148, S (O ₂ ) NA149A150, S (O ₂ ) OA151, P (O) (OA152) (OA153), Si (A154) (A155) (A156) "

Where A105, A106, A107, A108, A109, A110, A111, A112, A113, A114, A115, A116, A117, A118, A119, A120, A121, A122, A123, A124, A125, A126, A127, A128, A129, A130, A131, A132, A133, A134, A135, A136, A137, A138, A139, A140, A141, A142, A143, A144, A145, A146, A147, A148, A149, A150, A151, A152, A153, A154, A155, A156 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, A111, A112 and / or A120, A121 and / or A133, A134 and / or A140, A141 and / or A149, A150 are also in each case" heterocycle Reels ",

or

(E) one of the Z1, Z2 radicals or both Z1, Z2 radicals is each independently selected from the group consisting of:

(a) NZ24Z25;

Provided that either one of the Z24, Z25 radicals or both Z24, Z25 radicals is each independently selected from the group consisting of:
(1a) "C (O) C (O) T1"
Wherein T1 is selected from the group consisting of:
(I) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroarylalkyl, F, Cl, Br, I, CN, CF ₃ , N ₃ , NH ₂ , NHT 4, NT5T6, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T7, C (O) OT8, C (O) NHT9, C (O) NT10T11, OT12, O (T13-O) _p H (p = 1 , 2, 3, 4, 5), O (T14-O) _p T15 (p = 1, 2, 3, 4, 5), OC (O) T16, OC (O) OT17, OC (O) NHT18, OC (O) NT19T20, OP (O) (OT21) (OT22), OSi (T23) (T24) (T25), OS (O ₂ ) T26, NHC (O) T27, NT28C (O) T29, NHC (O ) OT30, NHC (O) NHT31, NHC (O) NT32T33, NT34C (O) OT35, NT36C (O) NHT37, NT38C (O) NT39T40, NHS (O ₂ ) T41, NT42S (O ₂ ) T43, ST44, S (O) T45, S (O ₂ ) T46, S (O ₂ ) NHT47, S (O ₂ ) NT48T49, S (O ₂ ) OT50, P (O) (OT51) (OT52), Si (T53) (T54 ) (T55) "
Provided that at least one of the Z24 and Z25 radicals or both Z24 and Z25 radicals are each independently selected from the group consisting of:
(1b) "S (O ₂ ) NT2T3"
Wherein T2 and T3 are each independently selected from the group consisting of:

(J) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroarylalkyl, F, Cl, Br, I, CN, CF ₃ , N ₃ , NH ₂ , NHT 4, NT5T6, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T7, C (O) OT8, C (O) NHT9, C (O) NT10T11, OT12, O (T13-O) _p H (p = 1 , 2, 3, 4, 5), O (T14-O) _p T15 (p = 1, 2, 3, 4, 5), OC (O) T16, OC (O) OT17, OC (O) NHT18, OC (O) NT19T20, OP (O) (OT21) (OT22), OSi (T23) (T24) (T25), OS (O ₂ ) T26, NHC (O) T27, NT28C (O) T29, NHC (O ) OT30, NHC (O) NHT31, NHC (O) NT32T33, NT34C (O) OT35, NT36C (O) NHT37, NT38C (O) NT39T40, NHS (O ₂ ) T41, NT42S (O ₂ ) T43, ST44, S (O) T45, S (O ₂ ) T46, S (O ₂ ) NHT47, S (O ₂ ) NT48T49, S (O ₂ ) OT50, P (O) (OT51) (OT52), Si (T53) (T54 ) (T55) "

delete

delete

Where T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42, T43, T44, T45, T46, T47, T48, T49, T50, T51, T52, T53, T54, T55 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T10, T11 and / or T19, T20 and / or T32, T33 and / or T39, T40 and / or T48, T49 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT56, NT57T58, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T59, C (O) OT60, C (O) NHT61, C (O) NT62T63, OT64, O (T65-O) _r H (r = 1, 2, 3, 4, 5), O (T66-O) _r T67 (r = 1, 2, 3, 4, 5), OC (O) T68, OC (O) OT69, OC (O) NHT70 , OC (O) NT71T72, OP (O) (OT73) (OT74), OSi (T75) (T76) (T77), OS (O ₂ ) T78, NHC (O) T79, NT80C (O) T81, NHC ( O) OT82, NHC (O) NHT83, NHC (O) NT84T85, NT86C (O) OT87, NT88C (O) NHT89, NT90C (O) NT91T92, NHS (O ₂ ) T93, NT94S (O ₂ ) T95, ST96, S (O) T97, S (O ₂ ) T98, S (O ₂ ) NHT99, S (O ₂ ) NT100T101, S (O ₂ ) OT102, P (O) (OT103) (OT104), Si (T105) ( T106) (T107) "

Where T56, T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90, T91, T92, T93, T94, T95, T96, T97, T98, T99, T100, T101, T102, T103, T104, T105, T106, T107 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T62, T63 and / or T71, T72 and / or T84, T85 and / or T91, T92 and / or T100, T101 are also in each case" heterocycle Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT108, NT109T110, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T111, C (O) OT112, C (O) NHT113, C (O) NT114T115, OT116, O (T117-O) _s H (s = 1, 2, 3, 4, 5), O (T118-O) _s T119 (s = 1, 2, 3, 4, 5), OC (O) T120, OC (O) OT121, OC (O) NHT122 , OC (O) NT123T124, OP (O) (OT125) (OT126), OSi (T127) (T128) (T129), OS (O ₂ ) T130, NHC (O) T131, NT132C (O) T133, NHC ( O) OT134, NHC (O) NHT135, NHC (O) NT136T137, NT138C (O) OT139, NT140C (O) NHT141, NT142C (O) NT143T144, NHS (O ₂ ) T145, NT146S (O ₂ ) T147, ST148, S (O) T149, S (O ₂ ) T150, S (O ₂ ) NHT151, S (O ₂ ) NT152T153, S (O ₂ ) OT154, P (O) (OT155) (OT156), Si (T157) ( T158) (T159) "

Where T108, T109, T110, T111, T112, T113, T114, T115, T116, T117, T118, T119, T120, T121, T122, T123, T124, T125, T126, T127, T128, T129, T130, T131, T132, T133, T134, T135, T136, T137, T138, T139, T140, T141, T142, T143, T144, T145, T146, T147, T148, T149, T150, T151, T152, T153, T154, T155, T156, T157, T158, T159 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T114, T115 and / or T123, T124 and / or T136, T137 and / or T143, T144 and / or T152, T153 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT160, NT161T162, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T163, C (O) OT164, C (O) NHT165, C (O) NT166T167, OT168, O (T169-O) _t H (t = 1, 2, 3, 4, 5), O (T170-O) _t T171 (t = 1, 2, 3, 4, 5), OC (O) T172, OC (O) OT173, OC (O) NHT174 , OC (O) NT175T176, OP (O) (OT177) (OT178), OSi (T179) (T180) (T181), OS (O ₂ ) T182, NHC (O) T183, NT184C (O) T185, NHC ( O) OT186, NHC (O) NHT187, NHC (O) NT188T189, NT190C (O) OT191, NT192C (O) NHT193, NT194C (O) NT195T196, NHS (O ₂ ) T197, NT198S (O ₂ ) T199, ST200, S (O) T201, S (O ₂ ) T202, S (O ₂ ) NHT203, S (O ₂ ) NT204T205, S (O ₂ ) OT206, P (O) (OT207) (OT208), Si (T209) ( T210) (T211) "

Where T160, T161, T162, T163, T164, T165, T166, T167, T168, T169, T170, T171, T172, T173, T174, T175, T176, T177, T178, T179, T180, T181, T182, T183, T184, T185, T186, T187, T188, T189, T190, T191, T192, T193, T194, T195, T196, T197, T198, T199, T200, T201, T202, T203, T204, T205, T206, T207, T208, T209, T210, T211 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T166, T167 and / or T175, T176 and / or T188, T189 and / or T195, T196 and / or T204, T205 are also in each case" heterocycle. " Reels ";

Here, alternatively, T2, T3 may also together form "heterocyclyl",

And one of the Z24, Z25 radicals is independently selected from the group consisting of, or neither of the Z24, Z25 radicals is independently selected from the group consisting of:

(2) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Here, optionally, the aforementioned substituents of the substitution group (2) may each be further substituted by one or more substituents independently or identically selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT212, NT213T214, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T215, C (O) OT216, C (O) NHT217, C (O) NT218T219, OT220, O (T221-O) _u H (u = 1, 2, 3, 4, 5), O (T222-O) _u T223 (u = 1, 2, 3, 4, 5), OC (O) T224, OC (O) OT225, OC (O) NHT226 , OC (O) NT227T228, OP (O) (OT229) (OT230), OSi (T231) (T232) (T233), OS (O ₂ ) T234, NHC (O) T235, NT236C (O) T237, NHC ( O) OT238, NHC (O) NHT239, NHC (O) NT240T241, NT242C (O) OT243, NT244C (O) NHT245, NT246C (O) NT247T248, NHS (O ₂ ) T249, NT250S (O ₂ ) T251, ST252, S (O) T253, S (O ₂ ) T254, S (O ₂ ) NHT255, S (O ₂ ) NT256T257, S (O ₂ ) OT258, P (O) (OT259) (OT260), Si (T261) ( T262) (T263) "

Where T212, T213, T214, T215, T216, T217, T218, T219, T220, T221, T222, T223, T224, T225, T226, T227, T228, T229, T230, T231, T232, T233, T234, T235, T236, T237, T238, T239, T240, T241, T242, T234, T244, T245, T246, T247, T248, T249, T250, T251, T252, T253, T254, T255, T256, T257, T258, T259, T260, T261, T262, T263 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T218, T219 and / or T227, T228 and / or T240, T241 and / or T247, T248 and / or T256, T257 are also in each case" heterocycle. " Reels ";

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT264, NT265T266, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T267, C (O) OT268, C (O) NHT269, C (O) NT270T271, OT272, O (T273-O) _v H (v = 1, 2, 3, 4, 5), O (T274-O) _v T275 (v = 1, 2, 3, 4, 5), OC (O) T276, OC (O) OT277, OC (O) NHT278 , OC (O) NT279T280, OP (O) (OT281) (OT282), OSi (T283) (T284) (T285), OS (O ₂ ) T286, NHC (O) T287, NT288C (O) T289, NHC ( O) OT290, NHC (O) NHT291, NHC (O) NT292T293, NT294C (O) OT295, NT296C (O) NHT297, NT298C (O) NT299T300, NHS (O ₂ ) T301, NT302S (O ₂ ) T303, ST304, S (O) T305, S (O ₂ ) T306, S (O ₂ ) NHT307, S (O ₂ ) NT308T309, S (O ₂ ) OT310, P (O) (OT311) (OT312), Si (T313) ( T314) (T315) "

Where T264, T265, T266, T267, T268, T269, T270, T271, T272, T273, T274, T275, T276, T277, T278, T279, T280, T281, T282, T283, T284, T285, T286, T287, T288, T289, T290, T291, T292, T293, T294, T295, T296, T297, T298, T299, T300, T301, T302, T303, T304, T305, T306, T307, T308, T309, T310, T311, T312, T313, T314, T315 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T270, T271 and / or T279, T280 and / or T292, T293 and / or T299, T300 and / or T308, T309 are also in each case" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT316, NT317T318, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T319, C (O) OT320, C (O) NHT321, C (O) NT322T323, OT324, O (T325-O) _w H (w = 1, 2, 3, 4, 5), O (T326-O) _w T327 (w = 1, 2, 3, 4, 5), OC (O) T328, OC (O) OT329, OC (O) NHT330 , OC (O) NT331T332, OP (O) (OT333) (OT334), OSi (T335) (T336) (T337), OS (O ₂ ) T338, NHC (O) T339, NT340C (O) T341, NHC ( O) OT342, NHC (O) NHT343, NHC (O) NT344T345, NT346C (O) OT347, NT348C (O) NHT349, NT350C (O) NT351T352, NHS (O ₂ ) T353, NT354S (O ₂ ) T355, ST356, S (O) T357, S (O ₂ ) T358, S (O ₂ ) NHT359, S (O ₂ ) NT360T361, S (O ₂ ) OT362, P (O) (OT363) (OT364), Si (T365) ( T366) (T367) "

Where T316, T317, T318, T319, T320, T321, T322, T323, T324, T325, T326, T327, T328, T329, T330, T331, T332, T333, T334, T335, T336, T337, T338, T339, T340, T341, T342, T343, T344, T345, T346, T347, T348, T349, T350, T351, T352, T353, T354, T355, T356, T357, T358, T359, T360, T361, T362, T363, T364, T365, T366, T367 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T322, T323 and / or T331, T332 and / or T344, T345 and / or T351, T352 and / or T360, T361 may also in each case be" heterocycle. " Reels ",

(b) NZ26Z27 wherein one of the Z26, Z27 radicals or both Z26, Z27 radicals is each independently selected from the group consisting of:

(1) "C (Y4) NZ28Z29, C (= NZ30) Z31"

Wherein Y4 is independently selected from the group consisting of "O, S, = NH, = NZ32",

only,

At least one of the Z28, Z29 radicals and at least one of the Z30, Z31 radicals is independently selected from the group consisting of:

(I) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C (O) alkyl, C (O) aryl, C (O) heteroaryl"

Further provided that the aforementioned substituents in substituent group (i) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "(C ₉ -C ₃₀ ) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, N3, NT368T369, NHC (O) cycloalkylalkyl, NHC (O) heterocyclylalkyl, NT370C (O) T371, NHC (O) OT372, NHC (O) NHT373, NHC (O) NT374T375, NT376C (O) OT377, NT378C (O) NHT379, NT380C (O) NT381T382, NHS (O ₂ ) cycloalkylalkyl , NHS (O ₂ ) heterocyclylalkyl, NT383S (O2) T384, OT385, O (T386-O) _x T387 (x = 1, 2, 3, 4, 5), O (T388-O) _x H ( x = 1, 2, 3, 4, 5), OC (O) -cycloalkylalkyl, OC (O) -heterocyclylalkyl, OC (O) OT389, OC (O) NHT390, OC (O) NT391T392, OS (O ₂ ) cycloalkylalkyl, OS (O 2) heterocyclylalkyl, —OP (O) (OT393) (OT394), OSi (T395) (T396) (T397), CHO, C (O) cycloalkyl, C (O) heterocyclyl, C (O) cycloalkylalkyl, C (O) heterocyclylalkyl, C (O) arylalkyl, C (O) heteroarylalkyl, S cycloalkylalkyl, S heterocyclylalkyl , Sarylalkyl, Sheteroarylalkyl, S (O) cycloalkyl, S (O) hetero Cyclyl, S (O) heteroaryl, S (O) cycloalkylalkyl, S (O) heterocyclylalkyl, S (O) arylalkyl, S (O) heteroarylalkyl, S (O ₂ ) cycloalkyl, S (O2) heterocyclyl, S (O2) heteroaryl, S (O ₂ ) cycloalkylalkyl, S (O2) heterocyclylalkyl, S (O2) arylalkyl, S (O2) heteroarylalkyl, S ( O ₂ ) NH cycloalkyl, S (O ₂ ) NH heterocyclyl, S (O ₂ ) NH cycloalkylalkyl, S (O ₂ ) NH heterocyclylalkyl, S (O ₂ ) NH heteroarylalkyl, S (O ₂ ) NT398T399, S (O ₂₎ O-cycloalkyl, S (O ₂₎ O-heterocyclyl, S (O ₂₎ O-heteroaryl, S (O ₂₎ O-cycloalkyl-alkyl, S (O2) O heterocycle rilal attempts. S (O2) O Heteroarylalkyl, P (O) (OH) 2, P (O) (OT400) (OT401), Si (T402) (T403) (T404) "

Further provided that "N (alkyl) ₂ ", "C (O) N (alkyl) ₂ ", "C (O) N (cycloalkyl) ₂ ", "C (O) N (aryl) ₂ ", " C (O) N (heteroaryl) ₂ ″ is further substituted by one or more substituents selected from the following substituent group (ii);

Where T368, T369, T370, T371, T372, T373, T374, T375, T376, T377, T378, T379, T380, T381, T382, T383, T384, T385, T386, T387, T388, T389, T390, T391, T392, T393, T394, T395, T396, T397, T398, T399, T400, T401, T402, T403, T404 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cyclo Alkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", wherein, alternatively, T374, T375 and / or T381, T382 and / or T391, T392 and And / or T398, T399 may also in each case together form a “heterocyclyl”,

Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT405, NT406T407, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T408, C (O) OT409, C (O) NHT410, C (O) NT411T412, OT413, O (T414-O) _y H (y = 1, 2, 3, 4, 5), O (T415-O) _y T416 (y = 1, 2, 3, 4, 5), OC (O) T417, OC (O) OT418, OC (O) NHT419 , OC (O) NT420T421, OP (O) (OT422) (OT423), OSi (T424) (T425) (T426), OS (O ₂ ) T427, NHC (O) T428, NT429C (O) T430, NHC ( O) OT431, NHC (O) NHT432, NHC (O) NT433T434, NT435C (O) OT436, NT437C (O) NHT438, NT439C (O) NT440T441, NHS (O2) T442, NT443S (O2) T444, ST445, S ( O) T446, S (O ₂ ) T447, S (O ₂ ) NHT448, S (O ₂ ) NT449T450, S (O ₂ ) OT451, P (O) (OT452) (OT453), Si (T454) (T455) (T456) "

Where T405, T406, T407, T408, T409, T410, T411, T412, T413, T414, T415, T416, T417, T418, T419, T420, T421, T422, T423, T424, T425, T426, T427, T428, T429, T430, T431, T432, T433, T434, T435, T436, T437, T438, T439, T440, T441, T442, T443, T444, T445, T446, T447, T448, T449, T450, T451, T452, T453, T454, T455, T456 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T411, T412 and / or T420, T421 and / or T433, T434 and / or T440, T441 and / or T449, T450 are also in each case" heterocycle. " Reels ";

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT457, NT458T459, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T460, C (O) OT461, C (O) NHT462, C (O) NT463T464, OT465, O (T466-O) _z H (z = 1, 2, 3, 4, 5), O (T467-O) _z T468 (z = 1, 2, 3, 4, 5), OC (O) T469, OC (O) OT470, OC (O) NHT471 , OC (O) NT472T473, OP (O) (OT474) (OT475), OSi (T476) (T477) (T478), OS (O ₂ ) T479, NHC (O) T480, NT481C (O) T482, NHC ( O) OT483, NHC (O) NHT484, NHC (O) NT485T486, NT487C (O) OT488, NT489C (O) NHT490, NT491C (O) NT492T493, NHS (O2) T494, NT495S (O2) T496, ST497, S ( O) T498, S (O ₂ ) T499, S (O ₂ ) NHT500, S (O ₂ ) NT501T502, S (O ₂ ) OT503, P (O) (OT504) (OT505), Si (T506) (T507) (T508) "

Where T457, T458, T459, T460, T461, T462, T463, T464, T465, T466, T467, T468, T469, T470, T471, T472, T473, T474, T475, T476, T477, T478, T479, T480, T481, T482, T483, T484, T485, T486, T487, T488, T489, T490, T491, T492, T493, T494, T495, T496, T497, T498, T499, T500, T501, T502, T503, T504, T505, T506, T507, T508 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T463, T464 and / or T472, T473 and / or T485, T486 and / or T492, T493 and / or T501, T502 are also in each case" heterocycle. " Reels ",

Or provided that at least one of the Z28, Z29 radicals and at least one of the Z30, Z31 radicals is independently selected from the group consisting of:

(II) "(C ₉ -C ₃₀ ) alkyl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, C (O) (C ₉ -C ₃₀ ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) arylalkyl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O ₂ ) (C ₉ -C ₃₀ ) alkyl, S (O ₂ ) cycloalkyl, S (O ₂ ) cycloalkylalkyl, S (O ₂ ) aryl, S (O ₂ ) arylalkyl, S (O ₂ ) heteroaryl, S (O ₂ ) heteroarylalkyl, S (O ₂ ) heterocyclyl, S (O ₂ ) heterocyclylalkyl "

Wherein, optionally, the aforementioned substituents of substitution group (II) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT509, NT510T511, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T512, C (O) OT513, C (O) NHT514, C (O) NT515T516, OT517, O (T518-O) _a H (a = 1, 2, 3, 4, 5), O (T519-O) _a T520 (a = 1, 2, 3, 4, 5), OC (O) T521, OC (O) OT522, OC (O) NHT523 , OC (O) NT524T525, OP (O) (OT526) (OT527), OSi (T528) (T529) (T530), OS (O ₂ ) T531, NHC (O) T532, NT533C (O) T534, NHC ( O) OT535, NHC (O) NHT536, NHC (O) NT537T538, NT539C (O) OT540, NT541C (O) NHT542, NT543C (O) NT544T545, NHS (O2) T546, NT547S (O2) T548, ST549, S ( O) T550, S (O ₂ ) T551, S (O ₂ ) NHT552, S (O ₂ ) NT553T554, S (O ₂ ) OT555, P (O) (OT556) (OT557), Si (T558) (T559) (T560) "

Where T509, T510, T511, T512, T513, T514, T515, T516, T517, T518, T519, T520, T521, T522, T523, T524, T525, T526, T527, T528, T529, T530, T531, T532, T533, T534, T535, T536, T537, T538, T539, T540, T541, T542, T543, T544, T545, T546, T547, T548, T549, T550, T551, T552, T553, T554, T555, T556, T557, T558, T559, T560 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T515, T516 and / or T524, T525 and / or T537, T538 and / or T544, T545 and / or T553, T554 are also in each case" heterocycle Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT561, NT562T563, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T564, C (O) OT565, C (O) NHT566, C (O) NT567T568, OT569, O (T570-O) _b H (b = 1, 2, 3, 4, 5), O (T571-O) _b T572 (b = 1, 2, 3, 4, 5), OC (O) T573, OC (O) OT574, OC (O) NHT575 , OC (O) NT576T577, OP (O) (OT578) (OT579), OSi (T580) (T581) (T582), OS (O ₂ ) T583, NHC (O) T584, NT585C (O) T586, NHC ( O) OT587, NHC (O) NHT588, NHC (O) NT589T590, NT591C (O) OT592, NT593C (O) NHT594, NT595C (O) NT596T597, NHS (O2) T598, NT599S (O2) T600, ST601, S ( O) T602, S (O ₂ ) T603, S (O ₂ ) NHT604, S (O ₂ ) NT605T606, S (O ₂ ) OT607, P (O) (OT608) (OT609), Si (T610) (T611) (T612) "

Here, T561, T562, T563, T564, T565, T566, T567, T568, T569, T570, T571, T572, T573, T574, T575, T576, T577, T578, T579, T580, T581, T585, T586, T587, T588, T589, T590, T591, T592, T593, T594, T595, T596, T597, T598, T599, T600, T601, T602, T603, T604, T605, T606, T607, T610, T611, T612 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T567, T568 and / or T576, T577 and / or T589, T590 and / or T596, T597 and / or T605, T606 are also in each case a" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT613, NT614T615, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T616, C (O) OT617, C (O) NHT618, C (O) NT619T620, OT621, O (T622-O) _c H (c = 1, 2, 3, 4, 5), O (T623-O) _c T624 (c = 1, 2, 3, 4, 5), OC (O) T625, OC (O) OT626, OC (O) NHT627 , OC (O) NT628T629, OP (O) (OT630) (OT631), OSi (T632) (T633) (T634), OS (O ₂ ) T635, NHC (O) T636, NT637C (O) T638, NHC ( O) OT639, NHC (O) NHT640, NHC (O) NT641T642, NT643C (O) OT644, NT645C (O) NHT646, NT647C (O) NT648T649, NHS (O2) T650, NT651S (O2) T652, ST653, S ( O) T654, S (O ₂ ) T655, S (O ₂ ) NHT656, S (O ₂ ) NT657T658, S (O ₂ ) OT659, P (O) (OT660) (OT661), Si (T662) (T663) (T664) "

Where T613, T614, T615, T616, T617, T618, T619, T620, T621, T622, T623, T624, T625, T626, T627, T628, T629, T630, T631, T632, T633, T634, T635, T636, T637, T638, T639, T640, T641, T642, T643, T644, T645, T646, T647, T648, T649, T650, T651, T652, T653, T654, T655, T656, T657, T658, T659, T660, T661, T662, T663, T664 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T619, T620 and / or T628, T629 and / or T641, T642 and / or T648, T649 and / or T657, T658 are also in each case" heterocycle. " Reels ",

And

One of the Z28, Z29 radicals is independently selected from the group consisting of: or neither of the Z28, Z29 radicals is independently selected from the group consisting of, and one of the Z30, Z31 radicals is independently selected from the group consisting of Or none of the Z30, Z31 radicals are independently selected from the group consisting of: and the Z32 radicals are independently selected from the group consisting of:

(III) "hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C (O) alkyl, C (O) aryl, C (O) heteroaryl"

Here, optionally, the aforementioned substituents of substituent group (III) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT665, NT666T667, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T668, C (O) OT669, C (O) NHT670, C (O) NT671T672, OT673, O (T674-O) _d H (d = 1, 2, 3, 4, 5), O (T675-O) _d T676 (d = 1, 2, 3, 4, 5), OC (O) T677, OC (O) OT678, OC (O) NHT679 , OC (O) NT680T681, OP (O) (OT682) (OT683), OSi (T684) (T685) (T686), OS (O ₂ ) T687, NHC (O) T688, NT689C (O) T690, NHC ( O) OT691, NHC (O) NHT692, NHC (O) NT693T694, NT695C (O) OT696, NT697C (O) NHT698, NT699C (O) NT700T701, NHS (O2) T702, NT703S (O2) T704, ST705, S ( O) T706, S (O ₂ ) T707, S (O ₂ ) NHT708, S (O ₂ ) NT709T710, S (O ₂ ) OT711, P (O) (OT712) (OT713), Si (T714) (T715) (T716) "

Where T665, T666, T667, T668, T669, T670, T671, T672, T673, T674, T675, T676, T677, T678, T679, T680, T681, T682, T683, T684, T685, T686, T687, T688, T689, T690, T691, T692, T693, T694, T695, T696, T697, T698, T699, T700, T701, T702, T703, T704, T705, T706, T707, T708, T709, T710, T711, T712, T713, T714, T715, T716 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T671, T672 and / or T680, T681 and / or T693, T694 and / or T700, T701 and / or T709, T710 are also in each case" heterocycle Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT717, NT718T719, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T720, C (O) OT721, C (O) NHT722, C (O) NT723T724, OT725, O (T726-O) _e H (e = 1, 2, 3, 4, 5), O (T727-O) _e T728 (e = 1, 2, 3, 4, 5), OC (O) T729, OC (O) OT730, OC (O) NHT731 , OC (O) NT732T733, OP (O) (OT734) (OT735), OSi (T736) (T737) (T738), OS (O ₂ ) T739, NHC (O) T740, NT741C (O) T742, NHC ( O) OT743, NHC (O) NHT744, NHC (O) NT745T746, NT747C (O) OT748, NT749C (O) NHT750, NT751C (O) NT752T753, NHS (O2) T754, NT755S (O2) T756, ST757, S ( O) T758, S (O ₂ ) T759, S (O ₂ ) NHT760, S (O ₂ ) NT761T762, S (O ₂ ) OT763, P (O) (OT764) (OT765), Si (T766) (T767) (T768) "

Where T717, T718, T719, T720, T721, T722, T723, T724, T725, T726, T727, T728, T729, T730, T731, T732, T733, T734, T735, T736, T737, T738, T739, T740, T741, T742, T743, T744, T745, T746, T747, T748, T749, T750, T751, T752, T753, T754, T755, T756, T757, T758, T759, T760, T761, T762, T763, T764, T765, T766, T767, T768 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T723, T724 and / or T732, T733 and / or T745, T746 and / or T752, T753 and / or T761, T762 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) are each independently substituted with one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT769, NT770T771, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T772, C (O) OT773, C (O) NHT774, C (O) NT775T776, OT777, O (T778-O) _f H (f = 1, 2, 3, 4, 5), O (T779-O) _f T780 (f = 1, 2, 3, 4, 5), OC (O) T781, OC (O) OT782, OC (O) NHT783 , OC (O) NT784T785, OP (O) (OT786) (OT787), OSi (T788) (T789) (T790), OS (O ₂ ) T791, NHC (O) T792, NT793C (O) T794, NHC ( O) OT795, NHC (O) NHT796, NHC (O) NT797T798, NT799C (O) OT800, NT801C (O) NHT802, NT803C (O) NT804T805, NHS (O2) T806, NT807S (O2) T808, ST809, S ( O) T810, S (O ₂ ) T811, S (O ₂ ) NHT812, S (O ₂ ) NT813T814, S (O ₂ ) OT815, P (O) (OT816) (OT817), Si (T818) (T819) (T820) "

Where T769, T770, T771, T772, T773, T774, T775, T776, T777, T778, T779, T780, T781, T782, T783, T784, T785, T786, T787, T788, T789, T790, T791, T792, T793, T794, T795, T796, T797, T798, T799, T800, T801, T802, T803, T804, T805, T806, T807, T808, T809, T810, T811, T812, T813, T814, T815, T816, T817, T818, T819, T820 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T775, T776 and / or T784, T785 and / or T797, T798 and / or T804, T805 and / or T813, T814 are also in each case" heterocycle. " Reels ",

(2) "C (Y5) NZ33Y6Z34"

Wherein Y5 and Y6 are each independently selected from the group consisting of "O, S, = NH, = NZ35",

Wherein Z33, Z34, Z35 are each independently selected from the group consisting of:

(I) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C ₉ -C ₃₀ ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O ₂ ) (C ₉ -C ₃₀ ) alkyl, S (O ₂ ) cyclo Alkyl, S (O ₂ ) cycloalkylalkyl, S (O ₂ ) aryl, S (O ₂ ) arylalkyl, S (O ₂ ) heteroaryl, S (O ₂ ) heteroarylalkyl, S (O ₂ ) heterocycle Reel, S (O ₂ ) heterocyclylalkyl "

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT821, NT822T823, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T824, C (O) OT825, C (O) NHT826, C (O) NT827T828, OT829, O (T830-O) _g H (g = 1, 2, 3, 4, 5), O (T831-O) _g T832 (g = 1, 2, 3, 4, 5), OC (O) T833, OC (O) OT834, OC (O) NHT835 , OC (O) NT836T837, OP (O) (OT838) (OT839), OSi (T840) (T814) (T842), OS (O ₂ ) T843, NHC (O) T844, NT845C (O) T846, NHC ( O) OT847, NHC (O) NHT848, NHC (O) NT849T850, NT851C (O) OT852, NT853C (O) NHT854, NT855C (O) NT856T857, NHS (O2) T858, NT859S (O2) T860, ST861, S ( O) T862, S (O ₂ ) T863, S (O ₂ ) NHT864, S (O ₂ ) NT865T866, S (O ₂ ) OT867, P (O) (OT868) (OT869), Si (T870) (T871) (T872) "

Where T821, T822, T823, T824, T825, T826, T827, T828, T829, T830, T831, T832, T833, T834, T835, T836, T837, T838, T839, T840, T841, T842, T843, T844, T845, T846, T847, T848, T849, T850, T851, T852, T853, T854, T855, T856, T857, T858, T859, T860, T861, T862, T863, T864, T865, T866, T867, T868, T869, T870, T871, T872 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T827, T828 and / or T836, T837 and / or T849, T850 and / or T856, T857 and / or T865, T866 are also in each case" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT873, NT874T875, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T876, C (O) OT877, C (O) NHT878, C (O) NT879T880, OT881, O (T882-O) _h H (h = 1, 2, 3, 4, 5), O (T883-O) _h T884 (h = 1, 2, 3, 4, 5), OC (O) T885, OC (O) OT886, OC (O) NHT887 , OC (O) NT888T889, OP (O) (OT890) (OT891), OSi (T892) (T893) (T894), OS (O ₂ ) T895, NHC (O) T896, NT897C (O) T898, NHC ( O) OT899, NHC (O) NHT900, NHC (O) NT901T902, NT903C (O) OT904, NT905C (O) NHT906, NT907C (O) NT908T909, NHS (O2) T910, NT911S (O2) T912, ST913, S ( O) T914, S (O ₂ ) T915, S (O ₂ ) NHT916, S (O ₂ ) NT917T918, S (O ₂ ) OT919, P (O) (OT920) (OT921), Si (T922) (T923) (T924) "

Where T873, T874, T875, T876, T877, T878, T879, T880, T881, T882, T883, T884, T885, T886, T887, T888, T889, T890, T891, T892, T893, T894, T895, T896, T897, T898, T899, T900, T901, T902, T903, T904, T905, T906, T907, T908, T909, T910, T911, T912, T913, T914, T915, T916, T917, T918, T919, T920, T921, T922, T923, T924 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T879, T880 and / or T888, T889 and / or T901, T902 and / or T908, T909 and / or T917, T918 are also in each case" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT925, NT926T927, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T928, C (O) OT929, C (O) NHT930, C (O) NT931T932, OT933, O (T934-O) _i H (i = 1, 2, 3, 4, 5), O (T935-O) _i T936 (i = 1, 2, 3, 4, 5), OC (O) T937, OC (O) OT938, OC (O) NHT939 , OC (O) NT940T941, OP (O) (OT942) (OT943), OSi (T944) (T945) (T946), OS (O ₂ ) T947, NHC (O) T948, NT949C (O) T950, NHC ( O) OT951, NHC (O) NHT952, NHC (O) NT953T954, NT955C (O) OT956, NT957C (O) NHT958, NT959C (O) NT960T961, NHS (O2) T962, NT963S (O2) T964, ST965, S ( O) T966, S (O ₂ ) T967, S (O ₂ ) NHT968, S (O ₂ ) NT969T970, S (O ₂ ) OT971, P (O) (OT972) (OT973), Si (T974) (T975) (T976) "

Where T925, T926, T927, T928, T929, T930, T931, T932, T933, T934, T935, T936, T937, T938, T939, T940, T941, T942, T943, T944, T945, T946, T947, T948, T949, T950, T951, T952, T953, T954, T955, T956, T957, T958, T959, T960, T961, T962, T963, T964, T965, T966, T967, T968, T969, T970, T971, T972, T973, T974, T975, T976 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T931, T932 and / or T940, T941 and / or T953, T954 and / or T960, T961 and / or T969, T970 are also in each case" heterocycle Reels ",

And one of the Z26, Z27 radicals is independently selected from the group consisting of, or neither of the Z26, Z27 radicals is independently selected from the group consisting of:

(2) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C ₉ -C ₃₀ ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, C (Y7) NZ36Z37, C (= NZ38) Z39, S (O ₂ ) alkyl, S (O ₂ ) ( C ₉ -C ₃₀ ) alkyl, S (O ₂ ) cycloalkyl, S (O ₂ ) cycloalkylalkyl, S (O ₂ ) aryl, S (O ₂ ) arylalkyl, S (O ₂ ) heteroaryl, S ( O ₂ ) heteroarylalkyl, S (O ₂ ) heterocyclyl, S (O ₂ ) heterocyclylalkyl "

Wherein Y7 is independently selected from the group consisting of "O, S, = NH, = NZ40",

Wherein the Z36, Z37, Z38, Z39, Z40 radicals are each independently selected from the group consisting of:

(I) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl, C (O) (C ₉ -C ₃₀ ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O ) Heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O ₂ ) (C ₉ -C ₃₀ ) alkyl, S (O ₂ ) cycloalkyl, S (O ₂ ) cycloalkylalkyl, S (O ₂ ) aryl, S (O ₂ ) arylalkyl, S (O ₂ ) heteroaryl, S (O ₂ ) heteroarylalkyl, S (O ₂ ) heterocyclyl, S (O ₂ ) heterocyclylalkyl "

Here, optionally, the aforementioned substituents of substituent group (3) and / or substituent group (I) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT977, NT978T979, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T980, C (O) OT981, C (O) NHT982, C (O) NT983T984, OT985, O (T986-O) _j H (j = 1, 2, 3, 4, 5), O (T987-O) _j T988 (j = 1, 2, 3, 4, 5), OC (O) T989, OC (O) OT990, OC (O) NHT991 , OC (O) NT992T993, OP (O) (OT994) (OT995), OSi (T996) (T997) (T998), OS (O ₂ ) T999, NHC (O) T1000, NT1001C (O) T1002, NHC ( O) OT1003, NHC (O) NHT1004, NHC (O) NT1005T1006, NT1007C (O) OT1008, NT1009C (O) NHT1010, NT1011C (O) NT1012T1013, NHS (O2) T1014, NT1015S (O2) T1016, ST1017, S ( O) T1018, S (O ₂ ) T1019, S (O ₂ ) NHT1020, S (O ₂ ) NT1021T1022, S (O ₂ ) OT1023, P (O) (OT1024) (OT1025), Si (T1026) (T1027) (T1028) "

Where T977, T978, T979, T980, T981, T982, T983, T984, T985, T986, T987, T988, T989, T990, T991, T992, T993, T994, T995, T996, T997, T998, T999, T1000, T1001, T1002, T1003, T1004, T1005, T1006, T1007, T1008, T1009, T1010, T1011, T1012, T1013, T1014, T1015, T1016, T1017, T1018, T1019, T1020, T1021, T1022, T1023, T1024, T1025 T1026, T1027, T1028 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T983, T984 and / or T992, T993 and / or T1005, T1006 and / or T1012, T1013 and / or T1021, T1022 are also in each case" heterocycle Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , CN, CF ₃ , N ₃ , NH ₂ , NHT 1029, NT 1030T1031, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, _{SO 3 H, P (O)} (OH) 2, C (O) T1032, C (O) OT1033, C (O) NHT1034, C (O) NT1035T1036, OT1037, O (T1038-O) k H (k = 1, 2, 3, 4, 5), O (T1039-O) _k T1040 (k = 1, 2, 3, 4, 5), OC (O) T1041, OC (O) OT1042, OC (O) NHT1043 , OC (O) NT1044T1045, OP (O) (OT1046) (OT1047), OSi (T1048) (T1049) (T1050), OS (O ₂ ) T1051, NHC (O) T1052, NT1053C (O) T1054, NHC ( O) OT1055, NHC (O) NHT1056, NHC (O) NT1057T1058, NT1059C (O) OT1060, NT1061C (O) NHT1062, NT1063C (O) NT1064T1065, NHS (O2) T1066, NT1067S (O2) T1068, ST1069, S ( O) T1070, S (O ₂ ) T1071, S (O ₂ ) NHT1072, S (O ₂ ) NT1073T1074, S (O ₂ ) OT1075, P (O) (OT1076) (OT1077), Si (T1078) (T1079) (T1080) "

Where T1029, T1030, T1031, T1032, T1033, T1034, T1035, T1036, T1037, T1038, T1039, T1040, T1041, T1042, T1043, T1044, T1045, T1046, T1047, T1048, T1049, T1050, T1051, T1052, T1053, T1054, T1055, T1056, T1057, T1058, T1059, T1060, T1061, T1062, T1063, T1064, T1065, T1066, T1067, T1068, T1069, T1070, T1071, T1072, T1073, T1074, T1075, T1076, T1077, T1077 T1078, T1079, T1080 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", where, alternatively, T1035, T1036 and / or T1044, T1045 and / or T1057, T1058 and / or T1064, T1065 and / or T1073, T1074 are also in each case" hetero " Cyclyl ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1081, NT1082T1083, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1084, C (O) OT1085, C (O) NHT1086, C (O) NT1087T1088, OT1089, O (T1090-O) _l H (l = 1, 2, 3, 4, 5), O (T1091-O) _l T1092 (l = 1, 2, 3, 4, 5), OC (O) T1093, OC (O) OT1094, OC (O) NHT1095 , OC (O) NT1096T1097, OP (O) (OT1098) (OT1099), OSi (T1100) (T1101) (T1102), OS (O ₂ ) T1103, NHC (O) T1104, NT1105C (O) T1106, NHC ( O) OT1107, NHC (O) NHT1108, NHC (O) NT1109T1110, NT1111C (O) OT1112, NT1113C (O) NHT1114, NT1115C (O) NT1116T1117, NHS (O2) T1118, NT1119S (O2) T1120, ST1121, S ( O) T1122, S (O ₂ ) T1123, S (O ₂ ) NHT1124, S (O ₂ ) NT1125T1126, S (O ₂ ) OT1127, P (O) (OT1128) (OT1129), Si (T1130) (T1131) (T1132) "

Where T1081, T1082, T1083, T1084, T1085, T1086, T1087, T1088, T1089, T1090, T1091, T1092, T1093, T1094, T1095, T1096, T1097, T1098, T1099, T1100, T1101, T1102, T1103, T1104 T1105, T1106, T1107, T1108, T1109, T1110, T1111, T1112, T1113, T1114, T1115, T1116, T1117, T1118, T1119, T1120, T1121, T1122, T1123, T1124, T1125, T1126, T1127, T1128, 29 T1130, T1131, T1132 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1087, T1088 and / or T1096, T1097 and / or T1109, T1110 and / or T1116, T1117 and / or T1125, T1126 are also in each case a" heterocycle Reels ",

And one of the Z1, Z2 radicals is independently selected from the group consisting of, or neither of the Z1, Z2 radicals is independently selected from the group consisting of:

(c) hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I, CN, CF ₃ , N ₃ , NH ₂ , NHT1133, NT1134T1135, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1136, C (O) OT1137, C (O) NHT1138, C (O) NT1139T1140, OT1141, O (T1142-O) _m H (m = 1, 2, 3, 4, 5), O (T1143-O) _m T1144 (m = 1, 2, 3, 4, 5), OC (O) T1145, OC (O) OT1146, OC (O) NHT1147, OC (O) NT1148T1149, OP (O) (OT1150) (OT1151), OSi (T1152) (T1153) (T1154), OS (O ₂ ) T1155, NHC (O) T1156, NT1157C (O) T1158, NHC (O) OT1159, NHC (O) NHT1160, NHC (O) NT1161T1162, NT1163C (O) OT1164, NT1165C (O) NHT1166, NT1167C (O) NT1168T1169, NHS (O2) T1170, NT1171S (O2) T1172, ST1173, S (O) T1174, S (O ₂ ) T1175, S (O ₂ ) NHT1176, S (O ₂ ) NT1177T1178, S (O ₂ ) OT1179, P (O) (OT1180) (OT1181), Si (T1182) (T1183 ) (T1184) "

Where T1133, T1134, T1135, T1136, T1137, T1138, T1139, T1140, T1141, T1142, T1143, T1144, T1145, T1146, T1147, T1148, T1149, T1150, T1151, T1152, T1153, T1154, T1155, T1156, T1156, T1157, T1158, T1159, T1160, T1161, T1162, T1163, T1164, T1165, T1166, T1167, T1168, T1169, T1170, T1171, T1172, T1173, T1174, T1175, T1176, T1177, T1178, T1179, T1180, T118 T1182, T1183, T1184 is selected from the group consisting of the following independently: "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1139, T1140 and / or T1148, T1149 and / or T1161, T1162 and / or T1168, T1169 and / or T1177, T1178 are also in each case a" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (c) may each be further substituted by one or more substituents, independently of one another, selected from the same or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1185, NT1186T1187, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1188, C (O) OT1189, C (O) NHT1190, C (O) NT1191T1192, OT1193, O (T1194-O) nH (n = 1 , 2, 3, 4, 5), O (T1195-O) nT1196 (n = 1, 2, 3, 4, 5), OC (O) T1197, OC (O) OT1198, OC (O) NHT1199, OC (O) NT1200T1201, OP (O) (OT1202) (OT1203), OSi (T1204) (T1205) (T1206), OS (O ₂ ) T1207, NHC (O) T1208, NT1209C (O) T1210, NHC (O) OT1211, NHC (O) NHT1212, NHC (O) NT1213T1214, NT1215C (O) OT1216, NT1217C (O) NHT1218, NT1219C (O) NT1220T1221, NHS (O2) T1222, NT1223S (O2) T1224, ST1225, S (O) T1226, S (O ₂ ) T1227, S (O ₂ ) NHT1228, S (O ₂ ) NT1229T1230, S (O ₂ ) OT1231, P (O) (OT1232) (OT1233), Si (T1234) (T1235) (T1236 ) "

Where T1185, T1186, T1187, T1188, T1189, T1190, T1191, T1192, T1193, T1194, T1195, T1196, T1197, T1198, T1199, T1200, T1201, T1202, T1203, T1204, T1205, T1206, T1207, T1208, T1209, T1210, T1211, T1212, T1213, T1214, T1215, T1216, T1217, T1218, T1219, T1220, T1221, T1222, T1223, T1224, T1225, T1226, T1227, T1228, T1229, T1230, T1231, T1232, T1232, T1232, T1234, T1235, T1236 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl , Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1191, T1192 and / or T1200, T1201 and / or T1213, T1214 and / or T1220, T1221 and / or T1229, T1230 are also in each case" hetero Cyclyl ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1237, NT1238T1239, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1240, C (O) OT1241, C (O) NHT1242, C (O) NT1243T1244, OT1245, O (T1246-O) oH (o = 1 , 2, 3, 4, 5), O (T1247-O) oT1248 (o = 1, 2, 3, 4, 5), OC (O) T1249, OC (O) OT1250, OC (O) NHT1251, OC (O) NT1252T1253, OP (O) (OT1254) (OT1255), OSi (T1256) (T1257) (T1258), OS (O ₂ ) T1259, NHC (O) T1260, NT1261C (O) T1262, NHC (O) OT1263, NHC (O) NHT1264, NHC (O) NT1265T1266, NT1267C (O) OT1268, NT1269C (O) NHT1270, NT1271C (O) NT1272T1273, NHS (O2) T1274, NT1275S (O2) T1276, ST1277, S (O) T1278, S (O ₂ ) T1279, S (O ₂ ) NHT1280, S (O ₂ ) NT1281T1282, S (O ₂ ) OT1283, P (O) (OT1284) (OT1285), Si (T1286) (T1287) (T1288 ) "

Where T1237, T1238, T1239, T1240, T1241, T1242, T1243, T1244, T1245, T1246, T1247, T1248, T1249, T1250, T1251, T1252, T1253, T1254, T1255, T1256, T1257, T1258, T1259, T1260 T1261, T1262, T1263, T1264, T1265, T1266, T1267, T1268, T1269, T1270, T1271, T1272, T1273, T1274, T1275, T1276, T1277, T1278, T1279, T1280, T1281, T1282, T1283, T1284, T1284, T1284, T1284 T1286, T1287, T1288 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1243, T1244 and / or T1252, T1253 and / or T1265, T1266 and / or T1272, T1273 and / or T1281, T1282 are also in each case" heterocycle Reels ",

(d) NZ41Z42 wherein the Z41 and Z42 radicals are each independently selected from the group consisting of:

(1) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl, C (O) (C ₉ -C ₃₀ ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O Heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl "

Here, optionally, the aforementioned substituents of substituent group (1) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1289, NT1290T1291, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1292, C (O) OT1293, C (O) NHT1294, C (O) NT1295T1296, OT1297, O (T1298-O) _rr H (rr = 1, 2, 3, 4, 5), O (T1299-O) _rr T1300 (rr = 1, 2, 3, 4, 5), OC (O) T1301, OC (O) OT1302, OC (O) NHT1303 , OC (O) NT1304T1305, OP (O) (OT1306) (OT1307), OSi (T1308) (T1309) (T1310), OS (O ₂ ) T1311, NHC (O) T1312, NT1313C (O) T1314, NHC ( O) OT1315, NHC (O) NHT1316, NHC (O) NT1317T1318, NT1319C (O) OT1320, NT1321C (O) NHT1322, NT1323C (O) NT1324T1325, NHS (O2) T1326, NT1327S (O2) T1328, ST1329, S ( O) T1330, S (O ₂ ) T1331, S (O ₂ ) NHT1332, S (O ₂ ) NT1333T1334, S (O ₂ ) OT1335, P (O) (OT1336) (OT1337), Si (T1338) (T1339) (T1340) "

Where T1289, T1290, T1291, T1292, T1293, T1294, T1295, T1296, T1297, T1298, T1299, T1300, T1301, T1302, T1303, T1304, T1305, T1306, T1307, T1308, T1309, T1310, T1311, T1311, T1311 T1313, T1314, T1315, T1316, T1317, T1318, T1319, T1320, T1321, T1322, T1323, T1324, T1325, T1326, T1327, T1328, T1329, T1330, T1331, T1332, T1333, T1334, T1335, T1336, T1336, T1338, T1339, T1340 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1295, T1296 and / or T1304, T1305 and / or T1317, T1318 and / or T1324, T1325 and / or T1333, T1334 are also in each case" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1341, NT1342T1343, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1344, C (O) OT1345, C (O) NHT1346, C (O) NT1347T1348, OT1349, O (T1350-O) _rs H (rs = 1, 2, 3, 4, 5), O (T1351-O) _rs T1352 (rs = 1, 2, 3, 4, 5), OC (O) T1353, OC (O) OT1354, OC (O) NHT1355 , OC (O) NT1356T1357, OP (O) (OT1358) (OT1359), OSi (T1360) (T1361) (T1362), OS (O ₂ ) T1363, NHC (O) T1364, NT1365C (O) T1366, NHC ( O) OT1367, NHC (O) NHT1368, NHC (O) NT1369T1370, NT1371C (O) OT1372, NT1373C (O) NHT1374, NT1375C (O) NT1376T1377, NHS (O2) T1378, NT1379S (O2) T1380, ST1381, S ( O) T1382, S (O ₂ ) T1383, S (O ₂ ) NHT1384, S (O ₂ ) NT1385T1386, S (O ₂ ) OT1387, P (O) (OT1388) (OT1389), Si (T1390) (T1391) (T1392) "

Where T1341, T1342, T1343, T1344, T1345, T1346, T1347, T1348, T1349, T1350, T1351, T1352, T1353, T1354, T1355, T1356, T1357, T1358, T1359, T1360, T1361, T1362, T1363, T1364, T1364, T1365, T1366, T1367, T1368, T1369, T1370, T1371, T1372, T1373, T1374, T1375, T1376, T1377, T1378, T1379, T1380, T1381, T1382, T1383, T1384, T1385, T1386, T1387, T1388, T1389 T1390, T1391, T1392 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1347, T1348 and / or T1356, T1357 and / or T1369, T1370 and / or T1376, T1377 and / or T1385, T1386 are also in each case a" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1393, NT1394T1395, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1396, C (O) OT1397, C (O) NHT1398, C (O) NT1399T1400, OT1401, O (T1402-O) _rt H (rt = 1, 2, 3, 4, 5), O (T1403-O) _rt T1404 (rt = 1, 2, 3, 4, 5), OC (O) T1405, OC (O) OT1406, OC (O) NHT1407 , OC (O) NT1408T1409, OP (O) (OT1410) (OT1411), OSi (T1412) (T1413) (T1414), OS (O ₂ ) T1415, NHC (O) T1416, NT1417C (O) T1418, NHC ( O) OT1419, NHC (O) NHT1420, NHC (O) NT1421T1422, NT1423C (O) OT1424, NT1425C (O) NHT1426, NT1427C (O) NT1428T1429, NHS (O2) T1430, NT1431S (O2) T1432, ST1433, S ( O) T1434, S (O ₂ ) T1435, S (O ₂ ) NHT1436, S (O ₂ ) NT1437T1438, S (O ₂ ) OT1439, P (O) (OT1440) (OT1441), Si (T1442) (T1443) (T1444) "

Where T1393, T1394, T1395, T1396, T1397, T1398, T1399, T1400, T1401, T1402, T1403, T1404, T1405, T1406, T1407, T1408, T1409, T1410, T1411, T1412, T1413, T1414, T1415, T1416, T1416, T1416 T1417, T1418, T1419, T1420, T1421, T1422, T1423, T1424, T1425, T1426, T1427, T1428, T1429, T1430, T1431, T1432, T1433, T1434, T1435, T1436, T1437, T1438, T1439, T1440, T1441, T1440 T1442, T1443, T1444 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1399, T1400 and / or T1408, T1409 and / or T1421, T1422 and / or T1428, T1429 and / or T1437, T1438 are also in each case a" heterocycle. " Reels ",

(2) "C (O) C (O) T1445, S (O ₂ ) NT1446T1447"

Wherein T1445, T1446, T1447 are each independently selected from the group consisting of:

(I) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF ₃ , N ₃ , NH ₂ , NHT1448, NT1449T1450, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1451, C (O) OT1452, C (O) NHT1453, C (O) NT1454T1455, OT1456, O (T1457-O) _ru H ( ru = 1, 2, 3, 4, 5), O (T1458-O) _ru T1459 (ru = 1, 2, 3, 4, 5), OC (O) T1460, OC (O) OT1461, OC (O NHT1462, OC (O) NT1463T1464, OP (O) (OT1465) (OT1466), OSi (T1467) (T1468) (T1469), OS (O ₂ ) T1470, NHC (O) T1471, NT1472C (O) T1473, NHC (O) OT1474, NHC (O) NHT1475, NHC (O) NT1476T1477, NT1478C (O) OT1479, NT1480C (O) NHT1481, NT1482C (O) NT1483T1484, NHS (O2) T1485, NT1486S (O2) T1487, ST1488, S (O) T1489, S (O ₂ ) T1490, S (O ₂ ) NHT1491, S (O ₂ ) NT1492T1493, S (O ₂ ) OT1494, P (O) (OT1495) (OT1496), Si (T1497) ( T1498) (T1499) "

Where T1448, T1449, T1450, T1451, T1452, T1453, T1454, T1455, T1456, T1457, T1458, T1459, T1460, T1461, T1462, T1463, T1464, T1465, T1466, T1467, T1468, T1469, T1470, T1471, T1471, T1472, T1473, T1474, T1475, T1476, T1477, T1478, T1479, T1480, T1481, T1482, T1483, T1484, T1485, T1486, T1487, T1488, T1489, T1490, T1491, T1492, T1493, T1494, T1495, T1495, T1495, T1495 T1497, T1498, T1499 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1454, T1455 and / or T1463, T1464 and / or T1476, T1477 and / or T1483, T1484 and / or T1492, T1493 are also in each case a" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substitution group (I) may each be further substituted by one or more substituents, independently or identically selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀₎ alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I _{, CN, CF 3, N 3} , NH 2, NHT1500, NT1501T1502, NO 2, OH, OCF 3, SH, OSO 3 H, OP (O) (OH) 2, CHO, COOH, C (O) NH 2, _{SO 3 H, P (O)} (OH) 2, C (O) T1503, C (O) OT1504, C (O) NHT1505, C (O) NT1506T1507, OT1508, O (T1509-O) rv H (rv = 1, 2, 3, 4, 5), O (T1510-O) rv T1511 (rv = 1, 2, 3, 4, 5), OC (O) T1512, OC (O) OT1513, OC (O) NHT1514 , OC (O) NT1515T1516, OP (O) (OT1517) (OT1518), OSi (T1519) (T1520) (T1521), OS (O 2) T1522, NHC (O) T1523, NT1524C (O) T1525, NHC ( (O) NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 _{O) T1541, S (O 2} ) T1542, S (O 2) NHT1543, S (O 2) NT1544T1545, S (O 2) OT1546, P (O) (OT1547) (OT1548), Si (T1549) (T1550) (T1551) "

Where: T1500, T1501, T1502, T1503, T1504, T1505, T1506, T1507, T1508, T1509, T1510, T1511, T1512, T1513, T1514, T1515, T1516, T1517, T1518, T1519, T1520, T1521, T1522, T1523 T1524, T1525, T1526, T1527, T1528, T1529, T1530, T1531, T1532, T1533, T1534, T1535, T1536, T1537, T1538, T1539, T1540, T1541, T1542, T1543, T1544, T1545, T1546, T1547, 1553 T1549, T1550, T1551 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1506, T1507 and / or T1515, T1516 and / or T1528, T1529 and / or T1535, T1536 and / or T1544, T1545 are also in each case" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1552, NT1553T1554, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1555, C (O) OT1556, C (O) NHT1557, C (O) NT1558T1559, OT1560, O (T1561-O) _rw H (rw = 1, 2, 3, 4, 5), O (T1562-O) _rw T1563 (rw = 1, 2, 3, 4, 5), OC (O) T1564, OC (O) OT1565, OC (O) NHT1566 , OC (O) NT1567T1568, OP (O) (OT1569) (OT1570), OSi (T1571) (T1572) (T1573), OS (O ₂ ) T1574, NHC (O) T1575, NT1576C (O) T1577, NHC ( O) OT1578, NHC (O) NHT1579, NHC (O) NT1580T1581, NT1582C (O) OT1583, NT1584C (O) NHT1585, NT1586C (O) NT1587T1588, NHS (O2) T1589, NT1590S (O2) T1591, ST1592, S ( O) T1593, S (O ₂ ) T1594, S (O ₂ ) NHT1595, S (O ₂ ) NT1596T1597, S (O ₂ ) OT1598, P (O) (OT1599) (OT1600), Si (T1601) (T1602) (T1603) "

Where T1552, T1553, T1554, T1555, T1556, T1557, T1558, T1559, T1560, T1561, T1562, T1563, T1564, T1565, T1566, T1567, T1568, T1569, T1570, T1571, T1572, T1573, T1574, T1575 T1576, T1577, T1578, T1579, T1580, T1581, T1582, T1583, T1584, T1585, T1586, T1587, T1588, T1589, T1590, T1591, T1592, T1593, T1594, T1595, T1596, T1597, T1598, T1599, T1599, T1599 T1601, T1602, T1603 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1558, T1559 and / or T1567, T1568 and / or T1580, T1581 and / or T1587, T1588 and / or T1596, T1597 are also in each case a" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1604, NT1605T1606, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1607, C (O) OT1608, C (O) NHT1609, C (O) NT1610T1611, OT1612, O (T1613-O) _rx H (rx = 1, 2, 3, 4, 5), O (T1614-O) _rx T1615 (rx = 1, 2, 3, 4, 5), OC (O) T1616, OC (O) OT1617, OC (O) NHT1618 , OC (O) NT1619T1620, OP (O) (OT1621) (OT1622), OSi (T1623) (T1624) (T1625), OS (O ₂ ) T1626, NHC (O) T1627, NT1628C (O) T1629, NHC ( O) OT1630, NHC (O) NHT1631, NHC (O) NT1632T1633, NT1634C (O) OT1635, NT1636C (O) NHT1637, NT1638C (O) NT1639T1640, NHS (O2) T1641, NT1642S (O2) T1643, ST1644, S ( O) T1645, S (O ₂ ) T1646, S (O ₂ ) NHT1647, S (O ₂ ) NT1648T1649, S (O ₂ ) OT1650, P (O) (OT1651) (OT1652), Si (T1653) (T1654) (T1655) "

Where: T1604, T1605, T1606, T1607, T1608, T1609, T1610, T1611, T1612, T1613, T1614, T1615, T1616, T1617, T1618, T1619, T1620, T1621, T1622, T1623, T1624, T1625, T1626, T1627 T1628, T1629, T1630, T1631, T1632, T1633, T1634, T1635, T1636, T1637, T1638, T1639, T1640, T1641, T1642, T1643, T1644, T1645, T1646, T1647, T1648, T1649, T1650, T1651, 2165 T1653, T1654, T1655 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1610, T1611 and / or T1619, T1620 and / or T1632, T1633 and / or T1639, T1640 and / or T1648, T1649 are also in each case" heterocycle. " Reel ", where, alternatively, T1446, T1447 together may also form" heterocyclyl ",

(3) "C (Y8) NZ43Z44, C (= NZ45) Z46, C (Y9) NZ47Y10Z48"

Wherein Y8, Y9, Y10 are each independently selected from the group consisting of "O, S, = NH, = NZ49",

Wherein the Z43, Z44, Z45, Z46, Z47, Z48, Z49 radicals are each independently selected from the group consisting of:

(I) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) alkyl , C (O) (C ₉ -C ₃₀ ) alkyl, C (O) cycloalkyl, C (O) cycloalkylalkyl, C (O) aryl, C (O) arylalkyl, C (O) heteroaryl, C (O) heteroarylalkyl, C (O) heterocyclyl, C (O) heterocyclylalkyl, S (O2) alkyl, S (O ₂ ) (C ₉ -C ₃₀ ) alkyl, S (O ₂ ) cyclo Alkyl, S (O ₂ ) cycloalkylalkyl, S (O ₂ ) aryl, S (O ₂ ) arylalkyl, S (O ₂ ) heteroaryl, S (O ₂ ) heteroarylalkyl, S (O ₂ ) heterocycle Reel, S (O ₂ ) heterocyclylalkyl "

Wherein, optionally, the aforementioned substituents of substituent group (i) may also be independently substituted by one or more substituents, each independently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT 1656, NT1657T1658, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1659, C (O) OT1660, C (O) NHT1661, C (O) NT1662T1663, OT1664, O (T1665-O) _ry H (ry = 1, 2, 3, 4, 5), O (T1666-O) _ry T1667 (ry = 1, 2, 3, 4, 5), OC (O) T1668, OC (O) OT1669, OC (O) NHT1670 , OC (O) NT1671T1672, OP (O) (OT1673) (OT1674), OSi (T1675) (T1676) (T1677), OS (O ₂ ) T1678, NHC (O) T1679, NT1680C (O) T1681, NHC ( O) OT1682, NHC (O) NHT1683, NHC (O) NT1684T1685, NT1686C (O) OT1687, NT1688C (O) NHT1689, NT1690C (O) NT1691T1692, NHS (O2) T1693, NT1694S (O2) T1695, ST1696, S ( O) T1697, S (O ₂ ) T1698, S (O ₂ ) NHT1699, S (O ₂ ) NT1700T1701, S (O ₂ ) OT1702, P (O) (OT1703) (OT1704), Si (T1705) (T1706) (T1707) "

Here, T1656, T1657, T1658, T1659, T1660, T1661, T1662, T1663, T1664, T1665, T1666, T1667, T1668, T1669, T1670, T1671, T1672, T1673, T1674, T1675, T1676, T1677, T1678, T1679 T1680, T1681, T1682, T1683, T1684, T1685, T1686, T1687, T1688, T1689, T1690, T1691, T1692, T1693, T1694, T1695, T1696, T1697, T1698, T1699, T1700, T1701, T1702, T1703, T1705, T1706, T1707 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, T1662, T1663 and / or T1671, T1672 and / or T1684, T1685 and / or T1691, T1692 and / or T1700, T1701 are also in each case" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be further substituted by one or more substituents, each independently selected from the same or differently selected from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT 1708, NT1709T1710, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1711, C (O) OT1712, C (O) NHT1713, C (O) NT1714T1715, OT1716, O (T1717-O) _rz H (rz = 1, 2, 3, 4, 5), O (T1718-O) _rz T1719 (rz = 1, 2, 3, 4, 5), OC (O) T1720, OC (O) OT1721, OC (O) NHT1722 , OC (O) NT1723T1724, OP (O) (OT1725) (OT1726), OSi (T1727) (T1728) (T1729), OS (O ₂ ) T1730, NHC (O) T1731, NT1732C (O) T1733, NHC ( O) OT1734, NHC (O) NHT1735, NHC (O) NT1736T1737, NT1738C (O) OT1739, NT1740C (O) NHT1741, NT1742C (O) NT1743T1744, NHS (O2) T1745, NT1746S (O2) T1747, ST1748, S ( O) T1749, S (O ₂ ) T1750, S (O ₂ ) NHT1751, S (O ₂ ) NT1752T1753, S (O ₂ ) OT1754, P (O) (OT1755) (OT1756), Si (T1757) (T1758) (T1759) "

Where: T1708, T1709, T1710, T1711, T1712, T1713, T1714, T1715, T1716, T1717, T1718, T1719, T1720, T1721, T1722, T1723, T1724, T1725, T1726, T1727, T1728, T1729, T1730, T1731 T1732, T1733, T1734, T1735, T1736, T1737, T1738, T1739, T1740, T1741, T1742, T1743, T1744, T1745, T1746, T1747, T1748, T1749, T1750, T1751, T1752, T1753, T1754, T1755, T1755, T1757, T1758, T1759 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1714, T1715 and / or T1723, T1724 and / or T1736, T1737 and / or T1743, T1744 and / or T1752, T1753 are also in each case a" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHT1760, NT1761T1762, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) T1763, C (O) OT1764, C (O) NHT1765, C (O) NT1766T1767, OT1768, O (T1769-O) _ra H (ra = 1, 2, 3, 4, 5), O (T1770-O) _ra T1771 (ra = 1, 2, 3, 4, 5), OC (O) T1772, OC (O) OT1773, OC (O) NHT1774 , OC (O) NT1775T1776, OP (O) (OT1777) (OT1778), OSi (T1779) (T1780) (T1781), OS (O ₂ ) T1782, NHC (O) T1783, NT1784C (O) T1785, NHC ( O) OT1786, NHC (O) NHT1787, NHC (O) NT1788T1789, NT1790C (O) OT1791, NT1792C (O) NHT1793, NT1794C (O) NT1795T1796, NHS (O2) T1797, NT1798S (O2) T1799, ST1800, S ( O) T1801, S (O ₂ ) T1802, S (O ₂ ) NHT1803, S (O ₂ ) NT1804T1805, S (O ₂ ) OT1806, P (O) (OT1807) (OT1808), Si (T1809) (T1810) (T1811) "

Where: T1760, T1761, T1762, T1763, T1764, T1765, T1766, T1767, T1768, T1769, T1770, T1771, T1772, T1773, T1774, T1775, T1776, T1777, T1778, T1779, T1780, T1781, T1782, T1783 T1784, T1785, T1786, T1787, T1788, T1789, T1790, T1791, T1792, T1793, T1794, T1795, T1796, T1797, T1798, T1799, T1800, T1801, T1802, T1803, T1804, T1805, T1806, T1807, T1807, T1809, T1810, T1811 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, T1766, T1767 and / or T1775, T1776 and / or T1788, T1789 and / or T1795, T1796 and / or T1804, T1805 are also in each case" heterocycle Reels ",

And

Z3 and Z4 radicals are each independently selected from the group consisting of:

(e) hydrogen;

(f) halogen, F, Cl, Br, I;

(g) unsubstituted and substituted alkyl, or (C ₉ -C ₃₀₎ alkyl, wherein, optionally, alkyl, or (C ₉ -C ₃₀₎ alkyl radical by one or more substituents the same or different selected from the group consisting of the following: Lt; / RTI >

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB457, NB458B459, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B460, C (O) OB461, C (O) NHB462, C (O) NB463B464, OB465, O (B466-O) _x H (x = 1, 2, 3, 4, 5), O (B467-O) _x B468 (x = 1, 2, 3, 4, 5), OC (O) B469, OC (O) OB470, OC (O) NHB471 , OC (O) NB472B473, OP (O) (OB474) (OB475), OSi (B476) (B477) (B478), OS (O ₂ ) B479, NHC (O) B480, NB481C (O) B482, NHC ( O) OB483, NHC (O) NHB484, NHC (O) NB485B486, NB487C (O) OB488, NB489C (O) NHB490, NB491C (O) NB492B493, NHS (O2) B494, NB495S (O2) B496, SB497, S ( O) B498, S (O ₂ ) B499, S (O ₂ ) NHB500, S (O ₂ ) NB501B502, S (O ₂ ) OB503, P (O) (OB504) (OB505), Si (B506) (B507) (B508) "

Where B457, B458, B459, B460, B461, B462, B463, B464, B465, B466, B467, B468, B469, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481, B482, B483, B484, B485, B486, B487, B488, B489, B490, B491, B492, B493, B494, B495, B496, B497, B498, B499, B500, B501, B502, B503, B504, B505, B506, B507, B508 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B463, B464 and / or B472, B473 and / or B485, B486 and / or B492, B493 and / or B501, B502 are also in each case" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB509, NB510B511, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B512, C (O) OB513, C (O) NHB514, C (O) NB515B516, OB517, O (B518-O) _y H (y = 1, 2, 3, 4, 5), O (B519-O) _y B520 (y = 1, 2, 3, 4, 5), OC (O) B521, OC (O) OB522, OC (O) NHB523 , OC (O) NB524B525, OP (O) (OB526) (OB527), OSi (B528) (B529) (B530), OS (O ₂ ) B531, NHC (O) B532, NB533C (O) B534, NHC ( O) OB535, NHC (O) NHB536, NHC (O) NB537B538, NB539C (O) OB540, NB541C (O) NHB542, NB543C (O) NB544B545, NHS (O2) B546, NB547S (O2) B548, SB549, S ( O) B550, S (O ₂ ) B551, S (O ₂ ) NHB552, S (O ₂ ) NB553B554, S (O ₂ ) OB555, P (O) (OB556) (OB557), Si (B558) (B559) (B560) "

Where B509, B510, B511, B512, B513, B514, B515, B516, B517, B518, B519, B520, B521, B522, B523, B524, B525, B526, B527, B528, B529, B530, B531, B532, B533, B534, B535, B536, B537, B538, B539, B540, B541, B542, B543, B544, B545, B546, B547, B548, B549, B550, B551, B552, B553, B554, B555, B556, B557, B558, B559, B560 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B515, B516 and / or B524, B525 and / or B537, B538 and / or B544, B545 and / or B553, B554 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB561, NB562B563, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B564, C (O) OB565, C (O) NHB566, C (O) NB567B568, OB569, O (B570-O) _z H (z = 1, 2, 3, 4, 5), O (B571-O) _z B572 (z = 1, 2, 3, 4, 5), OC (O) B573, OC (O) OB574, OC (O) NHB575 , OC (O) NB576B577, OP (O) (OB578) (OB579), OSi (B580) (B581) (B582), OS (O ₂ ) B583, NHC (O) B584, NB585C (O) B586, NHC ( O) OB587, NHC (O) NHB588, NHC (O) NB589B590, NB591C (O) OB592, NB593C (O) NHB594, NB595C (O) NB596B597, NHS (O2) B598, NB599S (O2) B600, SB601, S ( O) B602, S (O ₂ ) B603, S (O ₂ ) NHB604, S (O ₂ ) NB605B606, S (O ₂ ) OB607, P (O) (OB608) (OB609), Si (B610) (B611) (B612) "

Where B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571, B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, B596, B597, B598, B599, B600, B601, B602, B603, B604, B605, B606, B607, B608, B609, B610, B611, B612 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B567, B568 and / or B576, B577 and / or B589, B590 and / or B596, B597 and / or B605, B606 are also in each case" heterocycle. " Reels ",

(h) unsubstituted or substituted aryl, wherein optionally the aryl radical may be substituted by one or more substituents, identically or differently selected from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB613, NB614B615, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B616, C (O) OB617, C (O) NHB618, C (O) NB619B620, OB621, O (B622-O) _a H (a = 1, 2, 3, 4, 5), O (B623-O) _a B624 (a = 1, 2, 3, 4, 5), OC (O) B625, OC (O) OB626, OC (O) NHB627 , OC (O) NB628B629, OP (O) (OB630) (OB631), OSi (B632) (B633) (B634), OS (O ₂ ) B635, NHC (O) B636, NB637C (O) B638, NHC ( O) OB639, NHC (O) NHB640, NHC (O) NB641B642, NB643C (O) OB644, NB645C (O) NHB646, NB647C (O) NB648B649, NHS (O2) B650, NB651S (O2) B652, SB653, S ( O) B654, S (O ₂ ) B655, S (O ₂ ) NHB656, S (O ₂ ) NB657B658, S (O ₂ ) OB659, P (O) (OB660) (OB661), Si (B662) (B663) (B664) "

Where B613, B614, B615, B616, B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631, B632, B633, B634, B635, B636, B637, B638, B639, B640, B641, B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl "

Here, alternatively, B619, B620 and / or B628, B629 and / or B641, B642 and / or B648, B649 and / or B657, B658 may also in each case together form a “heterocyclyl”,

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB665, NB666B667, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B668, C (O) OB669, C (O) NHB670, C (O) NB671B672, OB673, O (B674-O) _b H (b = 1, 2, 3, 4, 5), O (B675-O) _b B676 (b = 1, 2, 3, 4, 5), OC (O) B677, OC (O) OB678, OC (O) NHB679 , OC (O) NB680B681, OP (O) (OB682) (OB683), OSi (B684) (B685) (B686), OS (O ₂ ) B687, NHC (O) B688, NB689C (O) B690, NHC ( O) OB691, NHC (O) NHB692, NHC (O) NB693B694, NB695C (O) OB696, NB697C (O) NHB698, NB699C (O) NB700B701, NHS (O2) B702, NB703S (O2) B704, SB705, S ( O) B706, S (O ₂ ) B707, S (O ₂ ) NHB708, S (O ₂ ) NB709B710, S (O ₂ ) OB711, P (O) (OB712) (OB713), Si (B714) (B715) (B716) "

Where B665, B666, B667, B668, B669, B670, B671, B672, B673, B674, B675, B676, B677, B678, B679, B680, B681, B682, B683, B684, B685, B686, B687, B688, B689, B690, B691, B692, B693, B694, B695, B696, B697, B698, B699, B700, B701, B702, B703, B704, B705, B706, B707, B708, B709, B710, B711, B712, B713, B714, B715, B716 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B671, B672 and / or B680, B681 and / or B693, B694 and / or B700, B701 and / or B709, B710 are also in each case" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB717, NB718B719, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B720, C (O) OB721, C (O) NHB722, C (O) NB723B724, OB725, O (B726-O) _c H (c = 1, 2, 3, 4, 5), O (B727-O) _c B728 (c = 1, 2, 3, 4, 5), OC (O) B729, OC (O) OB730, OC (O) NHB731 , OC (O) NB732B733, OP (O) (OB734) (OB735), OSi (B736) (B737) (B738), OS (O ₂ ) B739, NHC (O) B740, NB741C (O) B742, NHC ( O) OB743, NHC (O) NHB744, NHC (O) NB745B746, NB747C (O) OB748, NB749C (O) NHB750, NB751C (O) NB752B753, NHS (O2) B754, NB755S (O2) B756, SB757, S ( O) B758, S (O ₂ ) B759, S (O ₂ ) NHB760, S (O ₂ ) NB761B762, S (O ₂ ) OB763, P (O) (OB764) (OB765), Si (B766) (B767) (B768) "

Where B717, B718, B719, B720, B721, B722, B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733, B734, B735, B736, B737, B738, B739, B740, B741, B742, B743, B744, B745, B746, B747, B748, B749, B750, B751, B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B723, B724 and / or B732, B733 and / or B745, B746 and / or B752, B753 and / or B761, B762 are also in each case" heterocycle. " Reels ",

(j) unsubstituted or substituted heteroaryl wherein optionally, the heteroaryl radical may be substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB769, NB770B771, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B772, C (O) OB773, C (O) NHB774, C (O) NB775B776, OB777, O (B778-O) _d H (d = 1, 2, 3, 4, 5), O (B779-O) _d B780 (d = 1, 2, 3, 4, 5), OC (O) B781, OC (O) OB782, OC (O) NHB783 , OC (O) NB784B785, OP (O) (OB786) (OB787), OSi (B788) (B789) (B790), OS (O ₂ ) B791, NHC (O) B792, NB793C (O) B794, NHC ( O) OB795, NHC (O) NHB796, NHC (O) NB797B798, NB799C (O) OB800, NB801C (O) NHB802, NB803C (O) NB804B805, NHS (O2) B806, NB807S (O2) B808, SB809, S ( O) B810, S (O ₂ ) B811, S (O ₂ ) NHB812, S (O ₂ ) NB813B814, S (O ₂ ) OB815, P (O) (OB816) (OB817), Si (B818) (B819) (B820) "

Where B769, B770, B771, B772, B773, B774, B775, B776, B777, B778, B779, B780, B781, B782, B783, B784, B785, B786, B787, B788, B789, B790, B791, B792, B793, B794, B795, B796, B797, B798, B799, B800, B801, B802, B803, B804, B805, B806, B807, B808, B809, B810, B811, B812, B813, B814, B815, B816, B817, B818, B819, B820 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B775, B776 and / or B784, B785 and / or B797, B798 and / or B804, B805 and / or B813, B814 are also in each case" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB821, NB822B823, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B824, C (O) OB825, C (O) NHB826, C (O) NB827B828, OB829, O (B830-O) _e H (e = 1, 2, 3, 4, 5), O (B831-O) _e B832 (e = 1, 2, 3, 4, 5), OC (O) B833, OC (O) OB834, OC (O) NHB835 , OC (O) NB836B837, OP (O) (OB838) (OB839), OSi (B840) (B841) (B842), OS (O ₂ ) B843, NHC (O) B844, NB845C (O) B846, NHC ( O) OB847, NHC (O) NHB848, NHC (O) NB849B850, NB851C (O) OB852, NB853C (O) NHB854, NB855C (O) NB856B857, NHS (O2) B858, NB859S (O2) B860, SB861, S ( O) B862, S (O ₂ ) B863, S (O ₂ ) NHB864, S (O ₂ ) NB865B866, S (O ₂ ) OB867, P (O) (OB868) (OB869), Si (B870) (B871) (B872) "

Where B821, B822, B823, B824, B825, B826, B827, B828, B829, B830, B831, B832, B833, B834, B835, B836, B837, B838, B839, B840, B841, B842, B843, B844, B845, B846, B847, B848, B849, B850, B851, B852, B853, B854, B855, B856, B857, B858, B859, B860, B861, B862, B863, B864, B865, B866, B867, B868, B869, B870, B871, B872 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B827, B828 and / or B836, B837 and / or B849, B850 and / or B856, B857 and / or B865, B866 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB873, NB874B875, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B876, C (O) OB877, C (O) NHB878, C (O) NB879B880, OB881, O (B882-O) _f H (f = 1, 2, 3, 4, 5), O (B883-O) _f B884 (f = 1, 2, 3, 4, 5), OC (O) B885, OC (O) OB886, OC (O) NHB887 , OC (O) NB888B889, OP (O) (OB890) (OB891), OSi (B892) (B893) (B894), OS (O ₂ ) B895, NHC (O) B896, NB897C (O) B898, NHC ( O) OB899, NHC (O) NHB900, NHC (O) NB901B902, NB903C (O) OB904, NB905C (O) NHB906, NB907C (O) NB908B909, NHS (O2) B910, NB911S (O2) B912, SB913, S ( O) B914, S (O ₂ ) B915, S (O ₂ ) NHB916, S (O ₂ ) NB917B918, S (O ₂ ) OB919, P (O) (OB920) (OB921), Si (B922) (B923) (B924) "

Where B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898, B899, B900, B901, B902, B903, B904, B905, B906, B907, B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B879, B880 and / or B888, B889 and / or B901, B902 and / or B908, B909 and / or B917, B918 are also in each case" heterocycle Reels ",

(k) OZ6, wherein Z6 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB925, NB926B927, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B928, C (O) OB929, C (O) NHB930, C (O) NB931B932, OB933, O (B934-O) _g H (g = 1, 2, 3, 4, 5), O (B935-O) _g B936 (g = 1, 2, 3, 4, 5), OC (O) B937, OC (O) OB938, OC (O) NHB939 , OC (O) NB940B941, OP (O) (OB942) (OB943), OSi (B944) (B945) (B946), OS (O ₂ ) B947, NHC (O) B948, NB949C (O) B950, NHC ( O) OB951, NHC (O) NHB952, NHC (O) NB953B954, NB955C (O) OB956, NB957C (O) NHB958, NB959C (O) NB960B961, NHS (O2) B962, NB963S (O2) B964, SB965, S ( O) B966, S (O ₂ ) B967, S (O ₂ ) NHB968, S (O ₂ ) NB969B970, S (O ₂ ) OB971, P (O) (OB972) (OB973), Si (B974) (B975) (B976) "

Where B925, B926, B927, B928, B929, B930, B931, B932, B933, B934, B935, B936, B937, B938, B939, B940, B941, B942, B943, B944, B945, B946, B947, B948, B949, B950, B951, B952, B953, B954, B955, B956, B957, B958, B959, B960, B961, B962, B963, B964, B965, B966, B967, B968, B969, B970, B971, B972, B973, B974, B975, B976 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B931, B932 and / or B940, B941 and / or B953, B954 and / or B960, B961 and / or B969, B970 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB977, NB978B979, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B980, C (O) OB981, C (O) NHB982, C (O) NB983B984, OB985, O (B986-O) _h H (h = 1, 2, 3, 4, 5), O (B987-O) _h B988 (h = 1, 2, 3, 4, 5), OC (O) B989, OC (O) OB990, OC (O) NHB991 , OC (O) NB992B993, OP (O) (OB994) (OB995), OSi (B996) (B997) (B998), OS (O ₂ ) B999, NHC (O) B1000, NB1001C (O) B1002, NHC ( O) OB1003, NHC (O) NHB1004, NHC (O) NB1005B1006, NB1007C (O) OB1008, NB1009C (O) NHB1010, NB1011C (O) NB1012B1013, NHS (O2) B1014, NB1015S (O2) B1016, SB1017 O) B1018, S (O ₂ ) B1019, S (O ₂ ) NHB1020, S (O ₂ ) NB1021B1022, S (O ₂ ) OB1023, P (O) (OB1024) (OB1025), Si (B1026) (B1027) (B1028) "

Where B977, B978, B979, B980, B981, B982, B983, B984, B985, B986, B987, B988, B989, B990, B991, B992, B993, B994, B995, B996, B997, B998, B999, B1000, B1001, B1002, B1003, B1004, B1005, B1006, B1007, B1008, B1009, B1010, B1011, B1012, B1013, B1014, B1015, B1016, B1017, B1018, B1019, B1020, B1021, B1022, B1023, B1024, B1024 B1026, B1027, B1028 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B983, B984 and / or B992, B993 and / or B1005, B1006 and / or B1012, B1013 and / or B1021, B1022 are also in each case" heterocycle Reels ",

(l) SZ7, wherein Z7 is independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB1029, NB1030B1031, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B1032, C (O) OB1033, C (O) NHB1034, C (O) NB1035B1036, OB1037, O (B1038-O) _i H (i = 1, 2, 3, 4, 5), O (B1039-O) _i B1040 (i = 1, 2, 3, 4, 5), OC (O) B1041, OC (O) OB1042, OC (O) NHB1043 , OC (O) NB1044B1045, OP (O) (OB1046) (OB1047), OSi (B1048) (B1049) (B1050), OS (O ₂ ) B1051, NHC (O) B1052, NB1053C (O) B1054, NHC ( O) OB1055, NHC (O) NHB1056, NHC (O) NB1057B1058, NB1059C (O) OB1060, NB1061C (O) NHB1062, NB1063C (O) NB1064B1065, NHS (O2) B1066, NB1067S (O2) B1068, SB1069, SB1069 O) B1070, S (O ₂ ) B1071, S (O ₂ ) NHB1072, S (O ₂ ) NB1073B1074, S (O ₂ ) OB1075, P (O) (OB1076) (OB1077), Si (B1078) (B1079) (B1080) "

Where B1029, B1030, B1031, B1032, B1033, B1034, B1035, B1036, B1037, B1038, B1039, B1040, B1041, B1042, B1043, B1044, B1045, B1046, B1047, B1048, B1049, B1050, B1051, B1052, B1053, B1054, B1055, B1056, B1057, B1058, B1059, B1060, B1061, B1062, B1063, B1064, B1065, B1066, B1067, B1068, B1069, B1070, B1071, B1072, B1073, B1074, B1075, B1076, B1077, B1077 B1078, B1079, B1080 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B1035, B1036 and / or B1044, B1045 and / or B1057, B1058 and / or B1064, B1065 and / or B1073, B1074 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB1081, NB1082B1083, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B1084, C (O) OB1085, C (O) NHB1086, C (O) NB1087B1088, OB1089, O (B1090-O) _j H (j = 1, 2, 3, 4, 5), O (B1091-O) _j B1092 (j = 1, 2, 3, 4, 5), OC (O) B1093, OC (O) OB1094, OC (O) NHB1095 , OC (O) NB1096B1097, OP (O) (OB1098) (OB1099), OSi (B1100) (B1101) (B1102), OS (O ₂ ) B1103, NHC (O) B1104, NB1105C (O) B1106, NHC ( O) OB1107, NHC (O) NHB1108, NHC (O) NB1109B1110, NB1111C (O) OB1112, NB1113C (O) NHB1114, NB1115C (O) NB1116B1117, NHS (O2) B1118, NB1119S (O2) B1120, SB112 O) B1122, S (O ₂ ) B1123, S (O ₂ ) NHB1124, S (O ₂ ) NB1125B1126, S (O ₂ ) OB1127, P (O) (OB1128) (OB1129), Si (B1130) (B1131) (B1132) "

Where B1081, B1082, B1083, B1084, B1085, B1086, B1087, B1088, B1089, B1090, B1091, B1092, B1093, B1094, B1095, B1096, B1097, B1098, B1099, B1100, B1101, B1102, B1103, B1104 B1105, B1106, B1107, B1108, B1109, B1110, B1111, B1112, B1113, B1114, B1115, B1116, B1117, B1118, B1119, B1120, B1121, B1122, B1123, B1124, B1125, B1126, B1127, B1128, B1128, B1128 B1130, B1131, B1132 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B1087, B1088 and / or B1096, B1097 and / or B1109, B1110 and / or B1116, B1117 and / or B1125, B1126 are also in each case" heterocycle Reels ",

(m) NZ8Z9, wherein Z8 and Z9 are each independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C (O) B1133 , C (O) OB1134, C (O) NB1135B1136, S (O ₂ ) B1137, S (O ₂ ) OB1138 "

Wherein B1133, B1134, B1135, B1136, B1137, B1138 are each independently selected from the group consisting of: hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero Cyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl ", where, alternatively, B1135, B1136 together may also form" heterocyclyl ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB1139, NB1140B1141, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B1142, C (O) OB1143, C (O) NHB1144, C (O) NB1145B1146, OB1147, O (B1148-O) _k H (k = 1, 2, 3, 4, 5), O (B1149-O) _k B1150 (k = 1, 2, 3, 4, 5), OC (O) B1151, OC (O) OB1152, OC (O) NHB1153 , OC (O) NB1154B1155, OP (O) (OB1156) (OB1157), OSi (B1158) (B1159) (B1160), OS (O ₂ ) B1161, NHC (O) B1162, NB1163C (O) B1164, NHC ( O) OB1165, NHC (O) NHB1166, NHC (O) NB1167B1168, NB1169C (O) OB1170, NB1171C (O) NHB1172, NB1173C (O) NB1174B1175, NHS (O2) B1176, NB1177S (O2) B1178, SB1179 O) B1180, S (O ₂ ) B1181, S (O ₂ ) NHB1182, S (O ₂ ) NB1183B1184, S (O ₂ ) OB1185, P (O) (OB1186) (OB1187), Si (B1188) (B1189) (B1190) "

Where B1139, B1140, B1141, B1142, B1143, B1144, B1145, B1146, B1147, B1148, B1149, B1150, B1151, B1152, B1153, B1154, B1155, B1156, B1157, B1158, B1159, B1160, B1161, B1162, B1163, B1164, B1165, B1166, B1167, B1168, B1169, B1170, B1171, B1172, B1173, B1174, B1175, B1176, B1177, B1178, B1179, B1180, B1181, B1182, B1183, B1184, B1185, B1186, B1186, B1186 B1188, B1189, B1190 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", where, alternatively, B1145, B1146 and / or B1154, B1155 and / or B1167, B1168 and / or B1174, B1175 and / or B1183, B1184 are also in each case" heterocycle Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHB1191, NB1192B1193, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) B1194, C (O) OB1195, C (O) NHB1196, C (O) NB1197B1198, OB1199, O (B1200-O) _l H (l = 1, 2, 3, 4, 5), O (B1201-O) _l B1202 (l = 1, 2, 3, 4, 5), OC (O) B1203, OC (O) OB1204, OC (O) NHB1205 , OC (O) NB1206B1207, OP (O) (OB1208) (OB1209), OSi (B1210) (B1211) (B1212), OS (O ₂ ) B1213, NHC (O) B1214, NB1215C (O) B1216, NHC ( O) OB1217, NHC (O) NHB1218, NHC (O) NB1219B1220, NB1221C (O) OB1222, NB1223C (O) NHB1224, NB1225C (O) NB1226B1227, NHS (O2) B1228, NB1229S (O2) B1230, SB1231 O) B1232, S (O ₂ ) B1233, S (O ₂ ) NHB1234, S (O ₂ ) NB1235B1236, S (O ₂ ) OB1237, P (O) (OB1238) (OB1239), Si (B1240) (B1241) (B1242) "

Where B1191, B1192, B1193, B1194, B1195, B1196, B1197, B1198, B1199, B1200, B1201, B1202, B1203, B1204, B1205, B1206, B1207, B1208, B1209, B1210, B1211, B1212, B1213, B1214, B1214, B1214 B1215, B1216, B1217, B1218, B1219, B1220, B1221, B1222, B1223, B1224, B1225, B1226, B1227, B1228, B1229, B1230, B1231, B1232, B1233, B1234, B1235, B1236, B1237, B1238, B1239 B1240, B1241, B1242 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, B1197, B1198 and / or B1206, B1207 and / or B1219, B1220 and / or B1226, B1227 and / or B1235, B1236 are also in each case" heterocycle. " Reels ",

And

Z5 radicals are independently selected from the group consisting of:

(i) "hydrogen, alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br , I, CN, CF ₃ , N ₃ , NH ₂ , NHD1, ND2D3, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) D4, C (O) OD5, C (O) NHD6, C (O) ND7D8, OD9, O (D10-O) _r H ( r = 1, 2, 3, 4, 5), O (D11-O) _r D12 (r = 1, 2, 3, 4, 5), OC (O) D13, OC (O) OD14, OC (O ) NHD15, OC (O) ND16D17, OP (O) (OD18) (OD19), OSi (D20) (D21) (D22), OS (O ₂ ) D23, NHC (O) D24, ND25C (O) D26, NHC (O) OD27, NHC (O) NHD28, NHC (O) ND29D30, ND31C (O) OD32, ND33C (O) NHD34, ND35C (O) ND36D37, NHS (O2) D38, ND39S (O2) D40, SD41, S (O) D42, S (O ₂ ) D43, S (O ₂ ) NHD44, S (O ₂ ) ND45D46, S (O ₂ ) OD47, P (O) (OD48) (OD49), Si (D50) ( D51) (D52) "

Where D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D7, D8 and / or D16, D17 and / or D29, D30 and / or D36, D37 and / or D45, D46 may also in each case be" heterocycle. " Reels ",

Here, optionally, the aforementioned substituents of substituent group (i) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(ii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHD53, ND54D55, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) D56, C (O) OD57, C (O) NHD58, C (O) ND59D60, OD61, O (D62-O) _s H (s = 1, 2, 3, 4, 5), O (D63-O) _t D64 (t = 1, 2, 3, 4, 5), OC (O) D65, OC (O) OD66, OC (O) NHD67 , OC (O) ND68D69, OP (O) (OD70) (OD71), OSi (D72) (D73) (D74), OS (O ₂ ) D75, NHC (O) D76, ND77C (O) D78, NHC ( O) OD79, NHC (O) NHD80, NHC (O) ND81D82, ND83C (O) OD84, ND85C (O) NHD86, ND87C (O) ND88D89, NHS (O2) D90, ND91S (O2) D92, SD93, S ( O) D94, S (O ₂ ) D95, S (O ₂ ) NHD96, S (O ₂ ) ND97D98, S (O ₂ ) OD99, P (O) (OD100) (OD101), Si (D102) (D103) (D104) "

Where D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, D90, D91, D92, D93, D94, D95, D96, D97, D98, D99, D100, D101, D102, D103, D104 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D59, D60 and / or D68, D69 and / or D81, D82 and / or D88, D89 and / or D97, D98 are also in each case" heterocycle. " Reels ",

Wherein, optionally, the aforementioned substituents of substituent group (ii) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(iii) "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, F, Cl, Br, I , CN, CF ₃ , N ₃ , NH ₂ , NHD105, ND106D107, NO ₂ , OH, OCF ₃ , SH, OSO ₃ H, OP (O) (OH) ₂ , CHO, COOH, C (O) NH ₂ , SO ₃ H, P (O) (OH) ₂ , C (O) D108, C (O) OD109, C (O) NHD110, C (O) ND111D112, OD113, O (D114-O) _t H (t = 1, 2, 3, 4, 5), O (D115-O) _t D116 (t = 1, 2, 3, 4, 5), OC (O) D117, OC (O) OD118, OC (O) NHD119 , OC (O) ND120D121, OP (O) (OD122) (OD123), OSi (D124) (D125) (D126), OS (O ₂ ) D127, NHC (O) D128, ND129C (O) D130, NHC ( O) OD131, NHC (O) NHD132, NHC (O) ND133D134, ND135C (O) OD136, ND137C (O) NHD138, ND139C (O) ND140D141, NHS (O2) D142, ND143S (O2) D144, SD145, S ( O) D146, S (O ₂ ) D147, S (O ₂ ) NHD148, S (O ₂ ) ND149D150, S (O ₂ ) OD151, P (O) (OD152) (OD153), Si (D154) (D155) (D156) "

Where D105, D106, D107, D108, D109, D110, D111, D112, D113, D114, D115, D116, D117, D118, D119, D120, D121, D122, D123, D124, D125, D126, D127, D128, D129, D130, D131, D132, D133, D134, D135, D136, D137, D138, D139, D140, D141, D142, D143, D144, D145, D146, D147, D148, D149, D150, D151, D152, D153, D154, D155, D156 are each independently selected from the group consisting of: "alkyl, (C ₉ -C ₃₀ ) alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, Heteroaryl, heteroarylalkyl ", wherein, alternatively, D111, D112 and / or D120, D121 and / or D133, D134 and / or D140, D141 and / or D149, D150 are also in each case" heterocycle. " Reel ".

In order to avoid ambiguity, (A) to (E) are described below for the above formula (I):

In case (A), the novel pyrido [2,3-b] pyrazine derivatives can be substituted by "substituted aryl" in one or more of its Z3, Z4 radicals, with novelty by sub-case (a) Or by sub-case (c). If only one Z3, Z4 radical is a novel "substituted aryl", the other Z3, Z4 radicals may in each case have a substitution within the maximum ranges described ("and" bonds in sub-case (d)). Optionally, both Z3 and Z4 radicals may also have additional substitutions (sub-case (b) or (d)). Z1, Z2 and Z5 radicals may have substitutions within the maximum ranges indicated ((sub- In the case (A) to (D) "and" bond].

In case (B), the novel pyrido [2,3-b] pyrazine derivative may be substituted by “substituted heteroaryl” in one or more of its Z 3, Z 4 radicals, with novelty in sub-case (a) Or by sub-case (c). If only one Z3, Z4 radical is a novel "substituted heteroaryl", the other Z3, Z4 radicals may in each case have a substitution within the maximum ranges indicated (in the "sub-case (d)" and "bonds). Optionally, both Z3 and Z4 radicals may also have additional substitutions (sub-case (b) or (d)). Z1, Z2 and Z5 radicals may have substitutions within the maximum ranges described "And" bond in (A) to (D)].

In case (C), the novel pyrido [2,3-b] pyrazine derivatives are prepared by "substituted alkyl" or "(C ₉ -C ₃₀ ) alkyl" in a novel way in one or more of their Z3, Z4 radicals. Can be substituted. When only one Z3, Z4 radical is a novel "substituted alkyl" or "(C ₉ -C ₃₀ ) alkyl", the other Z3, Z4 radicals may in each case have the desired substitution within the maximum ranges described [( "And" bonds "(C ₉ -C ₃₀ ) alkyl" in sub-cases.Z1, Z2 and Z5 radicals have substitutions within the maximum ranges indicated (("and" bonds in cases (A) to (D)]). .

In case (D), the novel pyrido [2,3-b] pyrazine derivatives may be substituted by "OZ12, SZ13" in one or more of its Z3, Z4 radicals, the novelty being of sub-case (a) Or by sub-case (b). When only one Z3, Z4 radical is the novel "NZ10Z11, OZ12, SZ13", the other Z3, Z4 radicals may have the desired substitution within the maximum range described in each case [(in sub-case (b) " And "bond". The Z1, Z2 and Z5 radicals may have the desired substitution within the maximum range described ("and" bond in cases (A) to (D)).

In case (E), the novel pyrido [2,3-b] pyrazine derivative may be substituted by "NZ24Z25, NZ26Z27" in one or more of its Z1, Z2 radicals, the novelty being in sub-case (a) (1 By sub-case (b) (1) (I), by sub-case (b) (1) (II) or by sub-case (b) (2). If only one Z1, Z2 radical is the novel "NZ24Z25, NZ26Z27", then the remaining Z1, Z2 radicals may have substitutions within the maximum ranges described in each case [sub-case (c), (d)] [( "And" bonds in the sub-case (b) (2) .Z3, Z4 and Z5 radicals have substitutions within the maximum ranges described (("and" bonds in the sub-case (d))).

In a preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (A)

Z1 radicals are independently "NZ14Z15" where Z14 is hydrogen or "aryl" and Z15 is "C (O) NHalkyl" where "C (O) NHalkyl" is additionally, optionally, "OH" May be substituted by ";

Z 2 radicals are independently hydrogen;

Z 3 radicals are independently “substituted aryl” wherein “substituted aryl” is substituted by one or more substituents identically or differently selected from the group consisting of:

(a) "alkyl, OC (O) alkyl, Oalkyl, NHC (O) alkyl"

Provided that the substituents in Substituent Group (a) are each independently further substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "aryl, heterocyclyl, OalkylOalkyl, Oarylalkyl"

Or the Z 3 radicals are independently “substituted aryl” wherein “substituted aryl” is substituted by one or more substituents identically or differently selected from the group consisting of:

(c) "OC (O) Oalkyl, OC (O) Oaryl, OC (O) N (alkyl) ₂ , OC (O) NHalkyl, OC (O) (C ₉ -C ₃₀ ) alkyl, NHC ( O) Oalkyl, NHC (O) NHalkyl, NHC (O) N (alkyl) ₂ , Si (alkyl) ₃ "

Wherein, optionally, the aforementioned substituents of substituent group (c) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "Oalkyl, Oarylalkyl"

Here, optionally, the Z 3 radicals may also be independently substituted by one or more substituents selected identically or differently from the group consisting of:

(d) "halogen, F, Cl, Br, I, Oalkyl"

Z 4 radicals are independently hydrogen;

Z5 radicals independently hydrogen

In a preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) may be provided as follows, in (A)

Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl, NHC (O) NHbutylOH",

Z 2 radicals are independently hydrogen;

Z3 radicals are independently "4-phenyl methyl carbonate, 3-phenyl 2-methoxyethyl carbonate, 4-phenyl 2-methoxyethyl carbonate, 4-phenyl phenyl carbonate, 4-phenyl N-diethylcarbamate, 4- Phenyl 3-phenylacrylate, 4-phenyl nonadecanoate, 4-phenyl isobutyl carbonate, 4-phenyl but-2-ynyl carbonate, 4-phenyl N-dimethylcarbamate, 4-phenyl N-ethylcarbamate, Tert-butyl N- (4-phenyl) carbamate, 2-methoxyethyl N- (4-phenyl) carbamate, 4- (3-ethylurea) phenyl, 4- (3,3-methylurea) phenyl 4-morpholin-4-ylmethylphenyl, 4- [2- (2-methoxyethoxy) ethoxy] phenyl, N- (4-phenyl) -2- (2-methoxyethoxy) acetamide, 4- (2-methoxy) phenyl 2-methoxyethyl carbonate, 4-phenyl 2-benzyloxyethyl carbonate, 4- (2-methoxy) phenyl 2-benzyloxyethyl carbonate, N- (4-phenyl)- 2-benzyloxyacetamide, 3-trimethylsilanylphenyl, 4- (2-methoxy) phenyl N- Ethylcarbamate, 4- (2-chloro-6-methoxy) phenyl N-diethylcarbamate, 4- (2-methoxy) phenyl 2- [2- (2-methoxyethoxy) ethoxy] ethyl Carbonate ", and

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (B),

The Z1 radicals are independently "NZ14Z15", wherein Z14 is hydrogen and Z15 is "C (O) NHalkyl";

Z 2 radicals are independently hydrogen;

Z 3 radicals are independently “substituted heteroaryl” wherein “substituted heteroaryl” is substituted by one or more substituents, identically or differently selected from the group consisting of:

(a) "NHC (O) NHalkyl"

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (B),

Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl",

Z 2 radicals are independently hydrogen;

Z3 radicals are independently selected from the group consisting of "6- (3-ethylurea) pyridin-3-yl",

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula I are provided as follows, in (C),

The Z1 radicals are independently "NZ14Z15", wherein Z14 is hydrogen and Z15 is "C (O) NHalkyl";

Z 2 radicals are independently hydrogen;

Z 3 radicals are independently “substituted alkyl” wherein “substituted alkyl” is substituted by one or more substituents identically or differently selected from the group consisting of:

(a) "aryl, heteroaryl, cycloalkyl, N (alkyl) ₂ , Oalkyl"

Wherein, optionally, the aforementioned substituents of substituent group (a) may each be substituted independently of one another by one or more substituents selected identically or differently from the group consisting of:

(i) "halogen, F, Cl, Br, I"

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (C)

Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl",

Z 2 radicals are independently hydrogen;

Z3 radicals are independently "phenylethynyl, thiophen-3-ylethynyl, cyclopropylethynyl, N-dimethylaminoprop-1-ynyl, 2-cyclohexylvinyl, 3-methoxypropenyl, benzyl, 2- (4-fluorophenyl) ethyl, 2- (4-fluorophenyl) vinyl ", and

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (D)

The Z1 radicals are independently "NZ14Z15"; Wherein Z 14 is hydrogen and Z 15 is “C (O) NH alkyl”;

Z 2 radicals are independently hydrogen;

Z3 radicals are independently selected from the group consisting of:

(1) "NZ10Z11"

Wherein the Z10 and Z11 radicals are each independently selected from the group consisting of:

(a) "hydrogen, aryl"

Provided that the substituents of substituent group (a) are further substituted by one or more substituents, each of which is independently the same or differently selected from the group consisting of:

(i) "cycloalkyl, heteroaryl, heterocyclylalkyl, S (O) ₂ alkyl, NHS (O) ₂ alkyl, C (O) NHalkyl, NHC (O) alkyl, C (O) Oalkyl"

(b) "C (O) aryl"

Here, optionally, the aforementioned substituents of substituent group (a) and / or substituent group (b) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "alkyl"

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (D)

Z1 radicals are independently selected from the group consisting of "NHC (O) NHethyl",

Z 2 radicals are independently hydrogen;

Z3 radicals are independently "4-methylbenzamide, 4-cyclohexylphenylamino, 4-methanesulfonylphenylamino, 3- (N-methanesulfonamide) -4-methylphenylamino, 3-N-methylbenzamideamino , 4-piperidin-1-ylmethylphenylamino, 4-thiophen-3-ylphenylamino, 4-N-acetamidophenylamino, 3- (ethyl benzoate) amino ",

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (E),

Z 1 radical is independently selected from the group consisting of:

(a) "NZ24Z25" wherein Z24 is hydrogen and Z25 is "C (O) C (O) Oalkyl" or "C (O) C (O) NHalkyl" or "C (O) NHOalkyl" ego,

Wherein, optionally, the aforementioned substituents in substituent group (a) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "OSi (alkyl) ₃ , OC (O) NHalkyl, OC (O) Oalkyl, P (O) (Oalkyl) ₂ , P (O) (OH) ₂ , Oalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of:

(ii) “heterocyclyl, OH, N (alkyl) ₂ , OC (O) alkyl”

Here, optionally, the aforementioned substituents of substituent group (ii) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of:

(iii) "alkyl"

(b) "NZ26Z27" wherein Z26 is hydrogen and Z27 is "C (O) NHalkyl"

Provided that the substituents of substituent group (b) are each independently further substituted by one or more substituents selected the same or differently from the group consisting of:

(i) "OSi (alkyl) ₃ , OC (O) NHalkyl, OC (O) Oalkyl, P (O) (Oalkyl) ₂ , P (O) (OH) ₂ , Oalalkyl"

Here, optionally, the aforementioned substituents of substituent group (i) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of:

(ii) “heterocyclyl, OH, N (alkyl) ₂ , OC (O) alkyl”

Here, optionally, the aforementioned substituents of substituent group (ii) may also be further substituted by one or more substituents, each independently selected from the same or differently from the group consisting of:

(iii) "alkyl"

Z 2 radicals are independently hydrogen;

Z3 radicals are independently selected from the group consisting of:

(a) "aryl"

Wherein, optionally, the aforementioned substituents in substituent group (a) may each be independently substituted by one or more substituents selected identically or differently from the group consisting of:

(i) "Oalkyl, OH"

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

In a further preferred embodiment, the novel pyrido [2,3-b] pyrazine derivatives of formula (I) are provided as follows, in (E),

Z1 radicals are independently "3-methoxy-1-ylurea, 3- (prop-1-yn-3-yl) -1-ylurea, 3- [4- (tert-butyldimethylsilanyloxy ) Butyl] -1-ylurea, 4- (N-ethyl carbamate) butyl-1-ylurea, 4- (methyl carbonate) butyl-1-ylurea, 4- (2,3-dihydroxypropyl carbonate ) Butyl-1-ylurea, 4- (2,2-dimethyl- [1,3] dioxolan-4-ylmethyl carbonate) butyl-1-ylurea, 4- (diethyl phosphate) butyl-1-yl Urea, 4- (butyl phosphate) -1-ylurea, N-oxalic acid monoamide ethyl ester, N-ethyl-N'-oxalamide, 2- (diethyl phosphate) ethyl-1-ylurea, 2- ( Ethyl phosphate) -1-ylurea, 3- (2-diethylamino-ethoxy) propyl-1-ylurea, 4-[(2,2-dimethylpropionyloxymethoxy) phosphinoyloxymethyl 2, 2-dimethylpropanoate] butyl-1-ylurea, 4- [1- (1-acetoxyethoxy) ethoxyacetate] butyl-1-ylurea " Is selected,

Z 2 radicals are independently hydrogen;

Z3 radicals are independently selected from the group consisting of "phenyl, 4-hydroxy-3-methoxyphenyl",

Z 4 radicals are independently hydrogen;

Z 5 radicals are independently hydrogen.

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

delete

Preference is given to the following pyrido [2,3-b] pyrazine derivatives of the formula (I) which may exist in their free base or else in the form of a pharmaceutically acceptable salt of a physiologically acceptable acid:

Compound 1 1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazin-6-yl) urea

Compound 2 1-ethyl-3- (3-thiophen-3-ylethynylpyrido [2,3-b] pyrazin-6-yl) urea

Compound 3 1- (3-cyclopropylethynylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea

Compound 4 1- [3- (3-dimethylaminoprop-1-ynyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Compound 5 1- [3-((E) -2-cyclohexylvinyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Compound 6 1-ethyl-3- [3-((E) -3-methoxypropenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 7

Compound 8

Compound 9 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl methyl carbonate

Compound 10 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate

Compound 11 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl phenyl carbonate

Compound 12 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl diethylcarbamate

Compound 13 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (E) -3-phenylacrylate

Compound 14 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl nonadecanoate

Compound 15 1- (3-benzylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea

Compound 16 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate

Compound 17 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl isobutyl carbonate

Compound 18 But-2-ynyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate

Compound 19 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl dimethylcarbamate

Compound 20 4- [6- (3-ethyl-1-phenylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl ethylcarbamate

Compound 21 tert-butyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -carbamate

Compound 22 2-methoxyethyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -carbamate

Compound 23 1-ethyl-3- {3- [4- (3-ethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 24 1- {3- [4- (3,3-dimethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea

Compound 25 1-ethyl-3- {3- [6- (3-ethylurea) pyridin-3-yl] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 26 1-ethyl-3- {3- [2- (4-fluorophenyl) ethyl] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 27 1-ethyl-3- {3-[(E) -2- (4-fluorophenyl) vinyl] pyrido [2,3-b] pyrazin-6-yl} -urea

Compound 28 1-ethyl-3- [3- (4-morpholin-4-ylmethylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 29 1-ethyl-3- (3- {4- [2- (2-methoxyethoxy) ethoxy] phenyl} pyrido [2,3-b] pyrazin-6-yl) urea

Compound 30 N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -2- (2-methoxyethoxy) acetamide

Compound 31 N- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide

Compound 32 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2-methoxyethyl carbonate

Compound 33 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate

Compound 34 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl carbonate

Compound 35 2-benzyloxy-N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -acetamide

Compound 36 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- (3-phenylpyrido [2,3-b] -pyrazin-6-yl) urea

Compound 37 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazine-6- Urea

Compound 38 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ethyl carbamate

Compound 39 Methyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate

Compound 40 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate

Compound 41 2,3-dihydroxypropyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] -butyl carbonate

Compound 42 diethyl {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} -phosphate

Compound 43 {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphate

Compound 44 diethyl (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphate

Compound 45 (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphate

Compound 46 1-ethyl-3- [3- (3-trimethylsilanylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 47 1- [3- (4-cyclohexylphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Compound 48 1-ethyl-3- [3- (4-methanesulfonylphenylamino) pyrido [2,3-b] -pyrazin-6-yl] urea

Compound 49 N- {5- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -2-methyl-phenyl} methanesulfonamide

Compound 50 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -N-methyl-benzamide

Compound 51 1-ethyl-3- [3- (4-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] -pyrazin-6-yl] urea

Compound 52 1-ethyl-3- [3- (4-thiophen-3-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 53 N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] phenyl} -acetamide

Compound 54 ethyl 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] benzoate

Compound 55 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate hydrochloride

Compound 56 2-methoxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate p-toluenesulfonate

Compound 57 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate

Compound 58 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate hydrochloride

Compound 59 N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalic acid monoamide ethyl ester

Compound 60 N-ethyl-N '-(3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamide

Compound 61

Compound 62 Diethyl {2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} -phosphate

Compound 63 {2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} phosphate

Compound 64 1- [3- (2-diethylaminoethoxy) propyl] -3- [3- (4-hydroxy-3-methoxy-phenyl) pyrido [2,3-b] pyrazine-6- Urea

Compound 65 (2,2-dimethylpropionyloxymethoxy)-(4- {3- [3- (4-hydroxy-3-methoxy-phenyl) pyrido [2,3-b] pyrazine-6- Urea} butyl) phosphinoyloxymethyl 2,2-dimethyl-propanoate

Compound 66 1-[(1-acetoxyethoxy)-(4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazin-6-yl ] Urea} butyl) phosphinoyloxy] ethyl acetate

Compound 67 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] 2-methoxyphenyl diethylcarbamate

Compound 68 2-chloro-4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -6-methoxy-phenyl diethylcarbamate

Compound 69 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2- [2- (2-methoxyethoxy) ethoxy] Ethyl carbonate

Compound 70 1-ethyl-3- [4- (morpholin-4-sulfonyl) phenylamino] pyrido [2,3-b] pyrazin-6-ylurea

Compound 71 Ethyl 5- [6- (3-ethylureido) pyrido [2,3-b] pyrazin-3-ylamino] -2-hydroxy-benzoate

Compound 72 1- [3- (3-diethylaminomethyl-4-hydroxyphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Compound 73 1-ethyl-3- [3- (6-morpholin-4-ylpyridin-3-ylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 74 1-ethyl-3- {3- [3- (1H-tetrazol-5-yl) phenylamino] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 75 1-ethyl-3- [3- (3-morpholin-4-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 76 1-ethyl-3- [3- (4-imidazol-1-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 77 1-ethyl-3- [3- (4-pyrrolidin-1-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 78 1-ethyl-3- {3- [4- (4-methylpiperazin-1-yl) phenylamino] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 79 1-ethyl-3- [3- (3-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 80 1-ethyl-3- [3- (4-morpholin-4-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 81 1- {3- [3- (2-cyclohexylethoxy) phenylamino] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea

Compound 82 1-ethyl-3- [3- (3- [1,2,4] triazol-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 83 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazine- 6-yl] ureido} butyl carbonate

Compound 84 2,3-dihydroxypropyl 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] ureido} butyl carbonate

Compound 85 1- [3- (2-diethylaminoethoxy) propyl] -3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl Urea

In order to avoid ambiguity: If the chemical structure and chemical name of the above-mentioned clear compound are incorrect and do not match each other, the chemical structure clearly defines the specific clear compound.

The aforementioned compounds of formula (I), preferred embodiments and the pyridopyrazines of compounds 1 to 85 mentioned explicitly are collectively referred to below as "compounds of the invention".

The expressions and terms specified to describe the compounds of the present invention are, in principle, defined as follows, unless otherwise indicated in the specification and claims:

In the present invention, the expression “alkyl” may be branched or straight chain and is an acyclic saturated or unsaturated hydrocarbon radical having 1 to 8 carbon atoms, ie C _1-8 -alkanyl, C _2-8 -alkenyl and C _2-8 -alkynyl. Alkenyl has one or more CC double bonds, and alkynyl has one or more CC triple bonds. Alkynyl may additionally also have one or more CC double bonds. Preferred alkyl radicals are methyl, ethyl, n -propyl, 2-propyl, n -butyl, secondary -butyl, tert-butyl, n -pentyl, iso-pentyl, neo-pentyl, n -hexyl, 2-hexyl, n-heptyl, n -octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, ethylenyl (vinyl), ethynyl, propenyl (-CH ₂ CH = CH ₂ -CH = CH- CH ₃ , -C (= CH ₂ ) -CH ₃ ), propynyl (-CH ₂ -C≡CH, -C≡C-CH ₃ ), butenyl, butynyl, pentenyl, pentynyl, hexenyl, Hexynyl, heptenyl, heptynyl, octenyl, octadienyl and octinyl.

In the present invention, the expression “(C ₉ -C ₃₀ ) alkyl” may be branched or straight chain and is an acyclic saturated or unsaturated hydrocarbon radical having 9 to 30 carbon atoms, ie C _{9-30 -alkanyl} , C _9-30 -alkenyl and C _9-30 -alkynyl. C _9-30 -alkenyl has one or more CC double bonds, and C _9-30 -alkynyl has one or more CC triple bonds. C _{9-30 -alkynyl} may additionally also have one or more CC double bonds. Preferred (C ₉ -C ₃₀ ) alkyl radicals are tetradecyl, hexadecyl, octadecyl, eicosanyl, cis-13-docosenyl (erucyl), trans-13-docosenyl (brasidyl), cis-15-tetra Cosenyl (nerbonyl) and trans-15-tetracosenyl.

For the purposes of the present invention, the expression "cycloalkyl" is a cyclic nonaromatic hydrocarbon having 3 to 20, preferably 3 to 12 atoms and having 1 to 3 rings, which may be saturated or unsaturated, and more Preferably (C ₃ -C ₈ ) cycloalkyl. Cycloalkyl radicals may also be part of a bi- or polycyclic system, where, for example, cycloalkyl radicals are aryl, heteroaryl or as defined herein by any possible and desired reduction (s). Fused to a heterocyclyl radical. Bonding to a compound of formula I may be effective through any possible reduction of the cycloalkyl radical. Preferred cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclohexenyl, cyclopentenyl and cyclooctadienyl.

The expression "heterocyclyl" is a 3- to 14-membered, preferably 3-, 4-, 5, 6-, 7- or 8-membered, cyclic organic radical, at least one heteroatom, optionally 2, 3, 4 or 5 heteroatoms, which in particular are nitrogen, oxygen and / or sulfur, heteroatoms are the same or different, and the cyclic radicals are saturated or unsaturated but not aromatic. The heterocyclyl radical may also be part of a bi- or polycyclic system, where, for example, the heterocyclyl radical is any possible and desired ring to the aryl, heteroaryl or cycloalkyl radicals defined herein. Fused by circle (s). Bonding to a compound of formula I may be effective through any possible reduction of the heterocyclyl radical. Preferred heterocyclyl radicals are tetrahydrofuryl, pyrrolidinyl, imidazolidinyl, thiazolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiapyrrolidinyl, oxapirazinyl, Oxapiperidinyl and oxadiazolyl.

In the present invention, the expression "aryl" is an aromatic hydrocarbon having 3 to 14 carbon atoms, preferably 5 to 14 carbon atoms, more preferably 6 to 14 carbon atoms. The aryl radicals may also be part of a bi- or polycyclic system, where, for example, the aryl radicals may be selected from any possible and desired reduction in the heterocyclyl, heteroaryl or cycloalkyl radicals defined herein. S), for example, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, thiazolidine, tetrahydropyran, dihydropyran, piperidine, furan, thiophene, Imidazole, thiazole, oxazole, isoxazole. Bonding to a compound of formula (I) may be effective through any possible reduction of the aryl radical. Preferred aryl radicals are phenyl, biphenyl, naphthyl and anthracenyl, but are also indanyl, indenyl or 1,2,3,4-tetrahydronaphthyl.

The expression “heteroaryl” is a 5-, 6- or 7-membered cyclic aromatic radical, which comprises at least one heteroatom, if appropriate also 2, 3, 4 or 5 heteroatoms, in particular nitrogen, oxygen And / or sulfur, heteroatoms are the same or different. The number of nitrogen atoms is preferably 0 to 3, and the number of oxygen and sulfur atoms is preferably 0 or 1. Heteroaryl radicals are also part of a bi- or polycyclic system, where, for example, the heteroaryl radical is any possible and desired reduction (s) to the heterocyclyl, aryl or cycloalkyl radicals defined herein. Fused by). The bond to the compound of formula (I) may be effective through any possible reduction of the heteroaryl radical. Preferred heteroaryl radicals are pyrrolyl, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, oxdiazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazole, tetrazole, pyridinyl, pyrimidinyl , Pyridazinyl, pyrazinyl, triazine, phthalazinyl, indolyl, indazolyl, indolinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pterridinyl, carbazolyl, phena Genyl, phenoxazinyl, phenothiazinyl, and acridinyl.

For the purposes of the present invention, the expressions "alkyl-cycloalkyl", "cycloalkylalkyl", "alkyl-heterocyclyl", "heterocyclylalkyl", "alkyl-aryl", "arylalkyl", "alkyl- Heteroaryl "and" heteroarylalkyl "are alkyl, cycloalkyl, heterocycle, aryl and heteroaryl as defined above, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl radicals are alkyl radicals of the compound of formula (I), It is preferably meant to be bonded via a C ₁ -C ₈ -alkyl radical, more preferably via a C ₁ -C ₄ -alkyl radical.

"Alkyl", "cycloalkyl", "heterocyclyl", "aryl", "heteroaryl", "alkyl-cycloalkyl", "alkyl-heterocyclyl", "alkyl-aryl" and "alkyl-heteroaryl In connection with "in the present invention," the term "substituted", unless expressly indicated in the specification or claims, F, Cl, Br, I, CN, CF ₃ , NH ₂ , NH-alkyl of one or more hydrogen radicals , NH-aryl, N (alkyl) ₂ , NO ₂ , SH, S-alkyl, OH, OCF ₃ , O (-alkyl-O) _p -alkyl, O-aryl, OSO ₃ H, OP (O) (OH ) ₂ , OP (O) (Oalkyl) ₂ , OP (O) (Oaryl) ₂ , CHO, C (O) OH, C (O) OR36, C (O) NH ₂ , C (O) NHR36, C (O) NR 36 R 37, SO ₃ H, SO ₂ alkyl, SO ₂ aryl, P (O) (OH) ₂ , P (O) (Oalkyl) ₂ , P (O) (Oaryl) ₂ , alkyl, cyclo Understood to mean a substitution with alkyl, heterocyclyl, aryl, heteroaryl or alkylaryl, where p can be a value of 0, 1, 2, 3, 4 or 5, where R36 and R37 radicals Are each independently alkyl, cycloalkyl, Interrogating heterocyclyl, aryl, heteroaryl, alkyl-cycloalkyl, alkyl-heterocyclyl, alkyl-aryl or alkyl- may be a heteroaryl group, R36 and R37 may together form a heterocyclyl ring. Substituents may be the same or different and the substitution may occur at the desired and possible positions of the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl radicals.

In the present invention, the expression "halogen" includes halogen atoms, fluorine, chlorine, bromine and iodine.

Polysubstituted radicals mean, for example, di- or trisubstituted radicals which are polysubstituted at different atoms or at the same atom, for example in the case of CF ₃ , -CH ₂ CF ₃ Or trisubstituted at different positions in the case of CH (OH) —CH═CH—CHCl ₂ . Multisubstitution may be effective with the same substituent or with different substituents.

If the compounds of the invention have one or more asymmetric centers, they are in racemic form, pure enantiomer and / or diastereomeric form, or in the form and mixtures of these enantiomers and / or diastereomers. Or as pharmaceutically acceptable salts of these compounds. The mixture may be present in the preferred mixing ratio of stereoisomers.

For example, the compounds of the present invention having one or more chiral centers and produced as racemates can be separated by methods known per se as their optical isomers, ie enantiomers or diastereomers. Separation is followed by radical separation by chiral phase column separation or by recrystallization from an optically active solvent, or by using an optically active acid or base, or by induction with an optically active reagent such as an optically active alcohol. It may be possible to separate.

The compounds of the present invention may exist in the form of their double bond isomers, such as "pure" E or Z isomers or in the form of mixtures of these double bond isomers.

Where possible, compounds of the invention may exist in tautomeric forms.

The compounds of the present invention can be changed using inorganic and organic acids as their physiologically acceptable salts if they have sufficient basic groups, for example primary, secondary, or tertiary amines. Pharmaceutically acceptable salts of the compounds of the invention are preferably hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, trifluoroacetic acid, sulfoacetic acid, oxalic acid , Malonic acid, maleic acid, succinic acid, tartaric acid, pyruvic acid, malic acid, embonic acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid. The salts formed are hydrochloride, hydrobromide, sulfate, hydrogensulfate, phosphate, methanesulfonate, tosylate, carbonate, hydrogencarbonate, formate, acetate, triflate, sulfoacetate, oxalate, malonate, maleate, succinate Nates, tartrates, maleates, emcarbonates, mandelate, fumarate, lactates, citrate, glutamate and aspartate. The stereochemistry of the salts of the compounds of the present invention formed may be one whole or a subset.

The compounds of the present invention can be converted using inorganic and organic bases into their physiologically acceptable salts if they have sufficient acidic groups, such as carboxyl groups or phosphoric acid groups. Examples of useful inorganic bases include sodium hydroxide, potassium hydroxide, calcium hydroxide; Examples of useful organic bases include ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dibenzylethylenediamine and lysine. It may be one whole or a subset of the stoichiometry of the salts of the compounds of the invention formed.

Preference is given to providing solvates and in particular hydrates of the compounds of the invention which can be obtained, for example, by crystallization from solvents or aqueous solutions. One, two, three or as many solvates or water molecules as possible can be bound to a compound of the invention to form solvates and hydrates.

Chemicals form solids that exist in various order states, which are known to be referred to as polymorphs or modifications. The physical properties of the different modifications of the polymorphic material can be very different.

Compounds of the invention can exist in a variety of polymorphs; Certain modifications may be metastable.

delete

delete

delete

The compounds of the present invention have also been found to be surprisingly advantageous methods that act on two or more signaling pathways or enzymes of these pathways, i.e. may have a modulating or inhibitory effect. It has been found that the compounds of the present invention can act with high selectivity, ie, have a modulating or inhibitory effect.

Two or more signaling pathways, for example ras-Raf-Mek-Erk signaling, PI3K-Akt signaling and / or SAPK signaling, more particularly Erk1 / Erk2 and / or PI3K and / or Jnk and / or p38 Simultaneous, eg, dual, modulation or inhibition, is advantageous over only a single regulation or inhibition of one signaling pathway, which is a synergistic therapeutic effect, eg, improved apoptosis and more rapid and efficient tumor regression. Because it can cause.

With the surprising beneficial effects of the compounds of the present invention, various therapeutic approaches can be pursued in physiological and / or pathophysiological conditions or conditions that are sensitive to treatment or control or mediated by two or more signaling pathways.

The compounds of the present invention may also act with high selectivity on the ras-Raf-Mek-Erk signaling pathway or enzymes thereof, ie, have a modulating or inhibiting effect, and the various mechanisms of action and therapeutic approaches described above It has surprisingly been found to be an advantageous method to discover the use of such signal pathways or enzymes.

The compounds of the present invention may also act with high selectivity on the PI3K-Akt signaling pathway or enzymes thereof, ie, have a modulating or inhibiting effect, and the various mechanisms of action and therapeutic approaches described above may also provide such signaling pathways or It has been surprisingly found that the use of enzymes can be found.

The compounds of the present invention may also act with high selectivity on the SAPK signaling pathway or enzymes thereof, ie, have a modulating or inhibiting effect, and various mechanisms of action and therapeutic approaches described above may also be useful for It has been found that surprisingly advantageous methods can be found for use.

In addition, the compounds of the invention may also act with high selectivity on enzymes such as ATM, ATR, mTOR, DNA-PK and / or hSMG-1, ie, have a modulating or inhibitory effect, It has been surprisingly found that various mechanisms of action and the therapeutic approaches described above can also find use with such enzymes.

According to the invention, the term "modulation" is understood to mean: "activation, partial activation, inhibition, partial inhibition". Within the average technical knowledge of those skilled in the art, such activation, partial activation, inhibition or partial inhibition is measured and determined through conventional measurement and determination methods. For example, partial activation can be measured and determined in connection with complete activation; Partial inhibition can also be measured and determined in relation to complete inhibition.

According to the invention, the term "inhibition" is understood to mean: "partial or complete inhibition". Within the technical knowledge of the average skilled person, such partial or complete inhibition is measured and determined through conventional measurement and determination methods. For example, partial inhibition can be measured and determined in connection with complete inhibition.

The terms "modulation" and "inhibition" are used herein to refer to an "enzyme" and / or "kinase" in an inactive form (enzymatically inactive) and / or active form (enzymatically active) of a particular enzyme and / or kinase. It's about both. In the present invention, this means that a compound of the present invention may exhibit its regulatory action in an inactive form, in an active form or in both an enzyme and / or a kinase.

In a further aspect, the object of the invention may surprisingly be achieved by providing a medicament comprising at least one compound of the invention.

In a further aspect, the object of the present invention may surprisingly be achieved by providing one or more compounds of the invention with a medicament comprising one or more additional active pharmaceutical ingredients and / or pharmaceutically acceptable carriers and / or excipients. .

In a further aspect, the object of the present invention is to surprisingly provide a pharmaceutical formulation by processing one or more compounds of the invention together with a pharmaceutically acceptable carrier and / or excipient, ie causing a therapeutically useful form. It can be achieved by providing a method for producing a medicament.

In a further aspect, it is an object of the present invention to surprisingly misregulate cellular signaling processes, in particular active and inactive receptor tyrosine kinases, and also cytoplasmic tyrosine, serine / threonine and lipid kinases such as c-Raf. Can be used as active ingredients in pharmaceuticals to influence the action of B-Raf, Mek, MAPKs, PDGFRbeta, Flt-3, IGF1R, PI3K, PKB / Akt1, c-Kit, c-Abl, FGFR1 and KDR It can be achieved by providing a compound of the present invention.

In a further aspect, the object of the present invention may surprisingly be achieved by providing a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, the treatment or Prevention is caused by the regulation of a signaling pathway (s) selected from the group consisting of "ras-Raf-Mek-Erk signaling pathway, PI3K-Akt signaling pathway and / or SAPK signaling pathway."

In a further aspect, the object of the present invention is surprisingly in a mammal a physiological and / or pathophysiological condition mediated by an enzyme selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1". It can be accomplished by providing a compound of the present invention that can be used to prepare a therapeutic or prophylactic agent.

In a further aspect, the object of the present invention may surprisingly be achieved by providing a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, the treatment or Prevention is caused by modifying one or more enzymes selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1".

In a preferred embodiment, the compounds of the invention treat and / or prevent the physiological and / or pathophysiological conditions mediated by the ras-Raf-Mek-Erk signaling pathway and / or the PI3K-Akt signaling pathway in mammals. For the manufacture of a medicament and / or for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, wherein the treatment or prophylaxis is provided by ras-Raf-Mek-Erk signaling. Caused by regulation of the pathway and PI3K-Akt signaling pathway.

In a further aspect, the object of the present invention is surprisingly applicable to the manufacture of a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions mediated by ras-Raf-Mek-Erk signaling pathways in mammals. It can be achieved by providing a compound of the present invention.

In a further aspect, an object of the invention is surprisingly a compound of the invention which can be used to prepare a medicament for the treatment or prevention of a physiological and / or pathophysiological condition mediated by the PI3K-Akt signaling pathway in a mammal. Can be achieved by providing

In a further aspect, the object of the present invention may surprisingly be achieved by providing a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, the treatment or Prevention is caused by the regulation of the PI3K-Akt signaling pathway.

In a preferred embodiment, the compounds of the invention are for the manufacture of a medicament for the treatment and / or prophylaxis of physiological and / or pathophysiological conditions mediated by SAPK signaling pathway and / or PI3K-Akt signaling pathway in mammals. , And / or for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, wherein the treatment or prophylaxis is by regulation of the SAPK signaling pathway and the PI3K-Akt signaling pathway. Is caused.

In a further aspect, the object of the present invention surprisingly provides a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of physiological and / or pathophysiological conditions mediated by SAPK signaling pathways in a mammal. Can be achieved.

In a further aspect, the object of the present invention may surprisingly be achieved by providing a compound of the invention which can be used to prepare a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal, the treatment or Prevention is caused by the regulation of SAPK signaling pathways.

In a preferred embodiment, the compounds of the invention are selected from the group wherein the regulation of the ras-Raf-Mek-Erk signaling pathway consists of "tyrosine kinase, serine / threonine kinase, receptor tyrosine kinase, cytoplasmic tyrosine kinase, cytoplasmic serine / threonine kinase" It provides a use as described above, preferably caused by the regulation of one or more enzymes selected from the group consisting of "Erk, Erk1, Erk2".

In a further preferred embodiment, the compounds of the invention are selected from the group consisting of "lipid kinase", wherein the regulation of the PI3K-Akt signaling pathway is preferably "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K -C2 alpha, PI3K-C2beta, PI3K-Vps34p "provide the use as described above caused by the regulation of one or more enzymes selected from the group consisting of.

In a further preferred embodiment, the compounds of the invention are preferably wherein the regulation of the SAPK signaling pathway is selected from the group consisting of "tyrosine kinase, serine / threonine kinase, receptor tyrosine kinase, cytosolic tyrosine kinase, cytoplasmic serine / threonine kinase" Provides the uses as described above, caused by the modulation of one or more enzymes selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta".

In a further aspect, the object of the present invention is surprisingly the compounds of the present invention which can be used for the preparation of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal according to the above embodiments, preferred embodiments and uses. Can be achieved, treatment or prevention is caused by the regulation of two or more enzymes.

In a more preferred embodiment, the compounds of the present invention comprise at least two enzymes selected from the group consisting of "Erk, Erk1, Erk2" and "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K- The above uses of one or more enzymes in the treatment or prophylaxis caused by the modulation of one or more enzymes selected from the group consisting of C2beta, PI3K-Vps34p ".

In a more preferred embodiment, the compounds of the present invention comprise at least two enzymes selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" and "PI3K, PI3Kalpha, The above uses of one or more enzymes in the treatment or prophylaxis caused by the modulation of one or more enzymes selected from the group consisting of PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p ". to provide.

In a more preferred embodiment, the compound of the present invention is at least two enzymes selected from the group consisting of "Erk, Erk1, Erk2" and one selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1" The above uses of one or more enzymes in the treatment or prophylaxis caused by the regulation of the above enzymes are provided.

In a more preferred embodiment, the compounds of the present invention comprise at least two enzymes selected from the group consisting of "Jnk, Jnk1, Jnk2, Jnk3, p38, p38alpha, p38beta, p38gamma, p38delta" and "ATM, ATR, mTOR" The above uses of one or more enzymes in the treatment or prophylaxis caused by the modulation of one or more enzymes selected from the group consisting of DNA-PK, hSMG-1 ″.

In a more preferred embodiment, the compounds of the present invention comprise at least two enzymes selected from the group consisting of 'PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p "and The above uses of one or more enzymes in the treatment or prevention caused by one or more enzymes selected from the group consisting of "ATM, ATR, mTOR, DNA-PK, hSMG-1".

In another preferred embodiment, the compounds of the present invention provide the above uses, wherein the control is inhibition.

In the present invention, the compounds of the present invention can be administered to all known mammals, in particular humans, for treatment and / or prophylaxis.

In another preferred embodiment, the compounds of the present invention comprise a mammal as a “human, useful animal, livestock, domestic pet, beef cattle, cow, sheep, pig, goat, horse, pony, donkey, burrow, mule, hare, rabbit, Cats, dogs, guinea pigs, hamsters, rats, mice ", and preferably human.

In the present invention, the compounds of the present invention can be used for the treatment and / or prevention of all known physiological and / or pathophysiological conditions.

In a preferred embodiment, the compounds of the invention provide the above uses of physiological and / or pathophysiological conditions selected from the group consisting of: "malignant tumors, benign tumors, inflammatory disorders, inflammation, pain, rheumatic disorders, arthritis Disorders, HIV infection, nervous system or neurodegenerative disorders, rheumatism, arthritis, AIDS, ARC (AIDS related complexes), Kaposi's sarcoma, tumors spreading from the brain and / or nervous system and / or meninges, dementia, Alzheimer's disease, hyperproliferative disorders, Psoriasis, endometriosis, scar formation, prostatic hypertrophy (BPH), immune system disorders, autoimmune disorders, immunodeficiency disorders, colon tumors, gastric tumors, intestinal tumors, lung tumors, pancreatic tumors, ovarian tumors, prostate tumors, leukemias, melanoma , Liver tumor, kidney tumor, head tumor, throat tumor, glioma, breast tumor, uterine cancer, endometrial cancer, cervical cancer, brain tumor, acute cell tumor, bladder cancer, stomach tumor, Colon Tumor, Esophageal Cancer, Gynecologic Tumor, Ovarian Tumor, Thyroid Cancer, Lymphoma, Chronic Leukemia, Acute Leukemia, Restenosis, Diabetic Diabetic Nephropathy, Fibrotic Disorder, Cystic Fibrosis, Malignant Renal Sclerosis, Thrombomicroangiopathy Syndrome, Organs Transplant rejection, glomerulopathy, metabolic disorders, solid tumors, rheumatoid arthritis, diabetic retinopathy, asthma, allergies, allergic disorders, chronic obstructive pulmonary disease, inflammatory bowel disease, fibrosis, atherosclerosis, heart disorders, cardiovascular disorders, heart muscle Disorders, vascular disorders, angiogenesis disorders, kidney disorders, rhinitis, Grave disease, focal ischemia, heart failure, ischemia, cardiac hypertrophy, kidney failure, cardiomyocyte dysfunction, hypertension, vascular narrowing, stroke, irritable shock, platelet aggregation, skeletal muscle Atrophy, obesity, overweight, glucose homeostasis, congestive heart failure, angina pectoris, heart attack, myocardial infarction, hyperglycemia, hypoglycemia, hypertension ".

In a further aspect of the invention, the object of the present invention is surprisingly contemplated for use for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal in accordance with the foregoing aspects, preferred embodiments and uses. It can be accomplished by providing a compound of the invention, wherein the medicament comprises one or more additional pharmacologically active substances.

In a further aspect of the invention, the object of the present invention is surprisingly contemplated for use for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal in accordance with the foregoing aspects, preferred embodiments and uses. It can be accomplished by providing a compound of the invention, wherein the medicament is administered with one or more additional pharmacologically active substances before and / or during treatment and / or after treatment.

In a further aspect of the invention, the object of the present invention is surprisingly contemplated for use for the manufacture of a medicament for the treatment or prophylaxis of a physiological and / or pathophysiological condition in a mammal in accordance with the foregoing aspects, preferred embodiments and uses. It may be accomplished by providing a compound of the invention, wherein the medicaments are administered together before and / or during and / or after treatment using radiotherapy and / or surgery.

In the present invention, the compounds of the present invention can be administered with all known pharmacologically active substances in the detailed combination therapy.

In a preferred embodiment, the compounds of the invention further comprise pharmacologically active substances such as "DNA isomerase I and / or II inhibitors, DNA intercalators, alkylating agents, microtubule destabilizing agents, hormones and / or growth factor receptors. Agonists and / or antagonists, growth factors and antibodies to their receptors, kinase inhibitors, anti-metabolites.

In a preferred embodiment, the compounds of the present invention provide the above uses wherein the additional pharmacologically active substance is selected from the group consisting of: "asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, Cisplatin, Colaspase, Cyclophosphamide, Cytarabine, Dcarbazine, Darktinomycin, Daunorubicin, Doxorubicin (Adriamycin), Epirubicin, Etoposide, 5-Fluorouracil, Hexamethylmelamine, Hyde Loxyurea, Iphosphamide, Irinotecan, Leucovorin, Lomustine Mechlorethamine, 6-mercaptopurine, Mesna, Methotrexate, Mitomycin C, Mitoxantrone, Prednisolone, Prednisone, Procarbazine, Raloxifene, Streptozosin , Tamoxifen, thioguanine, topotecan, vinblastine, vincristine, vindesine, aminoglutetimide, L-asparaginase, azathioprine, 5- Azacytidine cladribine, busulfan, diethylstilbestrol, 2 ', 2'-difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine, ethynylestradiol, 5-fluorode Oxyuridine, 5-fluorodeoxyuridine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idarubicin, interferon, hydroxyprogesterone acetate, megestrol acetate , Mephalan, mitotan, paclitaxel, oxaliplatin, pentostatin, N-phosphonoacetyl-L-aspartate (PALA), plicamycin, semustine, teniposide, testosterone propionate, thiotepa, trimethylmelamine, Uridine, vinorelbine, epothilones, gemcitabine, taxotere, BCNU, CCNU, DTIC, 5-fluorouracil, herceptin, avastin, erbitux, sorafenib, gleevec, iresa, tar Bar, rapamycin, arc actinomycin D ".

Oral administration may be effective, for example, in the form of solids such as tablets, capsules, gel capsules, coated tablets, granules or powders, as well as in drinkable solution forms. For oral administration, the novel compounds of the invention described above are known and commonly used physiologically acceptable carriers and excipients such as gum arabic, talc, starch, sugars such as mannitol, methylcellulose , Lactose, gelatin, surfactants, magnesium stearate, cyclodextrins, aqueous or non-aqueous carriers, diluents, disintegrants, emulsifiers, preservatives, and flavoring agents (eg, essential oils). The compounds of the present invention may also be dispersed in microparticulates, such as nanoparticulate compositions.

Parenteral administration can be effective, for example, via intravenous, subcutaneous or intramuscular injection of sterile aqueous or oily solutions, suspensions or emulsions, through implantation or via ointments, creams or suppositories. If appropriate, administration may also be effective with sustained release. Implants may include inert materials such as biodegradable polymers or synthetic silicones such as silicone rubber. Intravaginal administration can be effective, for example, with a vaginal ring. Intrauterine administration can be effective, for example, with a diaphragm or other suitable intrauterine device. In addition, transdermal administration is in particular contemplated as a suitable formulation and / or suitable means, for example as a plaster.

The medicaments of the present invention may be administered in suitable dosage forms, into the skin, epicutaneously, as solutions, suspensions, emulsions, foams, ointments, pastes or plasters; Oral and tongue mucosa, mouth, tongue or sublingual, as tablets, pastilles, coated tablets, potions or gargles; Gastric and intestinal mucosa, intestinal, tablets, coated tablets, capsules, solutions, suspensions or emulsions; Rectal mucosa, rectally, as suppositories, rectal capsules or ointments; Through the nasal mucosa, intranasally, as drops, ointments or sprays; Bronchial and alveolar epithelium, lung or inhalation, as aerosols or inhalants; Conjunctiva, into the conjunctiva, as eye drops, ophthalmic ointments, ophthalmic tablets, lamellas or eye drops; Genital mucosa, intravaginally, as vaginal suppository, ointment and douche, intrauterine, as uterine pessary; As urinary tract, into the urethra, as an irrigation, ointment or bougie; Arteries, into arteries, as injections; Intravenously, intravenously, by injection or infusion; As skin, intradermal, by injection or implant; Under the skin, subcutaneously, by injection or as an implant; Intramuscularly, intramuscularly, as injections or implants; It may be administered intraperitoneally, intraperitoneally, by injection or infusion.

Depending on the actual therapeutic requirements, the pharmaceutical action of the compounds of the present invention may be extended in a suitable manner. This object can be achieved by chemical and / or pharmaceutical routes. Examples of achieving prolonged action are the use of grafts and liposomes, the formation of weakly soluble salts and complexes, or the use of crystalline suspensions.

As described above, the novel compounds of the present invention may also be combined with additional pharmaceutically active ingredients. In combination therapy, the individual active ingredients can be administered simultaneously or separately by the same route (eg oral) or by separate routes (eg oral and injection). They may be present or administered in unit doses in the same or different amounts. In addition, certain suitable modes of administration may be employed. In this way, many of the novel compounds of the invention can also be combined with others.

The dosage can be within a wide range depending on the indication form, the severity of the disorder, the dosage form, and the age, sex, weight, and sensitivity of the subject to be treated. The "pharmacologically active amount" of a pharmaceutical composition formulated within the capabilities of those skilled in the art is determined. Administration can be effective in a single dose or in multiple individual doses.

Suitable unit doses are, for example, from 0.001 mg to 100 mg of active ingredient, ie one or more compounds of the present invention and any further active pharmaceutical ingredient, per kg of body weight of the patient.

In a further aspect of the invention, the invention accordingly also relates to a pharmacologically active amount of at least one compound of the invention, preferably compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84 and / or Compound 85, and also optionally a pharmaceutical composition comprising a pharmaceutically acceptable carrier and / or excipient.

Preferred and particularly preferred compositions of the invention comprise one or more of the aforementioned preferred compounds of the invention. In the pharmaceutical compositions according to the invention, not only one or more compounds described above, but also one or more additional pharmaceutically active ingredients mentioned above may be present.

In the pharmaceutical compositions of the present invention, one or more of the novel compounds of the present invention described above are present in pharmacologically active amounts, preferably in unit doses, for example in the above unit doses, preferably in oral administrable dosage forms. do.

For pharmaceutical compositions comprising the compounds of the invention, and for the use of the compounds of the invention as medicaments, reference is made to those already described in connection with the use of the novel compounds of the invention pertaining to possible uses and methods of administration. .

In a further aspect of the invention, it is an object of the present invention to surprisingly provide a kit comprising at least one preferred pharmacologically active amount of a compound of the invention as described above and at least one additional pharmacologically active ingredient of said pharmacologically active amount. Can be achieved.

General methods for the synthesis of the compounds of the invention

The preparation of the substituted pyrido [2,3-b] pyrazine of the invention is illustrated below.

Compounds of the present invention can be obtained according to the following schemes (Scheme 1-9) and corresponding methods known to those skilled in the art:

The definitions of the R1 to R36 radicals shown in the following schemes correspond to the aforementioned substituents relating to formula I, for example Z radicals, R radicals, X radicals, T radicals and the like. Individual studies can be carried out in a simple manner by those skilled in the art based on their average technical knowledge.

Scheme 1

Precursors for selected examples of the pyrido [2,3-b] pyrazines of the invention wherein substituents R2 and R4 are substituted by hydrogen are described, for example, in the methods of Scheme 2 or the corresponding known to those skilled in the art. Obtained by the method.

Scheme 2

Precursors for selected examples of the pyrido [2,3-b] pyrazine of the invention wherein the substituents R3 and / or R4 are OR31, SR32, NR33R34 radicals are described, for example, to the methods of Scheme 3 or those skilled in the art. Obtained by known corresponding methods.

Scheme 3

For precursor 11 described above, intermediates 22 from Scheme 6 or other intermediates 20, 21, 21a and 21b from Scheme 5 can be used.

Precursors for selected examples of the pyrido [2,3-b] pyrazine of the invention wherein substituent R9 is not H are obtained, for example, by the method of Scheme 4 or by a corresponding method known to those skilled in the art. .

Scheme 4

Precursors 4, 7, 9 and 15 from Schemes 1-4 are substituted pyrido [2,3-b] pyrazine of the present invention, for example, the methods of Scheme 5 or those known to those skilled in the art. Can be converted in a corresponding manner.

Scheme 5

Selected examples of pyrido [2,3-b] pyrazines of the invention, which may be selected from aryl, heteroaryl, alkyl, alkenyl or alkynyl radicals substituted with substituents R3 and / or R4, are described, for example, in Scheme 6 Or by a corresponding method known to those skilled in the art.

Scheme 6

Of the pyrido [2,3-b] pyrazine of the invention wherein the substituents R3 and / or R4 are NC (O)-, -N-SO2-, -NC (O) -O- and NC (O) -N- Selected examples can be obtained, for example, by the method of Scheme 7 or corresponding methods known to those skilled in the art.

Scheme 7

Selected examples of pyrido [2,3-b] pyrazine of the invention wherein substituents R3 and / or R4 are urea-, carbamate- or carbonate-substituted radicals are described, for example, in the methods of Scheme 8 or in the art. It can be obtained by the corresponding method known to the skilled person.

Scheme 8

Selected examples of pyrido [2,3-b] pyrazine of the invention wherein the substituents R3 and / or R4 can be selected from O-, S-, N-substituted radicals are described, for example, in the method of Scheme 9 or It can be obtained by corresponding methods known to those skilled in the art.

Scheme 9

Starting compounds and intermediates are either commercially available or can be prepared by methods known per se to those skilled in the art. Reactants 4, 7, 9-15, 22, 26, 31, 34 and 37 are important intermediates for the preparation of pyridopyrazines of the invention.

To prepare the starting compounds, intermediates and pyridopyrazines of the invention, reference is made to the parent applications WO2004 / 104002 and WO2004 / 104003, and also to the following basic documents, for example, incorporated herein by reference.

General Methods for the Preparation of Compounds of the Invention:

General Method for Making Compounds of the Invention

Reaction Scheme 1: Step 1

2,6-Diamino-3-nitropyridine or 2-amino-3,5-dinitropyridine was dissolved in a suitable inert solvent such as methanol, ethanol, dimethylformamide or dioxane. After addition of a catalyst such as laney nickel, palladium on carbon or platinum (IV), the reaction mixture was placed under hydrogen atmosphere and a pressure of 1 to 5 bar was achieved. The reaction mixture was reacted for several hours, for example 1-16 hours, at a temperature ranging from 20 ° C. to 60 ° C. After completion of the reaction, the insoluble residue was filtered off, for which the filter medium could consist of silica gel, celite or commercially available glass fiber filters, which were washed with a suitable solvent. The crude product present in solution is used without further purification for the next reaction.

Step 2

1,2-dione derivatives were initially charged in a suitable inert solvent such as methanol, ethanol, dioxane, toluene or dimethylformamide. 2,3,6-triaminopyridine or 2,3,5-triaminopyridine is added directly after reduction to the initially filled 1,2-dione as a solution of the crude product in one of the solvents described above, Optionally filled with the addition of an acid such as acetic acid or a base such as potassium hydroxide. The reaction mixture was reacted at a temperature in the range of 20 ° C. to 80 ° C. for a certain time, for example 20 minutes to 40 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. If dimethylformamide is used, the reaction mixture is stirred with a large amount of water and the precipitated solid is filtered off or the aqueous phase is extracted with a suitable organic solvent such as dichloromethane or ethyl acetate and the organic phase is concentrated under reduced pressure. I was. The remaining crude product was recrystallized from a suitable solvent such as dioxane or purified by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.

Reaction Scheme 2: Step 1

Pyridopyrazinone derivative 8 was initially charged in a suitable inert solvent such as dimethylformamide, dioxane or toluene, or without solvent. A chlorinating agent such as phosphoryl chloride or thionyl chloride is added at room temperature and the reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 10 ° C. for a certain time, for example 1 hour to 24 hours. . After the reaction was terminated, the reaction mixture was poured into water and neutralized with a suitable aqueous base such as sodium hydroxide solution. The precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining residues are dried under reduced pressure or the aqueous phase is fitted with a suitable organic solvent, for example, Extract with dichloromethane or ethyl acetate and concentrate the organic phase under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane or toluene or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Scheme 3: Step 1

2,3,6-triaminopyridine or 2,3,5-triaminopyridine was initially charged after reduction directly with one of the solvents described above, as a solution of the crude product. After addition of an oxalic acid derivative, for example diethyl oxalate or oxalyl chloride, the reaction mixture is specified at a temperature ranging from 20 ° C. to 150 ° C., optionally with the addition of an acid such as hydrochloric acid, sulfuric acid or glacial acetic acid. The reaction is carried out for a time, for example, for 10 minutes to 24 minutes. After completion of the reaction, the precipitated solids are filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solids are dried under reduced pressure or the reaction mixture under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off, or the aqueous phase may be neutralized with a suitable aqueous base such as sodium hydroxide solution, and a suitable organic solvent such as For example, it can be extracted with dichloromethane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane or toluene or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Step 2

Dione derivative 10 was initially charged in a suitable inert solvent such as dimethylformamide, dioxane or toluene, or without solvent. A chlorinating agent such as phosphoryl chloride or thionyl chloride is added at room temperature and the reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 10 ° C. for a certain time, for example 1 hour to 24 hours. . After completion of the reaction, the reaction mixture is poured into water and neutralized with a suitable aqueous base such as sodium hydroxide solution. The precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining residues are dried under reduced pressure or the aqueous phase is fitted with a suitable organic solvent, for example, Extract with dichloromethane or ethyl acetate and concentrate the organic phase under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane or toluene or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Step 3

Intermediate 11 is selected from a suitable alcohol, thiol or amine and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol, and a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide The reaction can be carried out in the side, methanol, toluene, or as a solvent, in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 140 ° C. for a specific time, for example, from 30 minutes to 2 days. Alternatively, intermediate 11 may be prepared by using a suitable amine and a suitable catalyst such as tris (dibenzylideneacetone) dipalladium (0) or tetrakis (triphenylphosphine) palladium (0), and suitable ligands such as , 2- (dicyclohexylphosphanyl) biphenyl, and a suitable base such as sodium tert-butoxide may be reacted in a suitable solvent such as toluene or dimethylformamide. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. to 120 ° C. for a specific time, for example 2 to 30 hours. After completion of the reaction, the precipitated solids are filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solids are dried under reduced pressure or the reaction mixture under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane, ethyl acetate or toluene, or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Scheme 4: Step 1

Intermediates 4 and 7 are suitable chlorides, bromide or tosylate and optionally suitable bases such as sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol and a suitable inert solvent such as dimethylformamide , In dimethyl sulfoxide, methanol, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 150 ° C. for a specific time, for example 1 hour to 24 hours. Alternatively, intermediates 4 and 7 may be substituted with suitable aryl bromide or iodide and suitable catalysts such as palladium acetate or Pd ₂ (dba) ₃ , and suitable ligands such as BINAP, and suitable bases such as For example, potassium carbonate or sodium tert-butoxide can be reacted in a suitable solvent such as toluene or dioxane. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. to 120 ° C. for a specific time, for example 10 to 30 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent, the remaining solid is dried under reduced pressure, or all catalyst residues are filtered off. Remove and wash with a suitable solvent and either dry the solvent under reduced pressure or remove the solvent under reduced pressure. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or toluene, or purified by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.

Scheme 5: Step 1

After the basic process, the product formed in the basic process can be converted to the conversion product of the present invention by a conversion reaction by methods known to those skilled in the art.

For example, when the product is a derivative of compound 16 according to Scheme 5, reaction products 4, 7, 9 or 15 are suitable isocyanates and optionally suitable bases, preferably sodium hydride, potassium hexamethyldisilazide, pyridine, In triethylamine or potassium carbonate and a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, dichloromethane, 1,2-dichlorethane or dioxane, or as a solvent, for example a base such as The reaction can be carried out in pyridine or triethylamine or without solvent. The reaction mixture is allowed to react at a temperature in the range of 0 to 80 ° C. for several hours, for example 1 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Alternatively, if the product is a derivative of compound 17 according to Scheme 5, reaction products 4, 7, 9 or 15 may be phosgene or carbonyldiimidazole and a suitable amine and a suitable inert solvent such as dimethylformamide. , Tetrahydrofuran, toluene, dichloromethane or acetonitrile. Where appropriate, suitable bases are used, preferably pyridine, sodium hydrogencarbonate, triethylamine, N-methylmorpholine or sodium acetate. The reaction mixture is allowed to react at a temperature in the range of 0 to 60 ° C. for a specific time, for example 15 minutes to 24 hours. Alternatively, reaction products 4, 7, 9 or 15 may be prepared with a suitable amine-phenyl-carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium hydride, and a suitable inert solvent such as The reaction may be carried out in tetrahydrofuran, dioxane, dichloromethane, dimethylformamide or acetonitrile, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 0 ° C. to 120 ° C. for a specific time, for example 1 hour to 18 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, when the product is a derivative of compound 18 according to Scheme 5, reaction products 4, 7, 9 or 15 are suitable isothiocyanates and suitably suitable bases, preferably sodium hydride, triethylamine, Potassium carbonate or pyridine can be reacted in a suitable inert solvent such as dimethylformamide, tetrahydrofuran, acetone or toluene, or as a solvent in a base such as pyridine or triethylamine, or without solvent. . The reaction mixture is allowed to react at 0-115 degrees for a certain time, for example, 30 minutes to 90 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Alternatively, when the product is a derivative of compound 19 according to Scheme 5, reaction products 4, 7, 9 or 15 may be thiophosphene or thiocarbonyldiimidazole and a suitable amine and a suitable inert solvent such as dimethyl It may be reacted in formamide, tetrahydrofuran, toluene, dichloromethane, ethanol or acetonitrile. Optionally, suitable bases are used, preferably pyridine, sodium hydrogencarbonate, potassium carbonate, triethylamine or imidazole. The reaction mixture is allowed to react at a temperature in the range of −10 to 80 ° C. for several hours, for example 1 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the residual solid is dried under reduced pressure, or the reaction mixture is dried under reduced pressure. Was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, if the product is a derivative of compound 20 according to Scheme 5, reaction products 4, 7, 9 or 15 may be reacted with phosgene or carbonyldiimidazole and a suitable hydroxylamine and a suitable inert solvent such as dimethylformamide. , Tetrahydrofuran, dioxane, dichloromethane or toluene. Optionally, suitable bases are used, preferably pyridine, sodium carbonate, triethylamine or sodium acetate. The reaction mixture is allowed to react in a temperature range of 0 to 100 ° C. for a specific time, for example 1 hour to 24 hours. Alternatively, reaction products 4, 7, 9 or 15 may be reacted with a suitable hydroxylamine-phenyl-carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium acetate, and a suitable inert solvent, for example For example, it may be reacted in tetrahydrofuran, dioxane, dichloromethane, dimethylformamide or toluene, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react in a temperature range of room temperature to 100 ° C. for a specific time, for example 1 hour to 18 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, when the product is a derivative of compound 21 according to Scheme 5, reaction products 4, 7, 9 or 15 may be reacted with phosgene or carbonyldiimidazole and a suitable hydrazine with a suitable inert solvent such as dioxane, chloroform, It may be reacted in toluene or ethanol. Optionally, suitable bases are used, preferably pyridine, sodium carbonate, diisopropylethylamine or sodium acetate. The reaction mixture is allowed to react in a temperature range of 0 to 100 ° C. for a specific time, for example 1 hour to 24 hours. Alternatively, reaction products 4, 7, 9 or 15 may be reacted with a suitable hydrazine-phenyl-carbamate reagent and optionally with a suitable base, preferably pyridine, sodium carbonate, triethylamine or sodium acetate, and a suitable inert solvent such as It can be reacted in tetrahydrofuran, dioxane, dichloromethane, dimethylformamide or toluene, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 0 ° C. to 10 ° C. for a specific time, for example 1 hour to 15 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Alternatively, when the product is a derivative of compound 21a according to Scheme 5, reaction products 4, 7, 9 or 15 can be converted to oxalyl chloride and a suitable alcohol, optionally a suitable base, preferably pyridine, sodium hydroxide, triethyl The amine can be reacted in a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol or as a solvent in a base such as pyridine or triethylamine. The reaction mixture is allowed to react at a temperature in the range of −10 to 60 ° C. for a specific time, for example 15 minutes to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Alternatively, when the product is a derivative of compound 21b according to Scheme 5, reaction products 4, 7, 9 or 15 can be converted to oxalyl chloride or ethyloxalyl chloride and a suitable amine, optionally a suitable base, preferably pyridine, Sodium hydroxide, triethylamine can be reacted in a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol, or as a solvent in a base such as pyridine or triethylamine. The reaction mixture is allowed to react at a temperature in the range of −10 to 60 ° C. for a specific time, for example 15 minutes to 24 hours. Alternatively, intermediate 21a may be used in a suitable amine, optionally a suitable base, preferably pyridine, sodium hydride or triethylamine, with a suitable inert solvent such as tetrahydrofuran, toluene, dichloromethane, ethanol, or as a solvent. The reaction may be carried out in a base such as pyridine or triethylamine. The reaction mixture is allowed to react at a temperature in the range of 10 to 120 ° C. for a specific time, for example 1 to 50 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture can be stirred with a large amount of water and the precipitated solid can be filtered off, or the aqueous phase can be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then suitable organic solvent, for example , Dichloromethane or ethyl acetate, and the organic phase was concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Scheme 6: Step 1

After the basic process, the product formed in the basic process can be converted to a conversion product of the present invention by a method known to those skilled in the art by a conversion reaction.

For example, if the product is a derivative of compound 23 according to Scheme 6, according to Scheme 6, the reaction product 22 may be replaced with a suitable aryl / heteroarylboronic acid derivative or aryl / heteroarylorganotin compound and a suitable catalyst, for example For example, Pd (PPh ₃ ) ₄ , [1,1′-bis (diphenylphosphino) ferrocene] -dichloropalladium (II) or Pd ₂ (dba) ₃ , and suitable bases such as sodium carbonate, cesium carbonate Or triethylamine with a suitable solvent such as dimethylformamide, dimethylformamide / water, toluene, acetonitrile, dimethoxyethane or dioxane. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. and 120 ° C. for a specific time, for example, from 6 hours to several days. After completion of the reaction, the precipitated solids are filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent, the residual solids are dried under reduced pressure, or any catalyst residues present Filter off, wash with a suitable solvent and remove the solvent under reduced pressure, or remove the solvent under reduced pressure. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, when the product is a derivative of compound 23a according to Scheme 6, the reaction product 22 is converted into a suitable alkylzinc halide and a suitable catalyst such as Pd (PPh ₃ ) ₄ , [1,1'-bis (diphenyl). Phosphino) ferrocene] -dichloropalladium (II) or PdCl ₂ (PPh ₃ ) ₂ can be reacted in a suitable solvent such as dimethylformamide, tetrahydrofuran, toluene, dimethoxyethane or dioxane. The reaction mixture is allowed to react at a temperature ranging from room temperature to 120 ° C. for a specific time, for example, from 30 minutes to 48 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or any catalyst residue present Was filtered off, washed with a suitable solvent and the solvent was removed under reduced pressure, or the reaction mixture was removed under reduced pressure. Alternatively, the reaction mixture can be stirred with a large amount of water, the precipitated solid can be filtered off, or the aqueous phase can be extracted with a suitable organic solvent, such as dichloromethane or ethyl acetate, and the organic phase under reduced pressure. Concentrated. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, when the product is a derivative of compound 24 according to Scheme 6, the reaction product 22 may be converted into a suitable vinylboronic acid derivative, vinylorganotin compound or alkene derivative and a suitable catalyst such as Pd (PPh ₃ ) ₄ , [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) or Pd (OAc) ₂ , and suitable ligands such as triphenylphosphine or tri-o-tolylphosphine, and suitable Reaction with a base such as potassium carbonate, sodium carbonate, triethylamine or sodium acetate in a suitable solvent such as toluene, dimethylformamide, dimethylformamide / water, acetonitrile, dimethoxyethane or dimethylacetamide You can. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. and 140 ° C. for a specific time, for example, from 3 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or any catalyst residue present Was filtered off, washed with a suitable solvent and the solvent was removed under reduced pressure, or the reaction mixture was removed under reduced pressure. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or toluene, or purified by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, when the product is derivative 25 of a compound according to Scheme 6, the reaction product 22 is a suitable alkyne derivative and a suitable catalyst, such as Pd (PPh ₃ ) ₄ , PdCl ₂ (PPh ₃ ) ₂ or Pd ₂ ( dba) ₃ , and suitable additives such as copper (I) iodide, and suitable bases such as potassium carbonate, triethylamine or potassium acetate, and suitable solvents such as dimethylformamide, It may be reacted in tetrahydrofuran, tetrahydrofuran / water, toluene or dimethylacetamide. The reaction mixture is allowed to react at a temperature in the range of room temperature to 120 ° C. for a certain time, for example, from 1 hour to several days. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or any catalyst residue present Was filtered off, washed with a suitable solvent and the solvent was removed under reduced pressure, or the reaction mixture was removed under reduced pressure. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or toluene, or purified by column or flash chromatography on silica gel or alumina. The eluent used is, for example, a mixture of methanol and dichloromethane.

Scheme 7: Step 1

After the basic process, the product formed in the basic process can be converted to a conversion product of the present invention by a method known to those skilled in the art by a conversion reaction.

Intermediate 22 may be selected from a suitable amine and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, potassium carbonate or sodium methoxide in methanol and a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, methanol, It may be reacted in toluene or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react at a temperature in the range of 20 ° C. to 140 ° C. for a certain time, for example, from 1 hour to several days. Alternatively, intermediate 22 may be substituted with a suitable amine and a suitable catalyst such as palladium acetate or Pd ₂ (dba) ₃ , and a suitable ligand such as BINAP, and a suitable base such as potassium carbonate or sodium 3 The quat-butoxide may be reacted with a suitable solvent such as toluene or dioxane. The reaction mixture is allowed to react at a temperature in the range of 60 ° C. to 120 ° C. for a specific time, for example 10 to 30 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or any catalyst present The residue was filtered off, washed with a suitable solvent and the solvent was removed under reduced pressure, or the reaction mixture was removed under reduced pressure. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane, ethyl acetate or toluene, or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Step 2

For example, when the product is a derivative of compound 27 according to Scheme 7, reaction product 26 is selected from suitable carbonyl chlorides and optionally suitable bases, preferably sodium hydride, potassium hydroxide, pyridine, triethylamine or potassium carbonate, and optionally In a catalyst such as dimethylaminopyridine and a suitable inert solvent such as tetrahydrofuran, toluene, acetonitrile, dichloromethane, acetone or dioxane, or as a solvent, a base such as pyridine or tri The reaction can be carried out in ethylamine or without solvent. The reaction mixture can be reacted at a temperature in the range of 0 to 110 ° C. for a specific time, for example, 30 minutes to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, when the product is a derivative of compound 28 according to Scheme 7, reaction product 26 is prepared with a suitable sulfonyl chloride and optionally a suitable base, preferably sodium hydride, potassium hydroxide, pyridine, triethylamine or potassium carbonate, and Base in any catalyst, such as dimethylaminopyridine and a suitable inert solvent such as tetrahydrofuran, toluene, acetonitrile, dichloromethane, acetone, dimethylformamide or dioxane, or as a solvent, for example For example, it can be reacted in pyridine or triethylamine or without solvent. The reaction mixture is allowed to react at a temperature in the range of 0 to 120 ° C. for a specific time, for example 30 minutes to 16 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, when the product is a derivative of compound 29 according to Scheme 7, reaction product 26 is prepared with a suitable chlorocarboxylic acid ester and optionally with a suitable base, preferably sodium hydride, sodium hydroxide, pyridine, triethylamine or potassium carbonate, and In any catalyst such as dimethylaminopyridine and a suitable inert solvent such as dioxane, tetrahydrofuran, dichloromethane, acetone, dimethylformamide or dichloroethane, or as a base, for example The reaction can be carried out in pyridine or triethylamine or without solvent. The reaction mixture is allowed to react at a temperature in the range of −10 ° C. to 100 ° C. for a specific time, for example 1 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, when the product is a derivative of compound 30 according to Scheme 7, the reaction product 26 is selected from suitable isocyanates or carbamoyl chlorides and optionally of suitable bases, preferably sodium hydride, pyridine, triethylamine, piperidine or potassium carbonate. And, optionally in a catalyst such as dimethylaminopyridine and a suitable inert solvent such as dioxane, tetrahydrofuran, dimethylformamide, toluene or acetonitrile, or as a solvent, a base such as pyridine or The reaction can be carried out in triethylamine or without solvent. The reaction mixture is allowed to react in a temperature range of room temperature to 100 ° C. for a specific time, for example 2 to 40 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Scheme 8: first step

After the basic process, the product formed in the basic process can be converted to a conversion product of the present invention by a method known to those skilled in the art by a conversion reaction.

For example, if the product is a derivative of compound 32 or 35 according to Scheme 8, the reaction product 31 or 34 can be a suitable chlorocarbonate ester and optionally a suitable base, preferably sodium hydride, sodium hydroxide, pyridine, triethylamine or Potassium carbonate, and any catalyst such as dimethylaminopyridine and a suitable inert solvent such as dioxane, tetrahydrofuran, dichloromethane, acetone, dimethylformamide or dichloroethane, or as a solvent, such as a base For example, it can be reacted in pyridine or triethylamine or without solvent. The reaction mixture is allowed to react at a temperature in the range of −10 ° C. to 100 ° C. for a specific time, for example 1 to 24 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

For example, if the product is a derivative of compound 33 or 36 according to Scheme 8, reaction product 31 Or 34 is a suitable isocyanate or carbamoyl chloride and optionally a suitable base, preferably sodium hydride, pyridine, triethylamine, piperidine or potassium carbonate, and optionally a catalyst such as dimethylaminopyridine and a suitable inert solvent, For example, it can be reacted in dioxane, tetrahydrofuran, dimethylformamide, toluene or acetonitrile, or as a solvent in a base such as pyridine or triethylamine, or without solvent. The reaction mixture is allowed to react for a specific time period, for example from 2 to 40 hours, in the temperature range from room temperature to 100 ° C. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the residual solid is dried under reduced pressure, or the reaction mixture is dried under reduced pressure. Was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as ethanol or ethyl acetate or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Scheme 9: first step

After the basic process, the product formed in the basic process can be converted to a conversion product of the present invention by a method known to those skilled in the art by a conversion reaction.

For example, when the product is a derivative of compound 38 according to Scheme 9, reaction product 37 is, for example, a suitable chloride, bromide or iodide and optionally a suitable base, preferably sodium hydride, pyridine, triethyl in methanol In amines, potassium carbonate or sodium methoxide, in a suitable inert solvent such as dimethylformamide, dimethyl sulfoxide, methanol, dioxane, tetrahydrofuran, toluene, or as a solvent, a base such as pyridine or The reaction can be carried out in triethylamine or without solvent. The reaction mixture is allowed to react in a temperature range of 0 to 14 ° C. for a specific time, for example, from 30 minutes to 2 days. Alternatively, the amino-substituted intermediate 37 can be reacted with a suitable base such as, for example, a suitable chloride, bromide or iodide and a suitable catalyst such as tris (dibenzylideneacetone) dipalladium (0) or tetrakis For example sodium hydride, in the presence of a suitable base such as palladium (0), palladium (0) and a suitable ligand such as 2- (dicyclohexylphosphanyl) biphenyl and a suitable base such as sodium tert- The reaction can be carried out in toluene or dimethylformamide. The reaction mixture is allowed to react in a temperature range of 6 to 12 ° C. for a specific time, for example 2 to 30 hours. After completion of the reaction, the precipitated solid is filtered off, for which the filtration medium consists, for example, of filter paper, washed with a suitable solvent and the remaining solid is dried under reduced pressure or the reaction mixture is reduced under reduced pressure. Solvent was removed. Alternatively, the reaction mixture may be stirred with a large amount of water and the precipitated solids may be filtered off or the aqueous phase may be neutralized with a suitable aqueous acid, for example hydrochloric acid, and then a suitable organic solvent, for example dichloro It can be extracted with methane or ethyl acetate and the organic phase is concentrated under reduced pressure. The remaining crude product was recrystallized from a suitable solvent such as dioxane, ethyl acetate or toluene, or purified by column chromatography on silica gel or alumina or flash chromatography. The eluent used is, for example, a mixture of methanol and dichloromethane.

Under the specified reaction conditions, the OH, SH and NH ₂ groups can be introduced as undesired side reactions. Therefore, it is preferable to protect them with protecting groups or, in the case of NH ₂ , replace them with NO ₂ and then remove the protecting groups or reduce the NO ₂ groups. For example, in variations of the process described above one or more OH groups in the starting compound may be substituted, for example by benzyloxy groups, and / or one or more SH groups may be replaced by, for example, S-benzyl groups And / or one or more NH ₂ groups may be substituted, for example, by NH-benzyl groups or NO ₂ groups. Subsequently, one or more-preferably all-benzyloxy group (s) or NH-benzyl group (s) can be removed with, for example, hydrogen and palladium on carbon, and / or one or more preferably All —S-benzyl group (s) may be removed, for example, with sodium in ammonia, and / or one or more—preferably all—NO ₂ group (s) are, for example, hydrogen and ranei nickel. May be reduced to NH ₂ .

Under the above reaction conditions, the OH, NH ₂ and COOH groups can be introduced as undesired side reactions. It is therefore preferred to convert starting compounds and intermediates comprising at least one OH group and / or at least one NH ₂ group and / or at least one COOH group to the corresponding carboxylic acid esters and carboxamide derivatives. In a variant of the process described above, starting compounds and intermediates having at least one OH group and / or having at least one NH ₂ group are reacted with a carboxylic acid group activated with a carboxylic ester or carboxamide derivative, for example a carbonyl chloride group. Can be switched. Starting compounds and intermediates comprising at least one COOH in a variant of the above process are reacted with an activating agent such as thionyl chloride or carbonyldiimidazole with a carboxylic acid ester or carboxamide derivative, and with a suitable alcohol or amine Can be converted to a subsequent reaction. Subsequently, at least one of the starting compounds and intermediates—preferably all—carboxylic acid esters or carboxamide group (s) can be separated, for example, by dilution with an aqueous acid or base, and then one, preferably all, OH. The group (s) and / or NH ₂ group (s) and / or COOH group (s) can be removed.

Compounds of the invention and in particular compounds 1 to 85 were named AutoNom 2000 software (ISIS / Draw 2.5; MDL).

The present invention may be described in detail with reference to the following examples, which are not intended to be limiting.

I) Preparation of Compounds of the Invention

Synthetic general methods based on Schemes 1-9 were then used to synthesize the compounds of the present invention. Also included are their NMR spectroscopic data and mass spectroscopic data and melting points.

Precursors used in the preparation of compounds of the present invention can be synthesized by methods known to those skilled in the art - unless otherwise indicated.

The chemicals and solvents used can be obtained or synthesized from conventional suppliers (Acros, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, etc.).

Example 1:

1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 1)

Preparation of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethyl urea (Reaction according to Scheme 5)

100 mg of 3-chloropyrido [2,3-b] pyrazin-6-ylamine (0.55 mmol) was initially charged in 5 ml of pyridine and 44 μl of ethyl isocyanate (0.55 mmol) was added at room temperature. The mixture was stirred at 75 캜 for 3 hours, and another 132 총 total amount of ethyl isocyanate (1.65 mmol) was added to the reaction mixture in a small fraction for 18 hours. Then the solvent was removed under reduced pressure. The resulting solid was purified via silica gel column chromatography (dichloromethane / methanol eluant). This gave a light yellow solid.

Preparation of 1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazin-6-yl) urea (reaction according to Scheme 6)

(0.39 mmol) of l- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea, 10.1 mg of copper (I) iodide (0.05 mmol) Of triethylamine (1.38 mmol) was initially charged in 2 ml of anhydrous dimethylformamide under nitrogen as a protective gas. Subsequently 29.1 mg of dichlorobis (triphenylphosphine) palladium (II) (0.04 mmol) and 54 μl of phenylacetylene (0.49 mmol) were added and the mixture was stirred at room temperature for 16 hours. The mixture was diluted with dichloromethane for workup and added to diluted hydrochloric acid. The precipitated solid was filtered off with suction and the organic phase was washed with dilute hydrochloric acid and distilled water. After phase separation, the organic solvent was removed under reduced pressure. Further purification was carried out by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

Melting Point: 236-238 ° C (Decomposition)

ESI-MS: found m / z = 318.0 (M + H ⁺ ); Calc 317 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.35-3.45 (m, 2H), 7.51-7.59 (m, 3H), 7.68 (d, 1H), 7.75 (d, 2H) , 8.37 (d, 1H), 9.01 (s, 1H), 9.14 (s, 1H), 10.23 (s, 1H) ppm.

The following examples were synthesized according to Example 1 and general synthetic methods:

Example 2:

1-ethyl-3- (3-thiophen-3-ylethynylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 2)

m.p .: 239-242 ° C. (decomposition)

ESI-MS: found m / z = 324.2 (M + H ⁺ ); Calculated 323 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.25-3.35 (m, 2H), 7.43 (d, 1H), 7.66 (d, 1H), 7.76 (dd, 1H), 8.21 (d, 1H), 8.36 (d, 1H), 8.97 (s, 1H), 9.14 (s, 1H), 10.23 (s, 1H) ppm.

Example 3:

1- (3-cyclopropylethynylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (Compound 3)

m.p .: 227-228 ° C. (decomposition)

ESI-MS: found m / z = 282.3 (M + H ⁺ ); Calculation 281 amu

¹ H NMR (d ₆ -DMSO): δ = 1.00-1.10 (m, 2H), 1.19 (t, 3H), 1.69-1.79 (m, 1H), 3.25-3.35 (m, 2H), 7.63 (d, 1H), 8.32 (d, 1H), 8.77 (s, 1H), 9.11 (s, 1H), 10.18 (s, 1H) ppm.

Example 4:

3-ethyl urea (Compound 4) was obtained in the same manner as in [3- (3-dimethylaminoprop-1-ynyl) pyrido [

ESI-MS: found m / z = 299.2 (M + H ⁺ ); Calc 298 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.19 (t, 3H), 2.33 (s, 6H), 3.27 - 3.35 (m, 2H), 3.67 (s, 2H), 7.67 (d, 1H), 8.34 (d, 1 H), 8.85 (s, 1 H), 9.05 (s, 1 H), 10.19 (s, 1 H) ppm.

Example 5:

Yl) -3-ethyl urea (Compound 5) was obtained in the same manner as in [1- (3-chlorophenyl)

Preparation of 1- [3 - ((E) -2-cyclohexylvinyl) pyrido [2,3- b] pyrazin-6-yl]

(0.40 mmol) of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea, 73.6 mg of cyclohexylvinylboronic acid (0.48 mmol) Sodium carbonate (0.80 mmol) and 33.4 mg of [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium (II) (0.04 mmol) were initially charged in 6 ml of dimethylformamide / water (1: 1). Filled under. The mixture was then heated to 90 ° C. for 6.5 hours. Distilled water was then added to the reaction mixture, and the precipitate obtained was suctioned off and filtered off. Further purification was carried out by column chromatography on silica gel (ethyl acetate / heptane eluent mixture). A light brown solid was obtained.

m.p .: 202-204 ° C. (decomposition)

ESI-MS: found m / z = 326.0 (M + H ⁺ ); 325 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.10 - 1.40 (m, 8H), 1.65 - 1.90 (m, 5H), 2.28 - 2.38 (m, 1H), 3.25 - 3.35 (m, 2H), 6.69 ( d, 1H), 7.15 (dd, 1H), 7.58 (d, 1H), 8.28 (d, 1H), 8.98 (s, 1H), 9.15 (s, 1H), 10.05 (s, 1H) ppm.

The following examples were synthesized according to Example 5 and general synthetic methods:

Example 6:

6-yl] urea (Compound 6) was obtained in the same manner as in Reference Example 1, except that 1-ethyl-3- [3 - ((E) -3- methoxypropenyl) pyrido [

ESI-MS: found m / z = 288.3 (M + H ⁺ ); Calculation 287 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.25 - 3.35 (m, 2H), 3.39 (s, 3H), 4.25 (d, 2H), 6.92 (d, 1H), 7.15 1H), 7.25 (s, 1H), 7.62 (d, 1H), 8.30 (d, 1H), 9.02 (s, 1H), 9.15

Example 7:

Vinyl] pyrido [2,3-b] pyrazin-6-yl urea (Compound 27)

m.p .: 217-219 ° C

ESI-MS: found m / z = 338.2 (M + H ⁺ ); Calc 337 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.25 - 3.38 (m, 2H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.54 (d, 1H), 7.61 (d, 1H), 7.87 (t, 2H), 8.02 (d, 1H), 8.31 (d, 1H), 9.09 (s, 1H), 9.17 (bs, 1H), 10.09

Example 8

4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl methyl carbonate (Compound 9)

Preparation of 1-ethyl-3- [3- (4-hydroxyphenyl) pyrido [2,3- b] pyrazin-6-yl] urea (Reaction according to Scheme 5)

0.50 g of 4- (6-aminopyrido [2,3-b] pyrazin-3-yl) phenol (2.10 mmol) was initially charged in 5.0 ml of pyridine. 183 μl ethyl isocyanate (2.31 mmol) was added dropwise at room temperature and the mixture was heated to 70-80 ° C. for 2 hours. Thereafter, another 183 μl of ethyl isocyanate was added and the mixture was heated to 70-80 ° C. for an additional 2 hours. After the reaction was terminated, the reaction mixture was added to ice water and neutralized with 1N hydrochloric acid. The precipitated product was filtered off under suction and dried. The filtered product was partially dissolved in ethanol, mixed with 52 mg of potassium hydroxide (0.93 mmol) and dissolved in water. The mixture was heated to 40 ° C. for about 1 hour. Thereafter, the reaction solution was neutralized with 1N hydrochloric acid, and the solvent was removed under reduced pressure. The obtained solid was purified by silica gel column chromatography (dichloromethane / methanol eluate). This gave a yellow solid.

Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenylmethyl carbonate (reaction according to Scheme 8)

(0.32 mmol) of 1-ethyl-3- [3- (4-hydroxyphenyl) pyrido [2,3- b] pyrazin-6-yl] urea, 30 μl of methyl chloroformate ) And 45 [mu] l triethylamine (0.32 mmol) were initially charged in 10 ml anhydrous dioxane and heated to 10 < 0 > C for 1 hour. After cooling, the precipitated solid was filtered off with suction and dried. Recrystallization from ethanol gave a pale yellow solid.

m.p .: 243-245 ° C

ESI-MS: found m / z = 368.2 (M + H ⁺ ); Calc 367 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.30 - 3.39 (m, 2H), 3.90 (s, 3H), 7.49 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.42 (d, 2H), 9.03 (s, 1H), 9.47 (s, 1H), 10.09 (s, 1H) ppm.

The following examples were synthesized according to Example 8 and general synthetic methods:

Example 9:

Phenyl (2-methoxyethyl) carbonate (Compound 10) was reacted with 4- [6- (3-

m.p .: 230-232 ℃

ESI-MS: found m / z = 412.2 (M + H ⁺ ); Calculated 411 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.30 - 3.39 (m, 5H), 3.68 (t, 2H), 4.40 (t, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (s, 1H), 9.10 (s,

Example 10:

4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl phenyl carbonate (Compound 11)

ESI-MS: found m / z = 430.2 (M + H ⁺ ); Calculation 429 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.21 (t, 3H), 3.30 - 3.33 (m, 2H), 7.33 7.38 (m, 1H), 7.43 (d, 2H), 7.51 (t, 2H), 1H), 9.15 (d, 2H), 8.39 (d, 1H), 8.45 (d, 2H), 9.11

Example 11:

4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl diethylcarbamate (Compound 12)

ESI-MS: found m / z = 409.4 (M + H ⁺ ); Calculated 408 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.15 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.30 - 3.39 (m, 4H), 3.45 (q, 2H), 7.37 (d, 2H), 7.69 (d, 1H), 8.34-8.39 (m, 3H), 9.11 (s, 1H), 9.48 (s, 1H), 10.15 (s, 1H) ppm.

Example 12:

3-yl] phenyl 2-methoxyethyl carbonate (Compound 16) The title compound

ESI-MS: found m / z = 412.2 (M + H ⁺ ); Calculated 411 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.33 - 3.38 (m, 5H), 3.63-3.66 (m, 2H), 4.37-4.39 (m, 2H), 7.48 (d, 2H), 7.68 (d, IH), 7.72 (d, IH), 8.22 (s, IH), 8.29 (d, IH), 8.39 ), 10.14 (s, 1H) ppm.

Example 13:

4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl isobutyl carbonate (Compound 17)

ESI-MS: found m / z = 410.3 (M + H ⁺ ); Calculation 409 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 0.97 (d, 6H), 1.20 (t, 3H), 2.02 (sep, 1H), 3.25 3.38 (m, 2H), 4.06 (d, 2H), 7.50 ( 1H, d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.10 (s, 1H), 9.47

Example 14:

(Compound 18) < RTI ID = 0.0 > 4- [6- (3-Ethylurea) pyrido [

ESI-MS: found m / z = 406.1 (M + H ⁺ ); Calc. 405 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 1.89 (t, 3H), 3.25 3.38 (m, 2H), 4.90 (q, 2H), 7.50 (d, 2H), 7.70 ( 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (s, 1H), 9.47

Example 15:

Phenyl] dimethylcarbamate (Compound 19) was obtained in the same manner as in Reference Example 1, except that 4- [6- (3-ethylurea) pyrido [

Example 15 was prepared using sodium hydride as the base and dimethylformamide as the solvent.

m.p .:> 230 ° C. (decomposition)

ESI-MS: found m / z = 381.2 (M + H ⁺ ); 380 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 2.95 (s, 3H), 3.09 (s, 3H), 3.25 - 3.38 (m, 2H), 7.37 (d, 2H), 7.68 (d, 1H), 8.35-8.38 (m, 3H), 9.11 (s, 1H), 9.46 (s, 1H), 10.12 (s, 1H) ppm.

Example 16:

3-yl] -2-methoxyphenyl 2-methoxyethyl carbonate (Compound 32) was prepared in accordance with the general method of < RTI ID =

ESI-MS: found m / z = 442.3 (M + H ⁺ ); Calculation 441 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.25-3.38 (m, 5H), 3.62 (dd, 2H), 3.97 (s, 3H), 4.35 (dd, 2H), 7.45 (d, IH), 7.74 (d, IH), 7.97 (d, IH), 8.06 (s, IH), 8.39 s, 1H) ppm.

Example 17:

3-yl] phenylcarbonate (Compound 33) was obtained in the same manner as in Reference Example 1, except that 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [

ESI-MS: found m / z = 488.2 (M + H ⁺ ); Calculation 487 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.28 - 3.38 (m, 2H), 3.75 (t, 2H), 4.43 (t, 2H), 4.57 (s, 2H), 7.31 (d, IH), 8.41 (d, 2H), 9.09 (bs, IH), 7.36-7.40 (m, 9.47 (s, 1 H), 10.13 (s, 1 H) ppm.

Example 18:

3-yl] -2-methoxyphenyl carbonate (Compound 34) was obtained in the same manner as in Reference Example 1, except that 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [

m.p .: 172-174 ° C

ESI-MS: found m / z = 518.3 (M + H ⁺ ); Calc 517 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.28-3.38 (m, 2H), 3.74 (dd, 2H), 3.96 (s, 3H), 4.41 (dd, 2H), 4.56 (s, 2H), 7.31 (t, 1H), 7.35-7.40 (m, 3H), 7.44 (d, 2H), 7.74 8.39 (d, 1 H), 8.99 (bs, 1 H), 9.51 (s, 1 H), 10.14 (s, 1 H) ppm.

Example 19:

3-yl] -2-methoxyphenyl diethylcarbamate (Compound 67) was reacted with 4- [6- (3-ethylurea) pyrido [

m.p .: 220-222 ° C

ESI-MS: found m / z = 439.3 (M + H ⁺ ); Calc 438 amu

¹ H NMR (d ₆ -DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 1.24 (t, 3H), 3.28-3.36 (m, 4H), 3.44 (q, 2H), 3.94 (s, 3H), 7.31 (d, IH), 7.73 (d, IH), 7.94 (d, IH), 8.01 (s, IH), 8.37 s, 1H), 10.11 (s, 1H) ppm.

Example 20:

6-methoxyphenyl diethylcarbamate (Compound 68) was reacted with 2-chloro-4- [6- (3-ethylurea) pyrido [

m.p .: 237-239 ° C

ESI-MS: found m / z = 473.4 (M + H ⁺ ); Calc 472 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.14 (t, 3H), 1.19 (t, 3H), 1.27 (t, 3H), 3.25-3.38 (m, 4H), 3.46 (q, 2H), 3.97 (s, 3H), 7.76 (d, IH), 8.00 (s, IH), 8.09 (s, IH), 8.39 s, 1H) ppm.

Example 21:

Methoxyphenyl 2- [2- (2-methoxyethoxy) -ethoxy] ethyl (2-methoxyphenyl) Carbonate (Compound 69)

m.p .: 166-167 ° C

ESI-MS: found m / z = 530.2 (M + H ⁺ ); Calc 529 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.25 (s, 3H), 3.28-3.35 (m, 2H), 3.45 (t, 2H), 3.53-3.60 (m, 6H) 1H), 7.71 (d, IH), 7.76 (d, IH), 7.76 (d, 8.39 (d, 1 H), 8.96 (bs, 1 H), 9.51 (s, 1 H), 10.12 (s, 1 H) ppm.

Example 22:

4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (E) -3-phenylacrylate (Compound 13)

Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (E) -3-phenylacrylate

(0.13 mmol) of 1-ethyl-3- [3- (4-hydroxyphenyl) pyrido [2,3- b] pyrazin-6-yl] urea was initially charged in 3.0 ml of anhydrous pyridine. 17.5 mg of dimethylaminopyridine (0.14 mmol) and 22.9 mg of trans-cinnamyl chloride (0.13 mmol) were added at room temperature and the reaction mixture was stirred at room temperature. After 3 hours, an additional 22.9 mg of trans-cinnamyl chloride (0.13 mmol) was added and the mixture was stirred at room temperature for a further 3 hours. The reaction mixture was poured into iced water for workup and neutralized with 1N hydrochloric acid. The precipitated solid was filtered off under suction and dried under reduced pressure. Without further purification, the obtained product gave a yellow solid.

m.p .: 236-238 ° C

ESI-MS: found m / z = 440.3 (M + H ⁺ ); Calculation 439 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.25 - 3.40 (m, 2H), 6.95 (d, 1H), 7.46 - 7.51 (m, 5H), 7.70 (d, 1H) 2H), 7.94 (d, 1H), 8.38 (d, 1H), 8.43 (d, 2H), 9.12 ) ppm.

Example 23:

Phenyl] nonadecanoate (Compound 14) was obtained in the same manner as in Reference Example 1, except that 4- [6- (3-ethylurea) pyrido [

Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl nonadecanoate

Ethyl] -3- [3- (4-hydroxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (0.16 mmol) was initially charged in 5.0 ml of anhydrous pyridine. 19.7 mg of dimethylaminopyridine (0.16 mmol) and 51.2 mg of nonadecanoyl chloride (0.16 mmol) were added at room temperature, and the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was added to about 200 ml of distilled water for workup. The precipitated solid was filtered off with suction and washed with water. The crude product was purified by column chromatography on silica gel (dichloromethane / methanol eluant) to give a white solid.

m.p .: 147.2 ° C

_{^{1 H NMR (d 6 -DMSO)}} : δ = 0.90 (t, 3H), 1.20 1.50 (m, 33H), 1.75 - 1.85 (m, 2H), 2.60 - 2.68 (m, 2H), 3.50 - 3.60 (m , 2H), 7.26-7.36 (m, 3H), 8.25-8.31 (m, 3H), 8.71 (s, 1H), 9.22 (s, 1H), 9.75 (s, 1H) ppm.

Example 24:

1- (3-benzylpyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (Compound 15)

Preparation of 1- (3-benzylpyrido [2,3-b] pyrazin-6-yl] -3-ethyl urea (Reaction according to Scheme 6)

Benzylzinc bromide (1.20 mmol) and 2.4 mg of tetrakis (triphenylphosphine) palladium (0) (0.02 mmol) in a 0.5 M solution of 2.4 ml of THF were initially charged under 1 ml of dioxane nitrogen. Subsequently, 102.4 mg of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.41 mmol) and 1 ml of dioxane were added in portions. The mixture was then heated to 100 ° C. After 7 hours, the reaction mixture was cooled and then saturated ammonium chloride solution was added. The aqueous phase was repeatedly extracted with dichloromethane, the organic phase was washed with saturated sodium chloride solution, dried over sodium sulphate and the solvent was removed under reduced pressure. Silica gel column chromatography purification (dichloromethane / methanol eluant) gave a yellow solid.

ESI-MS: found m / z = 308.3 (M + H ⁺ ); Calc. 307 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.19 (t, 3H), 3.25 - 3.35 (m, 2H), 4.35 (s, 2H), 7.25 (t, 1H), 7.30 - 7.39 (m, 4H) , 7.64 (d, 1H), 8.32 (d, 1H), 8.77 (s, 1H), 9.05 (s, 1H), 10.08 (s, 1H) ppm.

Example 25:

1-methoxy-3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 7)

Preparation of 3-phenylpyrido [2,3-b] pyrazin-6-ylamine (reaction according to Scheme 6)

(5.54 mmol) of 3-chloropyrido [2,3-b] pyrazin-6-ylamine, 743 mg of phenylboronic acid (6.09 mmol), 640 mg of tetrakis (triphenylphosphine) palladium (0.55 mmol) and 1.76 sodium carbonate (16.6 mmol) were initially charged in 100 ml of dimethylformamide / water (1: 1) as a protective gas under nitrogen and stirred at 80 ° C for 2 hours. After completion of the reaction, the mixture was filtered off with suction and the filtrate was poured into 800 ml of distilled water. The aqueous phase was extracted repeatedly with ethyl acetate. The organic phase was removed under reduced pressure. The obtained solid was purified by silica gel column chromatography (dichloromethane / methanol eluate). This gave a yellow solid.

Preparation of 1-methoxy-3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea (reaction according to Scheme 5)

100 mg of 3-phenylpyrido [2,3-b] pyrazin-6-ylamine (0.45 mmol) was dissolved in pyridine and mixed with 191 mg of p -nitrophenyl N-methoxycarbamate (0.90 mmol). The mixture was heated at reflux for 4 h. Pyridine was removed under reduced pressure for workup and the residue was partitioned between ethyl acetate and distilled water. The phases were separated and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dried over MgSO ₄ and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (dichloromethane / methanol eluent). A light beige solid was separated.

ESI-MS: found m / z = 296.2 (M + H ⁺ ); Calculated 295 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 3.75 (s, 3H), 7.58 - 7.65 (m, 3H), 8.03 (s, 1H), 8.36 (d, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 10.16 (s, 1H), 11.01 (s, 1H) ppm.

The following examples were synthesized according to Example 25 and general synthetic methods:

Example 26:

1-allyloxy-3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea (Compound 8)

ESI-MS: found m / z = 322.2 (M + H ⁺ ); Calculated 321 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 4.44 (d, 2H), 5.33 (d, 1H), 5.41 (d, 1H), 6.02 - 6.10 (m, 1H), 7.58 - 7.65 (m, 3H) , 8.00 (s, 1H), 8.36 (d, 2H), 8.45 (d, 1H), 9.52 (s, 1H), 10.13 (s, 1H), 11.07 (s, 1H) ppm.

Example 27:

(Compound 36) was obtained by reacting 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- (3-phenylpyrido [2,3- b] pyrazin-

ESI-MS: found m / z = 452.6 (M + H ⁺ ); Calculated 451 amu

¹ H NMR (DMSO-d ₆ )? = 0.02 (s, 6H), 0.84 (s, 9H), 1.62-1.65 (m, 4H), 3.30-3.33 ), 7.59-7.62 (m, 3H), 7.64 (d, 1H), 8.35 (d, 2H), 8.38 (d, 1H), 9.37 (s, 1H), 9.47 (s, 1H), 10.15 (s, 1H) ppm.

Example 28:

3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] Urea (Compound 37)

ESI-MS: found m / z = 498.5 (M + H ⁺ ); Calculation 497 amu

_{^{1 H NMR (DMSO-d 6}} ) = 0.01 (s, 6H), 0.83 (s, 9H), 1.61-1.66 (m, 4H), 3.30-3.33 (m, 2H), 3.65-3.68 (m, 2H) , 3.93 (s, 3H), 6.96 (d, IH), 7.59 (d, IH), 7.86 (dd, 9.42 (s, 1 H), 9.73 (s, 1 H), 10.08 (s, 1 H) ppm.

Example 29:

Yl} urea] butyl} phosphonate (Compound 42) was reacted with diethyl {4- [3- (3-phenylpyrido [

ESI-MS: found m / z = 458.2 (M + H ⁺ ); Calculated 457 amu

_{^{1 H NMR (DMSO-d 6}} ) δ = 1.16 (t, 6H), 1.59-1.69 (m, 4H), 1.77-1.84 (m, 2H), 3.33-3.36 (m, 2H), 3.90-3.99 (m 2H), 8.38 (d, 1H), 9.22 (s, 1H), 9.47 (s, 1H), 10.16 s, 1H) ppm.

Example 30:

Yl] urea} butyl) phosphonate (Compound 44) was reacted with diethyl (4- {3- [3- (4- hydroxy-

ESI-MS: found m / z = 504.5 (M + H ⁺ ); Calc. 503 amu

_{^{1 H NMR (DMSO-d 6}} ) δ = 1.15 (t, 6 H), 1.58-1.69 (m, 4H), 1.76-1.82 (m, 2H), 3.30-3.33 (m, 2H), 3.89-3.97 ( 1H), 7.93 (d, 1H), 7.93 (d, 1H), 7.93 (d, , 1H), 9.71 (s, 1H), 10.07 (s, 1H) ppm.

Example 31:

6-yl] urea (Compound 61) was synthesized in the same manner as in Example 1, except that 1-methoxy-3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [

ESI-MS: found m / z = 342.3 (M + H ⁺ ); Calc 341 amu

¹ H NMR (d ₆ -DMSO):? = 3.74 (s, 3H), 3.93 (s, 3H), 6.98 , 1H), 8.39 (d, 1H), 9.46 (s, 1H), 9.74 (s, 1H), 10.03 (s, 1H), 10.84 (s, 1H) ppm.

Example 32:

Yl} ethyl} phosphonate (Compound 62) was reacted with diethyl {2- [3- (3-phenylpyrido [

ESI-MS: found m / z = 430.1 (M + H ⁺ ); Calculation 429 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.21 (t, 6H), 2.08-2.14 (m, 2H), 3.48-3.55 (m, 2H), 3.98-4.08 (m, 4H), 7.58-7.63 ( (m, 3H), 7.72 (d, 1H), 8.35 (d, 2H), 8.39 (s, 1H), 9.14

Example 33:

(3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ethyl carbamate (Compound 38)

Preparation of 1- (4-hydroxybutyl) -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea

360 ml (0.22 mmol) of 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea was dissolved in 20 ml of dichloro It was dissolved in methane and mixed with 5 ml of 2 mol isopropanol HCl solution. After stirring for 12 hours at room temperature, the reaction mixture was washed with water and dried (Na ₂ SO ₄ ). The solvent was removed under reduced pressure to give a light yellow solid.

ESI-MS: found m / z = 338.3 (M + H ⁺ ); Calc 337 amu

_{^{1 H NMR (DMSO-d 6}} ) δ = 1.58-1.64 (m, 4H), 3.30-3.34 (m, 2H), 3.48-3.53 (m, 2H), 4.48 (t, 1H), 7.57-7.63 (m , 3H), 7.66 (d, 1H), 8.35-8.38 (m, 2H), 9.30 (s, 1H), 9.46 (s, 1H), 10.13 (s, 1H) ppm.

Preparation of 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl ethyl carbamate

30 mg (0.08 mmol) of 1- (4-hydroxybutyl) -3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea are dissolved in 5 ml of pyridine and 7.6 μL (0.10) mmol) ethyl isocyanate and stirred at 10 ° C. for 6 h. The reaction mixture was poured into 200 ml of water and stirred for 15 minutes. The precipitated solid was filtered off and dried. This gave a white solid.

ESI-MS: found m / z = 409.4 (M + H ⁺ ); Calculated 408 amu

_{^{1 H NMR (DMSO-d 6}} ) = 0.97 (t, 3H), 1.60-1.77 (m, 4H), 2.96-3.00 (m, 2H), 3.33-3.35 (m, 2H), 4.01-4.04 (m, 2H), 7.07 (t, 1H), 7.58-7.64 (m, 3H), 7.66 (d, 1H), 8.35 (d, 2H), 8.38 , 1H), 10.17 (s, 1H) ppm.

Example 34:

Methyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate (Compound 39)

Preparation of Methyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate

3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea was suspended in 2 ml of dichloromethane and 9.3 μl (0.08 mmol) 0.12 mmol) of methyl chloroformate, 23 μl (0.16 mmol) of triethylamine and 1 mg (0.01 mmol) of dimethylaminopyridine. The solution was stirred at rt for 4 h. The reaction mixture was diluted with 50 ml of dichloromethane, washed with water and dried (Na ₂ SO ₄ ). The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (dichloromethane / methanol eluent). The white solid was separated.

ESI-MS: found m / z = 396.3 (M + H ⁺ ); Calc 395 amu

_{^{1 H NMR (DMSO-d 6}} ) = 1.61-1.66 (m, 2H), 1.76-1.78 (m, 2H), 3.34-3.36 (m, 2H), 3.67 (s, 1H), 4.17-4.19 (m, 2H), 7.59-7.63 (m, 3H), 7.66 (d, 1H), 8.35 (d, 2H), 8.38 , 1H) ppm.

The following examples were synthesized according to Example 34 and general synthetic methods:

Example 35:

(3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate (Compound 40)

ESI-MS: found m / z = 496.0 (M + H ⁺ ); Calc 495 amu

_{^{1 H NMR (DMSO-d 6}} ) = 1.24 (s, 3H), 1.29 (s, 3H), 1.61-1.67 (m, 2H), 1.77-1.82 (m, 2H), 3.34-3.37 (m, 2H) , 3.65 (dd, IH), 3.98 (dd, IH), 4.03 (dd, IH), 4.15 (dd, IH), 4.17-4.28 (m, 3H), 7.58-7.63 , 8.36 (d, 2H), 8.38 (d, 1H), 9.34 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm.

Example 36:

(3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate (Compound 41)

Preparation of 2,3-dihydroxypropyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl carbonate

50 mg (0.10 mmol) of 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl The carbonate was dissolved in 20 ml of dichloromethane, mixed with 17 μl (0.13 mmol) of boron trifluoride ethyl etherate and stirred at room temperature for 4 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (dichloromethane / methanol eluent). The white solid was separated.

ESI-MS: found m / z = 456.4 (M + H ⁺ ); 455 amu

_{^{1 H NMR (DMSO-d 6}} ) = 1.62-1.67 (m, 2H), 1.76-1.82 (m, 2H), 3.28-3.52 (m, 4H), 3.62-3.66 (m, 1H), 3.96 (dd, (D, IH), 7.67 (d, IH), 8.35 (m, 2H) (d, 2H), 8.38 (d, 1H), 9.31 (s, 1H), 9.47 (s, 1H), 10.17 (s, 1H) ppm.

Example 37:

{4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphonic acid (Compound 43)

Preparation of {4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl} phosphonic acid

60 mg (0.13 mmol) of diethyl 4- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] butyl were dissolved in 5 ml of each dichloromethane and hexamethyldisilazane. And 100 mg (0.66 mmol) of bromotrimethylsilane. After stirring for 6 hours at room temperature, the reaction mixture was concentrated under reduced pressure and the residue was stirred with water for 2 hours. This gave a yellow solid.

ESI-MS: found m / z = 402.3 (M + H ⁺ ); 401 amu

¹ H NMR (DMSO-d ₆ )? = 1.51-1.68 (m, 6H), 3.33-3.36 (m, 2H), 7.58-7.63 (m, 3H), 7.73 (d, 1H), 8.33-8.37 , 3H), 9.06 (s, 1H), 9.44 (s, 1H), 10.12 (s, 1H) ppm.

The following examples were synthesized according to Example 37 and general synthetic methods:

Example 38:

(4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphonic acid (Compound 45)

ESI-MS: found m / z = 448.3 (M + H ⁺ ); 447 amu

_{^{1 H NMR (DMSO-d 6}} ) δ = 1.48-1.67 (m, 6H), 3.24-3.28 (m, 2H), 3.92 (s, 3H), 6.98 (d, 1H), 7.70 (d, 1H), 1H), 7.85 (d, 1H), 7.89 (d, 1H), 8.28 (s, 1H), 8.95 (s, 1H), 9.38

Example 39:

{2- [3- (3-phenylpyrido [2,3-b] pyrazin-6-yl) urea] ethyl} phosphonic acid (Compound 63)

ESI-MS: found m / z = 374.2 (M + H ⁺ ); Calc 373 amu

¹ H NMR (d ₆ -DMSO): δ = 1.86-1.93 (m, 2H), 3.45-3.52 (m, 2H), 7.57-7.63 (m, 3H), 7.76 (d, 1H), 8.35 (d, 2H), 8.37 (d, 1H), 8.96 (s, 1H), 9.45 (s, 1H), 10.17 (s, 1H) ppm.

Example 40:

Ethyl N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamidate (Compound 59)

Preparation of ethyl N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamidate (reaction according to scheme 5)

200 mg (0.90 mmol) of 3-phenylpyrido [2,3-b] pyrazin-6-ylamine were dissolved in 20 ml of pyridine and mixed with 0.11 ml (0.99 mmol) of ethyl oxalyl chloride. After stirring for 2 hours at room temperature, the solution was poured into ice water. The solid precipitated was filtered off and washed thoroughly with water. This gave a light yellow solid.

ESI-MS: found m / z = 323.2 (M + H ⁺ ); Calc 322 amu

_{^{1 H NMR (DMSO-d 6}} ) δ = 1.37 (t, 3H), 4.35-4.41 (m, 2H), 7.60-7.66 (m, 3H), 8.38 (d, 2H), 8.43 (bs, 1H), 8.61 (d, 1 H), 9.63 (s, 1 H), 11.67 (s, 1 H) ppm.

Example 41:

N-ethyl-N '-(3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamide (Compound 60)

Preparation of N-ethyl-N '-(3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamide (reaction according to Scheme 5)

23 mg (0.07 mmol) of ethyl N- (3-phenylpyrido [2,3-b] pyrazin-6-yl) oxalamidate is dissolved in 5 ml of dry THF and 0-15 ml (0.38 mmol) in THF Mixed with 2.0M ethylamine solution.

After stirring for 48 hours at room temperature, the reaction mixture was neutralized. The precipitated solid was filtered off and the filtrate was concentrated to dryness under reduced pressure. The obtained solid was purified by silica gel column chromatography (dichloromethane / methanol eluate). This gave a light yellow solid.

ESI-MS: found m / z = 322.3 (M + H ⁺ ); Calculated 321 amu

¹ H NMR (DMSO-d ₆ ) δ = 1.13 (t, 3H), 3.27 (q, 2H), 7.60-7.66 (m, 3H), 8.39 (d, 2H), 8.54 (d, 1H), 8.65 ( d, 1H), 9.24 (t, 1H), 9.64 (s, 1H), 10.31 (s, 1H) ppm.

Example 42:

Ethyl 4- [6- (3-ethyl-1-phenylurea) pyrido [2,3-b] pyrazin-3-yl] phenylcarbamate (compound 20)

Preparation of ethyl 4- [6- (3-ethyl-1-phenylurea) pyrido [2,3-b] pyrazin-3-yl] phenylcarbamate (reaction according to Scheme 5)

100 mg of 4- (6-phenylaminopyrido [2,3-b] pyrazin-3-yl) phenol hydrochloride (0.28 mmol) were initially charged in 3 ml of pyridine and 65.3 mg of ethyl isocyanate (0.90 mmol) was added. Add at room temperature. The mixture was stirred at 80 ° C. for 5 hours, then another 32.0 mg of ethyl isocyanate (0.45 mmol) was added and the mixture was stirred at 80 ° C. for an additional 4 hours. Then the solvent was removed under reduced pressure. The obtained solid was purified twice by column chromatography on silica gel (dichloromethane / methanol and n-heptane / acetone eluent). This gave a light yellow solid.

m.p .: 147-151 ° C

ESI-MS: found m / z = 457.3 (M + H ⁺ ); 456 amu

_{^{1 H NMR (CDCl 3):}} δ = 1.28 (t, 3H), 1.40 (t, 3H), 3.39 (quint, 2H), 3.57 (quint, 2H), 5.09 (t, 1H), 6.80 (d, 1H 1H), 7.35 (d, 2H), 7.40 (d, 2H), 7.50 (t, , 10.76 (t, 1 H) ppm.

To prepare 4- (6-phenylaminopyrido [2,3-b] pyrazin-3-yl) phenol hydrochloride, reference was made to WO 99/17759.

Example 43:

Tert-butyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} carbamate (Compound 21)

Preparation of tert-butyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} carbamate (reaction according to Scheme 6)

83 mg of 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.33 mmol), 120 mg of tert-butyl [4- (4,4,5,5 Tetramethyl [1,3,2] dioxaborolan-2-yl) phenyl] carbamate (0.36 mmol), 106 mg sodium carbonate (1.00 mmol) and 19 mg tetrakis- (triphenylphosphine) (0.02 mmol) ) Was initially charged to 7 ml of degassed dimethylformamide / water mixture. The mixture was heated to 10 ° C for 4 h. The cooled mixture was mixed with water. The precipitated solid was filtered off and washed with water and dichloromethane. This gave a beige solid.

m.p .: 281-283 ° C

ESI-MS: found m / z = 409.4 (M + H ⁺ ); Calculated 408 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 1.52 (s, 9H), 3.25 - 3.38 (m, 2H), 7.65 (d, 1H), 7.69 (d, 2H), 8.29 (d, 2H), 8.33 (d, 1H), 9.09 (bs, 1H), 9.41 (s, 1H), 9.72 (s, 1H), 10.09 (s, 1H) ppm.

The following examples were synthesized according to Example 43 and general synthetic methods:

Example 44:

2-methoxyethyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} carbamate (Compound 22)

m.p .: 249-251 ° C

ESI-MS: found m / z = 411.3 (M + H ⁺ ); Calculated 410 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.20 (t, 3H), 3.31 (s, 3H), 3.45 - 3.38 (m, 2H), 3.58 - 3.64 (m, 2H), 4.24 - 4.27 (m, 2H), 7.65 (d, 1H), 7.70 (d, 2H), 8.31 (d, 2H), 8.37 ), 10.11 (s, 1H) ppm.

Example 45:

1-ethyl-3- {3- [4- (3-ethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} urea (Compound 23)

m.p .:> 350 ° C (decomposition)

ESI-MS: found m / z = 380.2 (M + H ⁺ ); Calc 379 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.08 (t, 3H), 1.20 (t, 3H), 3.14 (quint, 2H), 3.32 - 3.38 (m, 2H), 6.33 (t, 1H), 7.60 1H), 9.39 (s, 1H), 10.06 (s, 1H) ppm (m, 3H) .

Example 46:

1- {3- [4- (3,3-dimethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea (Compound 24)

m.p .:> 350 ° C

ESI-MS: found m / z = 380.3 (M + H ⁺ ); Calc 379 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 2.98 (s, 6H), 3.25-3.38 (m, 2H), 7.63 (d, 1H), 7.74 (d, 2H), 8.26 (d, 2H), 8.33 (d, 1H), 8.63 (s, 1H), 9.12 (bs, 1H), 9.41 (s, 1H), 10.07 (s, 1H) ppm.

Example 47:

1-ethyl-3- {3- [6- (3-ethylurea) pyridin-3-yl] pyrido [2,3-b] pyrazin-6-yl} urea (Compound 25)

ESI-MS: found m / z = 381.2 (M + H ⁺ ); 380 amu

¹ H NMR (d ₆ -DMSO): δ = 1.13 (t, 3H), 1.20 (t, 3H), 3.23 (quint, 2H), 3.25 3.38 (m, 2H), 7.63 (d, 1H), 7.67 ( d, 1H), 8.25 (d, 1H), 8.00 (bs, 1H), 8.35 (d, 1H), 8.61 (d, 1H), 9.08 (bs, 1H), 9.17 (s, 1H), 9.44 (s , 1H), 9.55 (s, 1H), 10.12 (s, 1H) ppm.

Example 48:

1-ethyl-3- [3- (4-morpholin-4-ylmethylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 28)

ESI-MS: found m / z = 393.4 (M + H ⁺ ); Calc 392 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 2.41 (bs, 4H), 3.33-3.38 (m, 2H), 3.58 (s, 2H), 3.61 (t, 4H), 7.55 (d, 2H), 7.69 (t, 1H), 8.30 (d, 2H), 8.37 (d, 1H), 9.10 (bs, 1H), 9.44 (s, 1H), 10.13 (s, 1H) ppm.

Example 49:

N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -2- (2-methoxyethoxy) acetamide (Compound 30)

m.p .: 212-215 ° C

ESI-MS: found m / z = 425.2 (M + H ⁺ ); 424 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.32 (s, 3H), 3.34-3.38 (m, 2H), 3.56 (dd, 2H), 3.71 (dd, 2H), 4.15 (s, 2H), 7.66 (d, 1H), 7.89 (d, 2H), 8.33-8.36 (m, 3H), 9.11 (bs, 1H), 9.43 (s, 1H), 9.97 (s, 1H), 10.11 (s, 1 H) ppm.

Example 50:

2-benzyloxy-N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} acetamide (Compound 35)

m.p .: 254-256 ° C.

ESI-MS: found m / z = 457.3 (M + H ⁺ ); 456 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.28-3.38 (m, 2H), 4.16 (s, 2H), 4.66 (s, 2H), 7.31 (t, 1H), 7.33 (t, 1H), 7.40 (t, 2H), 7.44 (d, 1H), 7.66 (d, 1H), 7.91 (d, 2H), 8.33-8.36 (m, 3H), 9.11 (bs, 1H), 9.44 (s, 1 H), 10.10 (s, 1 H), 10.14 (s, 1 H) ppm.

Example 51:

1-ethyl-3- [3- (3-trimethylsilanylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 46)

m.p .: 224-228 ° C

ESI-MS: found m / z = 366.4 (M + H ⁺ ); Calculated 365 amu

¹ H NMR (d ₆ -DMSO): δ = 0.35 (s, 9H), 1.21 (t, 3H), 3.28-3.38 (m, 2H), 7.60 (t, 1H), 7.73 (t, 2H), 8.32 (d, 1H), 8.37 (d, 1H), 8.46 (s, 1H), 9.04 (bs, 1H), 9.48 (s, 1H), 10.12 (s, 1H) ppm.

In Example 51, dioxane / water is used instead of dimethylformamide / water as the solvent.

Commercially available boronic acid derivatives are prepared by the following methods or by methods known to those skilled in the art:

Preparation of 2-methoxyethyl [4- (4,4,5,5-tetramethyl [1,3,2] dioxaborolan-2-yl) phenyl]

107 mg of 4- (4,4,5,5-tetramethyl [1,3,2] dioxaborolan-2-yl) phenylamine (0.48 mmol) was dissolved in tetrahydrofuran. 96 mg 2-methoxyethyl chloroformate (0.68 mmol) and 79 mg N-methylmorpholine (0.78 mmol) were added at room temperature. The mixture was stirred at rt for 1 day, the precipitated solid was filtered off and the solvent was removed under reduced pressure. This gave a yellow oil which was used for the next reaction without further purification.

The following boronic acid derivatives were prepared by the methods described above or by methods known to those skilled in the art:

1-ethyl-3- [4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) phenyl] urea

1,1-dimethyl-3- [4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) phenyl] urea

1-ethyl-3- [5- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) pyridin-2-yl] urea

2- (2-methoxyethoxy) -N- [4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) phenyl] acetamide

2-benzyloxy-N- [4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) phenyl] acetamide

Example 52:

1-ethyl-3- {3- [2- (4-fluorophenyl) ethyl] pyrido [2,3-b] pyrazin-6-yl} urea (Compound 26)

Preparation of 1-ethyl-3- {3- [2- (4-fluorophenyl) ethyl] pyrido [2,3-b] pyrazin-6-yl} urea

108 mg of 1-ethyl-3-3- [2- (4-fluorophenyl) vinyl] pyrido [2,3-b] pyrazin-6-ylurea (0.32 mmol) (Example 27) was heated to ethanol Dissolved in. 112 mg ammonium formate (1.78 mmol) and 110 mg palladium on carbon (10%) were added and the reaction mixture was heated to reflux for 7.5 h. The catalyst was filtered off from the cooled reaction mixture and the mother liquor was removed from the solvent. The crude product was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

m.p .: 207-209 ° C

ESI-MS: found m / z = 340.2 (M + H ⁺ ); Calc 339 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.12 (t, 2H), 3.25-3.38 (m, 4H), 7.10 (t, 2H), 7.32 (dd, 2H), 7.63 (d, 1H), 8.31 (d, 1H), 8.71 (s, 1H), 9.09 (bs, 1H), 10.06 (s, 1H) ppm.

Example 53:

1-ethyl-3- (3- {4- [2- (2-methoxyethoxy) ethoxy] phenyl} pyrido [2,3-b] pyrazin-6-yl) urea (Compound 29)

Preparation of 1-ethyl-3- (3- {4- [2- (2-methoxyethoxy) ethoxy] phenyl} pyrido [2,3-b] pyrazin-6-yl) urea (Scheme 9) According to

29 mg of sodium hydride (0.71 mmol) (60% suspension in mineral oil) was initially charged in 4 ml of anhydrous dimethylformamide. At 0 ° C., 70 mg of 1-ethyl-3- [3- (4-hydroxy-phenyl) pyrido [2,3-b] pyrazin-6-yl] urea (0.23 mmol) is added and 2.5 ml of dimethyl Dissolved in formamide. The mixture was stirred at room temperature for 1 hour. Subsequently, 68 mg of 1-bromo-2- (2-ethoxymethoxy) ethane (0.34 mmol) was added at 0 ° C. and the reaction mixture was stirred at rt for 17 h. Thereafter, another 22 mg of 1-bromo-2- (2-ethoxymethoxy) ethane (0.12 mmol) was added and the reaction mixture was stirred at 80 ° C. for 2 hours. Water was added to the cooled reaction mixture and the aqueous phase was extracted with dichloromethane. After drying the organic phase over sodium sulfate, the solvent is removed and the crude product is purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

ESI-MS: found m / z = 412.3 (M + H ⁺ ); Calculated 411 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.26 (s, 3H), 3.29-3.38 (m, 2H), 3.48 (dd, 2H), 3.62 (dd, 2H), 3.80 (dd, 2H), 4.22 (dd, 2H), 7.17 (d, 2H), 7.64 (t, 1H), 8.31-8.35 (m, 3H), 9.14 (bs, 1H), 9.42 (s, 1H), 10.09 (s, 1H) ppm.

Example 54:

N- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide (Compound 31)

Preparation of N- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide (reaction according to Scheme 7)

100 mg of 1- (3-aminopyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.43 mmol) was initially charged in 5 ml of anhydrous pyridine and 57 μl of p-tolyl chloride ( 0.43 mmol) was added dropwise. The mixture was stirred at 60 ° C. for 2 hours. Thereafter, another 29 μl of ptolyl chloride (0.22 mmol) was added dropwise and the reaction mixture was stirred at 60 ° C. for an additional 2 hours. The cooled reaction mixture was added to ice water, neutralized with 1N HCl, and the solids were aspirated off. The crude product was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

ESI-MS: found m / z = 351.1 (M + H ⁺ ); Calculated 350 amu

¹ H NMR (d ₆ -DMSO): δ = 1.18 (t, 3H), 2.42 (s, 3H), 3.31 (quint, 2H), 7.37 (d, 2H), 7.55 (d, 1H), 8.04 (d , 2H), 8.31 (d, 1H), 9.10 (bs, 1H), 9.56 (s, 1H), 9.96 (s, 1H), 11.39 (bs, 1H) ppm.

Example 55:

1- [3- (4-cyclohexylphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (Compound 47)

Preparation of 1- [3- (4-cyclohexylphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea (reaction according to Scheme 3)

83 mg 1- (3-chloropyrido [2,3-b] pyrazin-6-yl) -3-ethylurea (0.33 mmol), 99 mg 4-cyclohexylaniline (0.55 mmol), 30 mg sodium tertiary Initially 1.5 ml of anhydrous butoxide (0.30 mmol), 29 mg tris (dibenzylideneacetone) dipalladium (0) (0.03 mmol) and 68 mg 2 (dicyclohexylphosphanyl) biphenyl (0.19 mmol) Toluene was charged. The reaction mixture was heated at 10 ° C. under nitrogen in microwave (100 watts) for 30 minutes. The solvent was removed under reduced pressure and the crude product was purified by column chromatography on silica gel (dichloromethane / methanol eluent). This gave a yellow solid.

m.p .: 246-248 ° C

ESI-MS: found m / z = 391.3 (M + H ⁺ ); Calc 390 amu

¹ H NMR (d ₆ -DMSO): δ = 1.18 (t, 3H), 1.22-1.26 (m, 1H), 1.33-1.44 (m, 4H), 1.71 (d, 1H), 1.80 (d, 4H) , 2.45-2.51 (m, 1H), 3.25-3.30 (m, 2H), 7.22 (d, 2H), 7.40 (d, 1H), 7.89 (d, 2H), 8.08 (d, 1H), 8.37 (s , 1H), 8.73 (bs, 1H), 9.87 (s, 1H), 10.06 (s, 1H) ppm.

The following examples were synthesized according to Example 55 and general synthetic methods:

Example 56:

1-ethyl-3- [3- (4-methanesulfonylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 48)

m.p .: 275-280 ° C

ESI-MS: found m / z = 387.3 (M + H ⁺ ); Calc. 386 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.19 (s, 3H), 3.25-3.38 (m, 2H), 7.54 (d, 1H), 7.92 (d, 2H), 8.16 (d, 1H), 8.24 (d, 2H), 8.49 (s, 1H), 8.62 (bs, 1H), 9.93 (s, 1H), 10.56 (s, 1H) ppm.

Example 57:

N-5- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -2-methylphenyl (Compound 49)

m.p .: 247-250 ° C

ESI-MS: found m / z = 416.2 (M + H ⁺ ); Calc 415 amu

¹ H NMR (d ₆ -DMSO): δ = 1.17 (t, 3H), 2.28 (s, 3H), 3.03 (s, 3H), 3.25-3.38 (m, 2H), 7.23 (d, 1H), 7.33 (d, 1H), 7.75 (d, 1H), 8.06-8.09 (m, 2H), 8.37 (s, 1H), 8.92 (bs, 1H), 9.09 (s, 1H), 9.77 (s, 1H), 10.09 (s, 1H) ppm.

Example 58:

3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -N-methylbenzamide (Compound 50)

m.p .: 228-234 ° C

ESI-MS: found m / z = 366.4 (M + H ⁺ ); Calculated 365 amu

¹ H NMR (d ₆ -DMSO): δ = 1.19 (t, 3H), 2.80 (d, 3H), 3.25-3.38 (m, 2H), 7.39-7.48 (m, 3H), 8.09-8.11 (m, 2H), 8.41 (s, 2H), 8.46 (s, 1H), 8.83 (bs, 1H), 9.86 (s, 1H), 10.22 (s, 1H) ppm.

Example 59:

1-ethyl-3- [3- (4-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 51)

 m.p .: 221-224 ° C

ESI-MS: found m / z = 406.4 (M + H ⁺ ); Calc. 405 amu

¹ H NMR (d ₆ -DMSO): δ = 1.19 (t, 3H), 1.39 (bs, 2H), 1.49 (quint, 4H), 2.32 (bs, 4H), 3.25 3.35 (m, 2H), 3.39 ( s, 2H), 7.27 (d, 2H), 7.39 (d, 1H), 7.92 (d, 2H), 8.08 (d, 1H), 8.38 (s, 1H), 8.78 (bs, 1H), 9.82 (s , 1H), 10.05 (s, 1H) ppm.

Example 60:

1-ethyl-3- [3- (4-thiophen-3-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea (Compound 52)

m.p .: 264-267 ℃

ESI-MS: found m / z = 391.4 (M + H ⁺ ); Calc 390 amu

¹ H NMR (d ₆ -DMSO): δ = 1.21 (t, 3H), 3.25-3.35 (m, 2H), 7.47 (d, 1H), 7.58 (d, 1H), 7.65 (dd, 1H), 7.74 (d, 2H), 7.82 (d, 1H), 8.05 (d, 2H), 8.11 (d, 1H), 8.42 (s, 1H), 8.62 (bs, 1H), 9.86 (s, 1H), 10.18 ( s, 1H) ppm.

Example 61:

N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] phenyl} acetamide (Compound 53)

ESI-MS: found m / z = 366.2 (M + H ⁺ ); Calculated 365 amu

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 2.03 (s, 3H), 3.25-3.35 (m, 2H), 7.27 (d, 1H), 7.34 (d, 2H), 7.57 (d, 2H), 7.90 (d, 1H), 8.07 (d, 1H), 8.94 (bs, 1H), 9.79 (s, 1H), 9.89 (s, 1H), 10.03 (s, 1H) ppm.

Example 62:

Ethyl 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] benzoate (compound 54)

m.p .: 252-255 ° C

ESI-MS: found m / z = 381.3 (M + H ⁺ ); 380 amu

¹ H NMR (d ₆ -DMSO): δ = 1.19 (t, 3H), 1.35 (t, 3H), 3.25-3.35 (m, 2H), 4.35 (q, 2H), 7.40 (d, 1H), 7.52 (t, 1H), 7.64 (d, 1H), 8.12 (d, 1H), 8.29 (d, 1H), 8.41 (s, 1H), 8.62 (s, 1H), 8.90 (bs, 1H), 9.86 ( s, 1 H), 10.31 (s, 1 H) ppm.

Example 63:

4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate hydrochloride (Compound 55)

Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate hydrochloride

21 mg of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate (0.05 mmol) (Example 10) in 2.5 ml of dichloromethane Dissolved in methanol (2: 1). 0.02 ml of 5-6N HCl solution in 2-propanol was added and the mixture was stirred at room temperature for 1 day. The solvent was then removed. This gave a yellow solid.

m.p .: 190-193 ° C

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 3.31 3.35 (m, 5H), 3.63-3.66 (m, 2H), 4.37 (dd, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s, 1H), 10.14 (s, 1H) ppm.

Example 64:

4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate p-toluenesulfonate (Compound 56)

Preparation of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate p-toluenesulfonate

48 mg of 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate (0.12 mmol) were initially added with 4 ml of dichloromethane and 0.7 ml Filled with methanol. 23 mg of p-toluenesulfonic acid monohydrate (0.12 mmol) was added at room temperature and dissolved in 2 ml of dichloromethane and 0.5 ml of methanol. The reaction mixture was stirred at 0 ° C. for 1 hour and at room temperature for 1 day. Solvent was removed and recrystallized from residue dichloromethane / n-heptane. The precipitated product was filtered off under suction and washed with n-heptane. This gave a yellow solid.

m.p .: 145-147 ° C

¹ H NMR (d ₆ -DMSO): δ = 1.20 (t, 3H), 2.29 (s, 3H), 3.30 3.36 (m, 5H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.11 ( d, 2H), 7.47 (d, 2H), 7.50 (d, 2H), 7.70 (d, 1H), 8.38 (d, 1H), 8.41 (d, 2H), 9.09 (bs, 1H), 9.47 (s , 1H), 10.14 (s, 1H) ppm.

Example 65:

4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate hydrochloride (Compound 58)

Preparation of 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate hydrochloride

117 mg of 4-6- [3- (4- (tert-butyldimethylsilanyloxy) butyl) urea] pyrido [2,3-b] pyrazin-3-yl-phenyl 2-methoxyethyl carbonate ( 0.21 mmol) was dissolved in 40 ml of pre-dried dichloromethane. 0.5 ml of 5-6N HCl solution in 2-propanol was added and the reaction mixture was stirred at room temperature for 15 minutes. The organic phase was washed with water, dried over sodium sulphate and concentrated. This gave a yellow solid.

m.p .: 165-168 ° C.

ESI-MS: found m / z = 456.2 (M + H ⁺ ); 455 amu

¹ H NMR (d ₆ -DMSO): δ = 1.61 (quint, 4H), 2.29 (s, 3H), 3.30-3.36 (m, 2H), 3.49 (t, 2H), 3.64 (dd, 2H), 4.38 (dd, 2H), 7.49 (d, 2H), 7.66 (d, 1H), 8.38 (d, 1H), 8.43 (d, 2H), 9.33 (bs, 1H), 9.48 (s, 1H), 10.17 ( s, 1 H) ppm.

Preparation of 4- {6- [3- (4- (tert-butyldimethylsilanyloxy) butyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate For reference, see Schemes 5, 6 and 8, general synthetic methods and methods known to those skilled in the art.

Example 66:

2,2-dimethylpropionyloxymethoxy- (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl Phosinoyloxymethyl 2,2-dimethylpropionate (Compound 65)

2,2-dimethylpropionyloxymethoxy- (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl Preparation of phosphinoyloxymethyl 2,2-dimethylpropionate

15 ml of 94 mg 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphonic acid (0.20 mmol) It was dissolved in DMF, mixed with 360 μl of chloromethyl pivalate (2.40 mmol) and 30 μl triethylamine (0.21 mmol) and stirred at 60 ° C. for 10 hours. The mixture was poured into 50 ml of water and extracted three times with ethyl acetate. The combined organic phases were dried over MgSO ₄ and the solvent was removed under reduced pressure. The residue was subsequently purified by column chromatography (eluent: dichloromethane / methanol). Beige solid was separated.

ESI-MS: found m / z = 676.4 (M + H ⁺ ); Calculated 675 amu

_{^{1 H NMR (d 6 -DMSO)}} : δ = 1.12 (s, 18H), 1.57-1.68 (m, 4H), 1.90-1.97 (m, 2H), 3.28-3.31 (m, 3.93 (s, 3H), (D, 1H), 7.86 (d, 1H), 7.86 (d, 1H) , 9.41 (s, 1 H), 9.70 (s, 1 H), 10.06 (s, 1 H) ppm.

II) Biological Effects of Compounds of the Invention

II.1) Cell-Free Kinase Assay (Using ALPHA Technology)

Inhibitory effects of the compounds of the invention were tested in enzymatic assays in various human serine / threonine kinases, tyrosine kinases and lipid kinases. Recombinant human kinases such as Erk2, PI3Kalpha, -beta, -gamma, -delta, p38alpha, p38gamma, Jnkl, Jnk2 and others in some cases as full-length kinases, in some cases as nodulated short sides Although used, it consists of at least a functional kinase domain. The commercially available kinase protein (Proqinase, Upstate) was used as a recombinant fusion protein having a GST (glutathione S-transferase) tag or a His tag. Depending on the substrate morphology, different kinase reactions are quantified through suitable ALPHA ^™ beads (PerkinElmer).

exam

Substrate testing in the Erk assay is described in detail below. Selected test results of the Erk2, PI3Kalpha assay are cited below. To determine IC ₅₀ values, potential inhibitor substances are studied at 10 half-logarithm grading concentrations of 3.16 nM-100 nM.

a) Erk2-ALPHA: A test substance, 0.625 ng of Erk2 (# 14-173, Upstate), 10 uM ATP and 15 nM biotinylated MBP (myelin basic protein) substrate was loaded on a 384-well Optiplate (Perkin Elmer) with the volume for one hour incubation at pH 7.5 in _{25mM Tris, 10mM MgCl 2, 0.1} % Tween-20, 100μM NaVO 4, 2mM DTT. The kinase reaction was then stopped by adding 10 μl of ALPHA bead mix (10 g / ml, # 6760617 / PerkinElmer) and incubated with anti-phospho MBP antibody (320 # 05-429 / Upstate) in 25 mM Tris, 200 mM NaCl, 100 mM Pre-incubated in EDTA and 0.3% BSA and left overnight.

b) PI3K-ALPHA (e.g., PI3K alpha): the test substance, an alpha PI3K (# 14-602, Upstate), 100μM ATP 20μM and PIP ₂ substrate of 1ng (# P4508, Echelon) the 384-well Opti plate ( Perkin Elmer) for 1 hour at pH 7.4 in 50 mM Hepes, 50 mM NaCl, 5 mM MgCl ₂ , 0.05% Chaps, 5 mM DTT. Subsequently, the kinase reaction was stopped by adding ALPHA bead mix (10 g / ml, # 6760603 / PerkinElmer and incubated with 1 mM GST: Grp1 fusion protein (Upstate) and 15 nM biotinylated PIP3 (# C-39B6 / Echelon) Pre-incubated in Hepes, 50 mM NaCl, 50 mM EDTA and 0.1% BSA and allowed to stand overnight.

Fluorescence is measured in the morning Fusion ^TM ALPHA apparatus (Perkin Elmer).

evaluation

Calculation of inhibition rate (%) values per material concentration is performed from the original data values measured in Fusion ^TM ALPHA with the following formula:

Controls are measured 8 times each and material samples are measured 2 times each. 0% control does not contain ATP or substrate; 100% control does not contain test substance. IC ₅₀ values are measured with GraphPadPrism.

The compounds of the present invention exhibited effective inhibition of Erk, PI3K, p38 alpha and Jnkl + Jnk2 with IC ₅₀ values of 88 nM or less (see Table 1).

II.2) Cell Assay: Assay for Antiproliferative Action (XTT Assay)

The principle of this test is that tetrazolium dye XTT (sodium 3'-1- (phenylaminocarbonyl) -3,4-tetrazolium bis (4-methoxy-6-nitro) benzenesulfonic acid by particulate dehydrogenase , Sigma) is based on intracellular reduction to formazan dye. Dyes are only formed metabolically by active cells; Its photometric intensity is a quantitative indicator of the presence of living cells. The reduction in dye formation as a result of incubation of cells with the substance serves as a parameter for antiproliferative action.

exam

Tumor cell lines (ATCC) were seeded (5000 cells / well, in the case of BxPC3 and Hct116; 10000 cells / well, MDA MB468) in 96-well microtiter plates and then incubated at 37 < 0 & Incubated at 5% CO ₂ and 95% air humidity. The test substance consists of a raw material solution (10 mM) in DMSO. To determine EC50 values, potential inhibitor substances are added to the cells in quad- logarithmic grade dilutions to a final concentration of 0.28 μM-50 μM. Then, the cell plate was incubated in an incubator at 37 ℃, 5% CO ₂ and 95% air humidity for 45 hours.

For the detection reaction, the XTT substrate is mixed with PMS (N-methyldibenzopyrazine methylsulfate, Sigma) and added into the cells, resulting in XTT / ml and 2.5 μg PMS / ml at a final concentration of 325 μg. The mixture was then incubated for 3 hours at 37 ° C., 95% air humidity. Subsequently the formazan salt formed by cellular dehydrogenase was quantified at 490 nm absorbance.

evaluation

Evaluation of% inhibition values is in each case carried out by the following formula from the value of optical density measured at 490 nm:

Controls are measured 8 times each and material samples are measured 2 times each. 0% control does not contain cells; 100% control does not contain test substance. EC50 values are measured with GraphPadPrism.

Compounds of the present invention showed effective inhibition of cell proliferation with EC50 values of 2.2 μM or less (see Table 2).

II.3) Cell Assay: Test for Substrate Inhibition (Western Blotting)

It can be explained whether the kinase modulators studied by this method also achieve the desired effect in the cell background, ie in this case, the substrate protein downstream of the target kinase was tested for its phosphorylation state. Finally, the cells incubated with the material are lysed and the whole protein is separated on the reduced polyacrylamide gel. Subsequently, the proteins were transferred to PVDF membrane by western blotting and the sought substrate bands were visualized with specific antibodies and suitable detection methods. Substrate protein downstream of the target kinase is detected simultaneously with an anti-phospho antibody, which is the specific antibody in each case and at the same time a total antibody that recognizes the substrate whole protein. The dual technique of ODYSSEY imaging (LiCOR) makes this simultaneous measurement possible. The intensity of the entire substrate band is used to normalize and quantify phosphorylation inhibition or activation.

exam

A suitable tumor cell line (e. G., BxPC3, Hct116 or MDA MB468) is seeded in a specific standard finished batch with a cell count (e.g., for 350 000 cells / well, BxPC3 and Hct116) confined to 6 microtiter plates Then, it was incubated overnight at 37 ° C., 5% CO ₂ and 95% air humidity in an incubator. Cells were then incubated for an additional 24 hours in reduced serum conditions, ie only 0.25% serum in certain media. The test material consisted of a stock solution in DMSO (10 mM) and the cells were incubated for 5 hours at final concentrations of 5, 15.8 and 50 μM. Was dissolved glycerophosphate, 25mM NaF, 10% glycerol, 0.75% NP-40, 100μM NaVO ₄ cells in buffer solution - then, 25mM Tris, 150mM NaCl, 10mM sodium pyrophosphate, 2mM EGTA, 25mM beta. Protein was quantitated by BCA (Sigma), and the amount of protein of about 20 g per track was separated from the rammyl polyacrylamide gel and then transferred to a semi-dried western blot with PVDF membrane (Millipore) The loting was run at 0.8 mA / cm 3 for 21 hours. This was pre-compounded with I-block reagent (Applied Biosystems) for 1 hour and incubated overnight with specific antibody. To measure Erk and PI3K inhibition, the following substrate Rsk1 downstream was incubated with whole antibody (Rsk # sc-231g C-21, Santa Cruz), phospho-antibody (Phospho-p90RSK (S380) # 9341, NEB Cell Signaling) (Akt # sc-1618 C-20, Santa Cruz) and a phospho-antibody (Phospho-Akt (Ser 473) # 9271, NEB Cell Signaling). After washing the membrane, the second antibody was incubated with anti-rabbit IR dye 800 (# 611-732-127, Rockland) against phospho antibody and anti-goat Alexa Fluor 680 (# A-21081, Molecular samples Incubated with). After incubation in the dark at room temperature for 30 minutes, the matching of the detection antibodies was detected by scanning on ODYSSEY images (LiCOR) in the membrane.

evaluation

At concentrations of 5-50 μM, the compounds of the present invention exhibit double inhibition of Erk (MAPK1 / 2) and PI3K (Table 3), which is by inhibition of the band intensities of the two corresponding phospho-substrate proteins Rsk1 and Akt. appear.

Abbreviation

Akt from: murine Akt8 retrovirus or protein kinase B (PKB)

Ask1 Apoptosis Signal-regulating Kinase

ATR capillary dysregulation and Rad3-related

ATM capillary dysregulation mutation

Bag1 Bcl-2 related atanogen-1

Bcl-2 B-cell leukemia / lymphoma-2 gene

DNA-PK DNA-dependent Protein Kinase

Erk Extracellular Signal-regulated Kinase

Flt-3 fms pseudotyrosine kinase 3

GSK-3 glycogen synthase kinase-3

Human ortholog of the product of hSMG-1 seven nematode gene-1

JAK-3 Janus Kinase 3

JNK c-jun N-terminal kinase

MAPK Mitogen Activated Protein Kinase

Mek MAP or Erk Kinase

Mammalian Target of mTOR Rapamycin

PDGFR Platelet-Induced Growth Factor Receptor

PI3K Phosphoinisitol 3-kinase

PIKK Phosphoiniditol 3-kinase Related Kinases

PIP2 Phosphatidyl Inisitol Biphosphate

PIP3 Phosphatidyl Innisitol Triphosphate

PtdIns Phosphatidyl Inisitol

Raf Rapid Accelerated Fibrosarcoma

Ras Rat Sarcoma

RTK Receptor Tyrosine Kinase

SAPK Stress-activated Protein Kinase

Ser Serine

Syk Spleen Tyrosine Kinase

Thr threonine

Tyr tyrosine

VEGFR Vascular Endothelial Growth Factor Receptor

Claims (60)

Novel pyrido [2,3-b] pyrazine derivatives of Formula I, or physiologically acceptable salts, solvates or hydrates thereof, or racemic forms thereof, pure enantiomers or diastereomeric forms thereof, Mixtures or tautomeric forms of enantiomers and diastereomers. Formula I

In the formula (I) Z2, Z4 and Z5 are hydrogen; Z3 is selected from the group consisting of (A1) , (A2) , (C) and (D) : (A1) "substituted aryl" wherein "substituted aryl" is substituted by one or more substituents identically or differently selected from the group (a1) consisting of: (a1) "alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NH-X1, -N (alkyl) ₂ , -NHC O) - heterocyclyl, -NHC (O) - aryl, -NHC (O) - heteroaryl, -NHC (O) - aryl, -NHC (O) - heteroarylalkyl, -NHS (O ₂₎ - alkyl, -NHS (O ₂₎ - cycloalkyl, -NHS (O ₂₎ - heterocyclyl, -NHS (O ₂₎ - aryl, -NHS (O ₂₎ - heteroaryl, -NHS (O ₂₎ - aryl alkyl, -NHS (O ₂₎ - heteroaryl-alkyl, -S- alkyl, -S- aryl, -S- heteroaryl, -O-X2, -OC (O ) - alkyl, -OC (O) - cycloalkyl, -OC (O) -heterocyclyl, -OC (O) -aryl, -OC (O) -heteroaryl, -OC O ₂₎ - alkyl, -OS (O ₂₎ - cycloalkyl, -OS (O ₂₎ - heterocyclyl, -OS (O ₂₎ - aryl, -OS (O ₂₎ - heteroaryl, -OS (O ₂₎ - aryl, -OS (O ₂₎ - heteroarylalkyl, -C (O) - alkyl, -C (O) - aryl, -C (O) - heteroaryl, -C (O) O-X3 , -C (O) NH-X4, -C (O) N (alkyl) ₂ , -C (O) N (cycloalkyl) ₂ , -C (O) N (aryl) ₂ , -C (O) N (heteroaryl) _2, -S (O) - alkyl, -S (O) - aryl, -S (O ₂₎ - alkyl, -S (O ₂₎ - aryl, -S (O ₂₎ NH- alkyl, -S (O ₂₎ NH- aryl, -S (O ₂₎ NH- heteroaryl, -S (O ₂₎ NH- aryl, -S (O ₂₎ O- alkyl, -S (O ₂ ) O-aryl, and —S (O ₂ ) O-arylalkyl ”; Wherein X 1, X 2, X 3, and X 4 are each independently from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl” Selected; Provided that the substituents of the substitution group (a1) are each independently further substituted by one or more substituents selected the same or differently from the group (a2) consisting of: (a2) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, N _3, -NH- cycloalkyl, -NH- cycloalkylalkyl, -NH-heteroaryl, -NH-heteroarylalkyl, -NH-arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NX5X6, -S-cycloalkyl, -S-aryl, -S-arylalkyl, -S-heteroaryl, -S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O-cycloalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O (-X7-O) _p- X8 (p = 1, 2, 3, 4, 5), -OP (O) (OX9) (OX10), -C (O) O-X11, -C (O) NH 2, -C (O) NH-X12, - C (O) NX13X14, -S ( O 2) -X15, -P (O) (OH) 2, -P (O) (OX16) (OX17), -Si (X18) (X19) (X20), - (O) -NH-X25, -OC (O) -NX26X27, -NH-C (O) -O -X28, -NH-C (O) -NH-X29,- NH-C (O) -NX30X31, -NX32-C (O) -O-X33, -NX34-C (O) -NH-X35, -NX36-C (O) -NX37X38, -OS (O 2) - (O) -X40, -NH-C (O) -X40, -NX41-C _{2) -NHX46, -S (O 2} ) -NX47X48, -S (O 2) -OX49, and _{-O (-X50-O) p -H} (p = 1, 2, 3, 4, 5) "; Additionally, "-N (alkyl) ₂ " is further substituted by one or more substituents selected from the group consisting of (a3); Wherein X 5 to X 50 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or X14, X26 and X27, X30 and X31, X37 and X38 or X47 and X48 may each independently form a "heterocyclyl"; Wherein Z 3 is independently further substituted by one or more substituents, identically or differently, selected from the group (a3) consisting of: (a3) "an alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHX51, -NX52X53, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O _{) NH 2, -SO 3 H,} -P (O) (OH) 2, -C (O) X54, -C (O) O-X55, -C (O) NH-X56, -C (O) NX57X58 , -O-X59, -O (-X60 -O) r H (r = 1, 2, 3, 4, 5), -O (-X61-O) r -X62 (r = 1, 2, 3, -OC (O) -X63, -OC (O) -O-X64, -OC (O) -NHX65, -OC (O) -NX66X67, , -OSi (X70) (X71) (X72), -OS (O 2) -X73, -NHC (O) -X74, -NX75C (O) -X76, -NH-C (O) -O-X77, -NH-X84, -NX85-C (O) -NH-X78, -NH-C (O) -NX86X87, -NHS (O 2) -X88, -NX89S (O 2) -X90, -S-X91, -S (O) -X92, -S (O 2) -X93, -S (O _{2) NH-X94, -S (} O 2) NX95X96, -S (O 2) O-X97, -P (O) (OX98) (OX99), and -Si (X100) (X101) ( X102) "; Wherein X 51 to X 102 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or X58, X66 and X67, X79 and X80, X86 and X87 or X95 and X96 may each independently form a "heterocyclyl"; (A2) "Substituted aryl"("substitutedaryl" is substituted by one or more substituents identically or differently selected from the group (a4) consisting of: (O) -X210, - (CH2) n-alkyl, -NHC (O) -lower alkyl, -NHC (O) -alkyl, -NHC (O) -OX212, -NX213C (O) -OX214, -NHC (O) -NHX215, -NHC (O) NX216X217, -NX218C _{) -NX221X222, -NHS (O 2)} - cycloalkyl-alkyl, -NHS (O ₂₎ - _{heterocyclylalkyl, -NX223S (O 2) -X224,} -O- alkyl, -S- cycloalkyl, -S- (O) -cycloalkylalkyl, -OC (O) -lower alkyl, -S-cycloalkylalkyl, -S-heterocyclyl, -S-arylalkyl, -S-heteroarylalkyl, O) heterocyclyl-alkyl, -OC (O) - alkyl, -OS (O ₂₎ - cycloalkyl-alkyl, -OS (O ₂₎ - heterocyclyl-alkyl, -OS (O ₂₎ - alkyl, -OC ( (O) - OX225, -OC (O) -NHX226, -OC (O) -NX227X228, -OP (O) (OX229) -C (O) -arylalkyl, -C (O) -heteroarylalkyl, -C (O) -cycloalkylalkyl, -C (O) -heterocyclylalkyl, -C (O) O-alkyl, -C (O) -NH-alkyl, -C (O) -C (O) -S (O) -cycloalkyl, -C (O) -NH2O2, -C (O) -S (O) -heteroaryl, -S (O) -heteroaryl, -S (O) -heteroaryl, -S (O) - heterocyclyl-alkyl, -S (O) - alkyl, -S (O ₂₎ - cycloalkyl, -S (O ₂₎ - heterocyclyl, -S (O ₂₎ - heteroaryl, -S (O ₂₎ - aryl, -S (O ₂₎ heteroaryl-alkyl, -S (O ₂₎ cycloalkylalkyl, -S (O ₂₎ heterocyclyl-alkyl, -S (O ₂₎ - alkyl, -S (O ₂₎ NH- cycloalkyl, -S (O ₂₎ NH- heterocyclyl, -S (O ₂₎ NH- heteroaryl-alkyl, -S (O ₂₎ NH- cycloalkylalkyl, -S (O ₂ ) NH- heterocyclylalkyl, -S (O ₂₎ NH- alkyl, -S (O ₂₎ O- cycloalkyl, -S (O ₂₎ O- heterocyclyl, -S (O ₂₎ O- heteroaryl aryl, -S (O ₂₎ O- heteroaryl-alkyl, -S (O ₂₎ O- cycloalkylalkyl, -S (O ₂₎ O- heterocyclylalkyl, -S (O ₂₎ O- alkyl, - P (O) (OH) ₂ , -P (O) (OX241) (OX242), -Si (X243) (X244) Si (X246) (X247) (X248) "; Wherein X207 to X248 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or X217, X221 and X222, X227 and X228, X231 and X232, X236 and X237 or X239 and X240 may each independently form a "heterocyclyl"; However, the substituent "-N _{(alkyl) 2", "-C (O} ) N ( _{alkyl) 2", "-C (O} ) N ( _{cycloalkyl) 2", "-C (O} ) N ( aryl) ₂ ", And" -C (O) N (heteroaryl) ₂ "are further substituted by one or more substituents selected from the following substituent groups (a5); Wherein said substituents in substitution group (a4) may each be independently substituted by one or more substituents selected identically or differently from group (a5) consisting of: (a5) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHX249, NX250X251, -NO} 2, -OH, -OCF 3, -SH, -OSO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH 2 _{, -SO 3 H, -P (O} ) (OH) 2, -C (O) -X252, -C (O) O-X253, -C (O) NH-X254, -C (O) NX255X256, - O-X257, -O (-X258- O) u -H (u = 1, 2, 3, 4, 5), -O (-X259-O) u -X260 (u = 1, 2, 3, 4 , -OC (O) -X261, -OC (O) -O-X262, -OC (O) -NHX263, -OC (O) -NX264X265, -OSi (X268) (X269) ( X270), -OS (O 2) -X271, -NHC (O) -X272, -NX273C (O) -X274, -NH-C (O) -O-X275, - (O) -NH-X276, -NH-C (O) -NX277X278, -NX279-C (O) -O-X280, -NX281- _{-NX284X285, -NHS (O 2) -X286} , -NX287S (O 2) -X288, -S-X289, -S (O) -X290, -S (O 2) -X291, -S (O 2) NH _{-X292, -S (O 2) NX293X294} , -S (O 2) O-X295, -P (O) (OX296) (OX297), and -Si (X298) (X299) ( X300) "; Wherein X 249 to X 300 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or X256, X264 and X265, X277 and X278, X284 and X285 or X293 and X294 may each independently form a "heterocyclyl"; Wherein Z 3 may be independently substituted by one or more substituents, independently or identically selected from group (a6) consisting of: (a6) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N3, NH _{2, -NHX301, -NX302X303, -NO 2} , -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) _{NH 2, -SO 3 H, -P} (O) (OH) 2, -C (O) -X304, -C (O) O-X305, -C (O) NH-X306, -C (O) NX307X308 , -O-X309, -O (-X310 -O) uu -H (uu = 1, 2, 3, 4, 5), -O (-X311-O) uu X312 (uu = 1, 2, 3, -OC (O) -X313, -OC (O) -O-X314, -OC (O) -NHX315, -OC (O) -NX316X317, , -OSi (X320) (X321) (X322), -OS (O 2) -X323, -NHC (O) -X324, -NX325C (O) -X326, -NH-C (O) -OX327, -NH (O) -NHX328, -NH-C (O) -NX329X330, -NX331-C (O) O-X332, -NX333-C _{, -NHS (O 2) -X338,} -NX339S (O 2) -X340, -S-X341, -S (O) -X342, -S (O 2) -X343, -S (O 2) NH-X344 _{, -S (O 2) NX345X346,} -S (O 2) O-X347, -P (O) (OX348) (OX349), and -Si (X350) (X351) ( X352) "; Wherein X 301 to X 352 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or 308, X316 and X317, X329 and X330, X336 and X337 or X345 and X346 together may each independently form "heterocyclyl"; (C) "Substituted alkyl" (wherein "substituted alkyl" is substituted by one or more substituents selected from the group consisting of (c1) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHW1, -NW2W3, -NO} 2, -OH, -OCF 3, -SH, -OSO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH _{2, -SO 3 H, -P (} O) (OH) 2, -C (O) -W4, -C (O) O-W5, -C (O) NH-W6, -C (O) NW7W8, -O-W9, -O (-W10- O) r -H (r = 1, 2, 3, 4, 5), -O (-W11-O) r -W12 (r = 1, 2, 3, -OC (O) -W13, -OC (O) -O-W14, -OC (O) -NHW15, , -OSi (W20) (W21) (W22), -OS (O 2) -W23, -NHC (O) -W24, -NW25C (O) -W26, -NHC (O) -O-W27, -NHC (O) -NH-W28, -NHC (O) -NW29W30, -NW31-C (O) -O-W32, -NW33C- _{(O 2) -W38, -NW39S (} O 2) -W40, -S-W41, -S (O) -W42, -S (O 2) -W43, -S (O 2) NH-W44, -S _{(O 2) NW45W46, -S (} O 2) O-W47, -P (O) (OW48) (OW49), and -Si (W50) (W51) ( W52) "; Wherein W 1 to W 52 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or W8, W16 and W17, W29 and W30, W36 and W37 or W45 and W46 together may each independently form a "heterocyclyl"; Provided that "-C (O) NH-aryl", "-C (O) NH-heteroaryl", "-C (O) NH-cycloalkyl", and "-C (O) NH-heterocyclyl" Is further substituted by one or more substituents selected from the following substituent groups (c2); Wherein said substituents in substitution group (a1) may each be independently substituted by one or more substituents, identically or differently selected from group (c2), consisting of: (c2) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHW53, -NW54W55, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O _{) NH 2, -SO 3 H,} -P (O) (OH) 2, -C (O) -W56, -C (O) O-W57, -C (O) NH-W58, -C (O) NW59W60, -O-W61, -O ( -W62-O) s H (s = 1, 2, 3, 4, 5), -O (-W63-O) t -W64 (t = 1, 2, 3 , O (O) -W65, -OC (O) -O-W66, -OC (O) -NHW67, -OC ), -OSi (W72) (W73 ) (W74), -OS (O 2) -W75, -NHC (O) -W76, -NW77C (O) -W78, -NH-C (O) -O-W79 , -NH-C (O) -NH-W80, -NH-C (O) -NW81W82, -NW83-C C (O) -NW88W89, -NHS ( O 2) -W90, -NW91S (O 2) -W92, -S-W93, -S (O) -W94, -S (O 2) -W95, -S ( _{O 2) NH-W96, -S} (O 2) NW97W98, -S (O 2) O-W99, -P (O) (OW100) (OW101), and -Si (W102) (W103) ( W104) "; Wherein W53 to W104 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or W60, W68 and W69, W81 and W82, W88 and W89 or W97 and W98 may each independently form a "heterocyclyl"; Wherein said substituents in substitution group (c2) may each independently be substituted again by one or more substituents identically or differently selected from group (c3) consisting of: (c3) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHW105, -NW106W107, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O _{) NH 2, -SO 3 H,} -P (O) (OH) 2, -C (O) -W108, -C (O) O-W109, -C (O) NH-W110, -C (O) NW111W112, -O-W113, -O ( -W114-O) t -H (t = 1, 2, 3, 4, 5), -O (-W115-O) t -W116 (t = 1, 2, -OC (O) -W117, -OC (O) -O-W118, -OC (O) -NHW119, -OC (O) -NW120W121, OW123), -OSi (W124) ( W125) (W126), -OS (O 2) -W127, -NHC (O) -W128, -NW129C (O) -W130, -NH-C (O) -O- (O) -NH-W131, -NH-C (O) -NH-W132, -NH-C (O) -NW133W134, -NW135-C -C (O) -NW140W141, -NHS ( O 2) -W142, -NW143S (O 2) -W144, -S-W145, -S (O) -W146, -S (O 2) -W147, -S _{(O 2) NH-W148,} -S (O 2) NW149W150, -S (O 2) O-W151, -P (O) (OW152) (OW153), and -Si (W154) (W155) ( W156) "; Wherein W 105 to W 156 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or W112, W120 and W121, W133 and W134, W140 and W141 or W149 and W150 may each independently form "heterocyclyl"; (D) Wherein one of the Z10 and Z11 radicals or both of the Z10 and Z11 radicals and both of the Z12 and Z13 radicals are each independently selected from the following groups (d1) and (d5): < EMI ID = (d1) "hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl"; Provided that both Z10 and Z11 radicals are not simultaneously hydrogen; Further provided that the Z12 radical is not hydrogen; And further provided that said substituents of substitution group (d1) are further substituted, if they are not hydrogen, each independently by one or more substituents identically or differently selected from group (d2) consisting of: (d2) "cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, N _3, -NH- cycloalkyl, cycloalkylalkyl -NH-, -NH -NH-arylalkyl, -NH-arylalkyl, -NH-heterocyclyl, -NH-heterocyclylalkyl, -NQ1Q2, -S-cycloalkyl, -S-cycloalkylalkyl, -S -S-arylalkyl, -S-heteroaryl, -S-heteroarylalkyl, -S-heterocyclyl, -S-heterocyclylalkyl, -O-cycloalkyl, -O-heteroaryl, -O-heteroarylalkyl, -O-heterocyclyl, -O-heterocyclylalkyl, -O (-Q3-O) _p- -O (-Q4-O) _p- Q5 (p = 1,2,3,4,5), -OP (O) (OQ6) ) O-Q8, -C (O ) NH2, -C (O) NH-Q9, -C (O) NQ10Q11, -S (O 2) -Q12, -P (O) (OH) 2, -P ( -OC (O) -O-Q21, -OC (O) O (OQ) OQ14, -Si (Q15) -NH-Q22, -OC (O) -NQ23Q24, -NH-C (O) -O-Q2 -N (O) -NH-Q26, -NH-C (O) -NQ27Q28, -NQ29-C (O) -O-Q30, -NQ31-C -C (O) -NQ34Q35, -NQ36- S (O 2) -Q37, -NH-S (O 2) -Q38, -OS (O 2) -Q39, -NH-C (O) -Q40, - NQ41-C (O) -Q42, -C (O) -Q43, -OC (O) -Q44, -S (O) -Q45, -S (O 2) -NHQ46, -S (O 2) -NQ47Q48 , And -S (O ₂ ) -OQ49 "; "-N (alkyl) ₂ " is further substituted by one or more substituents selected from the following substituent group (d3); Wherein Q 1 to Q 49 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or Q11, Q23 and Q24, Q27 and Q28, Q34 and Q35 or Q47 and Q48 together may each independently form a "heterocyclyl"; Wherein said substituents of substitution group (d1) or substitution group (d2) may each be independently substituted by one or more substituents, identically or differently selected from group (d3) consisting of: (d3) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHQ50, -NQ51Q52, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O _{) NH 2, -SO 3 H,} -P (O) (OH) 2, -C (O) -Q53, -C (O) O-Q54, -C (O) NH-Q55, -C (O) NQ56Q57, -O-Q58, -O ( -Q59-O) r -H (r = 1, 2, 3, 4, 5), -O (-Q60-O) r -Q61 (r = 1, 2, -OC (O) -O-Q63, -OC (O) -NHQ64, -OC (O) -NQ65Q66, -OP (O) OQ68), -OSi (Q69) ( Q70) (Q71), -OS (O 2) -Q72, -NHC (O) -Q73, -NQ74C (O) -Q75, -NH-C (O) -O- (O) -NH-Q77, -NH-C (O) -NH-Q77, -NH-C (O) -NQ78Q79, -NQ80-C (O) -NQ85Q86, -NHS (O 2) -Q87, -NQ88S (O 2) -Q89, -S-Q90, -S (O) -Q91, -S (O 2) -Q92, -S (O _{2) NH-Q93, -S (} O 2) NQ94Q95, -S (O 2) O-Q96, -P (O) (OQ97) (OQ98), and -Si (Q99) (Q100) ( Q101) "; Wherein Q50 to Q101 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or Q57, Q65 and Q66, Q78 and Q79, Q85 and Q86 or Q94 and Q95 may each independently form a "heterocyclyl"; Wherein said substituents in substitution group (d3) may each be independently substituted again with one or more substituents selected identically or differently from group (d4) consisting of: (d4) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHQ102, -NQ103Q104, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O _{) NH 2, -SO 3 H,} -P (O) (OH) 2, -C (O) -Q105, -C (O) O-Q106, -C (O) NH-Q107, -C (O) NQ108Q109, -O-Q110, -O ( -Q111-O) s -H (s = 1, 2, 3, 4, 5), -O (-Q112-O) s -Q113 (s = 1, 2, -OC (O) -Q114, -OC (O) -O-Q115, -OC (O) -NHQ116, -OC (O) -NQ117Q118, OQ120), -OSi (Q121) ( Q122) (Q123), -OS (O 2) -Q124, -NHC (O) -Q125, -NQ126C (O) -Q127, -NH-C (O) -O- (O) -NH-Q129, -NH-C (O) -NH-Q129, -NH-C (O) -NQ130Q131, -NQ132- -C (O) -NQ137Q138, -NHS ( O 2) -Q139, -NQ140S (O 2) -Q141, -S-Q142, -S (O) -Q143, -S (O 2) -Q144, -S _{(O 2) NH-Q145,} -S (O 2) NQ146Q147, -S (O 2) O-Q148, -P (O) (OQ149) (OQ150), and -Si (Q151) (Q152) ( Q153) "; Wherein Q102 to Q153 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or Q109, Q117 and Q118, Q130 and Q131, Q137 and Q138 or Q146 and Q147 may each independently form a "heterocyclyl"; (d5) "-C (O) Q154, -C (O) OQ155, -C (O) NQ156Q157, -S (O 2) Q158, and -S (O ₂₎ OQ159"; Wherein Q 154 to Q 159 are each independently selected from the group consisting of “hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, Q156 and Q157 together may form “heterocyclyl”; Wherein said substituents in substitution group (d5) may each be independently substituted by one or more substituents selected the same or differently from the group (d6) consisting of: (d6) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHQ160, -NQ161Q162, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O _{) NH 2, -SO 3 H,} -P (O) (OH) 2, -C (O) -Q163, -C (O) O-Q164, -C (O) NH-Q165, -C (O) NQ166Q167, -O-Q168, -O ( -Q169-O) t -H (t = 1, 2, 3, 4, 5), -O (-Q170-O) t -Q171 (t = 1, 2, O (O) -Q172, -OC (O) -Q173, -OC (O) -NHQ174, -OC (O) -NQ175Q176, ), -OSi (Q179) (Q180 ) (Q181), -OS (O 2) -Q182, -NHC (O) -Q183, -NQ184C (O) -Q185, -NH-C (O) -O-Q186 , -NH-C (O) -NH-Q187, -NH-C (O) -NQ188Q189, -NQ190- C (O) -NQ195Q196, -NHS ( O 2) -Q197, -NQ198S (O 2) -Q199, -S-Q200, -S (O) -Q201, -S (O 2) -Q202, -S ( _{O 2) NH-Q203, -S} (O 2) NQ204Q205, -S (O 2) O-Q206, -P (O) (OQ207) (OQ208), and -Si (Q209) (Q210) ( Q211) "; Wherein Q160 to Q211 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or Q167, Q175 and Q176, Q188 and Q189, Q195 and Q196 or Q204 and Q205 may each independently form a "heterocyclyl"; Wherein said substituents in substitution group (d6) may each be independently substituted by one or more substituents, identically or differently selected from group (d7), consisting of: (d7) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHQ212, -NQ213Q214, -NO} 2, -OH, -OCF 3, -SH, -OSO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH _{2, -SO 3 H, -P (} O) (OH) 2, -C (O) -Q215, -C (O) O-Q216, -C (O) NH-Q217, -C (O) NQ218Q219, -O-Q220, -O (-Q221- O) u -H (u = 1, 2, 3, 4, 5), -O (-Q222-O) u -Q223 (u = 1, 2, 3, O (O) -Q224, -OC (O) -O-Q225, -OC (O) -NHQ226, -OC (O) -NQ227Q228, , -OSi (Q231) (Q232) (Q233), -OS (O 2) -Q234, -NHC (O) -Q235, -NQ236C (O) -Q237, -NH-C (O) -O-Q238, (O) -NH-Q239, -NH-C (O) -NQ240Q241, -NQ242-C (O) -O-Q243, -NQ244- (O) -NQ247Q248, -NHS (O 2) -Q249, -NQ250S (O 2) -Q251, -S-Q252, -S (O) -Q253, -S (O 2) -Q254, -S (O _{2) NH-Q255, -S (} O 2) NQ256Q257, -S (O 2) O-Q258, -P (O) (OQ259) (OQ260), and -Si (Q261) (Q262) ( Q263) "; Wherein Q212 to Q263 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or Q219, Q227 and Q228, Q240 and Q241, Q247 and Q248 or Q256 and Q257 can each independently form a "heterocyclyl"; Wherein said substituents in substitution group (d7) may each be independently substituted again by one or more substituents, identically or differently selected from the group (d8) consisting of: (d8) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHQ264, -NQ265Q266, -NO} 2, -OH, -OCF 3, -SH, -OSO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH _{2, -SO 3 H, -P (} O) (OH) 2, -C (O) -Q267, -C (O) O-Q268, -C (O) NH-Q269, -C (O) NQ270Q271, -O-Q272, -O (-Q273- O) vv -H (v = 1, 2, 3, 4, 5), -O (-Q274-O) v -Q275 (v = 1, 2, 3, -OC (O) -Q276, -OC (O) -O-Q277, -OC (O) -NH-Q278, -OC (O) -NQ279Q280, OQ282), -OSi (Q283) ( Q284) (Q285), -OS (O 2) -Q286, -NHC (O) -Q287, -NQ288C (O) -Q289, -NH-C (O) -O- (O) -NH-Q291, -NH-C (O) -NH2Q293, -NQ294-C (O) -O-Q295, -NQ296-C -C (O) -NQ299Q300, -NHS ( O2) -Q301, -NQ302S (O2) -Q303, -S-Q304, -S (O) -Q305, -S (O 2) -Q306, -S (O _{2) NH-Q307, -S (} O 2) NQ308Q309, -S (O 2) O-Q310, -P (O) (OQ311) (OQ312), and -Si (Q313) (Q314) ( Q315) "; Wherein Q264 to Q315 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or Q271, Q279 and Q280, Q292 and Q293, Q299 and Q300 or Q308 and Q309 may each independently form a "heterocyclyl"); Z1 is selected from the group consisting of "hydrogen and NHZ15"; Wherein Z15 is selected from the group (e1) consisting of: (e1) "Hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -C (Y1) NZ16Z17, -C (= NZ18) Z19 And -C (Y2) NZ20Y3Z21 "; Wherein Y1, Y2 and Y3 are each independently "O"; Wherein Z16, Z17, Z18, Z19, Z20 and Z21 are each independently selected from groups (e2), (e3), (e5) and (e9) consisting of: (e8) Z16 and Z17 can independently form "heterocyclyl"; (e2) hydrogen; (e3) "alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl"; Wherein said substituents of substitution group (e1) or substitution group (e3) may each be independently substituted by one or more substituents selected identically or differently from group (e4) consisting of: (e4) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, NHU1, NU2U3, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O) NH _{2, -SO 3 H, -P (} O) (OH) 2, -C (O) -U4, -C (O) O-U5, -C (O) NH-U6, -C (O) NU7U8, -O-U9, -O (-U10- O) r -H (r = 1, 2, 3, 4, 5), -O (-U11-O) r -U12 (r = 1, 2, 3, -O (O) -O-U14, -OC (O) -NHU15, -OC (O) -NU16U17, -OP (O) , -OSi (U20) (U21) (U22), -OS (O 2) -U23, -NHC (O) -U24, -NU25C (O) -U26, -NH-C (O) -O-U27, -NH-C (O) -NH-C (O) -NH-U28, -NH-C (O) -NU36U37, -NHS (O 2) -U38, -NU39S (O 2) -U40, -S-U41, -S (O) -U42, -S (O 2) -U43, -S (O _{2) NH-U44, -S (} O 2) NU45U46, -S (O 2) O-U47, -P (O) (OU48) (OU49), and -Si (U50) (U51) ( U52) "; Wherein U 1 to U 52 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or U8, U16 and U17, U29 and U30, U36 and U37 or U45 and U46 together may each independently form a "heterocyclyl"; (e5) -C (O) -Z23, wherein Z23 is independently selected from the group consisting of group (e6) consisting of: (e6) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl"; Wherein said substituents of substitution group (e6) are each independently further substituted by one or more substituents selected identically or differently from group (e7) consisting of: (e7) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHU157, -NU158U159, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O _{) NH 2, -SO 3 H,} -P (O) (OH) 2, -C (O) -U160, -C (O) O-U161, -C (O) NH-U162, -C (O) NU163U164, -O-U165, -O ( -U166-O) t -H (t = 1, 2, 3, 4, 5), -O (-U167-O) t -U168 (t = 1, 2, O (O) -U169, -OC (O) -O-U170, -OC (O) -NHU171, -OC (O) -NU172U173, OU175), -OSi (U176) ( U177) (U178), -OS (O 2) -U179, -NHC (O) -U180, -NU181C (O) -U182, -NH-C (O) -O- (O) -NH-U184, -NH-C (O) -NH185 U186, -NU187-C (O) -O-U188, -NU189-C -C (O) -NU192U193, -NHS ( O 2) -U194, -NU195S (O 2) -U196, -S-U197, -S (O) -U198, -S (O 2) -U199, -S _{(O 2) NH-U200,} -S (O 2) NU201U202, -S (O 2) O-U203, -P (O) (OU204) (OU205), and -Si (U206) (U207) ( U208) "; Wherein U157 to U208 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or U164, U172 and U173, U185 and U186, U192 and U193 or U201 and U202 together may each independently form a "heterocyclyl"; (e9) "-C (O) -C (O) -U313 or -S (O ₂₎ -NU314U315", where, U313, U314 and U315 is selected from the group (e10) made to independently: (e10) "hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHU316, -NU317U318} , -NO 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C _{(O) NH 2, -SO 3} H, -P (O) (OH) 2, -C (O) -U319, -C (O) O-U320, -C (O) NH-U321, -C ( O) NU322U323, -O-U324, -O (-U325-O) w -H (w = 1, 2, 3, 4, 5), -O (-U326-O) w -U327 (w = 1, -OC (O) -O-U329, -OC (O) -NHU330, -OC (O) -NU331U332, -OP ) (OU334), -OSi (U335 ) (U336) (U337), -OS (O 2) -U338, -NHC (O) -U339, -NU340C (O) -U341, -NH-C (O) - -NH-C (O) -NH-C (O) -NH-C (O) -NH-U342, -NH-C -NU350-C (O) -NU351U352, -NHS (O 2) -U353, -NU354S (O 2) -U355, -S-U356, -S (O) -U357, -S (O 2) -U358, _{-S (O 2) NH-U359} , -S (O 2) NU360U361, -S (O 2) O-U362, -P (O) (OU363) (OU364), and -Si (U365) (U366) ( U367) "; Wherein U316 to U367 are each independently selected from the group consisting of "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl", or U323, U331 and U332, U344 and U345, U351 and U352 or U360 and U361 together may each independently form a "heterocyclyl"; Wherein said substituents in substitution group (e10) may each be further substituted by one or more substituents, each independently selected from the same or differently from group (e11) consisting of: (e11) "alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl-alkyl, F, Cl, Br, I, CN, CF _3, N _{3, NH 2, -NHU368, -NU369U370, -NO} 2, -OH, -OCF 3, -SH, -O-SO 3 H, -OP (O) (OH) 2, -CHO, -COOH, -C (O _{) NH 2, -SO 3 H,} -P (O) (OH) 2, -C (O) -U371, -C (O) O-U372, -C (O) NH-U373, -C (O) NU374U375, -O-U376, -O ( -U377-O) x -H (x = 1, 2, 3, 4, 5), -O (-U378-O) x -U379 (x = 1, 2, -OC (O) -O-U381, -OC (O) NH-U382, -OC (O) -NU383U384, -OP (O) (OU386), -OSi (U387) (U388) (U389), -OS (O 2) -U390, -NHC (O) -U391, -NU392C (O) -U393, -NH-C (O) -O -NH-C (O) -NH-C (O) -NH-C (O) -NH-C NU402-C (O) -NU403U404, -NHS (O 2) -U405, -NU406S (O 2) -U407, -S-U408, -S (O) -U409, -S (O 2) -U410, - _{S (O 2) NH-U411} , -S (O 2) NU412U413, -S (O 2) OU-414, -P (O) (OU415) (OU416), and -Si (U417) (U418) ( U419 ) "; Wherein U 368 to U 419 are each independently selected from the group consisting of “alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl”, or U375, U383 and U384, U396 and U397, U403 and U404 or U412 and U413 can each independently form "heterocyclyl", or U314 and U315 together can form "heterocyclyl"; Wherein "alkyl" is an acyclic saturated or unsaturated hydrocarbon radical which may be branched or straight chain and has 1 to 8 carbon atoms; "Cycloalkyl" is a cyclic non-aromatic hydrocarbon which may be saturated or unsaturated and has 3 to 20 carbon atoms and 1 to 3 rings; "Heterocyclyl" is a 3- to 14-membered cyclic organic radical comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein the heteroatoms are the same or different and are cyclic radicals Is saturated or unsaturated but not aromatic; "Aryl" is an aromatic hydrocarbon having 3 to 14 carbon atoms; "Heteroaryl" is a 5-, 6- or 7-membered cyclic aromatic radical comprising at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, said heteroatoms being the same or different. The method according to claim 1, In (A), The Z1 radicals are independently "NHZ15", wherein Z15 is "-C (O) NHalkyl" and "-C (O) NHalkyl" may be substituted by "OH"; Z 2 radicals are independently hydrogen; Z 3 radicals are independently “substituted aryl” wherein “substituted aryl” is substituted by one or more substituents identically or differently selected from group (a) consisting of: (a) "alkyl, -OC (O) -alkyl, -O-alkyl, and -NHC (O) -alkyl"; Provided that the substituents of substitution group (a) are each independently further substituted by one or more substituents selected the same or differently from group (b) consisting of: (b) "aryl, heterocyclyl, -O-alkyl-O-alkyl, and -O-arylalkyl"; Or the Z 3 radicals are independently “substituted aryl” wherein “substituted aryl” is substituted by one or more substituents identically or differently selected from group (c) consisting of: (c) "-OC (O) -O- alkyl, -OC (O) -O- aryl, -OC (O) -N (alkyl) _2, -OC (O) -NH- alkyl, -OC (O ) -alkyl, -NHC (O) -O- alkyl, -NHC (O) -NH- alkyl, -NHC (O) -N (alkyl) _2, and -Si (alkyl) ₃ "; Wherein said substituents in substitution group (c) may each be independently substituted by one or more substituents, identically or differently, selected from the group (d) consisting of: (d) "-O-alkyl, and -O-arylalkyl"; Wherein the Z 3 radicals may also be independently substituted by one or more substituents identically or differently selected from group (e) consisting of: (e) "F, Cl, Br, I, -O-alkyl"; Z 4 radicals are independently hydrogen; Z5 radicals are independently hydrogen Novel pyrido [2,3-b] pyrazine derivatives of formula (I). The method according to claim 1, In (A), Z1 radicals are independently selected from the group consisting of "-NHC (O) NH-ethyl, and -NHC (O) NH-butyl-OH", Z 2 radicals are independently hydrogen; Z3 radicals are independently "4-phenyl methyl carbonate, 3-phenyl 2-methoxyethyl carbonate, 4-phenyl 2-methoxyethyl carbonate, 4-phenyl phenyl carbonate, 4-phenyl N-diethylcarbamate, 4- Phenyl 3-phenylacrylate, 4-phenyl nonadecanoate, 4-phenyl isobutyl carbonate, 4-phenyl but-2-ynyl carbonate, 4-phenyl N-dimethylcarbamate, 4-phenyl N-ethylcarbamate, Tert-butyl N- (4-phenyl) carbamate, 2-methoxyethyl N- (4-phenyl) carbamate, 4- (3-ethylurea) phenyl, 4- (3,3-methylurea) phenyl 4-morpholin-4-ylmethylphenyl, 4- [2- (2-methoxyethoxy) ethoxy] phenyl, N- (4-phenyl) -2- (2-methoxyethoxy) acetamide, 4- (2-methoxy) phenyl 2-methoxyethyl carbonate, 4-phenyl 2-benzyloxyethyl carbonate, 4- (2-methoxy) phenyl 2-benzyloxyethyl carbonate, N- (4-phenyl)- 2-benzyloxyacetamide, 3-trimethylsilanylphenyl, 4- (2-methoxy) phenyl N- Ethylcarbamate, 4- (2-chloro-6-methoxy) phenyl N-diethylcarbamate, and 4- (2-methoxy) phenyl 2- [2- (2-methoxyethoxy) ethoxy] Ethyl carbonate ", and Z 4 radicals are independently hydrogen; Z5 radicals are independently hydrogen Novel pyrido [2,3-b] pyrazine derivatives of formula (I). delete delete The method according to claim 1, In (C), Z 1 radicals are independently “NHZ 15”; Wherein Z 15 is “—C (O) NH-alkyl”; Z 2 radicals are independently hydrogen; Z 3 radicals are independently “substituted alkyl” wherein “substituted alkyl” is substituted by one or more substituents identically or differently selected from group (a) consisting of: (a) "aryl, heteroaryl, cycloalkyl, -N (alkyl) 2, and -O-alkyl"; Wherein said substituents of substitution group (a) may each be further substituted by one or more substituents, independently or identically selected from group (b) consisting of: (b) "F, Cl, Br, and I"; Z 4 radicals are independently hydrogen; Z5 radicals are independently hydrogen Novel pyrido [2,3-b] pyrazine derivatives of formula (I). The method according to claim 1, In (C), Z1 radicals are independently selected from the group consisting of "-NHC (O) NH-ethyl", Z 2 radicals are independently hydrogen; Z3 radicals are independently "phenylethynyl, thiophen-3-ylethynyl, cyclopropylethynyl, N-dimethylaminoprop-1-ynyl, 2-cyclohexylvinyl, 3-methoxypropenyl, benzyl, 2- (4-fluorophenyl) ethyl, and 2- (4-fluorophenyl) vinyl ", and Z 4 radicals are independently hydrogen; Z5 radicals are independently hydrogen Novel pyrido [2,3-b] pyrazine derivatives of formula (I). The method according to claim 1, In (D), The Z 1 radical is independently “NHZ 15”, wherein Z 15 is “—C (O) NH-alkyl”; Z 2 radicals are independently hydrogen; Z3 radicals are independently selected from group (a) consisting of: (a) "-NZ10Z11"; Wherein the Z10 and Z11 radicals are each independently selected from groups (b) and (d) consisting of: (b) "hydrogen and aryl"; Provided that the substituents of substitution group (a) are further substituted by one or more substituents, each of which is the same or differently selected from the group (c) consisting of: (c) "cycloalkyl, heteroaryl, heterocyclyl alkyl, -S (O) ₂ - _{alkyl, -NH-S (O) 2} - alkyl, -C (O) NH-alkyl, -NH-C (O) -Alkyl, and -C (O) O-alkyl "; (d) "-C (O) -aryl"; Wherein said substituents of substitution group (a) or substitution group (b) may each be independently substituted by one or more substituents selected the same or differently from group (e) consisting of: (e) "alkyl"; Z 4 radicals are independently hydrogen; Z5 radicals are independently hydrogen Novel pyrido [2,3-b] pyrazine derivatives of formula (I). The method of claim 1, In (D), Z1 radicals are independently selected from the group consisting of "-NHC (O) NH-ethyl", Z 2 radicals are independently hydrogen; Z3 radicals are independently "4-methylbenzamide, 4-cyclohexylphenylamino, 4-methanesulfonylphenylamino, 3- (N-methanesulfonamide) -4-methylphenylamino, 3-N-methylbenzamideamino , 4-piperidin-1-ylmethylphenylamino, 4-thiophen-3-ylphenylamino, 4-N-acetamidophenylamino, and 3- (ethyl benzoate) amino ” , Z 4 radicals are independently hydrogen; Z5 radicals are independently hydrogen Novel pyrido [2,3-b] pyrazine derivatives of formula (I). delete delete The pyrido [2,3-b] pyrazine derivatives of formula I according to claim 1 selected from the group consisting of: Compound 1 1-ethyl-3- (3-phenylethynylpyrido [2,3-b] pyrazin-6-yl) urea

Compound 2 1-ethyl-3- (3-thiophen-3-ylethynylpyrido [2,3-b] pyrazin-6-yl) urea

Compound 3 1- (3-cyclopropylethynylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea

Compound 4 1- [3- (3-dimethylaminoprop-1-ynyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Compound 5 1- [3-((E) -2-cyclohexylvinyl) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Compound 6 1-ethyl-3- [3-((E) -3-methoxypropenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 9 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl methyl carbonate

Compound 10 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate

Compound 11 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl phenyl carbonate

Compound 12 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl diethylcarbamate

Compound 13 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl (E) -3-phenylacrylate

Compound 14 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl nonadecanoate

Compound 15 1- (3-benzylpyrido [2,3-b] pyrazin-6-yl) -3-ethylurea

Compound 16 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate

Compound 17 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl isobutyl carbonate

Compound 18 But-2-ynyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate

Compound 19 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl dimethylcarbamate

Compound 20 4- [6- (3-ethyl-1-phenylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl ethylcarbamate

Compound 21 tert-butyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -carbamate

Compound 22 2-methoxyethyl {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -carbamate

Compound 23 1-ethyl-3- {3- [4- (3-ethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 24 1- {3- [4- (3,3-dimethylurea) phenyl] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea

Compound 25 1-ethyl-3- {3- [6- (3-ethylurea) pyridin-3-yl] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 26 1-ethyl-3- {3- [2- (4-fluorophenyl) ethyl] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 27 1-ethyl-3- {3-[(E) -2- (4-fluorophenyl) vinyl] pyrido [2,3-b] pyrazin-6-yl} -urea

Compound 28 1-ethyl-3- [3- (4-morpholin-4-ylmethylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 29 1-ethyl-3- (3- {4- [2- (2-methoxyethoxy) ethoxy] phenyl} pyrido [2,3-b] pyrazin-6-yl) urea

Compound 30 N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -2- (2-methoxyethoxy) acetamide

Compound 31 N- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -4-methylbenzamide

Compound 32 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2-methoxyethyl carbonate

Compound 33 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate

Compound 34 2-benzyloxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl carbonate

Compound 35 2-benzyloxy-N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl} -acetamide

Compound 37 1- [4- (tert-butyldimethylsilanyloxy) butyl] -3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazine-6- Urea

Compound 44 diethyl (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphate

Compound 45 (4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] urea} butyl) phosphate

Compound 46 1-ethyl-3- [3- (3-trimethylsilanylphenyl) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 47 1- [3- (4-cyclohexylphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Compound 48 1-ethyl-3- [3- (4-methanesulfonylphenylamino) pyrido [2,3-b] -pyrazin-6-yl] urea

Compound 49 N- {5- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -2-methyl-phenyl} methanesulfonamide

Compound 50 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] -N-methyl-benzamide

Compound 51 1-ethyl-3- [3- (4-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] -pyrazin-6-yl] urea

Compound 52 1-ethyl-3- [3- (4-thiophen-3-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 53 N- {4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] phenyl} -acetamide

Compound 54 ethyl 3- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-ylamino] benzoate

Compound 55 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl 2-methoxyethyl carbonate hydrochloride

Compound 56 2-methoxyethyl 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] phenyl carbonate p-toluenesulfonate

Compound 57 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate

Compound 58 4- {6- [3- (4-hydroxybutyl) urea] pyrido [2,3-b] pyrazin-3-yl} phenyl 2-methoxyethyl carbonate hydrochloride

Compound 61

Compound 64 1- [3- (2-diethylaminoethoxy) propyl] -3- [3- (4-hydroxy-3-methoxy-phenyl) pyrido [2,3-b] pyrazine-6- Urea

Compound 65 (2,2-dimethylpropionyloxymethoxy)-(4- {3- [3- (4-hydroxy-3-methoxy-phenyl) pyrido [2,3-b] pyrazine-6- Urea} butyl) phosphinoyloxymethyl 2,2-dimethyl-propanoate

Compound 66 1-[(1-acetoxyethoxy)-(4- {3- [3- (4-hydroxy-3-methoxyphenyl) -pyrido [2,3-b] pyrazin-6-yl ] Urea} butyl) phosphinoyloxy] ethyl acetate

Compound 67 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] 2-methoxyphenyl diethylcarbamate

Compound 68 2-chloro-4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -6-methoxy-phenyl diethylcarbamate

Compound 69 4- [6- (3-ethylurea) pyrido [2,3-b] pyrazin-3-yl] -2-methoxyphenyl 2- [2- (2-methoxyethoxy) ethoxy] Ethyl carbonate

Compound 70 1-ethyl-3- [4- (morpholin-4-sulfonyl) phenylamino] pyrido [2,3-b] pyrazin-6-ylurea

Compound 71 Ethyl 5- [6- (3-ethylureido) pyrido [2,3-b] pyrazin-3-ylamino] -2-hydroxy-benzoate

Compound 72 1- [3- (3-diethylaminomethyl-4-hydroxyphenylamino) pyrido [2,3-b] pyrazin-6-yl] -3-ethylurea

Compound 73 1-ethyl-3- [3- (6-morpholin-4-ylpyridin-3-ylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 74 1-ethyl-3- {3- [3- (1H-tetrazol-5-yl) phenylamino] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 75 1-ethyl-3- [3- (3-morpholin-4-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 76 1-ethyl-3- [3- (4-imidazol-1-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 77 1-ethyl-3- [3- (4-pyrrolidin-1-ylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 78 1-ethyl-3- {3- [4- (4-methylpiperazin-1-yl) phenylamino] pyrido [2,3-b] pyrazin-6-yl} urea

Compound 79 1-ethyl-3- [3- (3-piperidin-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 80 1-ethyl-3- [3- (4-morpholin-4-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 81 1- {3- [3- (2-cyclohexylethoxy) phenylamino] pyrido [2,3-b] pyrazin-6-yl} -3-ethylurea

Compound 82 1-ethyl-3- [3- (3- [1,2,4] triazol-1-ylmethylphenylamino) pyrido [2,3-b] pyrazin-6-yl] urea

Compound 83 2,2-dimethyl [1,3] dioxolan-4-ylmethyl 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazine- 6-yl] ureido} butyl carbonate

Compound 84 2,3-dihydroxypropyl 4- {3- [3- (4-hydroxy-3-methoxyphenyl) pyrido [2,3-b] pyrazin-6-yl] ureido} butyl carbonate

delete delete Processing at least one pyrido [2,3-b] pyrazine derivative according to any one of claims 1 to 3, 6 to 9 and 12 together with a pharmaceutically acceptable carrier or excipient. To provide a pharmaceutical formulation and to make it in a therapeutically useful form. delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete A physiological or pathophysiological condition in a mammal comprising a pyrido [2,3-b] pyrazine derivative according to any one of claims 1 to 3, 6 to 9 and 12. Pharmaceutical compositions for treatment, wherein the physiological or pathophysiological condition is "malignant tumor, inflammatory disorder, inflammation, rheumatic disorder, arthritis disorder, HIV infection, rheumatism, arthritis, AIDS, ARC (AIDS related complications), Kaposi Tumors spreading from sarcoma, brain, nervous system or meninges, dementia, Alzheimer's disease, hyperproliferative disorders, colon tumors, gastric tumors, intestinal tumors, lung tumors, pancreatic tumors, ovarian tumors, prostate tumors, leukemias, melanoma, liver tumors, kidneys Tumors, head tumors, throat tumors, glioma, breast tumors, uterine cancer, endometrial cancer, cervical cancer, brain tumors, stromal cell tumors, bladder cancers, colon tumors, esophageal cancers, gynecologic tumors, ovarian tumors, thyroid cancers, lymphomas , Chronic Selected from the group consisting of leukemia, acute leukemia, diabetes, metabolic disorders, solid tumors, rheumatoid arthritis, allergies, allergic disorders, atherosclerosis, heart disorders, cardiovascular disorders, angiogenesis disorders, ischemia, cardiac hypertrophy, obesity, overweight and hypertension Wherein said treatment is mediated by inhibiting at least two enzymes, at least one enzyme is selected from the group consisting of "Erk, Erk1, and Erk2", and at least one enzyme is selected from "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma." , PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, and PI3K-Vps34p "; pyrido [2,3-b] pyrazine derivatives are selected from the group consisting of" Erk, Erk1, and Erk2 " One or more enzymes selected and one or more enzymes selected from the group consisting of "PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, and PI3K-Vps34p" , Pharmaceutical compositions. delete delete delete delete delete 34. The mammal of claim 33, wherein the mammal is human, livestock, domestic pet, beef cattle, cow, sheep, pig, goat, horse, pony, donkey, burrow, mule, hare, rabbit, cat, dog, guinea pig, hamster, A pharmaceutical composition selected from the group consisting of rats, and mice. delete delete delete delete delete delete delete The pharmaceutical composition of claim 33, wherein the active ingredient is present in unit doses from 0.001 mg to 100 mg per kg body weight of the patient. The pharmaceutical composition of claim 33, further comprising one or more pharmaceutically acceptable carriers or excipients. delete delete delete delete delete delete delete delete delete delete delete delete